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Abstract 
Human immunodeficiency virus (HIV) that leads to acquired immune deficiency 
syndrome (AIDs) reduces immune function, resulting in opportunistic infections and 
later death. Use of antiretroviral therapy (ART) increases chances of survival, 
however, with some concerns regarding fat re-distribution (lipodystrophy) which may 
encompass subcutaneous fat loss (lipoatrophy) and/or fat accumulation 
(lipohypertrophy), in the same individual. This problem has been linked to 
Antiretroviral drugs (ARVs), majorly, in the class of protease inhibitors (PIs), in 
addition to older age and being female. An additional concern is that the problem 
exists together with the metabolic syndrome, even when nutritional status/ body 
composition, and lipodystrophy/metabolic syndrome are unclear in Uganda where the 
use of ARVs is on the increase.  
 
In line with the literature, the overall aim of the study was to assess physical 
characteristics of HIV-infected patients using a comprehensive anthropometric 
protocol and to predict body composition based on these measurements and other 
standardised techniques. The other aim was to establish the existence of 
lipodystrophy, the metabolic syndrome, andassociated risk factors. Thus, three 
studies were conducted on 211 (88 ART-naïve) HIV-infected, 15-49 year-old 
women, using a cross-sectional approach, together with a qualitative study of 
secondary information on patient HIV and medication status. In addition, face-to-face 
interviews were used to extract information concerning morphological experiences 
and life style. The study revealed that participants were on average 34.1±7.65 years 
old, had lived 4.63±4.78 years with HIV infection and had spent 2.8±1.9 years 
receiving ARVs. Only 8.1% of participants were receiving PIs and 26% of those 
receiving ART had ever changed drug regimen, 15.5% of whom changed drugs due 
to lipodystrophy. 
 
Study 1 hypothesised that the mean nutritional status and predicted percent body fat 
values of study participants was within acceptable ranges; different for participants 
receiving ARVs and the HIV-infected ART-naïve participants and that percent body 
fat estimated by anthropometric measures (BMI and skinfold thickness) and the BIA 
technique was not different from that predicted by the deuterium oxide dilution 
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technique. Using the Body Mass Index (BMI), 7.1% of patients were underweight 
(<18.5 kg/m
2
) and 46.4% were overweight/obese (≥25.0 kg/m2). Based on waist 
circumference (WC), approximately 40% of the cohort was characterized as centrally 
obese. Moreover, the deuterium dilution technique showed that there was no 
between-group difference in the total body water (TBW), fat mass (FM) and fat-free 
mass (FFM). However, the technique was the only approach to predict a between-
group difference in percent body fat (p = .045), but, with a very small effect (0.021). 
Older age (β = 0.430, se = 0.089, p = .000), time spent receiving ARVs (β = 0.972, se 
= 0.089, p = .006), time with the infection (β = 0.551, se = 0.089, p = .000) and 
receiving ARVs (β = 2.940, se = 1.441, p = .043) were independently associated with 
percent body fat. Older age was the greatest single predictor of body fat. 
Furthermore, BMI gave better information than weight alone could; in that, mean 
percentage body fat per unit BMI (N = 192) was significantly higher in patients 
receiving treatment (1.11±0.31) vs. the exposed group (0.99±0.38, p = .025). For the 
assessment of obesity, percent fat measures did not greatly alter the accuracy of BMI 
as a measure for classifying individuals into the broad categories of underweight, 
normal and overweight. Briefly, Study 1 revealed that there were more 
overweight/obese participants than in the general Ugandan population, the problem 
was associated with ART status and that BMI broader classification categories were 
maintained when compared with the gold standard technique. 
 
Study 2 hypothesized that the presence of lipodystrophy in participants receiving 
ARVs was not different from that of HIV-infected ART-naïve participants. Results 
showed that 112 (53.1%) patients had experienced at least one morphological 
alteration including lipohypertrophy (7.6%), lipoatrophy (10.9%), and mixed 
alterations (34.6%). The majority of these subjects (90%) were receiving ARVs; in 
fact, all patients receiving PIs reported lipodystrophy. Period spent receiving ARVs 
(t209 = 6.739, p = .000), being on ART (χ
2 
= 94.482, p = .000), receiving PIs (Fisher’s 
exact χ2 = 113.591, p = .000), recent T4 count (CD4 counts) (t207 = 3.694, p = .000), 
time with HIV (t125 = 1.915, p = .045), as well as older age (t209 = 2.013, p = .045) 
were independently associated with lipodystrophy. Receiving ARVs was the greatest 
predictor of lipodystrophy (p = .000). In other analysis, aside from skinfolds at the 
subscapular (p = .004), there were no differences with the rest of the skinfold sites 
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and the circumferences between participants with lipodystrophy and those without 
the problem. Similarly, there was no difference in Waist: Hip ratio (WHR) (p = .186) 
and Waist: Height ratio (WHtR) (p = .257) among participants with lipodystrophy 
and those without the problem. Further examination showed that none of the 4.1% 
patients receiving stavudine (d4T) did experience lipoatrophy. However, 17.9% of 
patients receiving EFV, a non-nucleoside reverse transcriptase inhibitor (NNRTI) had 
lipoatrophy. Study 2 findings showed that presence of lipodystrophy in participants 
receiving ARVs was in fact far higher than that of HIV-infected ART-naïve 
participants. 
 
A final hypothesis was that the prevalence of the metabolic syndrome in participants 
receiving ARVs was not different from that of HIV-infected ART-naïve participants. 
Moreover, data showed that many patients (69.2%) lived with at least one feature of 
the metabolic syndrome based on International Diabetic Federation (IDF, 2006) 
definition. However, there was no single anthropometric predictor of components of 
the syndrome, thus, the best anthropometric predictor varied as the component 
varied. The metabolic syndrome was diagnosed in 15.2% of the subjects, lower than 
commonly reported in this population, and was similar between the medicated and 
the exposed groups (χ 21 = 0.018, p = .893). Moreover, the syndrome was associated 
with older age (p = .031) and percent body fat (p = .012). In addition, participants 
with the syndrome were heavier according to BMI (p = .000), larger at the waist (p = 
.000) and abdomen (p = .000), and were at central obesity risk even when hip 
circumference (p = .000) and height (p = .000) were accounted for. In spite of those 
associations, results showed that the period with disease (p = .13), CD4 counts (p = 
.836), receiving ART (p = .442) or PIs (p = .678) were not associated with the 
metabolic syndrome. While the prevalence of the syndrome was highest amongst the 
older, larger and fatter participants, WC was the best predictor of the metabolic 
syndrome (p = .001). Another novel finding was that participants with the metabolic 
syndrome had greater arm muscle circumference (AMC) (p = .000) and arm muscle 
area (AMA) (p = .000), but the former was most influential. Accordingly, the easiest 
and cheapest indicator to assess risk in this study sample was WC should routine 
laboratory services not be feasible. In addition, the final study illustrated that the 
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prevalence of the metabolic syndrome in participants receiving ARVs was not 
different from that of HIV-infected ART-naïve participants. 
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Chapter 1:  INTRODUCTION 
1. Introduction 
Before a description and discussion on nutritional status and body composition, it is 
worth giving an outline on some of the nutritional manifestations notable among 
HIV-infected population to date. Specifically, the chapter outlines the background 
(Sections 1.1) and context (Section 1.2) of the study, the overarching aims of the 
study (Section 1.3), and the significance of the research (Section 1.4). 
 
1.1 Background to nutritional status and body composition in PLHIV  
Early evidence suggested that HIV infection has a direct effect on nutritional status 
(Kotler, 2000), as despite the maintenance of an ‘ideal’ body weight, body 
composition status may be affected. More recently, evidence shows that one of the 
direct effects is lipid abnormalities and fat re-distribution (lipodystrophy), and these 
appear to be more common in HIV patients (Gallagher, 2007) than in the general 
population. Lipodystrophy can occur to any patient, whether individuals are on 
treatment or not (Robinson, 2004), thus, long-term infection is implicated (Mondy et 
al., 2007). However, HAART is responsible for compounding any existing risk 
factors (Villarroya et al., 2007). Problems of lipodystrophy have been determined in 
patients on PIs (Grinspoon & Carr, 2005), NRTIs (Griensven et al., 2009) as well as 
NNRTIs (Miller et al., 2003). Coupled with the class of drugs, the problem is worse 
among patients on prolonged AIDs treatment (Han et al., 2009). Collectively, all 
these show that there is no single factor implicated in the aetiology of lipodystrophy 
in persons with HIV. 
 
In addition, lipodystrophy may encompass subcutaneous fat loss (lipoatrophy) and/or 
fat accumulation (lipohypertrophy) in the same individual (National AIDs Manual, 
NAM, 2009). Specifically, one patient may show lipoatrophy (fat loss) in the face 
and arms, and an enlarged fat pad in the dorsocervical area (Villarroya et al., 2007; 
Grinspoon and Carr, 2005). Even when lipodystrophy has been seen in perinatally 
HIV-infected older children (Arpadi et al., 2009), problems of lipoatrophy have also 
been associated with older age and being female (Chariyalertsak et al., 2008). 
Lipoatrophy was earlier reported in as many as 14% of infected persons (Worm et al., 
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2002) and has much more recently been seen to have more than doubled (Mutimura 
et al., 2009). 
 
Sadly, fat re-distribution exists together with the metabolic syndrome. For instance, 
metabolic syndrome was determined in 45% of the infected persons vs. 19% of those 
with no infection (Johnsen et al., 2006), as was earlier reported in 45% vs. 15% 
(Hadigan, 2003). While linked to HAART (Jerico et al., 2005), the syndrome has 
also been determined in HIV-infected but naïve patients (El-Sadr et al., 2005). Thus, 
two outstanding debates remain here, one on whether the metabolic syndrome is 
associated with HIV infection, and the other on the definition of the metabolic 
syndrome itself (Pao et al., 2008). Among the varied definitions for the metabolic 
syndrome is that given by the IDF (2006), the National Cholesterol Education 
Program (NCEP), ATP III, the American Association of Clinical Endocrinologists 
(AACE) as well as the European Group for the study of Insulin Resistance (EGIR) 
among others. With or without a single definition for the syndrome, the distribution 
of body fat can influence disease risk (Gallagher, 2007) such as type 2 diabetes 
mellitus (DM) (Smith and Ravussin, 2002), cardiovascular disease (CVD) (Rashid et 
al., 2003) and cancer (Calle et al., 2003). Additionally, people with the metabolic 
syndrome are twice as likely to die and three times as likely, to have a heart attack or 
stroke compared to people without the syndrome (Isomaa et al., 2001). Early 
detection and screening may prevent or reduce associated mortality and morbidity. 
 
It is also important to note that body weight alone does not provide any detail 
regarding the relative contributions of body fat and muscle (Heitmann and Garby, 
2002). Consequently, the use of body weight alone to gauge nutritional status can be 
very misleading. Thus, it is critical to monitor the body composition of populations at 
risk, including PLHIV, to enable appropriate nutrition and clinical decisions and 
prevent an exacerbation of the effects of the disease and its medication. Lipid 
abnormalities can best be determined by assessing body composition. However, only 
the accurate measurement of the body composition will enable a precise 
determination of TBW and the relative amounts of fat and lean tissue that comprise 
an individual’s body weight and thereby enable the most appropriate nutrition and 
other treatment decisions. Decisions on necessary lifestyle modifications include a 
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healthy diet, regular exercise, reduced smoking and alcohol consumption as well as a 
reduction in the use of other forms of drugs.  
 
On a whole, body composition is different components that when taken together 
makes up a person’s body weight, said to be the amount of lean tissue compared to 
fat (Shah and Bilal, 2009). Body composition, divided into different compartment 
models has a two-component model that divides the body into fat and lean tissue, or 
FFM as is the case for the earlier commonly used techniques involving 
anthropometry and hydrodensitometry (Ellis, 2001). A three-compartment model 
therefore, further divides lean mass (the FFM) into skeletal and non-skeletal 
components. While a four-compartment model additionally divides the lean body 
mass into extracellular (connective tissues and extracellular water) and intracellular 
components (the body cell mass) (De Lorenzo et al., 2004). Once FFM is determined, 
then body fat indirectly is the difference between body weight and FFM (Ellis, 2000). 
The estimation of TBW is based on the fact that the hydration of the FFM is 
generally very constant in normal healthy adults and approximates 73%, although 
ranges from 67 to 80% (Chumlea et al., 2001).  
 
Commonly in use, are simple indicators such as BMI, WC, WHR (WHO, 2000), and 
the sum of several skinfold thickness measurements. The use of skinfold thickness 
measurements assumes that under normal conditions, a relatively constant amount of 
body fat is in the subcutaneous tissues (Durnin and Womersley, 1974). The latter 
sum could reflect total body fat. The technique has also commonly been associated 
with selected circumferences or girth measurements to estimate the cross-sectional 
area of the trunk or limbs and reflect both body fat and skeletal muscle development 
(Durnin and Rahaman, 1967). The use of individual or sum of skinfold 
measurements have an additional advantage over estimated percent body fat from 
equations (generally utilizing selected skin folds) in that they can provide a general 
view of the fat distribution pattern across the body. These techniques do not require 
expensive equipment; however, major limitations are that they are operator-
dependent and difficult to standardize (Ellis, 2000). Thus, once measured, body 
composition can overcome some of the limitations posed by the common indicators. 
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Body composition can be measured using a range of techniques including 
anthropometry, hydro-densitometry and air-displacement plethysmography for 
measuring body density, three-dimensional body scanning, deuterium dilution 
technique for TBW, whole-body counting and neutron activation analysis, dual-
energy x-ray absorptiometry (DXA), computed tomography (CT), magnetic 
resonance imaging (MRI) and the BIA (Ellis, 2000). Unfortunately, information is 
still lacking on the topic; the technique(s) is seldom among populations from 
resource-limited settings. Body composition (Ellis, 2000), including the use of the 
deuterium oxide dilution technique and the BIA, provide a useful clinical alternative 
to the simple anthropometric measures including body weight. Elsewhere, 
bioimpedance vector analysis may be able to detect altered electrical properties of 
tissue in ill subjects and provide a better indication of prognosis than weight loss 
(Kyle et al., 2004). Detailed descriptions of body composition and compartment 
models are provided in the next chapter. 
 
As the HIV/AIDs pandemic continues, more studies to help understand the 
nutritional status of PLHIV including to affirm previous findings, some of which are 
contradictory remain vital.  Furthermore, the presence of disease such as AIDs may 
affect the normal characteristics of body tissues (Shah and Bilal, 2009), the basis of 
anthropometric measures. Anthropometric techniques alone may not be sufficiently 
sensitive to detect small changes in body composition. Moreover, this was the 
overarching objective for selecting to compare the usual clinical tools for assessing 
nutritional status and the deuterium oxide dilution technique, often regarded as the 
reference technique. Thus, it is very important to determine fat and lean body masses 
by direct measures, rather than relying on BMI alone, especially while describing 
obesity and malnutrition-related mortality risk and clinical outcomes (Kyle et al., 
2004). Moreover, at the time of conducting this study, there were no known 
comprehensive studies undertaken regarding the nutritional status of PLHIV in 
Uganda. More specifically, there was minimal access to research data on 
anthropometry and body composition of this population, including relationships 
between the body composition and medication profile and documentation of 
components of the metabolic syndrome. 
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1.2 Context 
Due to potential human and economic costs of ill health, knowing one’s disease risk 
and moving quickly to prevent further deterioration in or development of health 
problems becomes an imperative to long-term survival. Justification for further 
research was associated with the variability in reports on HIV prevalence in Uganda 
(detailed in the literature review), as the country remains at risk of increasing HIV 
prevalence (Uganda report, 2008). The need for change was noted most recently 
(UDHS, 2011) when men aged 15‐49 years reported having sex in the year prior to 
the national survey indicated that 19% had ≥2 sexual partners yet among this group 
only 19% reported using a condom the last time they had sex. Moreover, the survey 
found that participants had an average of 6.4 sexual partners over the course of their 
lifetimes. Another justification for the study was associated with knowledge gaps in 
the nutritional status and body composition between infected persons receiving ART 
and the ART-naïve (Grunfeld et al., 2008; Villarroya et al., 2007). It was also 
important that this study utilized valid and reliable body composition techniques in 
the HIV-infected Ugandan population where HAART was scaled-up prior to 
undertaking the study activities. 
1.3 Overarching aims, purposes and study hypotheses 
The assumptions underlying the traditional methods for estimating body composition 
may not be valid in patients with HIV infection where body composition is likely to 
be different from that of the wider population. Thus, the overall objective of the study 
was to assess nutrition and body composition of the participants, presence of 
lipodystrophy and metabolic syndrome and their associated risk factors. Specifically, 
this study aimed at establishing the nutrition and body composition status using a 
comprehensive anthropometric protocol that included skinfold thickness and 
circumference (girth) measures, and calculated anthropometric indices including the 
BMI and the ratios (WHR and WHtR). Furthermore, the study aimed at assessing 
TBW, and subsequently FFM and FM, using the BIA and deuterium oxide dilution. 
A second aim was to compare percent body fat predicted from the anthropometrics 
(BMI and skinfold thickness measures) and the BIA techniques against that estimated 
by deuterium oxide dilution technique. The purpose of this was to enable us establish 
the validity of the usual techniques in ongoing field and clinical assessments of body 
composition where the use of the deuterium method may be prohibitive. A third aim 
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was to assess the prevalence of the components to and the metabolic syndrome, and 
associated risk factors of the syndrome. A final aim was to assess for presence and 
risk factors of lipodystrophy. The purpose of these was to contribute to the debate of 
whether the two problems exist and indicate the risk factors. 
 
Thus, the study hypothesised that the mean nutritional status and predicted percent 
body fat values of study participants was within acceptable ranges. A second 
hypothesis was that the nutritional status and predicted percent body fat of 
participants receiving ARVs was not different from that of HIV-infected ART-naïve 
participants. A third hypothesis was that percent body fat estimated by 
anthropometric measures (BMI and skinfold thickness) and the BIA technique was 
not different from that predicted by deuterium oxide dilution technique. A fourth 
hypothesis was that the prevalence of the metabolic syndrome in participants 
receiving ARVs was not different from that of HIV-infected ART-naïve participants. 
Finally, we hypothesised that the presence of lipodystrophy in participants receiving 
ARVs was not different from that of HIV-infected ART-naïve participants. 
1.4 Significance of the study 
Results of this study should inform nutritionists and clinicians on the relative value 
of various measurements in assessing nutritional status and body composition of 
HIV-infected persons and consequently assist in the provision of improved care. In 
addition, the results should also highlight the relationship between HIV as well as 
AIDs medication status and the problems of lipodystrophy and the metabolic 
syndrome. Importantly, findings will contribute to an increase in our knowledge and 
understanding of the disease process and the application of research findings in the 
field context. 
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Chapter 2:  LITERATURE REVIEW 
2. Introduction 
This chapter will provide a background to the problem of HIV and ART (Section 2.1) 
plus a review of literature on HIV/ AIDs and lipodystrophy  (Section 2.2); HIV/ AIDs 
and biochemical alterations (Section 2.3), and Nutritional status and body 
composition plus techniques used in assessing HIV-infected persons (Section 2.4). 
The review is devoted to the techniques of central relevance to the study. Finally, 
Section 2.5 highlights the implications from the literature influencing this study. 
 
2.1 Background to HIV and antiretroviral therapy/ treatment 
2.1.1 What is HIV? 
Human immunodeficiency viruses infect cells of the immune systems, destroying or 
impairing their function. Infection with the virus results in the progressive 
deterioration of the immune system, leading to "immune deficiency." The immune 
system is deficient when it can no longer fulfil its role of fighting infection and 
disease. "Opportunistic infections" are infections associated with severe 
immunodeficiency; because they take advantage of a weakened immune system 
(WHO, 2009). 
2.1.2 What is AIDs? 
Acquired immunodeficiency syndrome is a surveillance term defined by the US CDC 
and by the European Centre for the Epidemiological Monitoring of AIDS (EuroHIV). 
Therefore, the term AIDs applies to the most advanced stages of HIV infection. This 
happens by the occurrence of any of more than 20 opportunistic infections or HIV-
related cancers (WHO, 2009; CDC, 1993). 
2.1.3 How quickly does a person infected with HIV develop AIDs? 
The length of time can vary widely between individuals and if left untreated, the 
majority of people infected with HIV will develop signs of HIV-related illness within 
5 - 10 years (WHO, 2009). The WHO adds that, the time between HIV infection and 
an AIDS diagnosis can be 10 – 15 years, or sometimes longer. At such a time, there 
is ‘uncontrolled’ viral replication thus a progressive drop of the peripheral blood 
CD4þ T lymphocyte count, by an average of 50 – 100 cells/ mm3 per year (Rodriguez 
et al., 2006). Antiretroviral therapy can slow the disease progression by decreasing an 
infected person’s viral load resulting affecting the peripheral blood CD4þ cell count; 
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the latter will not only stop dropping, but will recover, at least partially (Kelley et al., 
2009; Garcia et al., 2004). 
2.1.4 Antiretroviral therapy 
Human immunodeficiency virus is a retrovirus, meaning that it needs cells from a 
"host" in order to make more copies of itself (replication). In this case, CD4 cells are 
the host cells that aid HIV in replication. HIV attaches to the CD4 cells, allowing the 
virus to enter and infect the CD4 cells, damaging them in the process. The fewer the 
functioning CD4 cells, the weaker the immune system and therefore the more 
vulnerable a person is to infections and illnesses (so called opportunistic infections). 
One of the essential proteins needed for HIV replication is an enzyme called reverse 
transcriptase. Reverse transcriptase helps the single stranded ribonucleic acid (RNA) 
convert to the double stranded deoxynbonucleic acid (DNA). Deoxynbonucleic acid 
is the essential building block of all life, including HIV. Nucleoside reverse 
transcriptase inhibitor (a certain ARV class) or "nukes" block reverse transcriptase, 
preventing the transformation from RNA to DNA. Without the DNA, HIV is unable 
to make functional copies of it and its proliferation in the body ceases. 
 
Standard ART consists of the use of at least three ARV drugs to maximally suppress 
the HIV virus and stop the progression of HIV disease (Garcia et al., 2004). 
Accordingly, ART enables a prolongation of life in HIV-infected persons (Palella et 
al., 2010; El Sadr et al., 2008; Antiretroviral Therapy Cohort Collaboration (ATCC, 
2008), reduce morbidity and improve their quality of life. Therefore, issues related to 
ART in resource - limited settings seem to have become increasingly relevant to 
PLHIV, caregivers, service providers and programmers (Castleman et al., 2003) for 
similar reasons. For instance, in Uganda, access to ARVs increased in the past, 
among PLHIV (Uganda report, 2007), as was the case in other developing countries 
and the world at large, the result of local, national and international efforts (Ford et 
al., 2009). For example, United States Agency for International development 
(USAID) initiated projects that provided ARVs in Sub-Saharan Africa, and a key 
objective of the former US President’s emergency plan for AIDS relief (PEPFAR) 
was to treat two million HIV-infected people by the end of 2008. The US CDC, the 
Global Fund for AIDS, TB and Malaria and other groups supported efforts to expand 
access to ARVs in developing countries with funding extended beyond 2008 
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(Uganda report, 2008). As access to these drugs increases, so does chances of 
survival but also the possibility of side effects increases. One of the major side 
effects is lipodystrophy, a syndrome associated with HAART in the context of HIV 
infection. Lipodystrophy was identified as issue over a decade ago (Saint-Marc et al., 
2000; Carr et al., 1998) however there is a relatively poor understanding of the 
condition in the Ugandan context. Current HAART consists of major treatment 
modalities (Table 1).  
 
Each of the classes of ARVs (Table 1) ‘attacks’ a different site or stage of the HIV 
life cycle, thereby interfering with its reproduction (Hammer et al., 2002). For 
instance, NNRTIs stop HIV production by binding directly onto the reverse 
Transcriptase enzyme (one of the essential proteins needed for HIV replication), thus 
preventing the conversion of RNA to DNA (King, 1996).  Nucleoside/nucleotide 
reverse Transcriptase inhibitor incorporates themselves into the DNA of the viruses, 
thereby stopping the building process. The resulting DNA is incomplete and cannot 
create new viruses. Nucleoside/nucleotide reverse Transcriptase inhibitors act at the 
same stage of the viral life cycle as the NRTI's do. Protease inhibitors work at the last 
stage of the virus reproduction cycle, prevent assembling of HIV, and release from 
the infected CD4 cell (Roberts et al., 1990; Karacostas et al., 1989). Although the 
introduction of HAART has greatly reduced HIV-related morbidity and mortality, 
one of the principal long-term complications is fat redistribution (Worm et al., 2009; 
Lichtenstein, 2005; Grinspoon, 2005); coupled with other side effects (Table 1).  
 
Table 1: Classes and side effects of ARVs  
NNRTIs Possible side effects 
Efavirenz (EFZ) Elevated blood cholesterol and triglyceride levels, plus rash, dizziness, 
anorexia, nausea, vomiting, diarrhoea, dyspepsia, abdominal pain and 
flatulence 
Nevirapine (NVP) Nausea, vomiting, rash, fever headache, skin reactions, fatigue, stomatitis, 
abdominal pain, drowsiness, pares thesia, plus high hepatotoxicity 
NRTIs  
Abacavir (ABC) Nausea, vomiting, fever, allergic reaction, anorexia, abdominal pain, 
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diarrhoea, anaemia, rash, hypotension, pancreatitis, dyspnoea, weakness, 
insomnia and cough 
Didanosine (ddI) Anorexia, diarrhoea, nausea, vomiting, pain, headache, weakness, 
insomnia, rash, dry mouth, loss of taste, constipation, stomatitis, anaemia, 
fever, dizziness, pancreatitis 
Lamivudine 
(3TC) 
Nausea, vomiting, headache, dizziness, diarrhoea, abdominal pain, nasal 
symptoms, cough, fatigue, pancreatitis, anaemia, insomnia, muscle pain, 
rash 
Stavudine (d4T) Nausea, vomiting, diarrhoea, peripheral neuropathy, chills and fever, 
anorexia, stomatitis, anaemia, headaches, rash, bone marrow suppression, 
pancreatitis and may increase the risk of lipodystrophy 
Tenofovir (TDF) Abdominal pain, headache, fatigue and dizziness 
Zidovudine 
(ZDV/AZT) 
Anorexia, anaemia, nausea, vomiting, bone marrow suppression, headache, 
fatigue, constipation, dyspepsia, fever, dizziness, dyspnoea, insomnia, 
muscle pain, rash 
Emitricitabine 
(FTC) 
Vertigo, insomnia, diarrhoea, nausea, vomiting, abdominal pain, pruritus 
(severe skin itching), urticaria (red, itchy areas of skin), anaemia (low red 
blood cell count) 
 
PIs  
Indinavir (IDV) Nausea, abdominal pain, headache, kidney stones, taste changes, vomiting, 
regurgitation, diarrhoea, insomnia, ascites, weakness, dizziness and may 
increase the risk of lipodystrophy 
Lopinavir (LPV/r) Abdominal pain, diarrhoea, headache, weakness, nausea and may increase 
the risk of lipodystrophy and diabetes 
Nelfinavir (NFV) Diarrhoea, flatulence, nausea, abdominal pain, rash and may increase the 
risk of lipodystrophy 
Ritonavir (RTV) Nausea, vomiting, diarrhoea, hepatitis, jaundice, weakness, anorexia, 
abdominal pain, fever, diabetes, headache, dizziness and may increase the 
risk of lipodystrophy 
 Saquinavir 
(SQV) 
Mouth ulceration, taste changes, nausea, vomiting, abdominal pain, 
diarrhoea, constipation, flatulence, weakness, rash, headache, insomnia and 
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may increase the risk of lipodystrophy 
Atanavir (ATV) At the start of treatment, there is possibility of skin problems, jaundice 
(yellow colouring of the skin or eye, cause by an increase in levels of 
bilirubin in the blood) that is not harmful. Moreover, during treatment 
diarrhoea, nausea, abdominal pain, headache and fatigue may occur. 
Sources: Nerad et al., 2003; WHO, 2003; Pronsky et al., 2001. 
 
In addition, metabolic disorders (Haubrich et al., 2009) including fasting triglyceride 
level of ≥ 150 mg/ dL; HDL cholesterol level of ≥ 40 mg/ dL in men or ≥ 50 mg/ dL 
in women; Blood pressure of ≥130/ 85 mm Hg; fasting glucose level of ≥110 mg/ dL. 
In addition, insulin resistance and overt diabetes have been confirmed (De Wit et al., 
2008) in this population. In a 24-month cohort study to assess correlates of risk of 
lipodystrophy over time, Galli et al. (2003) found that about 55% of women on 
treatment developed adipose tissue alterations (ATAs). The ATAs were 
independently correlated with use of PIs in the initial 12 months (OR 2.81, p = .002) 
but by the end of 24 months, ATAs significantly related to overall duration of ART 
(OR 1.85, p = .041). Fat redistribution can lead to fatal biochemical effects as 
illustrated in more detail in the following pages however, morphological changes also 
present significant psychosocial challenges, particularly in terms of self-esteem 
(Robinson, 2004; Huang et al., 2006). 
 
Furthermore, it is worth noting that the majority of the pharmacological agents to 
ameliorate many of the effects by HAART adds significantly to healthcare utilization 
and costs (Huang et al., 2008) and the pill burden which negatively affects treatment 
adherence (Ammassari et al., 2002; Robinson, 2004). In a study to evaluate the 
longitudinal relationship between ATAs and adherence to HAART, Ammassari et al. 
(2002) reported that independently, self-perceived ATAs at baseline related to 
subsequent non-adherence. It is important to be able to identify such undesirable 
effects (Table 1) early during patient care and potentially offer different therapies 
where need be, such as general wellness programs. 
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Recommended starting (first line) regimens for adults and adolescents 
A 3-drug combination should be in use in initiating ART (Republic of Uganda, 
2003); this combination may contain two NRTIs plus one NNRTI or a PI. 
Combinations containing a PI are more powerful but more expensive. 
Recommended two first line regimens (Table 2) are quite powerful and reasonably 
priced. This ART initiation recommendation is for never exposed patients or those 
who had been on treatment but stopped all drugs at once for more than three 
months. 
 
Table 2: Recommended first line ART regimens for adults and adolescents in 
Uganda. NOTE: First line regimens combine NRTIs and NNRTs. 
Regimen Pregnancy and TB considerations 
ZDV/ 3TC + NVP or 
EFZ 
Give NVP in pregnant women or women for whom effective 
contraception cannot be assured 
OR 
d4T/ 3TC + NVP or 
EFZ 
Give EFV for patients requiring simultaneous ARV treatment 
and TB therapy containing Rifampicin 
Recommended second line regimens in adults and adolescents. Second line regimens 
are a combination of either NRTI/ NNRT and a PI. 
First line regimens Second line regimens for treatment failure 
ZDV/ 3TC + NVP or 
EFZ 
d4T/ ddI + LPV/r 
d4T/ 3TC + NVP or 
EFZ 
ZDV/ ddI + LPV/r 
 
Recommended are also fixed combinations containing the above drugs, as they may 
be cheaper, user friendly and facilitate better adherence because of low pill burden. 
Such combinations include ZDV/ 3TC and d4T/ 3TC/ NVP. Some of these fixed 
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combinations are available as generics and may be cheaper than branded names. In 
addition, recommended first line regimens should cover majority of patients at 
national level. There is consideration for different combinations, for various 
reasons, and the attending doctor must decide here. The use of one of the NNRTIs 
as the third drug makes the recommended first line regime less expensive, provides 
option to use a PI at a later date, preserves safety during pregnancy except for EFZ 
and allows to treat TB co-infected patients who are on Rifampicin with EFZ 
containing regimens. 
 
Recommended second line ART regimens for adults and adolescents 
Patients experiencing treatment failure can switch from a first line to a completely 
different second line combination regimen. There are two recommended options for 
second line regimens (Table 2). For economic reasons and for the simplicity of 
administration, only LPV/r (a PI) is in use for second line regiment for treatment 
failure (Uganda, 2003). LPV/r combined with low dose RTV is potent and well 
tolerated. On the negative side, experience in pregnancy is limited, and the drug is 
incompatible with Rifampicin. However, other PIs are available on the market can 
be used as alternatives to LPV/r. These include NFV. The latter is an alternative for 
the PI component of second line therapy if a boosted PI is not available or clinically 
contraindicated. Take Indinavir twice a day. Combine with low dose RTV for 
pharmacoenhancement and this is incompatible with Rifampicin. The pill burden is 
6 - 8 tablets/ day (800 mg 8-hourly or 12-hourly if combined with RTV 100 mg) and 
the patient needs to take plenty of fluids to avoid renal stones. In addition, there is a 
need to refrigerate RTV for longer-term stability. Administered SQV combined with 
low dose RTV once or twice a day is also compatible with Rifampicin. Its 
disadvantage is the need for refrigeration of current RTV formulation for stability 
beyond 30 days. 
 
Changing for treatment failure 
Treatment failure can be defined as clinical, immunologic and/ or virology failure. 
Clinical failure is a clinical disease progression with development of an 
opportunistic infection or malignancy. This usually happens at least six months 
from drug initiation to induce a protective immune system restoration. Immunologic 
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failure on the other hand is a fall in CD4 counts more than 30% on two or more 
occasions from the peak value or a return to, or below, the pre-therapy baseline. 
There is no accepted definition of immunologic failure in the absence of CD4 
counts. Virology failure has no uniformly accepted definition but continued 
detectable viremia is indicative of incomplete viral suppression. Measuring viral 
load is not an option in the majority of service-care provision centers in Uganda. 
Some of the drugs in ART have been identified as having more side effects than 
others (Haubrich et al., 2009) have. Even when WHO (2009) recommended 
avoiding combinations with d4T due to the potential disfiguring, unpleasant and 
life-threatening toxicity of this drug, several health facilities in resource constrained 
settings like Uganda still use the drug. In many cases, choice of ARV regimen is 
determined by cost and availability in spite of the risks and toxicity that some drugs 
may pose (Ford, 2009). One may conclude that quality of life issues are not a 
priority (Gatell, 2010) in settings such as in Ugandan. Otherwise, such toxic drugs 
would not be part of the recommended medications in that country. It is therefore of 
great importance to be able to evaluate changes in nutritional status and body 
composition that occur as the disease advances in PLHIV, common in developing 
countries.  
 
In brief, the use of ARVs continues to scale up despite the knowledge of the 
numerous associated side effects; including potential lipid abnormalities. Therefore, 
there is an important need to review the known abnormalities and explore 
associations between these health problems and medication status. The next section 
provides an overview of the problem of lipodystrophy. 
 
2.2 HIV and lipid abnormalities/ lipodystrophy 
2.2.1 Defining lipid abnormalities/ lipodystrophy 
Lipid abnormalities are often manifested in a number of physical changes; the 
appearance of a buffalo hump; increased fat deposition in the abdomen, breasts and 
visceral adipose tissue; and decreased fat deposition in the face, arms, legs and 
buttocks (Grinspoon, 2005), a condition referred to as lipodystrophy. Lipodystrophy 
is subcutaneous fat loss (lipoatrophy) or fat accumulation/ gain (lipohypertrophy). 
The two conditions may present in a patient at the same time, but fat from the 
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periphery is not necessarily moving to the central stores (NAM, 2009). In the re-
known FRAM study, results show no correlation between changes in central fat and 
peripheral fat in HIV-infected men, measured either by self-report or physical 
examination (Bacchetti et al., 2005). In fact, the amount of central accumulation of 
fat was equivalent in HIV-infected men and comparison men without HIV, and 
peripheral fat loss did not necessarily correlate with central fat loss. The study 
authors concluded that central fat accumulation and peripheral fat loss are not 
reciprocal processes; meaning that there is probably no "relocation" of fat between 
these two depots. NAM (2009) defines lipoatrophy as involving loss of fat in the 
face, extremities, buttocks and subcutaneous tissue of the abdominal area. Overtime, 
this fat accumulation presents in the neck and back area, abdomen and breasts. Not 
all the alterations have to occur together in the same person or with the same 
frequency. For example, subcutaneous loss of adipose tissue occurs relatively 
frequently, whereas the dorsocervical lipomatosis is more unusual. However, one 
patient may show lipoatrophy in the face and arms, and an enlarged fat pad in the 
dorsocervical area (Villarroya et al., 2007; Grinspoon and Carr, 2005).  
2.2.2 What is the cause of lipodystrophy? 
The etiology of lipodystrophy remains poorly understood, however, the recognition 
of lipodystrophy in HIV-infected patients occurred soon after the introduction of the 
PI drugs in HAART regimes, and this led to the first assumption that these drugs 
caused the syndrome. Despite these concerns, to date, there is not so much 
information about the causes of lipodystrophy, but, certain ARVs, such as PIs 
(Martinez et al., 2001) and intergrase inhibitors (Haubrich et al., 2009), among 
others, have been found to lead to the development of the problem. Problems of 
lipoatrophy have also been previously associated with older age, being female 
(Chariyalertsak et al., 2008; Homsanit et al., 2007; van Griensven et al., 2007; 
Jacobson et al., 2005), as well as length of time on AIDs treatment (Han et al., 2009; 
van Griensven et al., 2007). Cohort studies comparing HIV-infected patients’ 
subcutaneous adipose tissue (SAT) before and after ART, initiations have provided 
important pathways for the development of lipodystrophy. Several in vitro, ex vivo 
and in vivo experiments have shown that some drugs from the two classes are 
directly toxic to adipose tissue and could act in synergy to produce complex clinical 
and biological alterations (Villarroya et al., 2010). Most of the PIs exert direct effects 
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on adipocytes. The drugs generally cause the degeneration of the lining of the adipose 
tissue, thus increasing the probability of developing lipodystrophy due to abnormal 
functioning of the adipose tissue (Caron-Debarle et al., 2010). In studies of adipose 
tissue from HIV-infected naive patients, increased expression of pro-inflammatory 
cytokines take place in subcutaneous adipose tissue in the absence of treatment or 
overt lipoatrophy, simply because of HIV- infection (Giralt et al., 2006). Some parts 
of the body seem to be more susceptible to the problem than the other parts. 
Subcutaneous adipocytes are more susceptible to the deleterious effects of PIs than 
visceral adipocytes (Kovsan et al., 2009).  
 
Various other common factors such as insulin resistance or rejection, increased 
levels of lipids and cholesterol and HIV infection are major factors contributing to 
the development of lipodystrophy (NAM, 2009). Soon after the introduction of PIs in 
1996, patients developed a syndrome of fat redistribution with peripheral loss and 
central gain, generally associated with metabolic abnormalities and insulin resistance 
(Grinspoon and Carr, 2005). Although lipodystrophy is said to occur in some 
treatment-naive patients (Huang et al., 2001; Miller et al., 2003; Patella et al., 2004), 
HAART is considered responsible for compounding any existing risk factors (Carr et 
al., 1998; Saint-Marc et al., 2000; Villarroya et al., 2007). Protease inhibitors are 
responsible for impairment in the ability of certain enzymes responsible for mopping 
up excess fat and keeping fat cells functional. This, in turn, would account for the 
high levels of lipids seen in some PLHIV. This might also explain why fat 
accumulates around the gut, breasts, or neck. Nucleoside reverse transcriptase 
inhibitors linked to lipoatrophy [Zerit (that contains d4T) and Retrovir (that contains 
AZT)] may too lead to reduced insulin sensitivity and diabetes (NAM, 2009). There 
is clinical evidence linking d4T (NRTI) and the development of lipoatrophy 
(Villarroya et al., 2010, Griensven et al., 2009; Wohl et al., 2006). Six months of 
treatment with AZT increases visceral adipose tissue (VAT) and alters the expression 
of several key mitochondrial electron transport genes in SAT, which leads to 
increased oxidative stress (Boothby et al., 2009). For patients changed to ZDV, a 
progressive weight loss was seen while those on TDF/ABC showed a progressive 
weight increase from six months. In the latter study, the between-group difference in 
weight evolution was significant from nine months (difference at 12 months: 2.3 kg, 
  
 Page 17 
p = 0.02) (Griensven et al.,2009), when they assessed weight gain as a proxy for 
recovery after d4t substitution due to lipoatrophy. Their study justified earlier 
substantiation and access to better alternatives like TDF/ ABC. Because switching 
patients from d4T to TDF; or NVP, plus LPV/r improves fat mitochondrial function 
and decreases oxidative stress (Gerschenson et al., 2009); Negredo et al., 2009). 
These NRTIs exert severe adverse effects involved in lipoatrophy and once replaced, 
with little to no potential to induce mitochondrial dysfunction allows for the partial 
recovery of lipoatrophy or even causes fat hypertrophy (Caron-Debarle et al., 2010). 
In addition, this has resulted in removal of the very drug from the list of first-line 
ART in western (Ford et al., 2009), but not necessarily in developing countries. For 
long, NNRTIs have not been pinned for contributing to the problems of 
lipodystrophy. Although initial studies revealed no role for EFZ (NNRTI) in 
lipodystrophy (Miller et al., 2003), clinical associations of extremity fat loss (ACTG 
A5142) study much recently found that lipoatrophy was more frequent with EFZ than 
LPV/r (PI) when combined with NRTIs (d4T or AZT) (Haubbrich et al., 2009). This 
means that there is need to reconsider drug combinations with EFV (a NNRTI), with 
a possibility of combining d4T (a NRTI), with LPV/r (a PI) especially in countries 
that seem to be relying on the former for treating AIDs.  
 
Moreover, a number of ART-naive patients display increased amounts of both limb 
and visceral fat early after initiation of ARVs (Grinspoon and Carr, 2005; Dube, 
2005) and before the appearance of peripheral lipoatrophy. Lipoatrophy is an 
acquired alteration that begins at a time long after adipose tissue and fat storage have 
already developed. There is generally an early drug-induced mitochondrial 
dysfunction which could lead to an initial increase in SAT before fat loss associated 
with more advanced and severe mitochondrial dysfunction (Calmy et al., 2008); 
meaning that examinable problems of lipoatrophy may occur after 12 months from 
start of medication. It is important that research inclusion criteria consider this fact 
especially where rudimentary means of assessing the problem are the most feasible. 
Since the infection has its own contribution to lipodystrophy, change of ARVs do not 
necessarily or completely reverse the mechanism that results in the problem. The 
persistent infection of reservoir fat macrophages, probably related to the severity of 
the initial infection, could help maintain the lipodystrophic phenotype (Caron-
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Debarle et al., 2010) in treated patients. Older age is associated with some 
manifestations. Although equally linked to aging (Guaraldi and Baraboutis, 2009), 
long-term-treated adolescents or young adults perinatally HIV-infected have been 
found to also display characteristics of lipodystrophy (Arpadi et al., 2009). 
 
There are reports of a possible role for the virus itself, even before ART initiation. 
Consequently, the infection seems to be contributing to lipodystrophy in other parts. 
There are studies whose outcome shows that the severity of HIV infection is 
associated with an increased prevalence of lipodystrophy (Jacobson et al., 2005; 
Grinspoon and Carr, 2005). Lipodystrophy may be rare in ART-naive patients (Miller 
et al., 2003), but HIV infection of macrophages itself could result in low-grade fat 
inflammation and lead to the release of viral proteins that affect neighbouring 
adipocytes and decrease their differentiation (Caron-Debarle et al., 2010); 
consequently, cytokine production increases and adipogenesis decreases which could 
induce limited lipoatrophy. Consequently, both HIV, a conditioned worsened by 
ARVs are capable of differentially altering fat development depending on the 
environment and physiology of the different depots. In addition, in the case of 
lipoatrophy, because subcutaneous adipocytes cannot store triglycerides, non-
lipoatrophic fat depots such as VAT probably buffer the increases in FFA, which 
worsens lipohypertrophy (Caron-Debarle et al., 2010). It is reasonable to consider 
studies on the infection itself in contribution to lipodystrophy.  
2.2.3 How is lipodystrophy diagnosed/ assessed? 
Despite an understanding of what constitutes the problem of lipodystrophy, there is 
still an absence of a uniform definition (Tien and Grunfeld, 2004). Invariably, 
published research refers to the problem as lipoatrophy alone, lipohypertrophy alone 
or a combination of the two (lipodystrophy), through to body shape (Hoffmann et al., 
2008) or morphological alterations. Due to the lack of a standard definition, 
diagnosis may still pose some challenges (NAM, 2009). While a subcutaneous fat 
loss of 20% has been said to be the criterion for fat loss in lipodystrophy (Haubrich et 
al., 2007), others have suggested a range between 40 to 50% (McComsey et al., 
2004; Moyle et al., 2005). Despite the identification of a specific cut-point, the 
situation is of particular concern in poorly developed countries such as Uganda. 
Many patients may have lost considerable subcutaneous fat before presenting for care 
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and it is difficult to estimate how much subcutaneous fat loss has occurred. But 
simple and cost-effective questionnaires and classification approaches are in use in 
clinical practice and have been used for approximately the last decade (Carr et al., 
2003). In addition, objective measures such as anthropometry including skinfold 
thickness measurement (Ketel et al., 2007) plus DXA can assess body fat. In 
resource-constrained settings, the use of DXA is uncommon. Thus, self-report 
approaches combined with clinical examinations are necessary (Womack, 2009). 
Unfortunately, visual inspection on physical examination in some patients may reveal 
abdominal distension since VAT pushes the abdominal musculature forward (Palella 
et al., 2006). The current study opted for a bi-directional approach, through 
participant self-reports to assess lipodystrophy and the use of anthropometry 
(skinfolds and circumference measures) for assessing fat distribution. Standard 
anthropometry was an option since the tests have an advantage of being readily 
available to clinicians (Schwenk et al., 2001). Not long ago, a study in Thailand that 
used a related approach, although did not evaluate anthropometrics, found no 
differences in central fat mass among patients in the different ARV groups (Homsanit 
et al., 2007). To effectively detect PLHIV with high VAT content, some studies have 
used a composite criterion of WC > 75 cm and WHR ≥ 0.90 for women (Kotler et 
al., 2002). Moreover, this is because of the criteria to define visceral adiposity and 
increased CVD risk in adults (Molarius et al., 1998). What we see here is that studies 
of HIV lipodystrophy have relied on several different means of detecting and 
measuring changes in body shapes, but some data remains conservative. 
2.2.4 What is in literature in the area of lipodystrophy? 
The prevalence of this metabolic disorder has been difficult to determine because of 
lack of precise diagnostic criteria. However, 60% to 80% of individuals treated with 
ART had the problem (Heath et al., 2002). In a recent review of articles and abstracts 
on the problem of lipodystrophy in Africa and Asia, Womack (2009) revealed that 
the prevalence of lipodystrophy appears similar in the West, Africa and Asia. In 
addition that this ranges between 0 to 69.6%; yet, earlier research shows that in HIV-
infected individuals, fat redistribution abnormalities are variable, including an overall 
gain in fat mass without corresponding gain in body mass (Silva et al, 1998). For 
instance, about 50% of patients display mixed forms, with the loss of limb fat and 
marked expansion of VAT (Miller et al., 2003). Several researchers including 
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Gallagher (2007), Grinspoon, and Carr (2005) have confirmed this research more 
recently. Another study of lipoatrophy (fat loss) in HIV-infected male patients on 
HAART using a questionnaire and clinical examination reported the problem in 14% 
of the 168 patients who had been on HAART for a median length of 17 months 
(Worm et al., 2002). This finding was consistent with an earlier study where 14% of 
the patients who had been on HAART for a median of 18 months had lipoatrophy 
(Martinez et al., 2001). Moreover, a study in the region reported lipodystrophy in 
34% among 571 individuals placed on WHO-recommended first line ART in 
Rwanda (Mutimura et al., 2007). This prevalence went as far up as 70% after 72 
weeks on ART, of whom 72% presented with peripheral lipoatrophy combined with 
abdominal lipohypertrophy. Accordingly, in lipoatrophic ART-treated patients, who 
were mostly naive at inclusion, the expression of some adipogenic transcription 
factors increases in abdominal SAT after two months, whereas these same factors 
decrease in thigh-level SAT (Kratz M et al., 2009). Central fat hypertrophy in HIV-
infected patients relates to TNF-α circulating level (Lihn et al., 2003) and WC 
(Calmy et al., 2008). To assess lipodystrophy in the study in Rwanda, the use of both 
self-report and clinical confirmation came into consideration. Even then, patterns of 
lipodystrophy have not been widely documented in poorly resourced settings since 
other studies did not give a report on the problem (Boulle et al., 2006; Forna et al., 
2006; Kim et al., 2005). However, it was important to quantify both fat losses and 
gains separately in the sample included in our study since this seems a problem 
elsewhere (Grinspoon, 2005).  
 
The recent landmark FRAM study revealed that clinical features including peripheral 
lipoatrophy, the loss of subcutaneous fat, clinically apparent primarily in the face, 
limbs and buttocks is in fact generalized (Bacchetti et al., 2006) with central 
lipohypertrophy (manifested mainly as increased abdominal girth, and less frequently 
as an enlarged dorso-cervical fat pad; the buffalo hump). In this study, peripheral 
lipoatrophy was more frequent in HIV women (28%) than controls (4%). However, 
central lipohypertrophy was similar. The increase in abdominal girth has widely been 
attributed to increased levels of VAT (Saint-Marc et al., 2000). Problems of 
lipoatrophy have been associated with older age (Grinspoon and Carr, 2005; Miller et 
al., 2003) because aging adipocytes release more pro-inflammatory cytokines than 
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young ones (Wu et al., 2007). The problem has also been associated to being female 
(Chariyalertsak et al., 2008) as well as length of time on AIDs treatment (Han et al., 
2009). To address the confounding effects of aging, Tien et al. (2003) compared the 
incidence of confirmed self-reported lipoatrophy and central lipohypertrophy in HIV-
infected women and HIV sero-negative controls in the WIHS. Whereas the risk of 
peripheral lipoatrophy was more than two times greater in HIV-infected women, the 
incidence of central hypertrophy was identical between the groups. At the same time, 
women were reported to frequently show fat accumulation (Jacobson et al., 2005; 
Galli et al., 2003) than lipoatrophy, especially loss of limb fat (McComsey et al., 
2009). What this may imply is that genetic factors influence the occurrence of 
lipoatrophy and lipohypertrophy. Simply because genetic polymorphisms of genes 
involved in apoptosis and adipocyte metabolism as well as ART-associated 
lipodystrophy are significantly related. Particularly, ApoC3-455 plays a role in 
lipoatrophy and two variants of the adipogenic β2 receptor play a role in fat 
accumulation, whereas PPARg variants are not involved (Zanone et al., 2008). The 
toxicity of the medication also depends on a patient’s metabolism, a genetically 
determined orientation (Rodriguez-Novoa et al., 2006), thus, it is likely the effects of 
HIV infection follow a similar genetic path at an individual level. As a result, the 
factors for each are likely to be different in accordance with the partial independent 
occurrences of these two phenotypes; two genetic factors regulating fat and lipid 
metabolism as well as inflammation and mitochondrial function, in line with the 
pathophysiological alterations postulated for lipodystrophy (Caron-Debarle et al., 
2010). 
 
While lipodystrophy per se is not necessarily physically harmful, it may lead to 
changes in self-image and can cause stigma (Turner et al., 206; Persson, 2005). 
Changes in the neck and abdomen may be unpleasant to many patients and result in 
suffering. For instance, Power et al. (2003) using grounded theory; found that 
patients are often in distress due to physical changes in their appearance, especially if 
they developed facial lipoatrophy. Recently (Villarroya et al., 2010), positron 
emission tomography revealed the presence of brown adipose tissue (BAT) in healthy 
adults at the supraclavicular level. Therefore, the causal relationship between HIV-
linked Buffalo hump in HIV (Villarroya et al., 2009), is in doubt.  However, with or 
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without HIV, such morphologic abnormalities could have a significant impact on 
self-esteem. Yet, a survey among HIV-positive patients in the US found that HIV 
patients with body fat redistribution would trade off length of life or accepted greater 
risks or mortality in order to maintain a life free of body alterations (Lenert et al., 
2002). And 14.8% of participants directly responded that they wanted their ARV 
regimen changed because of lipodystrophy (Chariyalertsak et al., 2008) but this puts 
long-term adherence at risk (Duran et al., 2001). In addition, patients' anxieties 
regarding long-term skeletal and CVD risks can interfere with treatment decisions 
(Hawkins, 2006). Furthermore, unilateral or bilateral breast enlargement (another 
manifestation of lipohypertrophy) which may also occur infrequently in both men and 
women and is due to increased glandular fatty tissue (Mauss, 2000), affects women 
since it is believed that a woman with such features may be ‘labelled’ to have an 
“AIDs look” (Power et al., 2003). In a study to investigate attitudes towards health 
condition, well-being and individual appearance in relation to lipodystrophy 
syndrome, Oette et al. (2002) found that about 30% (with the syndrome) compared to 
approximately 18% (without the syndrome) felt recognizable as HIV-infected patient 
(p = .027). There are variable effects of this problem as well as various estimates of 
the problem due to lack of a standard definition and tools used in its measurement. 
Additionally, Amorosa et al. (2005) reported that obesity and overweight were more 
common than wasting; none the less, they all pose a risk for disease (Currier et al., 
2008; Gallagher, 2007) in this very population. Considering that PLHIV are suffering 
a pill burden, especially in resource poor settings, it would be prudent to diagnose 
lipid abnormalities accurately and early enough to intervene with proper nutrition and 
other therapeutic decisions before the conditions worsens. 
 
Lipodystrophy, or fear of developing it, may affect adherence to ART or the 
willingness to initiate such therapy (Ammassari et al., 2002). While numerous 
studies (Villarroya et al., 2010, Currier et al., 2008; Gallagher, 2007; van Griensvena 
et al., 2007; Bacchetti et al., 2006; etc.) have addressed fat distribution in HIV, more 
work is required. In the literature, there is a significant gap on Africans, particularly 
women, yet one of such studies on HIV-infected Rwandese reported that being 
female was associated with lipoatrophy (van Griensvena et al., 2007). In addition, 
World Bank (1993) asserts that investment in health; particularly women’s public 
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health, can contribute to sustainable economic growth through improving equity and 
quality of life, conferring widespread benefits and improving efficiency. Therefore, 
there is strong justification for an investment in studies of women in this research 
area. As much the problem has much to do with being female, older age is also in 
question (Homsanit et al., 2007; van Griensven et al., 2007). 
2.2.5 What is the gap in the area of lipodystrophy? 
In short, fat redistribution abnormalities exist in association with HIV/ AIDs. 
Treatment for the disease only makes it worse. Hence, there is a relationship between 
lipodystrophy and the medication used to manage the disease. Abnormalities present 
in different forms with some people gaining and others losing body fat and/ or 
displaying it in different patterns, commonly with many associated unpleasant 
features. Few studies in the area reveal much about women, particularly in resource-
limited settings such as Uganda. Findings from the present study have the potential to 
make a significant contribution to our knowledge and understanding of the 
prevalence of lipodystrophy and the risk factors associated with this problem. 
 
2.3 HIV and biochemical alterations 
2.3.1 Defining biochemical alterations 
Metabolic syndrome is an agglomeration of interrelated risk factors that indicate 
individuals at increased risk for type 2 DM and coronary artery disease (CAD) 
(Rosenson, 2005). Defining the syndrome is in a range of ways (Table 3). In addition, 
the NCEP (2002) criterion defines the problem as the presence of three of the 
following (NIH, 2001): -  
i. a WC of ≥ 102 cm in men or ≥ 88 cm in women 
ii. a fasting triglyceride level of ≥ 150 mg/ dL 
iii. an HDL cholesterol level of ≥ 40 mg/ dL in men or ≥ 50 mg/ dL in women 
iv. blood pressure of ≥130/ 85 mm Hg 
v. a fasting glucose level of ≥110 mg/ dL  
 
Since this definition embraces the issue of obesity through the measurement of WC, 
if employed by health workers it is easier to classify those at risk. Other definitions of 
the syndrome include the IDF (2006) and the WHO (Alberti et al., 2005). Insulin 
resistance is a key component in the WHO definition of the problem. However, 
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insulin may not be routine diagnosis in many resource-limited settings. The IDF 
(2006) classification is one of the most appropriate definitions (Alberti et al., 2005). 
The latter definition is globally useful, catering for resource-limited settings. The 
metabolic syndrome encompasses disturbances in glucose, insulin and lipid 
metabolism associated with abdominal obesity (Grundy et al., 2004). The 
inconsistency in definitions leads to inconsistent reporting of results in the same 
population or across populations. Scientists are yet to endorse a single international 
definition for clinical practice and public health context (Greenland, 2005). 
 
The AACE criterion is similar to those outlined but has different cut-off points, and 
no particular number of factors required for diagnosis but including the following: -  
i. high blood pressure (≥ 130 mm Hg systolic or ≥ 85 mm Hg diastolic) or 
taking blood pressure medication 
ii. plasma triglycerides ≥ 150 mg/ dL (≥ 1.7 mmol/ L) 
iii. HDL cholesterol < 40 mg/ dL (< 0.9 mmol/ L) in men or < 50 mg/ dL (1.0 
mmol/ L) in women 
iv. BMI > 25 kg/ m2 
 
Other risk factors include family history of Type 2 DM, high blood pressure, or heart 
disease; ethnic groups with an increased incidence of Type 2 DM, high blood 
pressure, or heart disease; polycystic ovary syndrome, sedentary lifestyle as well as 
advancing age. The American Heart Association (AHA) agrees with AACE, but adds 
WC of more than 88 cm (> 35 in) for women. Additionally, EGIR emphasizes insulin 
resistance plus any other two of the other common factors. In short, debate continues 
on the definition as well as whether the prevalence of the metabolic syndrome 
increases among HIV-infected patients or not (Pao et al., 2008). Many times, most of 
these classifications remain research tools rather than for routine clinical practice 
because of the numerous differences in definition. 
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Table 3: Definitions
*
 of the metabolic syndrome 
 
Risk factor 
IDF
1 
Must have obesity +  any 2 
others
 
ATP III
2 
Have any of the 3 
components below 
WHO
3 
must have impaired glucose 
regulation, diabetes or insulin resistance + ≥ 
2 others  
Obesity 
 
Must: central obesity or BMI 
> 30 kg/ m
2 
WC > 88 cm WHR > 0.85 or BMI > 30 kg/m
2 
Raised triglycerides ≥ 150 mg/ dL ≥ 150 mg/ dL ≥ 150 mg/ dL 
Reduced HDL 
cholesterol 
<5 0 mg/ dL < 50 mg/ dL < 39 mg/ dL 
Raised blood pressure Systolic BP ≥ 130 mm Hg 
/Diastolic ≥ 85 mm Hg 
Systolic BP ≥ 130 mm Hg Systolic BP ≥ 140 mm Hg 
/Diastolic ≥ 90 mm Hg 
Raised fasting plasma 
glucose 
≥ 100 mg/ dL or diabetic ≥ 110 mg/ dL must 
 
1
IDF (2006); 
2
NCEP ATPIII (2002); 
3
Alberti et al. (2005) 
*In the definitions above, cut-off  points for men were deliberately excluded 
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2.3.2 Pathogenesis of metabolic syndrome 
Reaven (1988) first suggested this cluster of metabolic abnormalities more than two 
decades ago. Insulin resistance, visceral adiposity, dyslipidemia and a systemic pro-
inflammatory and pro-coagulant state characterize the cluster. Obesity and inactivity 
promote insulin resistance (Abassi et al., 2002). Consequently, the two are strong 
risk factors for the problem. Stored fat remains not mobilised for as long as there is 
insulin in the blood. This means that diagnosis of the metabolic syndrome enhances 
prediction of diabetes and CVD, if these are not already present. The more resistant 
the tissue the more the need for insulin for normal glucose homeostasis; thus, patients 
with insulin resistance tend to have impaired fasting plasma glucose levels, which 
increase the prevalence of more atherogenic, small dense low-density lipoprotein 
(LDL) particles. The other associated abnormalities include – elevated levels of 
triglyceride-rich lipoproteins along with low levels of HDL cholesterol (Reaven, 
2005). The syndrome is associated with an increased risk of type 2 DM, accelerated 
atherosclerosis and cardiovascular events. Diabetes mellitus becomes inevitable 
when pancreatic beta cell function can no longer keep up with the demand and 
indeed, the grouping of the components of the metabolic syndrome was first 
described in patients with type 2 DM (Gale, 2005). Abdominal fat or accumulating 
adipose tissue, just like has been reported in PLHIV (Blass et al., 2008; Hadigan et 
al., 2001), mostly induces the insulin resistance, a crucial component of the 
metabolic syndrome (Mathieu et al., 2006). On the other hand, it is believed that 
insulin resistance is, unsatisfactory as a core feature of the syndrome as it cannot be 
defined or measured easily and is inconsistently related to the individual features of 
the syndrome (Samaras and Campbell, 2005; Reaven, 2005).  
 
While usingimpaired fasting glucose as one of the components of the metabolic 
syndrome, Blass et al. (2008) reported that it that the problem was observed in 28% 
of HAART-treated patients (21% with PI and 7% non-PI). In addition, the syndrome 
was determined in 13% of HAART-naive patients but none in healthy controls. The 
study continued to report that 58% of PI, 44% of non-PI, 38% of HAART-naive and 
none of healthy controls had a Homeostatic Model Assessment (HOMA) index > 2.5 
that indicates insulin resistance. Moreover, that  HAART-treated patients had 
significantly higher fasting glucose levels (PI: 97 +/- 11 mg/ dL, p = .048; non-PI: 
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109 +/- 58 mg/ dL, p = .009) compared to healthy controls (72 +/- 8 mg/ dL; Blass et 
al., 2008). Insulin resistance more closely relates to central or abdominal adiposity 
(NCEP, 2002). Because adipose tissue exerts systematic effects via substances such 
as free fatty acids (FFAs) that impair signalling in several organs contributing to 
disordered insulin signalling (Johnson and Weinstock, 2006). Thus, fat itself via 
several mediators is one pathologic impetus behind metabolic syndrome (Sattar et al., 
2003). For example, a study of the PI, amprenavir (APV) (in triple therapy HAART) 
found no change in surrogate measures of insulin resistance at 24 weeks (Dube et al., 
2002). However, by 48 weeks, there was a trend towards insulin resistance with 
increased truncal fat and hyperlipidaemia. This may explain the alterations in insulin 
resistance. The syndrome attributes to a double risk for death (Isomaa et al., 2001). 
Furthermore, the problem can lead to a number of other obesity-related diseases, 
including non-alcoholic fatty liver disease (Saito et al., 2007), chronic kidney disease 
(Lastra et al., 2006), polycystic ovary syndrome (Rader, 2007), and obstructive sleep 
apnea (Alam et al., 2007) which could all contribute to an overburdening of health 
care systems in resource-poor settings like Uganda.  
 
A large body of evidence reports that central fat is associated with increases in 
triglycerides and decreases in HDL cholesterol (Wohl et al., 2008). While 
lipoatrophy also associates with high triglyceride levels (Villarroya, et al., 2010; 
Wohl et al., 2008) and patients with lipodystrophy have metabolic alterations similar 
to those in the metabolic syndrome (Samaras et al., 2007) and are consequently at a 
higher risk. Both lower limb lipoatrophy, which reduces the amount of a fat depot 
with protective potential at the metabolic level (Snidjer et al., 2004) and central fat 
hypertrophy probably contribute to the cardiovascular and hepatic complications that 
lead to increased morbidity and mortality. HIV-linked lipodystrophy associates with 
subclinical atherosclerosis, hypertension and increased CVD risk (Grinspoon and 
Carr, 2005). The absolute risk of CVD is not attributable to metabolic syndrome 
alone but rather a composite risk factor profile of the latter, age, gender, DM status, 
family history and other modifiable risks. Some of the modifiable factors include use 
of alcohol, smoking, diet and physical activity level. While an assessment of the 
prevalence of these risk factors was not a major aim of this study, to a smaller extent, 
asked about were some questions on use of coffee, cigarettes, alcohol and nutritional 
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supplements plus physical activity. In the findings of the FRAM study (Currier et al., 
2008); authors reported that HIV-infected white women were more likely to have 
proatherogenic lipid profiles than HIV-infected African-American women were. 
Despite higher triglycerides in African-American HIV-infected women (116 vs. 83 
mg/ dL; p < .001) and similar HDL (52 vs. 50 mg/ dL; p = .60) compared to their 
white counterparts, the findings are still not high enough to constitute being at risk. 
This risk equates with plasma triglycerides ≥150 mg/ dL and HDL cholesterol < 50 
mg/ dL as defined by the IDF (2006), NCEP ATPIII (2002) and Alberti et al. (2005). 
An earlier study on HIV-infected women by Dolan et al. (2005) revealed a higher 
triglyceride level (163 vs. 75 mg/ dL, p = .0002), fasting glucose (81 vs. 45 mg/ dL, p 
=.0003) and lower HDL (45 vs. 56 mg/ dL, p < .0001) compared to their control 
counterparts. The same participants had increased abdominal visceral fat, WHR (0.92 
vs. 0.83, p < .0001) as well as decreased body fat in the limb extremities. Waist: 
Height ratio significantly related to CVD risk indices in both the study and control 
groups (Dolan et al., 2005). Findings supported by Torriani et al. (2006) reported 
reduced calf subcutaneous fat area (17.8 vs. 35 cm
2
, p < .0001) and extremity fat by 
DXA (11.8 vs. 15.6 kg, p = .024). The latter researchers also reported increased VAT 
(125.2 vs. 74.4 cm
2
, p = .004), triglycerides (131.1 vs. 66.3 mg/ dL, p = .0003) in a 
study of 46 women (25 of whom displayed fat redistribution) and 21 controls, 
respectively.   
 
Similarly, Sobieszczyk et al. (2008) reported that metabolic syndrome was more 
prevalent in HIV-seropositive than HIV-seronegative women were. In their study, the 
increased prevalence was due to dyslipidemia rather than higher blood pressure, 
glucose, or WC. In addition, HIV-infected women had higher mean triglyceride (154 
vs. 101 mg/ dL, p < .0001). Also, lower mean HDL cholesterol levels (46 vs. 55 mg/ 
dL, p < .0001). The findings of several additional studies are difficult to interpret due 
to shortcomings in design, including very small sample sizes. However, in recent 
times the presence of the metabolic syndrome in HIV-infected individuals did not 
appear to increase the CVD risk over and above that conferred by the components of 
the syndrome separately (Worm et al., 2009). Older age, a high BMI as well as 
insulin resistance seem to have a high place among the risk factors for the syndrome. 
It is an extension of the research, which argues for the role of the syndrome in 
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predicting disease risk. Whether or not the metabolic syndrome in HIV-infected 
individuals increases the CVD risk over and above that conferred by the components, 
it does not rule out the fact that having either is of any health advantage to HIV-
infected populations, considering the fact that they are already overburdened by 
lifelong medication. 
2.3.3 What is known in the area of metabolic syndrome in HIV? 
A number of studies have demonstrated that HIV-related lipodystrophy is associated 
with adverse metabolic variables that may predict greater risk of CVD (Currier et al., 
2008; Wohl et al., 2008; Sobieszczyk et al., 2008); the same scholars caution that 
other factors including diet be among research factors in future studies. The 
metabolic variables include elevations of the total triglycerides, raised levels of very 
low-density lipoprotein (VLDL) and low levels of HDL (Nair, 2005). Sobieszczyk et 
al. (2008) reported that the notable factors associated with higher prevalence of 
metabolic syndrome among HIV-infected women included older age (OR = 1.38 per 
five year increase, p < .0001); higher BMI; current smoking; HIV RNA (OR = 1.36, 
p = .019, for > 50,000 vs. < 80 copies/ mL); and use of d4T (OR = 1.28, p = .009). 
However, NVP use was protective (OR = 0.75, p = .016). A recent review noted that 
there are sound reasons for using d4T in poor-resource settings, including the fact 
that it forms part of a simple, affordable, fixed-dose combination (Ford et al., 2009). 
As such, the latter comes with the potential cost of metabolic syndrome among HIV-
infected persons as reported by Sobieszczyk et al. (2008). This study reported no 
significant association of the syndrome with RTV-boosted PIs (OR = 1.15, p = .134). 
On the other hand, NRTI exposure increased the relative risk of development of DM 
by 80% for NRTI exposure less than three years and more than doubled risk for 
exposure exceeding three years in HIV infected women (Tien et al., 2007). However, 
in an earlier study, patients with CD4-count-guided interruption of ART experienced 
a significantly increased risk of CVD compared with patients whose treatment was 
on going, suggesting a role for HIV infection in CVD that is independent of treatment 
(El-Sadr et al., 2006).  
 
Similarly, earlier researchers have reported an association between the metabolic 
syndrome and HAART among HIV-infected individuals (Jerico et al., 2005). Jerico 
et al. (2005) assessed the prevalence of the metabolic syndrome in HIV-infected 
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patients as defined by the NCEP. They reported an association of PI exposure with 
the metabolic syndrome and more specifically, with exposure to d4T and LPV/r or 
RTV when individual ARVs were analysed. In earlier studies, HIV-related ATAs 
were often associated with hypertriglyceridemia, low HDL concentrations and 
elevated FFA concentrations (Hadigan et al., 2002).  
 
In another study of HIV-infected patients (Grunfeld et al., 1992), total cholesterol 
levels prior to the initiation of HAART were lower, while triglyceride levels were 
higher than normal. During treatment, HDL cholesterol remained significantly lower 
than normal. Therefore, with such a disease or medication effect, one might question 
the merits of traditional anthropometrics as a useful nutrition assessment technique in 
the era of HIV especially as HAART use continues to scale up. Mondy et al. (2007) 
recently reported a similarity in the overall prevalence of metabolic syndrome 
between HIV-infected and a sero-negative group with 25.5% and 26.5% respectively. 
The study (Mondy et al., 2007) concluded that traditional risk factors play a more 
significant role in the development of the metabolic syndrome than do HIV 
treatment-associated factors. While data from Australia and the US provide an 
estimate of the metabolic syndrome being present in 20 to 25% of the adult 
population (Dustan et al. 2002; Ford et al. 2002), no such estimates are known in the 
Ugandan population, including those infected with HIV (medicated or non-
medicated).  
 
Additionally, both HIV disease and demographic characteristics seem to influence 
lipid values and glucose homeostasis in the absence of ART (El-Sadr et al., 2005). 
This means that whereas some researchers attribute the existence of the syndrome to 
ARVs while others report similar findings in treatment-naïve HIV-infected persons 
and the general population. Whether disease or therapy induced, what is clear is that 
lipoprotein lipase activity is less and hepatic lipid synthesis stimulated, thereby 
producing hypertriglyceridemia. Findings by Mondy et al. (2007) confirmed the 
results of Jerico et al., (2005), the overall prevalence of the metabolic syndrome in 
HIV-infected being similar to earlier studies of uninfected individuals. In this study, 
17% of the < 30-year and 27% of the > 50-year-olds had the metabolic syndrome 
according to the ATPIII definition. Other studies have revealed 14% and 18% 
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metabolic syndrome prevalence based on IDF and ATPIII criterion using the same 
data respectively (Samaras et al., 2007). This disagreement in the definitions of the 
syndrome and differences in observations highlights the need for more work in the 
area. Knowing one’s disease risk and moving to prevent conditions worsening is 
imperative for long-term survival, including lifestyle changes such as diet and 
exercise forming the underlying strategy of treatment (Hendricks et al., 2003). Data 
are still lacking, particularly in the Ugandan population including those infected with 
HIV. This underlines the importance of this research given the widespread use of 
HAART in the country, although the general incidence of metabolic syndrome 
elsewhere does not appear to increase (Jacobson et al., 2006) even when it appears 
higher in HIV-infected individuals. 
2.3.5 What are the gaps in the area? 
The metabolic syndrome is associated with increased health risks, not limited to 
CVD and coronary heart disease (CHD). Currently, there are many definitions of the 
metabolic syndrome. Thus, when an alternative definition is used, the reported 
prevalence of the syndrome differs in the same population. Additionally, there are 
diverse opinions on whether the metabolic syndrome exists in HIV-infected persons 
than there is in the general population. There are also varied findings on whether 
HIV-related metabolic syndrome is due to the infection or the medication. While 
many developed nations have national prevalence data on a range of disease states, 
data in Uganda is limited in these areas. Findings of the present study should make a 
modest contribution to a better understanding of the metabolic syndrome in the 
Ugandan context, including among patients with the HIV infection. 
 
2.4 HIV, nutritional status and body composition 
This section considers the techniques available to assess nutritional status and 
quantify body composition and changes resulting from illness and/ or medication. 
Commonly in use are simple indicators such as BMI, WC, WHR (WHO, 2000), and 
the sum of several skinfold thickness measurements. The use of skinfold thickness 
measurements assumes that under normal conditions, a relatively constant amount of 
body fat is in the subcutaneous tissues (Durnin and Womersley, 1974). In turn, the 
sum of several skinfolds to reflect total body fat becomes an option. The technique 
has also commonly been associated with selected circumference or girth 
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measurements to estimate the cross-sectional area of the trunk or limbs and reflect 
both body fat and skeletal muscle development (Durnin and Rahaman, 1967). The 
use of individual or sum of skinfold measurements have an additional advantage over 
estimated percent body fat from equations (generally utilizing selected skinfold 
thickness measures) in that they can provide a general view of the fat distribution 
pattern across the body. These techniques do not require expensive equipment; 
however, major limitations are that they are operator-dependent and difficult to 
standardize (Ellis, 2000). Furthermore, the presence of disease such as AIDs may 
affect the normal characteristics of body tissues (Shah and Bilal, 2009), the basis of 
anthropometric measures.  
 
2.4.1 Anthropometry for assessing nutritional status 
2.4.1.1 Height, weight and Body Mass Index 
Variations of lean body mass and FM in quantities and distributions can be indicators 
of the global nutritional status (Gibson, 2005). BMI, a marker of global nutritional 
status and the standard BMI categories are well established (WHO, 2000). Despite 
the inappropriateness of using a single BMI cut-off for determining nutritional status 
(Deurenberg-Yap et al., 2000; Deurenberg et al., 2003), the approach is still used in 
Uganda and other similar settings. Measurements of body mass and stature and the 
derivation of BMI are widely used in the Ugandan context with HIV/AIDs patients, 
as they are affordable, quick, and user-friendly. Kagawa and colleagues (2006) have 
reported shortcomings of the BMI in a study. In the latter study, there was different 
body fat deposition of Japanese and Caucasian males that displayed the same 
anthropometric status. This finding is similar to reports in earlier studies (Chang et 
al., 2003; Jackson et al., 2002; Ko et al., 2001; He et al., 2001; Gurrici et al., 1998) 
underlining that the BMI can only provide an approximation of relative body fatness 
which varies with age, sex, physical training and ethnicity. In addition, categories of 
percent body fat are not well standardized. According to a WHO expert committee, 
‘‘there is no agreement about cut-off points for the percent body fat that constitutes 
obesity’’ (WHO, 1995). The use of the BMI to classify relative weight as opposed to 
fat distribution is clear (Table 4).  
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Despite acknowledged shortcomings, the BMI has an important place in clinical and 
epidemiological settings to assess disease risk over time (Ellis, 2001). The underlying 
assumption of using BMI to define obesity is that at a given height, higher weight is 
associated with increased fatness (Ashwell et al., 2005). The relationship between 
BMI and percentage body fat is also dependent on age (Jackson et al., 2002). For 
example, data from the Rosetta study showed that older adults have, on average, 
more fat at any given BMI (Gallagher, 1996). The usefulness of BMI is also 
questionable when used in disease states including HIV in which there may be altered 
fat distribution and metabolism. However, BMI increased progressively in the HIV-
seronegative group over the study interval but remained constant in all the HIV-
infected groups. Like was in studies on men (Brown et al., 2006) and women (Tien et 
al., 2003). The former authors suggested that HIV infection plays an important role 
in preventing the weight gain observed in HIV-seronegative men. A more direct 
measure of FFM and FM is therefore preferred for the assessment of nutritional 
status (Shah and Bilal, 2009). 
 
Table 4: Classification of BMI  
Classification BMI (kg/ m
2
) Population description 
Underweight < 18.5 Thin 
Normal range 18.5 - 24.9 Normal, healthy, acceptable 
weight 
Overweight > 2 5  
Pre-obese 25 - 29.9 Overweight 
Obese class I 30.0 - 34.9 Obesity 
Obese class II 35.0 - 39.9 Obesity 
Obese class III > 40  
Source: (WHO, 2000; Seidell and Flegal, 1997) 
 
BMI remains in widespread use in many settings and contexts. In a study on body 
shape and composition in HIV-infected women, weight gain was associated with a 
higher FM (p = .005) (Karmon et al., 2005). In addition, metabolic syndrome 
presence was associated with higher BMI in a cohort of HIV-infected adults in the 
US (Jacobson et al., 2006). Elsewhere (Amorosa et al., 2005), the researchers 
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compared the prevalence of obesity and overweight among a large (N = 51 vs. 689) 
urban population of HIV-infected participants on ART. In that, study (Amorosa et 
al., 2005); obesity (14%) and overweight (31%) were more common than wasting 
(9%). Among women in that study, CD4 count ≥ 200 cells/ mL were associated with 
a greater BMI. However, BMI did not correlate with ART, treatment with PIs, or 
being ART-naive. In another study on 162 participants (Hodgson et al., 2001), 34% 
were reported overweight, 9% were obese and 6% were wasted. Like Amorosa et al. 
(2005), Hodgson et al. (2001) reported no correlation between ART and being 
overweight or obese. Briefly, there looks to be more overweight/ obese individuals 
than the wasted in all these studies. In contrast, Justman et al. (2008) reported no 
indication of progressive obesity among an urban cohort of HIV-infected women 
followed over five years.  
 
Although obesity has many risks, some researchers have reported beneficial findings 
in the infected populations. For instance, a study that examined the relationship 
between BMI and disease progression among PLHIV (Shor-Posner et al., 2000), over 
an 18-month follow-up period reported that BMI measurements among the HIV-
infected cohort were inversely related to progression to death, independent of CD4 
cell count (< 200 cells/ mm
3
). The former study reported that the risk of declining 
CD4 cell counts was lower in overweight/ obese participants than in non-obese 
participants. These findings indicated that obesity did not impair immune functioning 
in that population.  
 
In addition, Shuter et al. (2001) reported similar results among 189 HIV-infected 
subjects recruited from an urban HIV clinic. In this urban HIV clinic study (Shuter et 
al., 2001), overweight patients, without AIDs, experienced slower disease 
progression and had lower viral loads than participants who were not overweight, 
despite similar time to the initiation of ART and similar baseline CD4 cell counts. In 
addition, the study reported that a lower baseline BMI and decreases in BMI over 
time were independent predictors of progression to AIDs. In another study (Jones et 
al., 2003), there was decreased risk of disease progression among overweight/ obese 
HIV-infected subjects in a longitudinal study of 817 infected women, majority of 
whom were African-American. To assess the usefulness of BMI in the HIV-infected 
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Ugandan population, the current research sought to relate BMI findings with 
measures of percent body fat estimated by other techniques and markers of the 
metabolic syndrome as well as the relationship with lipodystrophy. Success of the 
validity of the BMI in the current population better characterizes individuals with 
excess fat, metabolic syndrome or lipodystrophy. 
 
2.4.1.2 Circumferences: waist, hip, and arm 
a) Waist and hip circumferences 
There is consensus that WC is a reliable surrogate marker for increased amounts of 
VAT and that the measurement should be incorporated into the routine assessment of 
all patients (Heitmann and Lissner, 2010; Janssen et al., 2002). The cut-off points of 
WC are well classified and recommended (Janssen et al., 2002; WHO, 2000). 
Evidence suggests that WC alone may be a better indicator of abdominal visceral fat 
(Rankinen et al., 1999) and a predictor of abdominal obesity-related diseases 
(Nordhamn et al., 2000; Molarius and Seidell, 1998) and mortality (Visscher et al., 
2006) than WHR or BMI. An increase (1 cm) in WC is associated with a 2% 
increase; while a 0.01 increase in WHR is associated with a 5% increase in risk of 
future CVD after adjusting for age and cohort characteristics (Koning et al., 2007). 
Table 5 summarizes the most widely used WC cut-off points. 
 
Table 5: Classification of WC 
Classification of risks by WC Female Male 
Low risk < 79 cm < 93 cm 
Increased risk 80 - 87 cm 94 - 101 cm 
Substantially increased risk > 88 cm > 102 cm 
Source: WHO (2000) 
 
A recent study (Geraix et al., 2008) aimed at learning about the nutritional profile of 
HIV-infected individuals receiving ART and at comparing the performance of 
nutritional-state indicators. In that study, the prevalence of abdominal obesity was 
7.44% according to WC. In the same study, the prevalence of abdominal obesity was 
38.3% according to WHR. However, in the FRAM study of HIV-infected and control 
subjects (Scherzer et al., 2008), the study outcomes were three metabolic risk 
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variables [HOMA (triglycerides, and HDL cholesterol)]. For HOMA and HDL, 
Scherzer et al. (2008) reported that WC appeared to be the best anthropometric 
correlate of metabolic complications, whereas for triglycerides, the best was WHR. 
These findings are in agreement with those from a study by Panagiotakos et al. 
(2009) in which WC was the best predictor of hypertension incidence. In relation to 
WC, Blass and colleagues (2008) in a study to identify patients at high risk for 
abnormalities in glucose metabolism taking into account HAART, familial 
disposition for DM and anthropometric parameters argued that the HOMA, BMI and 
WC should be routinely undertaken, especially in PI-medicated patients. A year 
earlier in the Multicenter AIDs Cohort Study (MACS), Brown and his colleagues 
(2007) found that WC increased more rapidly in HIV-infected men compared to 
uninfected men, after adjustment for cumulative ARV exposure, although baseline 
WC was markedly lower in the HIV-infected. They (Brown et al., 2007) attributed 
the rapid increase in WC associated with HIV-infection to represent a "return to 
health" phenomenon whereby effective ART allows a return to the pre-morbid body 
composition and "catch-up" to HIV-negative peers. It is in accordance with such 
mounting support of WC that is, but one of the key anthropometric outputs of the 
current research. 
 
However, despite the increased acceptance of WC as a useful indicator of abdominal 
fat deposition and obesity-related health problems (Dalton et al., 2003; Welborn et 
al., 2003; Bei-Fan, 2002), there has been inconsistencies in using WC (James, 2005).  
Shen and others (2006) found that WC is more highly correlated with metabolic 
syndrome components than percentage body fat and other anthropometric measures 
such as BMI and WHR. This implies that people with a large waist are most often at 
risk of ill health regardless of BMI level (Han et al., 2006). Indeed, after the adoption 
of the IDF (2006) definition for the metabolic syndrome that encompasses WC, a 
study in the US reported a higher prevalence of the metabolic syndrome than 
previously estimated (Ford, 2005). The former researcher sought to relate WC to 
measures of percent body fat, metabolic syndrome as well as the presence or absence 
of lipodystrophy. One such study (Jacobson et al., 2006), is where WC measures 
were lower in HIV-infected HAART recipients compared with the uninfected 
population, despite similar prevalence rates for metabolic syndrome. Additionally, 
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50% of HIV-infected HAART recipients met non-anthropometric criteria for 
metabolic syndrome, but this reduced to 17% when waist-based anthropometric cut-
offs were applied (Jacobson et al., 2006). The latter researchers concluded that 
metabolic syndrome definitions might not be sufficiently sensitive for HIV-infected 
HAART recipients. Perhaps it is because fat distribution rather than absolute total fat 
is more strongly associated with the metabolic risk factors (Boyko et al., 1995; 
Bjorntorp, 1988). The WC is one of the best simple measures of both intra-
abdominal fat mass and total fat (Ho et al., 2001; Rankinen et al., 1999), and, can be 
indicative of lipid distribution. Many of the studies regarding relationships between 
key anthropometric measures and health outcomes are from the developed world; 
therefore, there is merit in more research in developing countries. 
b) Anthropometric measures of the arm 
Anthropometric measurements of the upper arm are a quick, inexpensive, and non-
invasive way of assessing nutritional status (Frisancho, 1990). Such upper limb 
measures centre on the evidence that nutritional restriction leads to utilization 
nutritional reserves, stored in the form of skeletal muscle protein, visceral protein, 
and fat. Thus, provide an indication of underlying muscle tissue and subcutaneous 
fat. For example, the triceps skinfold thickness and AMC, where the former indicates 
the calorie reserves stored in the form of fat and the arm muscle size reflects the 
reserves of muscle protein (Frisancho, 1974). The latter measure takes into account 
the humeral diameter as well as the skeletal muscles and fat covering the limb. Mid-
upper arm circumference is a better indicator of peripheral muscle and subcutaneous 
tissue wasting than BMI (James et al., 1994). Mid-upper-arm muscular 
circumference and AMA are derived from the circumference and triceps skinfold 
thickness measures. They are both useful indicators of muscle mass (Frisancho, 
1990). Mid-upper-arm muscle area is a two-dimensional measure of muscle mass and 
provides more accurate information than the AMC. There is an assumption that the 
mid-upper-arm cross-section is circular and that triceps skinfold thickness is twice 
the average rim diameter (Lukaski, 1987). These measurements have been useful in 
the elderly because of the changes in fat redistribution as a function of age (Enoki et 
al., 2007). These measures may also be useful in HIV-infected populations in 
resource-poor settings as fat redistribution also occurs in many individuals and the 
use of more sophisticated techniques like DXA are not feasible for routine use.   
  
 Page 41 
2.4.1.3 Ratios: Waist: Hip; Waist: Height 
a)  Waist: Hip ratio 
The WHR has been one of the most widely used anthropometric methods for 
predicting central fat distribution (Wang et al., 2005). This ratio is a measure of the 
distribution of subcutaneous and intra-abdominal fat. In addition, it is a better marker 
of visceral fat (Stewart et al., 2003). The basis of this measure as a CHD risk factor is 
the assumption that fat stored around the waist poses a greater risk to health than fat 
stored elsewhere in the body (including hips) (Hu et al., 2007). People with high 
levels of fat around the abdomen tend to have a large WC relative to the hips. 
Commonly and unconventionally in use is the hip circumference measure but 
similarly as a contributor to a ratio such as WHR. The latter ratio is a superior 
predictor of CHD risk since it includes measurement of hip circumference, which is 
inversely associated with dysglycaemia, dyslipidaemia, diabetes, hypertension, CVD 
and death (Heitmann et al., 2004; Lissner et al., 2001; Seidell et al., 1997). In 
contrast to a high WC, there is an acknowledged protective advantage of a large hip 
circumference (Lissner et al., 2001). Latter researchers found a low hip 
circumference to be associated with excess CVD mortality and morbidity end-points 
in Swedish women. Elsewhere, Heitmann et al. (2004) have also reported that a large 
hip circumference, relative to body size and WC, predicted a lower incidence of 
CVD and CHD. Nevertheless, his finding was only present in women. Several years 
later, the same issue was addressed in a UK cohort, and it was once again confirmed 
that a smaller hip circumference predicted excess risk of CHD in both sex groups, 
after controlling for both BMI and WC (Canoy et al., 2007). Hip circumference per 
se may not give much detail, thus, one has to consider the waist or BMI to make 
sense of the effects of the hip. Although both WC and WHR are common proxy 
measures of VAT and consequently both correlated with VAT, WC remains the most 
strongly associated factor (Onat et al., 2004). In addition, WHR is more difficult to 
perform and a less reliable measure than WC. Rimm et al. (1990) and Kushi et al. 
(1988) showed that the intra-class correlation for repeat measures and Pearson’s 
correlations between self-reports and clinical measurements are lower for WHR. To 
illustrate the use of the WHR, Zhang et al. (2007) examined the association between 
WHR and mortality in the Shanghai Women’s Health Study (SWS). The SWS results 
confirmed that WHR was positively and significantly associated with 1456 deaths 
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from all causes; including 732 from cancer, 357 from CVD, 99 from DM and 268 
from other causes (p = .01 for trend). The study (Zhang et al., 2007) concluded that 
abdominal adiposity, independently predicts mortality risk particularly for non-obese 
women. The WHR is equal to WC divided with hip circumference. Patients 
exhibiting signs of HIV-associated adipose redistribution syndrome are likely to have 
higher WHR (Kotler et al., 2002). The suggested cut-off points of WHR vary 
between 0.80 and 0.90 for females, and 0.94 and 1.00 for males, respectively (Lahti-
Koski, 2001; Molarius and Seidell, 1998).  
 
There was yet another longitudinal comparative study (Brown et al., 2006) of body 
shape changes among HAART-treated HIV-infected men vs. HIV-seronegative men 
of similar age. The study reported that the increased rate of change in WHR in HIV-
infected men receiving HAART compared with HIV-seronegative men was 
attributable to slower increases in hip circumference rather than an increased rate of 
change in WC (Brown et al., 2006). These findings meant that there was an 
underscore in the importance of body fat composition changes in the peripheral 
compartment relative to the central compartment among HIV-infected men receiving 
HAART.  
b) Waist: Height ratio 
In addition to the commonest anthropometric measurements this study has already 
reviewed above, indices of the WHtR was also included. Some authors propose the 
WHtR as the best anthropometric index to predict CVD risk but of most importance 
the metabolic syndrome and its components that are of much interest to this study 
(Can et al., 2008; Gelber et al., 2008; Kagawa et al., 2007; Schneider et al., 2007; 
Hsieh and Muto, 2006; Hsieh and Muto, 2005; Fuchs et al., 2005). All this is because 
of wide views that WC does not take into account differences in body height, which 
WHtR does consider. But Gelber et al. (2008) concede that all the other 
anthropometric indices (BMI, WC, WHR) were capable of assessing for risk of 
CVD, although WHtR demonstrated statistically the strongest association with the 
risk and best model fit. Elsewhere, WHtR was reported to have correlated well (r 
ranged from 0.527 to 0.687 in Japanese, 0.496 to 0.576 in Australians) with trunk fat 
and percent body fat (Kagawa et al., 2007). Kagawa and colleagues (2007) in their 
study also observed that WHtR correlates with trunk lean mass compared to BMI and 
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WC, and that ethnicity and age do not affect WHtR in the Japanese and Australian 
populations where they used the indices to estimate percent body fat. An earlier study 
that explored the influence of height alone, the square and cube of height and hip 
circumference on the performance of WC in predicting hypertension confirmed that 
adjustments of the latter by height or hip circumference improve its association with 
the disease incidence (Fuchs et al., 2005).   
 
More recently, another study that compared prevalence of CAD between obese (BMI 
≥ 30) and abdominal obesity indicated by WHR, reported that participants showed 
that CAD was significantly higher in abdominal obese patients (WHtR ≥ 0.55) than 
in patients without abdominal obesity (odds ratio, OR = 1.63, p = .008) (Siavash et 
al., 2008). Besides, that there was a significant positive correlation between CAD 
score and age (p < .01) as well as WC (p < .05) and WHtR (p < .01) in the male 
participants. These researchers later concluded that WHtR might be a better marker 
of central obesity and might better predict CAD than BMI and WC. These views find 
support in another recent study by Can et al. (2008), who reported of an association 
of anthropometric indices with metabolic syndrome score and Framingham risk score 
being highest for WHtR. The latter study showed that areas under the receiver-
operating characteristic curves showed that WHtR was the best anthropometric index 
that discriminated between the presence and absence of hypertension, DM and 
metabolic syndrome, whereas WHR was better for dyslipidaemia. From such studies, 
there is an appreciation for an overwhelming use of WHtR in predicting disease. 
Hence, the current study sought to correlate WHtR with the percentage body fat, the 
metabolic syndrome and its components. A secondary aim was to find out if there 
were any relationships with WHtR and fat redistribution across the two study groups. 
 
2.4.1.4 Skinfold thickness measures 
Skinfold thickness measurements are preferred bearing in mind that they are 
inexpensive and one of the clinical and bedside techniques used to monitor long-term 
nutritional status (Batterham et al., 1999). The measurements are correspondingly 
good field techniques (Norgan, 2005). Prediction equations derived from skinfold 
thickness measurements provide good associations with the reference methods 
(Fogelholm and van Marken Lichtenbelt, 1997). The measurements of skinfold 
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thickness do assess body density and subsequently body fat as skinfold thickness at 
specific sites provides a reasonable correlation with total body fat (Peterson et al., 
2003). However, body fat distribution varies between individuals and according to 
the level of total body fat. Consequently, measurements are dependent on the level of 
fatness of an individual, and the reliability of the testers and instruments, which are 
generally low (Wagner and Heyward, 1999).  
 
A larger number of equations based on skinfold measurements have been developed 
including those by Peterson et al. (2003), based on a four-component model criterion 
method. Thus, skinfold thickness measures are a more valid (less biased) choice in 
assessment of fatness when using surface anthropometry taken by experienced 
practitioners (Nevill et al., 2006). However, Macallan et al. (2000) advises that 
conventional measures including 4-site skinfold and WHR are poor reflectors of the 
presence or absence of fat redistribution, and this view differs from studies that 
advocate for the technique. As a caution, the accuracy and precision of skinfold 
thickness measures like is for any other anthropometry, is largely dependent on the 
skill and experience of the anthropometrist who take the measurements (Wang et al., 
2000). The current study compared percent body fat estimated from the usual 4-site 
skinfold thickness with that predicted by the BMI, and that from TBW measured by 
BIA and deuterium oxide dilution technique, to gauge the applicability of the usual 
techniques in the infected Ugandan women. A number of the above mentioned 
techniques can be used to yield indices of nutritional status such as BMI, WC, WHR, 
and skinfold thickness, FM, FFM and TBW and thereby ascertain health and body 
composition status. While there are numerous ways of assessing body composition, 
only a selection of techniques described next was relevant to the current study. 
 
2.4.2 Assessing body composition – the techniques 
Because anthropometric techniques alone may not be sufficiently sensitive to detect 
small changes in body composition,  it is very important to determine fat and lean 
body masses by direct measures, rather than relying on the BMI only, especially 
while describing obesity and malnutrition-related mortality risk and clinical 
outcomes (Kyle et al., 2004). Collectively, body composition is different components 
that when taken together make up a person’s body weight, said to be the amount of 
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lean tissue compared to fat (Shah and Bilal, 2009). Evidence shows a relationship 
between body composition and morbidity (Heitmann and Garby, 2002). This means 
that an understanding of body composition models is critical in assessing the body 
better.  
 
In the basic two-component model, the body is, but two parts. In this model, the body 
consists of body fat, and all the remaining tissues are lumped together into the part 
known as the lean tissue, or FFM as is the case for the earlier commonly used 
techniques involving anthropometry and hydro densitometry (Ellis, 2001). Once FFM 
can be determined, indirectly body fat becomes the difference between body weight 
and FFM (Ellis, 2000). The most frequently used two-component model builds on 
the measurement of total body density and the most common method is 
hydrodensitometry, pioneered by Behnke et al. (1942). For decades now, the water 
content of the FFM has to be measured, and their relative concentrations were 
assumed to be constant (0.732 l/ kg for body water), for all ages (Pace and Rathbun, 
1945). Thus, the density of the FFM for the two-component model was assumed 
constant (Behnke et al., 1942) and was later discovered that these constants were 
‘population specific’. This discovery led to a three-component model. 
 
The three-component model approach requires that the hydrodensitometry 
measurement include a measure of TBW, usually by the isotopic dilution method. In 
this model, FFM is divided into two parts, i.e. its water content and the remaining 
solids (predominately protein and minerals), hence, the density of water, fat, and 
body solids are used. Nevertheless, patients with significantly depleted body protein 
mass and/ or bone mineral mass, the estimated values for the density for the solids 
compartment would be incorrect. Thus, the final estimate of body fat mass becomes 
inaccurate as well. Inaccuracies in this model resulted in the development of a four-
component model. 
 
The four-component model requires an accurate measure of protein and mineral 
compartments, in addition to that of TBW. Moreover, the assumption for body 
protein and bone mineral densities is 1.34 and 3.075 kg/ L, respectively (Snyder et 
al., 1984). Neutron activation analysis for body protein and DXA for bone mineral 
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content are a need to obtain a measure of the two additional measurements. The DXA 
value for the bone mineral compartment is relatively commonly available, but not so, 
with the direct measurement of body protein mass, thus the latter is assumed 
proportional to the bone mineral mass, independent of age and gender. Changes in 
the mass of the protein component, however, may be more of a concern if not 
accounted for accurately. This is because; it is rare that significant changes in FM 
will not be accompanied by changes in the size of body cell mass (BCM) or protein 
mass (Cohn et al., 1984, Cohn et al., 1983; Vaswani et al., 1983). On the other hand, 
one can split the body’s FFM into three basic cellular or physiological compartments: 
BCM, extracellular water fluid or water (ECW), and extracellular solids (ECS) 
(Moore et al., 1963). Accordingly, (Moore et al., 1963), FFM is then defined as 
BMC, ECW, ECS and total body fat mass as body weight minus FFM. 
Unfortunately, measurement errors are cumulative and transfer directly in mass units 
to the final estimate for body fat mass. 
 
Other developments show the use of multicompartment models, because if only one 
method is used, then there are technical or model limitations resulting in increased 
uncertainties associated with that method. One such example is the simultaneous 
measurement of body carbon and body hydrogen (by neutron activation) as assays for 
body fat mass and TBW, respectively (Kehayias et al., 1987; Kyere et al., 1982; 
Shypailo & Ellis, 1998). As is with the information obtained using DXA for FM and 
deuterium dilution TBW. Techniques such as CT and MRI also provide useful 
information about anatomical structure that enables monitoring specific organs. 
Multiple slices are necessary to reconstruct volumes, from which mass becomes 
predictable if density is known. One should not look at these two latter scanning 
techniques as equivalent to the basic chemical composition model, because in many 
diseases the apparent volume can be normal, when the chemical composition is 
significantly abnormal. Wang et al. (1992) present this as a comprehensive, five-level 
model of body composition; divided into elemental, molecular, cellular, tissue 
systems, and total body. The reconstruction of body composition from the elemental 
level is often more reliable and minimizes the assumptions related to tissue density, 
hydration, and/ or structure. While there is a range of models and techniques for 
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assessing body composition, the current research used BIA and deuterium dilution 
methods, thus, only these two in detail next. 
 
2.4.2.1 Bioelectrical impedance analysis 
Accurate measurement of FFM and FM are important in the clinical assessment of 
patients with HIV/AIDs. The BIA is one of the simplest and affordable body 
composition techniques choices in body composition estimates. The technique is a 
proven method for body composition studies (NIH, 2006). At the time of undertaking 
the current research, to our knowledge, devices were not readily available in Ugandan 
clinics. The aqueous tissues of the body, due to their dissolved electrolytes, are the 
major conductors of an electrical current, whereas body fat and bone have relatively 
poor conductance properties (Thomasset, 1962; Nyboer, 1959). It is possible to 
calculate bioelectrical impedance at either a single frequency (usually 50 kHz) or 
multiple frequencies (Soren and Brian, 2006). Exploited over 30 years ago to 
measure the TBW, many papers describe the principles of BIA in detail to date (Kyle 
et al., 2004; Kushner, 1992; Lukaski and Bolunchuk, 1988). The method involves 
passing an extremely low strength electrical current through the body and measuring 
the impedance to the flow of this current. Principally, resistance of an electric current 
is proportional to the amount of FFM and body fat, which correlates with height
2 
/ 
resistance (Kyle et al., 2004; Segal et al., 1985). BIA is probably the most frequently 
used method, due mainly to the relatively inexpensive cost of the basic instrument, its 
ease of operation, and its portability. The technique works through two key concepts. 
 
2.4.2.2 That the body contains water and conducting electrolytes 
The underlying principle in this concept is that when an electrical current passes 
through the body, it will mainly pass through water-containing tissues since bone and 
fat have large impedance and do not conduct significant current (Soren and Brian, 
2006; Thomasset, 1962; Nyboer, 1959). R gives the resistance, R, = ñL/ A Where: ñ 
is the resistivity of the tissue, L is the length of the cylinder and A is the cross-
sectional area of the cylinder. Re-arrangement of the above equation leads to the 
equation for the volume, V, of the conducting cylinder: V = ñL 2/ R. Although not 
the same quantity, the impedance (Z) is regularly interchangeable with R in these two 
equations. The generic BIA model assumes TBW to be proportional to the square of 
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height (Ht
2
) divided by Impendance (R), which are Ht
2
/ R. This model can be 
functional whether R is between a person’s wrist and ankle, or between both feet as 
is permitted by newer instruments (Dung et al., 2007). Thus, R is low for blood, 
urine and muscle but high for adipose tissue and bone, which contain little or no 
fluid, or electrolyte ions (Kushner, 1992), based on the logic that when a current is 
passed through the body, the voltage drop between two electrodes is proportional to 
the body’s fluid volume in that region of the body. Based on the above concepts, a 
value for impedance can be that from a fixed strength current passed through the 
body and this is inversely proportional to the amount of fluid. By appropriate choice 
of signal frequency, this can become specific for ECF or for total fluid 
determinations. When a current goes through the body, the water-containing fluids 
primarily conduct the electrical current.  
 
Water in the body exists both inside the cells, intracellular fluid (ICF) and outside the 
cells, ECF. At low frequency, current passes through the ECF space and does not 
penetrate the cell membrane. At high frequencies, however, the current passes 
through both the ICF and ECF. Equations used to predict FFM and body fat also take 
into account the body weight, electrical reactance and gender/ sex (Lukaski and 
Bolonchuk, 1987; Kyle et al., 2004). In addition, the other concept is that: 
Impedance of a geometrical system is related to conductor length, cross-
sectional area and signal frequency. 
The body may be considered as five interconnecting cylinders with two arms, two 
legs and the trunk. In the most common approach to BIA, the impedance is 
reasonable between the right wrist and ipsilateral ankle (Kushner and Schoeller, 
1986). In this tetra-polar arrangement: two drives and two measurement electrodes 
are in employment. The tetra-polar arrangement is necessary because the skin–
electrode contact impedance inhibits the use of a simple bipolar technique (Kushner, 
1992). One of the measurement electrodes is on the dorsal surface of the right wrist at 
the level of the process of the radius and ulna bones and the other on the anterior 
surface of the right ankle between protruding portions of the tibia and fibula bones. 
The drive electrodes are approximately 5 cm distally from the measurement 
electrodes, one on the dorsal surface of the third metatarsal bone of the right foot and 
the other on the dorsal surface of the third metacarpal bone of the right hand (Lukaski 
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et al., 1985). A constant ac current then passes between the two drive electrodes and 
the potential drop, and hence computing impedance, between the two measurement 
electrodes becomes possible.. 
2.4.2.2 Multiple-frequency BIA (MFBIA) 
Measurement of the impedance at zero frequency is not possible because of the high 
skin impedance and hence the present approach is to measure the impedance at many 
frequencies between about 10 kHz and 1 MHz and then plot resistance against 
reactance at these frequencies. This produces a semi-circular plot generally referred 
to as a Cole–Cole plot (Cole and Cole, 1941). Extrapolation of this plot to obtain the 
impedance at zero frequency is then possible and provides the best predictor of TBW 
and Extracellular water (ECW) both theoretically and experimentally (Cornish et al., 
1992). The MFBIA is superior to a single-frequency BIA. However, it was inevitable 
that this study used a single frequency BIA as the option within means at the time of 
collecting data and will consequently compare percent body fat estimated from 
measurements of the BMI, the usual 4-site skinfold thickness measures and that 
predicted from TBW measured by the BIA and deuterium oxide dilution technique. 
In Thailand, a study on HIV infected persons which assessed the correlation between 
BIA and anthropometry (skinfold thickness and BMI) revealed a moderate to high 
correlation (p < .001), the highest correlation (r = 0.86) being that between BIA and 
sub-scapular skinfold (Ludy et al., 2005). The study population was a convenience 
sample size of 77 persons so it may be difficult to generalize the findings. Several 
equations derived from TBW measured by BIA across different age, sex and race 
have been tested in persons living with HIV/AIDs and considered worthwhile 
(Dioum et al., 2005; Kyle et al., 2004). To calibrate the proportionality constants for 
the BIA technique, the TBW and ECW derived by deuterium dilution assays, can be 
used as the criterion or reference values, and height is used as a measure of the 
conductor’s length. 
2.4.2.3 Dilution techniques 
At the tissue or anatomical level, water is present in five compartments: 
(a) Intracellular water (in the cytoplasm and cell nucleus)  
(b) Plasma water 
(c) Interstitial water (in the lymphatic system) 
(d) Dense connective tissue water (in bone, cartilage, etc) 
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(e) Trans-cellular water (e.g. excretory ECF like bile), gastro intestinal (GI) 
secretions, mucous and cerebrospinal fluids 
 
The basic principle of dilution techniques for body composition analysis is that the 
volume of a compartment equates to the ratio of the dose of a tracer, administered to 
its concentration in that body compartment within a short time after the giving dose. 
Inherent in any tracer dilution technique are four basic assumptions:  
i) The tracer is distributed only in the exchangeable pool 
ii) It is equally distributed within this pool 
iii) It is not metabolized during the equilibration time 
iv) In addition, achieving tracer equilibration becomes relatively rapid.  
Violating any of these requirements requires adjustment of the ratio of administered 
dose to fluid concentration. For the measurements of TBW, ECW, and intracellular 
water (ICW), corrections for overexpansion, non-equilibrium and excretion of the 
tracers are needed (Bartoli et al., 1993; Schoeller, 1991; Gamble et al., 1953). In 
healthy adults, TBW is in harmony and constitutes; 73% of the FFM or 60% of body 
weight for non-obese subjects and will differ with disease (Kotler et al., 1999). This 
becomes a crucial aspect of body composition while assessing body fat mass based 
on body water parameters. The most direct measurement technique for TBW is that 
based on the dilution principle, using a tracer dose of labelled water such as 
deuterium oxide and the method has been reviewed (Schoeller, 1991). Generally, 
TBW values obtained using the dilution technique becomes the reference or criterion 
values for comparison with alternate measurement techniques. Although water is 
present in all cells and is an essential regulator of the body’s internal environment 
(Chumlea et al., 2001), hydration status can be altered by disease (Charra et al., 
1996), including HIV infection. As such, the total amount of water in the body and its 
distribution is subjective to many physiological and patho-physiological conditions.  
Total body water can be determined using the dilution principle where the volume of 
the compartment is equal to the amount of tracer added to the compartment divided 
by the concentration in that compartment (Mirinda-da-Cruz et al., 2003). The basic 
principle underlying the technique is that the volume of a compartment can be the 
dose of the tracer relative to its concentration in that compartment within a specified 
period following dose administration. At least two samples are collected: a pre-dose 
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sample to account for background isotope levels; and one or more post-dose samples 
collected following equilibration of the deuterium with body water (Ellis, 2000). The 
use of the isotope dilution technique to estimate body composition assumes that the 
FFM has relatively constant water with negligible water associated with fat. The 
common tracers used for determination of TBW are deuterium oxide (
2
H2O) or 
oxygen-18 (H2
18
O). The present study used the former. Stable isotopes are present in 
nature, including the human body and pose no radiation risk (Moore et al., 2007; Lof 
and Forsum, 2004). When consumed, the isotope rapidly distributes throughout the 
body but equilibrium after an oral administration requires a minimum of 3 - 4 hours 
or longer in some individuals. Based on samples of blood plasma, saliva or urine 
(and the present study collected the latter), analysis proceeds. For excretion and 
exchange with non-aqueous hydrogen or oxygen and in addition, physiological 
samples that undergo a chemical or physiological change may require correction for 
isotope fractionation. With careful attention to detail, TBW measurements receive 
excellent accuracy (Ellis, 2000). 
 
The use of stable isotope technique is time consuming since there is need for multiple 
samples and access to specialized equipment and laboratory capacity. As a result, use 
of stable isotope techniques to measure TBW remain in research contexts to date and 
clinicians have relied on equations derived from data collected on individuals from 
the normal population (Moon et al., 2008). However, the assessment of TBW using 
the deuterium dilution technique in a free-living context starts by ingesting a known 
quantity of the stable isotope with subsequent measurement of its concentration in 
samples of urine or saliva (Papathakis et al., 2005). Deuterium is the stable, naturally 
occurring and non-radioactive isotope of hydrogen and the technique is safe and non-
invasive. The capability, consequently, the appropriateness of many of the common 
body composition techniques is clear (Snijder et al., 2006) (Table 6). The present 
study uses percent body fat predicted from TBW, and measured by deuterium oxide 
dilution technique, against which the applicability of the other clinical approaches is.  
 
There are other options of dilution not applicable to the current study, but can be used 
to identify the body’s exchangeable electrolyte pools. Such techniques are not 
necessarily the same as TBW. In such an instance, the tracer adds to the water, while 
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the body fluid most often sampled is plasma (Brodie et al., 1939). An alternate is 
measurement of the ICW volume obtainable using dilution of a radioactive potassium 
tracer, which is short-lived and thus rarely performed.  
 
Table 6: Capability of different techniques to estimate total body fat and fat distribution  
Method Capability measuring 
total body fat 
Capability measuring fat 
distribution 
Applicability in large 
population studies 
BIA  Moderate Very low High 
CT Moderate  Very high  Low 
MRI  High  Very high  Low 
DXA  Very high  High  Moderate 
Densitometry  Very high  Very low  Low 
Dilution 
techniques  
High  Very low  Moderate 
Anthropometry: 
BMI 
WC, HC, WHR, 
SAD 
Skin folds 
Moderate 
Low 
Moderate 
Very low 
High 
Moderate 
Very high 
Very high 
High 
BIA, bioelectrical impedance analysis; CT, computed tomography; MRI, magnetic resonance 
imaging; DXA, dual energy X-ray absorptometry; BMI, body mass index; WC, waist 
circumference; HC, hip circumference; WHR, Waist: Hip ratio; SAD, sagittal abdominal 
diameter (adapted from Snijder et al., 2006). 
 
2.5 Summary 
HIV/AIDs weaken the immune system that in turn leads to opportunistic infections 
and later death. To prevent infections and increase the chance of survival, one starts 
ART at an appropriate time. From the literature, we have seen that HIV/AIDs 
worsened by HAART, results in lipid abnormalities which can result in many 
undesirable, not limited to physiological and morphological challenges. While the 
medical management and associated treatment of the disease should include nutrition 
and exercise, accurate clinical and nutritional assessment is paramount to optimise 
decision making for successful results. Although a range of body composition 
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techniques may be readily available, it was not so in the country where and at the 
time of undertaking the current study. Consequently, it was required to validate the 
usual bedside techniques for assessing nutritional status and body composition in the 
infected population. 
 
We have mainly reviewed body composition techniques that are feasible in 
ascertaining the nutritional status of HIV-infected individuals, including those 
feasible in the Ugandan setting. In addition, only high lights of the techniques that 
may serve best but not feasible at the study site are partly in the review. The 
researchers hoped to know if body fat derived from bedside techniques was valid in 
the present sample. Secondly, it was important to know if lipodystrophy existed and 
whether it was associated with HIV disease/ medication status. Finally, it was critical 
to understand if metabolic syndrome existed and if the syndrome was associated with 
HIV disease/ medication status. We therefore assessed the physical characteristics of 
the subjects using a comprehensive anthropometric protocol and predicted body 
composition based on these measures using validated techniques. Details of the steps 
that were taken are detailed in the chapter that follows. 
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Chapter 3:  GENERAL METHODOLOGY 
3. Introduction 
This chapter describes the design, study population, recruitment procedure including 
timeline, data management, safety and ethical issues. While the section on data 
management describes data collection steps undertaken for variables generally used 
throughout the study, the balance comes in the next three chapters. 
3.1 Design 
The study uses a cross-sectional approach employing quantitative techniques of 
anthropometry and laboratory techniques, along with qualitative study of the 
secondary information on participant medication profile and time with HIV infection 
from diagnosis. This is in addition to information on morphological changes, current 
and or recent life style through face-to-face interviews. 
3.1.1 Outcome variables 
The current study sought information on variables including anthropometric 
measurements of body mass (kg), height (cm), circumferences (cm) - waist, 
abdomen, hips, mid-upper arm and calf, as well as WHR and WHtR ratios. 
Additionally, body composition specifically percent body fat estimated from the 
BMI, the usual 4-site skinfold thickness measures; TBW drawn from measurements 
made by the BIA and deuterium dilution techniques. Elsewhere, morphological and 
biochemical changes to reflect presence of lipodystrophy and the metabolic syndrome 
as well components of the latter, respectively were among the key variable 
components gathered.  
3.1.2 Explanatory variables 
This study set out to relate the variables outlined above with time since HIV-
infection, time pent receiving ART, the class of ART (PIs or not) as well as one’s 
lifestyle indicators. The latter indicators included use of cigarettes, alcohol, 
nutritional supplements, physical activity, and frequency/ usual intake of common 
food groups. 
3.1.3 Potential confounding variables 
Potential confounding variables include age, medical/ family history of hypertension, 
diabetes, stroke or other heart-related diseases. The obtainable variables are in a 
conceptual plan (Table 7). 
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3.2 Study population 
3.2.1 Participants 
Studies have reported gender differences in the pattern of lipodystrophy (Galli et al., 
2003; Hadigan et al., 2003; Garg, 2000). Indeed, Hadigan et al. (2003) stress that 
although CHD poses health risks, there is an increase in HIV-infected patients with 
fat redistribution ─ the pattern of which together with ones’ sex are potentially 
important components in determining the possible risk in this population. 
Consequently, this study involved only women aged 15 - 49 years, living with the 
HIV infection and attending different services at Mildmay-Uganda. Few such studies 
indicate experience with women in developing countries, despite the significant 
disease burden in these locations (UNAIDs, 2009). 
 
Mildmay-Uganda, formerly Mildmay International, is a Christian AIDS palliative 
care and training specialist Non-Governmental Organization (NGO) that has been 
providing outpatient services in Uganda since 1998. The organization has HIV/AIDs 
programmes in Uganda, Kenya, Tanzania, Rwanda, Zimbabwe, the United Kingdom 
(UK) and Eastern Europe. Based on a long history of specialist AIDs care service 
provision in the UK and comprehensive research into the problem of AIDs in Africa, 
Mildmay, on request of the Ugandan government, provides a tertiary HIV/AIDs 
referral centre. Mildmay-Uganda is a government facility managed by Mildmay 
International whose headquarter location is the UK. The Centre works through five 
directorates, clinical, training and education, resources, residential care and nursing 
as well as quality assurance.
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Table 7: Variables measured, explanatory and confounding variables 
What was measured? 
(dependent variables) 
What explains the measured?  
(the independent variables) 
How variables were measured? 
(assessment techniques) 
i. Nutritional status 
ii. Body composition 
iii. Biochemical 
metabolites (lipid 
profile, fasting 
plasma glucose and 
blood pressure) 
iv. Morphological 
changes (increase, 
decrease, no change) 
i. Medication status (PIs or 
not) 
 
ii. Time with HIV infection 
and or on ART 
iii. Others (age, smoking, 
alcohol use, nutritional 
supplements, meal and food 
frequency as well as  
physical activity level) 
iv. Potential confounding 
variables (medical/ family 
history of diabetes, 
hypertension, stroke and 
other heart related disease)  
i. Anthropometry (body mass, height, 
circumferences - waist, abdomen, hip, upper 
arm and medial calf) 
ii. Skinfold measures: triceps, biceps, 
subscapular, suprailiac, abdominal, iliac 
crest and medial calf  
iii. Body composition - predicting FM from 
TBW assessed by BIA (Dioum et al., 2005) 
and deuterium oxide dilution technique 
(Forbes, 1996) 
iv. Metabolic syndrome (IDF, 2006) 
v. Fat distribution determined from skinfold 
thickness measures and self-reports on bi-
directional alteration (Carr et al., 1998) 
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At the time of this study, the Clinical Directorate which is one of the core 
Directorates with various departments that implement activities focusing on 
HIV/AIDs prevention, care and treatment and psycho-social support and had over 
8,000 registered patients (Mildmay records, December 2008), about 4,000 of whom 
regularly attended. Over 2500 (more than half female) patients had started on 
HAART before data collection commenced. The Centre provides a full range of good 
quality holistic and comprehensive care; has a purpose-built medical facility 
providing medical management of HIV infection and its associated opportunistic 
infections, AIDs management and rehabilitation therapies. There is provision of 
multi-disciplinary services by incorporating pastoral care and counseling, nutritional 
advice, physiotherapy, occupational therapy, children's rehabilitation within its 
palliative care package. Other clinical services include diagnostic laboratory 
investigations, electrocardiography, eye specialist care, dental care and ultrasound 
among others.  
  
To address the challenge of scaling up care and support services without 
compromising the quality, it became necessary to create peripheral drug refill outlets 
for stable patients while allowing the ‘more sickly’ to benefit from services at the 
main site. Taking advantage of the untapped community resources such as 
community-based volunteers, peer educators, retired nurses and many others, 
Mildmay sought an establishment of a functional community-based network. 
Designed to provide the much-needed continuum of care for those already on 
treatment, and a link for the community, the programme successfully piloted a radius 
of approximately 20 - 30 km around the main centre in Lweza, and was expanding 
into other Mildmay-affiliated satellite clinics in many other districts of Uganda. 
Before the study, more than 1200 beneficiaries were in this programme. At the time, 
all clinically stable patients were intentionally continuing routine follow-up from 
community clinics rather than the main Mildmay centre. The clinics are -  
 Makindye Sabagabo (Seguku health centre (HC) II 
 Ndejje HC IV 
 Mutungo HC II  
 Mutundwe HC II).  
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The clinics are located in Entebbe Municipality (Entebbe Hospital), Katabi (Kasenyi 
landing site), and Nabweru (Nabweru HC III) and another in Nakawa division, 
Kampala (Kamwokya Christian Caring Community). Thus, there has been a scaling 
up of care and support services, reducing patient waiting time at the major sites, 
taking services closer to the people and this reduces travel time costs, increasing 
awareness for orphans and vulnerable children’s (OVC) rights, HIV sensitization and 
reduction of stigma in the community, improved follow-up and care among other 
benefits. 
3.2.2 Sampling 
As of February 2009, a sampling frame containing a list of all eligible study 
participants at Mildmay-Uganda was in place. At the time, 1,200 patients had been 
receiving ARVs for at least a year and a further 633 had been in care for a minimum 
of a year although were not yet on AIDs medication. Based on an assessment of 
where eligible participants resided, it was established that only about half in either 
study category (AIDs medicated or not) lived ‘within reach’. This study minimized 
recruitment bias by sourcing subjects from both the main site as well as the 
community clinics. 
 
Sample size was calculated as has previously been proposed (Appendix 1) by Krejcie 
& Morgan (1970). This method was a choice because of its inbuilt mechanism for 
taking samples from small populations. In this study there were approximately 915 
(AIDs medicated plus non-medicated) eligible patients, hence a sample of about 269 
according to Krejcie & Morgan (1970) inbuilt table of calculating sample sizes. For 
any unforeseen reasons, the study anticipated at least 100 participants per study group 
(AIDs medicated and non-medicated); if there were any eligible candidates that did 
not consent, severe illness before the individual study appointment date, failure to 
honour appointments among many other challenges. A pilot came prior to collection 
of data that addressed aims to the present study (Appendix 2). 
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3.3 Recruitment 
3.3.1 Sensitization about the study 
Prior to any other activities of this study, sensitization about and recruitment of 
Mildmay - Uganda staff into the pilot study was but a need. Participant sensitization 
and completion of participant consent forms and enrolment followed. Design of the 
sensitization enhanced cooperation throughout the study. Translating the research 
language into a lay and practical format due to the very low literacy levels of the 
study population was also necessary. Many of the components of this study were new 
to the Ugandan setting and the specific target community; therefore, an increase in 
the knowledge and understanding of staff was critical to the successful 
implementation of the project. Once the staff embraced the study, it was much easier 
for participants to appreciate and hence cooperate during the project. 
3.3.2 Inclusion criteria 
Participants had to be registered a patients of Mildmay-Uganda; had been receiving 
care at the centre for at least 12 months; female and aged 15 - 49 years; consented to 
participate in the study; and live within reach to ensure safe and timely arrival on the 
study appointment date. Accordingly, participants from catchments that took less or 
equal to two hours by road transport to the study facility were the priority. 
3.3.3 Exclusion criteria 
A participant was not part if she was -  
 Pregnant 
 doubt regarding the ability of the participant to provide consistent information 
 Metal(s) in their bodies such as intrauterine coils for preventing pregnancy 
 Failure to consent to participation; known to be on medication for TB (due to 
difficulties voiding urine) 
 Extreme body weakness, bedridden and unable to tolerate data collection; in 
addition, none of the patients presented with any clinical signs of peripheral 
oedema or dehydration on the day of conducting measurements; the assumptions 
underlying body composition measurements may not be valid in persons with 
altered hydration (Pialoux et al., 2004; O’Brien et al., 2002). Upon consent, a 
subject would automatically belong to a study group of her characteristics. 
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3.3.4 Study groups 
One was either in, group A (those who had been taking ARVs for at least 12 months) 
or group B (the comparison group – those who had been in care but not taken ARVs).  
3.3.5 Activities and timeline 
Data collection started in July 2009 with the pilot study and the main study in 
September the same year. Data collection completion was in April 2010. Otherwise, 
dosing with the ‘heavy water’ occurred at night, which meant that a participant had to 
wake up to, undertake activities involved ahead of the actual appointment day. The 
‘heavy water’ and collection of urine samples was preferred at such a time when 
every participant was well rested but most importantly, to avoid meal and movement 
interference. Drawing blood plasma was first thing early in the morning first thing on 
arrival while still in an overnight fasted state to provide for fasting plasma glucose 
samples as well as that for lipid profile. While recruitment took place every Monday 
and Tuesday (on patient clinical days), the actual study activities were conducted on 
Wednesdays when there were no routine patient clinics conducted at the facility of 
the study to maximize participant concentration and engagement as well as maximum 
use of space and equipment at the medical facility. In the timeline (Section 3.3.6), 
Thursday and Fridays were devoted to analysis of the plasma samples and sourcing 
secondary information from participant files while data cleaning and entry as well as 
preparing for the following week’s data collection. 
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3.3.6 Timeline overview 
TIME LINE ACTIVITY 
PERFORMED 
During proposal writing Screened records for eligible 
participants, trained on 
relevant methods 
After ethical 
approvals and study 
endorsement 
Sensitized the community and 
fixed appointment dates for 
study activities 
Instructions on ‘heavy water’ 
to take home, other procedural 
rules, night phone call 
reminder 
During phase data 
collection - Monday and 
Tuesday 
On the appointment day - 
Wednesday at about 8.30 
am 
Received urine samples, drew 
plasma, participant ate, 
completed anthropometry, and 
BIA measures  
At about 10.30 am 
Self-reports on morphological 
alterations, photos for those 
who consented, questionnaire 
on lifestyle 
Provided transport 
Reconciled day’s work 
Thursday and Friday was for 
chemistry analysis 
At about 12.30 pm 
  
62 
 
3.3.7 Instruments for recruitment  
Before recruitment into the study, one underwent sensitization in larger groups at the 
reception area while awaiting action by the Triage Nurses on the day of clinical 
appointment. Only patients who showed interest on completion of the larger group 
sensitization sought further face-to-face discussion with the researcher. During this 
time, detailed verbal and written participant information (Appendix 3), indicating 
study purpose, requirements for participation and procedure for the activities was the 
focus. Upon consent, request to sign and return the consent form before engaging in 
any of the study activities followed. After signing, each participant received 
instructions for the consumption of ‘heavy water’ and provided with urine sample 
bottles. Instructions for collecting urine samples on a Tuesday evening were clear. A 
phone call followed on the night (Tuesday) preceding the actual individual 
appointment day (Wednesday); and this was to remind the participant(s) of 
instructions she had been given. This reminder was a repeat of both the verbal and 
written information given and the aim was to enhance recall of the procedure on 
heavy water consumption and urine sample collection. 
 
3.4 Data management 
3.4.1 Data collection 
Data collection occurred in three sub-studies:- nutritional status and body 
composition (Chapter 4); lipodystrophy and medication profile (Chapter 5) as well as 
metabolic syndrome and risk factors associated with the syndrome (Chapter 6).  
3.4.2 Anthropometric measurements 
Anthropometric measurements included body mass (kg) and height (cm) from which 
BMI in kg/m
2
 was calculated. Body mass was measured using a digital electronic 
personal scale (ES811) while a locally made stadiometer from the World Food 
program (WFP) Uganda, substituted for a height board. Sum of skinfold thickness 
measurements (mm) included triceps, biceps, subscapular and suprailiac sites using a 
Gima Plimetro - skinfold calliper (Gima Spa, Italy) plus girth measurements (cm) at 
the waist and hip using a flexible tape measured to the nearest 1.0 mm and 0.1 cm, 
respectively. Measurements took an approach according to the protocols of the 
International Society for the Advancement of Kinanthropometry (ISAK, 2001). The 
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overall aim was to assess the physical characteristics of participants using a 
comprehensive anthropometric protocol and to predict body composition based on 
these measures using standard equations. Details of measurements follow:- 
a) Body mass 
With a glass digital electronic personal scale (ES811) placed on a stable, flat surface 
and a participant on an empty stomach and bladder as well as minimal clothing/ 
ornaments, mobile phones, keys and shoes, weight recording was possible to the 
nearest 0.1 kg. The same observer took two measurements and the mean of two 
measurements recorded as the body weight score. When the first two measurements 
differed by > 0.5 kg, a third measurement was taken and the median value used. 
Calibrating electronic scale each day before use by a known weight of 2 kg soy flour 
was the norm. 
b) Height 
Recording height was in the upright standing position with a locally available 
stadiometer in a vertical position with equipment placed on a flat surface. The 
participant removed footwear or headgear. She then stood on the measuring board 
with shoulder blades, buttocks, and heels in contact with the vertical surface of the 
stadiometer. In addition, feet were in a flat position on the floor, slightly apart, legs 
and back straight and arms hanging comfortably at the sides. The participant stood 
“straight and tall” and to look straight ahead. An assistant (the recorder) checked that 
the participant stood flat-footed with the knees fully extended, with shoulders and 
buttocks in line with the heels and the head in the Frankfort plane. Then, the movable 
headpiece brought to rest firmly on the crown of the participant’s head while the head 
held so that the participant’s eyes pointed straight ahead. The measurer read the 
measurement to the nearest 0.1 cm, recording the mean of two measurements as the 
body height score. When the first two measurements differed by > 0.5 cm, a third 
measurement was taken and the median value used. 
 
Body mass index value as weight (in kg) divided by height squared (in meters): BMI 
= weight (kg) / height (m
2
) and the standard cut-off points retained (WHO, 2000; 
Seidell and Flegal, 1997). Although there is no agreement about cut-off points for the 
percentage of body fat that constitutes obesity (WHO, 1995), an estimation of body 
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fat derived from BMI was through procedures elsewhere (Jackson et al., 2002). The 
latter is adapted for age and sex: Adult percent body fat (see, 4.6%) = (1.39 x BMI) + 
(0.16 x Age) – (10.34 x gender) - 9 (female gender coded as zero). 
c) Skinfolds measurements 
The Gima Plimetro - skinfold calliper was the choice upon checking the correct jaw 
tension and gap width. For consistency, skinfold measurement had to be on the right 
side of the body. After marking each of the sites, the measurer pinched the skin at the 
site to raise a double layer of skin and the underlying adipose tissue, avoiding any 
muscle tissue. The calliper was applied 1 cm below and at right angles to the pinch, 
taking the reading in mm after approximately two seconds. Two measurements to the 
nearest mm (except in values ≤ 5 mm for which the nearest 0.5 mm was the option) 
and the mean of two measurements recorded as the skinfold thickness score. 
However, when the first two measurements differed greatly, a third measurement was 
taken and the median value used. Skinfolds sites included triceps, subscapular, 
biceps, calf, abdominal and iliac crest to determine fat distribution pattern. The Gima 
Plimetro - skinfold calliper was consistent through standardization before each test as 
per the manufacturer’s manual. 
 
An estimation of body composition was made by calculating body density in gm/ cc 
based on the mean sum of four sites and FFM according to the table developed by 
Durnin and Womersley (1961), adapted for age and sex. Body density was calculated 
to be equal to 1.1567 - 0.0717 (logX) where X was sum of four skinfolds (triceps, 
biceps, subscapular and suprailiac [which is equivalent to iliac crest using the ISAK 
protocol]). Fat mass content, thus, was estimation from the body density values 
above using the Siri equation (1954), namely, (4.95/ body density – 4.50) and FFM as 
weight minus FM. Consequently, percent body fat (see, depending on age group) = 
[(4.95/ body density – 4.50)] x 100. 
d) Girths 
Using a flexible girth tape, the upper relaxed arm (maximum), calf (maximum), 
abdomen (at the umbilicus) and waist (minimum) circumferences were measured to 
the nearest 0.1 cm, the latter at the end of expiration. Hip circumference to the 
nearest 0.1 cm at the widest point around the hips and buttocks as viewed from the 
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participant’s side and in both situations, two measurements to the nearest cm and the 
mean of two measurements recorded. In the event that the first two measurements 
differed greatly a third measurement was taken and the median value used. The 
flexible tape was standardised by calibrating each day against a standard HACO 
school ruler. 
 
WHR was equal to the division of the waist girth with the hip girth. WHR = WC / 
hip circumference as adapted from Janssen et al. (2002) (Table 8). At the time of 
conducting the present study, no definitive validated cut-off points were in known for 
HIV patients, 0.80 was the option as the normal limit based on Molarius and Seidell 
(1998); < 80 cm was the low risk cut-off (WHO, 2000).  
 
Table 8: Waist: Hip ratio cut-off points for women 
Acceptable  Unacceptable  
Excellent  Good  Average  High  Extreme  
< 0.75  0.75 - 0.80  0.80 - 0.85  0.85 - 0.90  > 0.90  
 
Waist: Hip ratio assessed for nutritional status in addressing aims of the initial sub-
study, while the other girths measures used in relation to questions of body fat 
distribution in the second sub-study. In addition to circumferences of the upper arm 
(relaxed) (maximum), calf (maximum) and abdomen, skinfolds at the calf 
(maximum) and iliac crest assessed for fat distribution pattern across the body. Arm 
muscle circumference and AMA were calculated using a standard formula 
(Frisancho, 1990) AMC = mid arm circumference (cm) minus  × triceps skinfold 
(mm)/ 10. While AMA (cm
2
) = (AMC (cm
2
))/ 4 . A related study reported that 
measures of WC and WHR increased in HIV-associated lipodystrophy syndrome 
(HALS) patients (Andersen et al., 2003). In this study, HALS patients were also 
slightly heavier than control subjects, which the reporters thought were due to an 
increased lean body mass in the former group. They also reported that the percentage 
of limb fat was significantly reduced in HALS patients compared with patients 
without lipodystrophy (36% vs. 46%; p = .0002) (Andersen et al., 2003). An 
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important fraction of participants in another major but related study reported that 
25% to 34% participants revealed peripheral lipoatrophy or 13% to 34% central 
obesity (Saint-Marc et al., 2000). Furthermore, most recently, Torriani et al. (2006) 
reported reduced calf subcutaneous fat area (17.8 vs. 35 cm
2
, p < .0001) and 
extremity fat by DXA (11.8 vs. 15.6 kg, p = .024) but increased VAT (125.2 vs. 74.4 
cm
2
, p = .004) in a study of 46 women (25 of whom displayed fat redistribution) and 
21 controls, respectively. This study sought to compare findings with those reported 
elsewhere. Specifically, by finding if the circumferences have any relations with the 
WHtR and the existence of fat redistribution across the two study groups. In the 
study, WHtR is the ratio of the WC (cm) to the height (m). 
3.4.3 Diet and nutrition history - meal and food frequency 
A participant was to reveal the number of times on an average day, when they 
typically consumed meals/ snacks. These times included breakfast, break, lunch, 
evening snack, and supper, and if they had any other meal or snack, to which they 
were required to specify. In addition, one had to indicate the average number of days 
in a week they often ate foods in different food groups (Table 9). 
 
Table 9: Food groups for average weekly consumption 
Food  5 - 7/ wk half the wk rarely never 
Fruits     
Vegetables     
High fat (e.g. fat cuts of meats, poultry, whole dairy products, palm oil, kimbo, 
cowboy, etc.) 
Low fat (e.g. low fat dairy products, fish, lean meats, refined cereals, legumes, 
roots and tubers) 
Whole cereals and grains     
 
In addition, there was a question on consumption and use of vitamin or nutritional 
supplements. If an answer was yes, then a request for details of the type or brand 
name and how much they used per day followed. 
 
 
  
67 
 
3.4.4 Consumption of coffee, alcohol and smoking 
A participant had to reveal if they were in use of coffee, alcohol or cigarette at the 
time of the study. If the answer was yes, the respondent had to estimate how much 
they used on average per day. If the response was no, this response called for a 
question on when the habit was stopped if at all they ever did consume any of these. 
3.4.5 Activity level and exercise 
Each participant had to describe her general daily activity level, particularly, if one 
was living a sedentary, active or very active lifestyle at the time of the study. 
Following this, one had to respond to whether they were undertaking regular physical 
activity or not, the type of activity if they did, how long the activity lasts whenever 
this was done and how often the activity was performed on a weekly basis. 
Information on attitude towards physical activity in this population would enrich 
study findings. Therefore, on a scale of one to five (from not likely through to 
extremely likely), each participant was asked to complete the following statements 
about physical activity below.  
“Doing physical activity/ exercise …...” Not likely - Most likely 
i Allows me to cope with stress better 1 2 3 4 5 
ii Helps me avoid falling ill  1 2 3 4 5 
iii Gives me a powerful sense of personal achievement 1 2 3 4 5 
iv Improves my physical strength 1 2 3 4 5 
v Makes me strong and less dependent on others 1 2 3 4 5 
vi Improves my ability to concentrate on what I do 1 2 3 4 5 
vii Gets me occupied or kill boredom 1 2 3 4 5 
viii Causes pain/ soreness/ discomfort/ injury 1 2 3 4 5 
ix Makes me very tired 1 2 3 4 5 
3.4.6 Family medical history to diseases of lifestyle 
Finally, a participant had to indicate if they were aware of any medical history to 
diabetes, hypertension, stroke or any other heart related diseases in themselves or 
among their biological family members. With this question, one had to either say 
they were aware, not aware or not sure. The latter response scored very low values 
and was problematic during data analysis, consequently, the ‘not sure ‘response was 
classified as a missing value which improved interpretation of the analysis.  
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3.4.7 Data processing and coding 
A four-digit unique numeric identification was assigned upon recruitment. The 
unique number replaced a subject’s name in the statistical package for social sciences 
(SPSS) for windows (18.0 Inc, Chicago, IL, US) spreadsheet, where each row 
contained information for only that participant identified by their special four-digit 
numeric code. Values of data were all logically coded as numbers, whether they were 
numeric or nominal such as being on ART (1) or not (0) or even ordinal and so on. 
However, there was no need for indicating value labels for all the continuous 
variables such as body mass, height, WC etc; hence, the variables were entered as 
had been captured. 
3.4.8 Computer entry and verification 
On each day of data collection, coding and entry into the spreadsheet was complete. 
In addition to data checking against what was on the original case recording form to 
reduce inconsistency. Many times there was need to return to participants medical 
files to cross check for information where there seemed to be miscoding. Counter-
checking during the cleaning of the data, after entry, of any irregular variables was 
critical and this enhanced quicker correction. Before data analysis, initial frequencies 
guided data cleaning since this allows detecting errors. Missing values were because 
actually data was unavailable. On a higher note, distributions of continuous variables 
for outliers with box plots and scatter plots was mandatory. 
3.4.9 Quality assurance and data cleaning 
Reliability of tests ensured by calibrating all equipment, before each use as per 
manufacturer’s instructions, proved worthwhile. Furthermore, the same equipment 
was in use for all subjects and there was only one measurer for parameters of 
anthropometry and similarly one recorder to avoid inconsistency in measurements 
throughout the study period. A pilot study on ten HIV-infected and an equal number 
of those whose HIV status was unknown at the timing of piloting became a necessity, 
to enhance and standardize skills of measuring and use of equipment. In addition, the 
pilot examined anthropometric measurement errors; the technical error of 
measurement (TEM) that evaluates anthropometric measure imprecision. The TEM 
is the standard deviation between repeated measurements taken independently by one 
observer (intra-observer) or between measurements performed by multiple 
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anthropometrists (inter-observer) (Norton, 1996). Indeed, findings of the pilot study 
were very informative on the feasibility and practicality of the initially proposed 
study activities that indeed improved the quality of the research. One such instance 
was for all participants having to undergo activities of urine collection during the 
night rather than daytime; resulting from the experience during piloting. During the 
pilot testing, it was difficult to standardize participant movement behaviour as 
several claimed to be in search of a clinician, having to attend to the sick, going to 
the banks, markets and so many other reasons. Additionally, it seemed also 
impossible to restrain participants from having meals during the times they should 
have been fasted while awaiting urine sample collection. Reasons for eating during 
‘restricted period’ ranged from having to ‘obey’ ARV – food restrictions (Appendix 
4). For the research to harmonize and standardize data collection with less external 
influences, the study resolved to taking of ‘heavy water’ and collection of urine 
samples at night when there were no required movements and when medication was 
long taken before retiring to bed. 
3.5 Safety issues 
Throughout the study time, there were no risk materials used and therefore there were 
no specific health and safety implications that arose from the study. This proves a 
point that stable isotopes; the ‘gold standard’ technique are indeed invaluable in 
clinical use like has been reported that there is virtually no health risk involved when 
used correctly (Mirinda-da-Cruz et al., 2003). 
3.6 Ethics 
Detailed participant information regarding study activities and an appropriate consent 
form both in English and an authentically translated copy (Appendix 3) were 
developed, certified and approved for use. At the start, an application to QUT 
research ethics approval committee number EC00171 was satisfactory and study 
accorded approval number 0800000621. Similarly, the Uganda National Council for 
Science and Technology (UNCST) approved and renewed the study for continuity, 
number 279/07/1. In the same way, the study received approval of Uganda Virus 
Research Institute (UVRI) GC/127/09/02/11 and so was with CDC - US (the major 
funding body to the study site) through CDC -Uganda as a Pro-forma as well as the 
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study site, Mildmay Uganda. There were no potential challenges met as far as ethical 
procedures were concerned and copies of all approvals are available (Appendix 3). 
 
Of emphasis was confidentiality, maintained at all times. To note also is that 
participants already have a 5-digit code used as the registration number for the 
routine HIV/AIDs care at Mildmay Uganda, maintaining the same number so as 
information is not lost since participants are entitled to feedback. The participant’s 
registration number matched with a 4-digit code and the latter used by all individuals 
that were involved in the research process including data collection and analysis. The 
5-digit code was and remains known and securely kept under key and lock in the safe 
cabins accessed by the principal investigator, already bound by the confidentiality 
agreement signed at the time of employment with Mildmay Uganda. A signed 
consent form was mandatory approval that a participant consented to undertake the 
study activities. The form provides for subjects aged between 15 and 18 years, and 
sought for consent from parent/ caretaker and the former’s understanding of being 
involved in the study. 
3.7 Overview of methodology 
This chapter has well illustrated that a cross-sectional approach was best suited for 
the present study and that both quantitative and qualitative data collection occurred. 
A pilot study that informed data collection steps preceded the data collection at 
Mildmay Uganda, a tertiary institution providing both specialized HIV/AIDs medical 
care and training services between July 2009 and April 2010. Women aged 15 - 49 
years were the study units and one had to either have been receiving ARVs for one 
year or more, or had to have been in care for a similar period but not yet on treatment. 
Patients on TB drugs, those with metal implants, the pregnant or those who required 
hospital admission did not take part in the study. Elaborated are steps for collecting 
data on anthropometric measurements; information on meal and food frequency; 
consumption of coffee, alcohol and smoking; activity level/ exercise as well as family 
medical history to diseases of lifestyle. Daily data entry with use of the SPSS 
(version 18) ensured quality. The study exposed no potential risks to the subjects and 
consequently received all the necessary ethical approvals. 
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Chapter 4: NUTRITIONAL STATUS AND BODY COMPOSITION 
4. Introduction 
The assumptions underlying the traditional methods for estimating body composition 
may not be valid in patients with HIV infection where body composition is likely to 
be different from that of the wider population. Thus, performing anthropometric 
measurements and using reliable techniques to establish nutritional status and body 
composition in the HIV-infected population remains of research interest. Clinically, 
body composition analysis along with non-pharmacological nutrition and physical 
activity prescriptions provide the foundation for further treatment. It is therefore of 
great importance to be able to evaluate changes in nutritional status and body 
composition that occur as the disease advances in PLHIV. Unfortunately, much of 
evaluations on this population are well uncommon in developing countries.  
 
One sure way to evaluate changes in body composition is the estimation of TBW, 
thus, increasing accuracy of these measures (Wang et al., 1998). Because, only body 
composition analysis can determine how much loss/ gain in muscle and fat there is in 
both health and disease, which proves the relationship between body composition, 
morbidity and mortality (Lahmann et al., 2002; Heitmann et al., 2000). In the latter, a 
low FFM index and a high body fat mass index relate to increased lengths of hospital 
stay. Thus, it is crucial to determine fat and lean body masses by direct measures, 
rather than relying on weight and the BMI only. This becomes much more critical 
especially while describing obesity and malnutrition-related mortality risk and 
clinical outcomes (Kyle et al., 2003).  
 
Obesity-related risk in HIV infection is currently inevitable. This is because reports 
suggest that infected populations are gaining excess weight (Ogden et al., 2006). One 
needs to establish FFM and FM, which makes it possible to evaluate nutritional 
status by comparing individuals or groups of individuals with themselves or with 
reference values. Because, total FFM body fat, can be calculated indirectly, as the 
difference between body weight and FFM (Kenneth, 2000). Unsophisticated 
anthropometric measures such as weight alone may not be very informative since 
weight gain may not necessarily come with corresponding gain in body mass (Silva et 
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al, 1998), even in HIV-infected persons. Kotler et al. (1989) showed that 
measurement of body weight alone failed to identify dramatic losses in BCM.  
 
The BIA is one of the closest to sophisticated techniques for estimating body fat and 
muscle, by utilizing impedance measurements of water contained within tissue, 
which gives an assessment of TBW. Through an indirect approach, predicting body 
composition becomes viable. Very recently, BIA, when compared to the method 
using anthropometry measures was reported to have a strong relationship to fat and 
lean mass, in drug naïve asymptomatic HIV-infected rural Kenyan women (Ernst et 
al., 2010). Anthropometric measures can also be applied to estimate body 
composition. For instance, prediction equations derived from skinfold thickness 
measurements are reported to provide good associations with the reference methods 
(Fogelholm and van Marken Lichtenbelt, 1997). Others Jackson et al. (2002) have 
extended prediction of body composition to the BMI; the measure of weight adjusted 
for height and does not measure body composition directly. The underlying 
assumption of using BMI to define obesity is that at a given height, higher weight is 
associated with increased fatness (Ashwell et al., 2005). There are effects of race-
ethnicity on body composition in healthy populations (Wagner and Heyward, 2000). 
Although several longitudinal studies in the area have been informative, they mostly 
exist in well do populations. To our knowledge, information is still lacking on many 
other races that are more likely to be malnourished, including HIV-infected 
Ugandans. Thus, use of standard techniques was critical to validating the usual 
techniques in environments such as Uganda where sophistication might not be close 
to routine care and use. This chapter aims to ascertain the uniqueness and relative 
clinical importance of the impact of HIV and associated treatment on the nutritional 
status and body composition changes that occur among Ugandan HIV-infected 
patients. Thus, the study assesses the nutritional status using a comprehensive 
anthropometric protocol that included skinfold thickness and circumference (girth) 
measures, and calculated anthropometric indices including the BMI and the ratios 
(WHR and WHtR). Furthermore, the study aimed at assessing TBW, and 
subsequently FFM and FM, using the BIA and deuterium oxide dilution techniques 
and predicting percent body fat from the usual 4-site skinfolds and the BMI. A 
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further aim in this chapter was to compare percent body fat predicted from deuterium 
oxide dilution technique between the AIDs-treated and the treatment naïve group. 
Consequently, the study addresses the following hypothesis: - that the nutritional 
status of the study participants was within acceptable ranges. A further hypothesis 
was that there is no significant difference in the percent body fat predicted from the 
BMI, skinfolds, the BIA and deuterium dilution techniques. Furthermore, that there is 
no significant difference in the nutritional status and the predicted percent body fat 
between AIDs-treated and treatment-naïve group. 
 
4.1 Methods 
4.1.1 Assessing TBW (and body composition) 
4.1.1.1 The BIA technique 
The assessment of body water is of a great diagnostic value and results in the 
estimation of body composition, a sensitive indicator of health and nutritional status. 
The main aim here was to assess TBW by the BIA technique and subsequently derive 
body composition values (percent body fat, FFM and FM).  The technique bases on 
the difference in resistance to current flow between the FFM and FM. The method is 
non-invasive, rapid, portable, convenient, technically precise, and highly 
reproducible (NIH, 1996). The manufacturers adopted the BODYSTAT® 1500 body 
composition monitoring unit (British Isles, UK) using a standardized protocol. This 
machine works by passing a safe battery generated signal through the body and 
measuring the impedance at a fixed frequency of 50 kHz. The following steps were 
followed while using the BODYSTAT
®
 1500 BIA machine in consideration of 
recommended standard conditions of the NIH in clinical practice (Kyle et al., 2004):-  
Taking of measurements was in a quiet and relaxed environment after a ≥ 5-minute 
rest period in a supine, with thighs apart and participant positioned on a flat non-
conductive therapy mat. On the right side of the body after cleaning the surface of the 
skin at each measurement site, a pair of electrodes was on the position of the right 
hand and wrist, and the right ankle and foot following a standardized procedure 
(Heyward, 1996). Then, bioelectrical impedance analysis resistance and reactance 
was measured using a tetra-polar impedance analyser with the participant’s arms and 
legs extended and not touching the sides of the body. The device uses two pairs of 
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electrodes with one electrode in each pair acting to administer the current and the 
other detecting the voltage drop, passing a small electrical current through the body 
and body composition estimated. Reading off results was directly from the machine’s 
digital display (Table 10); a machine calibrated using the manufacturer’s 
recalibration device before each use. 
 
Table 10: Recording results from the BIA out put 
characteristic Participant 
record 
Recommended cut 
offs  
remark 
Fat %   Body fat (%)  
Fat (kg)   Body fat (kg) 
Lean weight (%)   FFM (%) 
Lean weight (kg)   FFM (kg) 
Dry lean weight (kg)    
Water (%)   TBW (%) 
Water (litres)   TBW (L) 
BMI (kg/m
2
)  20-25  
WHR   ≤ 0.80 normal 
*R (Ω)    at 50 KHZ 
 
*R (the current resistance); TBW = 0.830 + 0.714 (Ht
2
/ R); FFM = TBW/ 0.7; FM = 
weight – FFM; percent body fat = FM/ weight X 100 
 
Predicting body fat from TBW measured by BIA 
The following equation was used to predict TBW (see, 2.50) = 0.830 + 0.714(Ht
2
/ R) 
and FFM (Dioum et al., 2009; Dioum et al., 2005; Schoeller and Luke, 2000; 
Zillikens and Conway, 1991; Kushner and Schoeller, 1986). The current resistance 
(R) was selected over impedance based on the assumption that less than 90% of the 
measured impedance in the human body is composed of R (Sun et al., 2003). 
Assuming that approximately 73% of FFM is water, FFM was TBW/0.73, and FM 
calculated as body weight - FFM (Forbes, 1996; Miranda da Cruz et al., 2003). 
Finally, FM defined, as percentage body fat was: 
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 (Weight - FFMTBW)/ Weight X 100 (Ellis, 2001). In other words TBW (see, 2.50) = 
0.830 + 0.714(Ht
2
/ R); FFM = TBW/ 0.73; FM = Weight – FFM. 
 
4.1.1.2 Deuterium oxide dilution technique 
The overall aim was to assess TBW by the deuterium dilution technique and 
subsequently calculate FFM and FM. The deuterium dilution technique was the 
reference, against which the measurement of body composition predicted using 
anthropometry (BMI and the usual 4-site skinfolds) and the BIA validated. Pre-dose 
urine determined the level of naturally occurring deuterium oxide in a participant’s 
body as detailed in the time line earlier elaborated. 
i) Preparation of the deuterium oxide dose  
To make a 10% solution of deuterium oxide, 100 mL of 99.9% atom 
(2845.10.0010/US/MKAA0789) together with 900 mL tap water, in a 1 L volumetric 
flask was thoroughly mixed. The solution was then divided evenly into four Schott 
bottles and autoclaved (2340MK N/B 136007, Tuttnauer autoclave steam sterilizer) 
for ten minutes at 134
o
C to sterilize. Six urine sample bottles clearly labelled with the 
participant code and date of assessment. A pair each, of the urine bottles was for the 
pre, 4-hour, and 6-hour (in duplicates) samples of urine. A pre-dose urine sample was 
obtainable from the participant by voiding the bladder. Participants were fasted for a 
minimum of four hours and assumed to be in a state of normal hydration and each 
dosed with weighed isotope. The weighed isotope was as estimate of 0.5 g/ kg body 
weight of a 10% solution of deuterium oxide. A post-dose urine sample then 
collected after four and six hours into the respective bottles. Samples were sealed, 
refrigerated and frozen below 18
0
C soon on collection. DHL Courier Company to 
IHBI, QUT in Brisbane (Australia) later delivered the frozen urine samples for 
analysis by isotope ratio mass spectrometry (IRMS; Hydra 20/20, SerCon).  
ii) Administration of dose 
The dose referred to as ‘heavy water’ was self-administered at the patient’s home on 
Tuesday night, using a sterile bottle whose cover was weighed using a Shimadzu 
electronic balance (BL3200HL) and tared the scale reflected values. The total take 
home ‘heavy water’ pack weights was the sum of the bottle + cover + calculated 
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dose. To account for any leftover dose in the cup, the bottle and cover after the 
participant drunk the dose was notable (Table 11). 
 
Table 11: Administration of the 10% solution of 99.9% deuterium oxide 
Subject 
ID  
Weight 
(kg) 
Required dose 
(0.5 x 86.6 kg) 
bottle + 
cover (g) 
bottle + 
cover + 
Dose (g) 
bottle + 
cover 
(post 
drink) (g) 
Actual dose 
(g) 
e.g. 101 86.6  43.3 g 4.15 g 47.66 4.23 g 43.43  
 
iii) Instructions to the participants on how to take ‘heavy water’ and 
collecting the urine sample 
The one page hand out material to a participant read: - On the night before your 
appointment for data collection, eat supper or dinner as usual. Go to bed the normal 
way and maintain or go into a fasting state of not less than four hours and this means 
you do not eat anything else after the usual supper for at least four hours. When you 
wake up to urinate towards early morning (for as long as it’s four hours or more since 
you last ate supper/anything else in the evening), collect urine in the two sample 
bottles marked ‘1’ (photo below). Drink the ‘heavy water’ immediately after that 
(note the time on paper). After another four hours from the time you have drunk the 
water, collect another urine sample in the two sample bottles marked ‘2’ (note the 
time again). Finally, ‘2’ hours from the 
time you collected urine sample ‘2’, 
collect another urine sample in sample 
bottles marked ‘3’ (note the time as well). 
NOTE: Do not completely fill the urine 
sample bottles but should be above half 
the bottle (cover tightly on completion. Do not eat anything from the time you drink 
the heavy water until you return to Mildmay, the next morning and, blood collected 
from you. The researcher (Hanifa) will give you the first meal to eat and you will 
then take your medication. Please do remember to come with all the six bottles and 
the empty ‘heavy water’ bottle (again remember to cover tightly please). For 
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clarification and reminders, call Hanifa on 0782 722303 or 0756 671209. On the day 
of dosing, duplicate urine samples in 20 mL sterile bottles filled starting with pre-
dose (marked bottle ‘1’), four-hour (marked bottle ‘2’) and finally the six-hour 
(marked bottle ‘3’) urine samples following the time of dosing (Table 12).  
 
Table 12: Urine sample collection timeline 
Timing Urine sample Received duplicate (tick) 
0.00 (≥ 4 hours since last evening 
meal, before drinking ‘heavy water’) 
Pre-dose (bottle 1) 
 
 
4 hour (= 4 hours after drinking 
‘heavy water’) 
4-hour (bottle 2) 
 
 
6 hour (= 6 hours after drinking 
‘heavy water’) 
6-hour (bottle 3) 
 
 
 
iv) Processing of the urine samples  
After receiving urine samples from each patient, they were re-labelled (photo below) 
to match the participant codes and immediately frozen below 18
0
C. At the end of the 
entire data collection exercise, Para-film sealed samples under dry ice pellets, and 
delivered by DHL Courier Company to QUT underwent analysis by IRMS (Hydra 
20/ 20, SerCon).  
 
The Hydra 20/ 20 at the QUT facility is a continuous-flow isotope ratio mass 
spectrometer system for measuring deuterium and oxygen-18 in aqueous samples 
following equilibration with a gas phase. It consists of a long deuterium spur 20-20 
stable isotope analyser with electromagnet (Sercon Cat. No.9014), gas auto sampler 
(Sercon Cat. No.17008) and 
an ABCA–G module 
(Sercon Cat. No.17010) and 
presently, gas samples for 
the isotope-ratio mass 
spectrometer in equilibration of the liquid sample with a gas. The usual gas for 
analysis of 
18
O is 99.99% CO2 and that for 
2
H is 99.99% H2. The CO2 put into the 
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liquid sample and exchanges unlabelled O for 
18
O from the water (Wong et al., 
1987). H2 is to the liquid sample and exchanges unlabelled H for 
2
H from the water, 
with platinum on alumina as a catalyst (Scrimgeour et al., 1993) and the gas sample 
into the system for on-line purification. A water trap of magnesium per chlorate, in 
the ABCA-G, removes moisture and the pure sample carried in a continuous stream 
of helium gas to the ionizer (in the Hydra 20/ 20). Helium gas is the carrier of choice 
because of its inert nature, high ionization energy, and low density. Within the Hydra 
20/ 20, ionization of the sample gas in the helium flow is by electron impact from 
electrons emitted from a hot filament within a high vacuum. Separation of the ions in 
a magnetic field is according to their mass to charge ratio (m/z). Then, measuring the 
current for each isotope mass as the charge generated by the ions impact a detector, 
called a Faraday cup.  
 
Hydrogen has a mass to charge ratio 2(H2) and 3(DH) and has two collector cups 
designated to collect masses two and three. Oxygen-18 measurements start on CO2 
molecular ions therefore; there are three collector cups to collect mass 44, 45, and 45. 
The most abundant and naturally occurring CO2 has a charge of 44 (
12
C
16
O
16
O), CO2 
with 
13
C having a mass of 45 (
13
C
16
O
16
O), CO2 with oxygen-18 has a mass of 46 
(
12
C
16
O
18
O). Standardization of the generated charge is against an internationally 
calibrated reference sample. The raw data is reprocessed using Hydra reprocessing 
software with the resulting data reported in Delta V-SMOW units or ppm. Correction 
for the H3
+
 by the Marquardt correction within the software supplied by Sercon 
(Cheshire, UK) suppliers of the Hydra 20/ 20 follows. Moreover, the data from the 
IRMS is set as unit, less delta value per mL (‰) with respect to a standard. Units to 
express isotopic abundance can be Delta V-SMOW (Vienna Standard Mean Ocean 
Water) or ppm, where the Delta V-SMOW units are δ or ‰. Between-unit 
conversion as 0 δ or 155.76 ppm for hydrogen and 0 δ or 2005 ppm for oxygen. 
Where ((R sample-R standard)/ R standard)  1000 = deltas. The international 
standard for 
1
H/
2
H and 
16
O / 
18
O is Vienna Standard Mean Ocean Water (V-SMOW) 
(Dolnikowski et al., 2005). These references are available from the IAEA while V-
SMOW is isotopic water standard defined in 1968 by the IAEA. 
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v) Predicting body fat from TBW using deuterium oxide dilution technique 
The concentration of 
2
H2O in urine was calculated as the 
2
H2O enrichment being 
equal to 6-hour 
2
H2O - baseline 
2
H2O and the concentration used to calculate the 
TBW. Hence TBW (kg) = [(W x A/a) x (Ea – Et)/ (Es – Ep)/ (1000 x 1.041)] 
(adapted from Abrahams and Wong, 2003) where: 
W = volume of tap water (mL) that (a) diluted in (200 mL) – used 200 mL; 
A = dose given in grams (bottle + cover + dose minus bottle and cover); 
a = amount of dose diluted in 200 mL; 
Ea = delta value of (a) the dose given in tap water; 
Et = delta value of tap water; 
Es = 6-hour delta value; 
Ep = delta value of pre dose sample (baseline sample). Assuming that approximately 
73% of FFM is water, the FFM = TBW/ 0.73, while FM = body weight - FFM 
(Forbes, 1996; Miranda da Cruz et al., 2003). Alternatively, FM can be represented 
as percentage body fat defined as (body weight - FFM)/ body weight multiplied by 
100 (Ellis, 2001). 
 
4.1.3 Data analysis 
Recording age was in years at the time of the data collection but categorical for 
analysis; into < 21, 21 - 30, 31 - 40 and > 40 years. First type error was set at 0.05 for 
all analyses. Chi square tested the degree of association of any categorical variables. 
Such variables included demographic values and any values less or equal and greater 
or equal reference cut-off points such as percent body fat (33% cut offs for obesity; 
Jackson et al., 2002), indices of BMI (based on Seidell and Flegal, 1997), WC 
(WHO, 2000) cut offs and WHR (Molarius and Seidell, 1998). For any categorical 
outputs with cells with more than 20% expected counts, Fisher’s exact was the 
option. An independent two-sample student’s t-test assessed differences between two 
means of the two groups at p < .05 significance 2-tailed level. Data exist as mean 
(standard deviation) unless stated otherwise. Pearson correlation analysed for 
relationships between the predicted percent body fat from BMI, sum of 4-site 
skinfolds and the BIA against that determined by deuterium oxide dilution technique; 
correlation coefficients above 0.80 are significant. Initial computation of the factors 
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is in a univariate analysis and if they demonstrate a univariate relationship (p < .05) 
with the outcome variable, they are included in the logistic regression analysis. 
Goodness-of-fit verification is by Hosmer and Lemeshow statistic method. Data was 
analysed using SPSS (18.0. Inc., Chicago, IL, USA). 
 
4.2 Results 
4.2.1 General results 
4.2.1.1 Participation by study group 
There were 211 participants, 123 (58.4%) of whom were receiving ARVs. The study 
aimed at achieving equal numbers in both groups. This was not realised because of the 
prevailing economic crisis at the time of data collection. Then, donor-dependent 
organisations like Mildmay Uganda, scaled down services towards AIDs care. In 
response, nearly all ‘clinically stable’ patients were to receive their medical care and the 
other services from community clinics rather than at the main site. Consequently, 
participants on prophylaxis (in many times clinically better since AIDs has not yet set in) 
were more stable and required to attend such clinics; thus, they were significantly hard to 
obtain.  
 
4.3.1.2 Participation by age 
On average, patients were 34.1 (7.65) years old. Majority (42.2%) of the participants 
were aged between 31 – 40 years (Fig. 1). The exposed group was younger 
(31.23±7.46) than the treated group (36.15±7.13) and the two were significantly 
different (p = .001). 
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Fig. 1: Overall participation by age category
 
 
4.2.1.3 Time on ART 
Study participants receiving AIDs medication were nearly three (2.8±1.9) years on 
HAART. Many (41.6%), were receiving CBV/NVP and others (27.4%) on either 
TDF/FTC/NVP, TDF/FTC/LPV/RTV, 3TC/D4T/NVP, 3TC/TDF/LPV/RTV or 
3TC/TDF/NVP (Fig. 2).  
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Fig. 2: HAART use by the medicated participants
  
 
At the time of data collection, up to 32 (26%) participants had ever changed drugs. 
Eleven (35.5%), ten (31.3%) and five (15.5%) had changed due to severe side effects, 
treatment failure and lipodystrophy in that order. One patient had changed because of 
pregnancy and another had been granted a drug holiday. The study could not 
establish reasons for changing drugs in five (15.6%) patients, for lack of information 
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in the respective medical files. Majority (91.9%) of the treated patients were 
receiving first line drugs and only 10 (8.1%) were on the second line; including four 
patients on TDF/FTC/LPV/RTV; three on 3TC/TDF/LPV; one on CBV/LPV/RTV; 
ddi/KLT/EFV and TVD/LPV/RTV each. 
  
4.2.1.4 Time with the HIV infection 
On record, only 198 (93.8%) patients had information on the date the HIV infection 
was diagnosed (Table 13). Thus, the mean time (years) with HIV infection since 
diagnosis was 3.95 (3.67) for the treated and 2.25 (2.21) for their counterparts and 
there was a between group difference (p = .001). Participants had on a whole lived 
for 3.2 (3.21) years with the infection. There is big variation in the average period 
one had lived with the HIV infection. This wide variation may be attributable to the 
fact that the study did not limit the maximum period one had to have lived with the 
infection before joining the study.  
 
Table 13: Time (years) with the HIV infection  
Time calculated from diagnosis date on record 
 Mean N Standard Deviation 
 
ART- Naive 2.25 87 2.21 
ART group 3.95 111 3.67 
Total 3.20 198 3.22 
Time calculated from participants (on possible initial infection recall dates) 
 ART- Naive 3.14 88 2.88 
 ART group 5.71 121 5.09 
 
Since not all participants had a date of initial infection diagnosis in the medical files, all 
patients had to recall as much as they could when they thought they had acquired the 
infection. Two hundred and nine participants could recall when they were initially 
infected, thus, had lived with the infection for 4.63 (4.78) years. AIDs-treated participants 
had lived longer (5.71±5.09) with the infection than the exposed group (3.15±2.88) and 
the study found statistically significant between group difference (t207 = 4.61, p = .000). 
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Since there were many participants that could recall the time at initial HIV infection, the 
latter is the period in use throughout the thesis. 
 
4.2.1.5 Results on lifestyle indicators 
i) Family medical history 
One hundred eleven (52.6%) patients were aware of medical history of hypertension 
in their families and so were in nearly a quarter (21.3%) with knowledge of diabetic 
history. Only 24 (11.4%) patients were knowledgeable of a history to stroke, while 
there were 34 (16.1%) patients aware of other heart diseases in their families (Table 
14). During analysis, all ‘don’t know’ responses were deliberately tagged missing 
values; there were no meaningful interpretations before this transformation. 
 
Table 14: Responses on knowledge of medical history of diseases of lifestyle 
Diseases  Frequency (%) 
Yes No Don’t know 
Diabetes 46 (21.3) 161 (76.3) 00 (0.0) 
Hypertension 111 (52.6) 99 (46.9) 01 (0.5) 
Stroke 24 (11.4) 184 (87.2) 03 (1.4) 
Other heart diseases 34 (16.1) 176 (83.4) 01 (0.5) 
 
ii) Food consumption frequency 
On a whole, less than half of the participants often consumed fruits. Specifically, 38.9% 
consumed fruits most (5 - 7/ week) of the days of the week (Table 15). On the contrary, 
low fats were highly consumed (84.8%), but participants rarely (58.8%) used high fats. 
 
Table 15: Participant average weekly food consumption 
Food group Frequency (%) 
Never Rarely Half the week 5 - 7/week 
Fruits 00 (0.0) 55 (26.1) 74 (35.1) 82 (38.9) 
Vegetables 00 (0.0) 49 (23.2) 79 (37.4) 83 (39.3) 
High fats (Fat cuts of meats, 
poultry, whole dairy products, 
3 (1.4) 124 (58.8) 35 (16.6) 49 (23.2) 
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palm oil, kimbo, cowboy) 
Low fats (Low fat dairy 
products, fish, lean meats, 
cereals, legumes, roots & tubers) 
00 (0.0) 07 (3.3) 25 (11.8) 179 (84.8) 
Whole grain and cereals 3 (1.4) 121 (57.3) 48 (22.7) 39 (18.5) 
 
iii) Other life style indicators 
Generally, (Table 16), many participants were not regularly using nutritional supplements 
(92.9%), alcohol (74.9%) or coffee (63.5%). Neither did they undertake regular physical 
activity (69.7%).  
 
Table 16: Participants’ other lifestyle indicators 
Indicator Frequency (%) 
yes No rarely 
Coffee 46 (21.8) 134 (63.5) 31 (14.9) 
Alcohol 30 (14.2) 158 (74.9) 23 (10.9) 
Nutritional supplements 15 (7.1) 196 (92.9) 00 (0.0) 
Regular physical activity 64 (30.3) 147 (69.7) 00 (0.0) 
 
However, one hundred twenty six (59.7%) participants reported to be lightly active, 45 
(21.3%) were active and 40 (19.0%) lived a sedentary lifestyle and there was a between 
group difference (p = .027). Specifically, many (75%) subjects receiving ARVs lived a 
sedentary life style (Table 17) and were different from their counterparts (p = .001). 
 
Table 17: Between group average daily physical activity level 
 ART group 
Frequency (%) 
ART-naïve 
Frequency (%) 
P-value 
Sedentary 30 (75.0) 10 (25.0)  
Lightly active 65 (51.6) 61 (48.4) .027* 
Active 28 (62.2) 17 (37.8)  
*statistically significant 
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At the time of data collection, thirty-two (15.2%) participants went walking (Fig. 3); 
while ten (4.7%) did jogging or gardening each and only a few did engage in the 
other physical activities. Accordingly, those who were involved in doing regular 
physical activity used an average of 39.10 (98.3) minutes for each exercise activity, 
for an average of 1.35 (2.4) days per week.  
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Fig. 3: Type of physical activity regularly performed
 
 
Additionally, on a scale of five (1 - 5) from ‘not likely’ through to ‘extremely likely’, 
(36.5%) participants reported that physical activity was ‘very likely’ to allow them 
cope with stress (Table 18). On the other hand, several participants reported that 
doing physical activity was ‘extremely’ (45.0%) or only ‘very likely’ (37.0%) to help 
them kill boredom. The latter attitude is unhealthy for a population like this since 
physical activity is widely reported to increase healthy gains. 
 
4.2.2 Anthropometry 
4.2.2.1 Body mass, stature and BMI  
On average, a subject weighed 61.7 (13.59) kg and the treated patients were not any 
heavier (p = .335) than their counter parts (62.5±13.36 vs. 60.6±13.92). Additionally, 
participants were on average 158.62 (6.5) cm tall, and there was no between-group 
difference (159.11±6.6 vs. 157.93±6.31; p = .195). The BMI data showed that the 
entire sample had a normal mean BMI (24.85±4.96), with no between-group 
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difference as well (p = .522). Furthermore, 46.4% were in the healthy range (18.5 – 
24.9 kg/ m
2
) while 7.1 % were underweight, and the two groups were not different (p 
= .837). 
4.2.2.2 Circumferences 
On average (Table 19), the mean (77.68±10.15) WC was considered acceptable (< 80 
cm) and there was no between-group difference (p = .118). In addition, 126 (59.7%) 
participants were determined to be at low risk (WC < 79 cm), 51 (24.2%) had an 
increased risk, while 34 (16.1%) had a substantially increased risk for central obesity. 
More details showed that there were no between-group differences (Table 19) in the 
means for the remaining circumferences. 
 
Table 19: Mean circumferences (cm) between the study groups 
Variable Girth mean (SD) Study group Group mean (SD) p-value 
Waist 77.68 (10.15) ART 
Naïve  
78.61 (10.18) 
76.38 (10.02) 
.118  
Abdomen 83.29 (12.73) ART 
Naïve  
83.74 (13.21) 
82.66 (12.09) 
.543  
Hip 97.46 (11.06) ART 
Naïve  
97.85 (10.35) 
96.92 (12.02) 
.547  
Calf 34.53 (3.47) ART 
Naïve  
34.37 (3.51) 
34.76 (3.41) 
.420  
Arm 29.41 (4.39) ART  
Naïve  
29.48 (4.33) 
29.29 (4.27) 
.745  
 
Moreover, other data (Table 20) showed that WC cut offs were independent of study 
group (p = .445). Further results showed that mean AMA (cm
2
) was 1.83 (0.24) and 
that there was no between-group differences (1.83±0.26 vs. 83±0.20; p > .05). 
Moreover, age was independently associated with each of the circumferences (WC = 
p < .0001; abdomen = p < .0001; hip = p < .0001, calf = p = .0230 and mid-upper 
arm = p < .0001). Nevertheless, the latter correlations (r) were weak (WC = 0.419; 
abdomen =0.427; hip = 0.340, calf = 0.157 and mid-upper arm = 0.303). 
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Table 18: Participant responses on the attitude towards physical activity 
Doing physical activity/ exercise: Not likely Slightly likely Moderately likely Very 
likely 
Extremely 
likely 
Not sure 
 Frequency (percent) 
Helps me cope with stress 11 (05.2) 10 (04.7) 43 (20.7) 77 (36.5) 60 (28.4) 10 (04.7) 
Helps me avoid illness 09 (04.3) 15 (07.1) 41 (19.4) 72 (34.1) 63 (29.9) 11 (05.2) 
Gives me personal achievement 08 (03.8) 08 (03.8) 38 (18.0) 79 (37.4) 73 (34.6) 05 (02.4) 
Improves my strength 04 (01.9) 03 (01.4) 18 (08.5) 95 (45.0) 91 (43.1) 00 (00.0) 
Gives me independence 05 (02.4) 07 (03.3) 27 (12.8) 100 (47.4) 70 (33.2) 02 (00.9) 
Improves my concentration 03 (01.4) 07 (03.3) 30 (14.2) 101 (47.9) 67 (31.8) 03 (01.4) 
Helps me kill boredom 09 (04.3) 05 (02.4) 22 (10.4) 78 (37.0) 95 (45.0) 02 (00.9) 
Causes me injury 58 (27.5) 58 (27.5) 56 (26.5) 27 (12.8) 11 (05.2) 01 (00.5) 
Makes me tired 44 (20.9) 48 (22.7) 48 (22.7) 49 (23.2) 22 (10.4) 00 (00.0) 
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Table 20: Categorised WC (cm) and BMI cut-offs between the groups 
  Frequency (%)  
Pearson χ2 
 
p-value 
 
Phi WC cut-offs  ART naive 
 
ART  
 
< 79 low risk 56 (63.6) 70 (56.9)  
1.618 
 
.445 
 
.088 80 – 87  increased risk 21 (23.9) 30 24.4) 
≥ 88 Substantially 
increased risk 
11 (12.5) 23 (18.7) 
BMI cut-offs between the groups   
< 18.5 underweight 6 (6.8) 10 (8.1)    
18.5 – 24.9 normal 43 (48.9) 54 (43.9)    
25.0 – 29.5 pre-obese 26 (29.5) 36 (29.3) 2.586 .764 .111 
30.0 – 34.9 obese class I 10 (11.4) 19 (15.4)    
35.0 – 39.9 obese class II 02 (2.3) 04 (3.3)    
> 40 obese class III 01 (1.1) 00 (0.0)    
 
Furthermore, as many participants as 120 (56.9%) had acceptable WHR. Of these, 77 
(36.5%) were in the good, while 32 (15.2%) were in the excellently acceptable 
categories. In spite of having many patients with acceptable WHR, 91 (43.1 %%) had 
unacceptable WHR; 28 (13.3%) and 15 (7.1%) of whom were in the highly and 
extremely unacceptable categories in that order. Being in the categories was 
independent of study group (χ2 = 5.008, p = .286). Lastly, the average WHtR was 
0.49 (0.06) and data showed no significant (p > .05) between-group differences 
[treated (0.49±0.06) vs. treatment naïve (0.48±0.07)]. 
 
4.2.3 Body composition 
Body composition assessed by the deuterium dilution technique showed there was no 
between-group difference in the TBW, FFM and FM. Additionally, the average 
percent body fat estimated from BMI was 31.30±7.37 and there were no between-
group differences (treated; 31.59±6.99 vs. treatment naïve; 30.18±7.77; p = .171). 
Other results showed that more than half (67.9%) of the participants receiving ART 
were obese (> 33 percentage body fat based on cut offs by Jackson et al., 2002) and 
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the two study groups were different (χ2 = 4.991; p = .025). Moreover, there was a 
close to medium Pearson correlation between fat estimated from the BMI and age (r
2 
= 0.438, p = .0001). Moreover, on modelling age and the study groups, the general 
regression model was significant (R
2
 = 0.083; p < .0001). Older age was the greatest 
single predictor of body fat, but explaining only 8.4% of the variation in the fat. 
Following this, data showed that BMI went up high (Fig. 4) with older age (F = 4.91, 
p = .003). However, there were no between-group differences (Table 20) in the usual 
BMI categories based on WHO (2000). 
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Fig. 4: Mean BMI across age categories
 
 
Secondly, the average percent body fat estimated from the four-site skinfolds was 
31.82 (7.05) and the study groups were similar (31.88±6.83 vs. 31.16±7.48; p > .05) 
(Table 26). Although significant (p = .002), age had low correlation (r
2 
= 0.211) with 
patients’ percent body fat estimated from skinfold measurements. Thirdly, the 
average percent body fat estimated from TBW predicted from manufacturer’s in-built 
BIA equation was 34.24±6.75, and similar between the groups (35.60±6.61 vs. 
34.11±7.25; p = .131), a significantly (p = .000) close to moderate correlation with 
age (r
2 
= .455). In addition, the average fat mass predicted from the equation 
suggested by Dioum et al. (2005) was 23.88 (10.40) and there were no differences 
between the treated and the naïve groups (p = .889). Green house-Geisser correction 
(p = .000) and a post-hoc comparison performed using Bonferroni adjustment (p = 
.000) indicate that fat mass estimated from the manufacturer’s inbuilt equation is 
higher (mean = 34.24, SD = 6.75, see = 0.473) than that (23.88, 10.71, 0.718) 
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predicted from the equation proposed by Dioum et al. (2005). Since neither predicted 
a difference in the FM of the two study groups, the manufacturer’s inbuilt equation 
remains in use throughout the rest of the discussions. 
 
There was some missing data in up to 19 (9.0%) subjects for TBW measured by the 
deuterium oxide dilution technique. Poor compliance with the procedural instructions on 
‘heavy water’ procedural resulted in some misleading results. Some participants did not 
drink the heavy water on time, while others missed timely collection of urine and in some 
instances, bottles for pre and post collections were mixed up. Wherever either of these 
occurred, the sample was not considered in the analysis. Thus, only 192 (91.0%) were 
included in the analysis for this technique and results showed that  the average percent 
body fat estimated from TBW measured by deuterium oxide dilution technique was 26.67 
(9.94). Unlike the other techniques, deuterium oxide dilution technique showed that there 
was a between-group difference in the mean percent body fat for the treated (27.91±9.39) 
and the non-treated group (24.97±10.48; p = .045). Thus, deuterium oxide dilution 
technique was the only approach to predict a statistical difference (Table 21) in percent 
body fat between the two groups but the difference showed a small effect (partial Eta
2
 = 
R
2
 =  0.021) (based on Cohen, 1988 guidelines). Unlike percent body fat predicted by the 
BMI (χ2 = 4.990, p = .025), all the other techniques showed no between-group differences 
in the cut offs for obesity based on Jackson et al. (2002). Moreover, 13 (6.8%) 
participants in the thin category according to BMI (WHO, 2000), were considered healthy 
according to Jackson et al. (2002) and none was determined to have excess fat in the thin 
category. Up to 76 (39.6%) subjects in the BMI healthy range were also considered 
healthy according to Jackson et al. (2002), while only nine (4.7%) had excess fat. 
Additionally, 54 (28.1%) in the overweight range were determined as normal, while 40 
(20.8%) had excess fat. 
 
The analysis extended to examine Pearson’s linear relationships among the four 
techniques. Accordingly, there was a highly significant (p = .0001), medium, linear 
relationship (r
 
= 0.443) between percent body fat estimated from the usual four-site 
skinfolds and that of the deuterium oxide dilution technique. This was similar to the 
highly significant (p = .0001), medium (r
 
= 0.563), relation between the BMI and the 
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BIA (r
 
= 0.522, p = .0001). Furthermore, repeated measures analysis indicated a 
violation of sphericity (Mauchly’s Test, p = .000). A Post-hoc comparisons 
performed using Bonferroni adjustment for multiple comparisons revealed that 
percent body fat quantified by all the four techniques was significantly different (p = 
.0001). To demonstrate this, the BIA estimated the highest percent mean body fat 
(35.24±6.75), followed by the usual four-site skinfolds (31.82±7.05), BMI 
(31.30±7.37) and the deuterium oxide dilution technique (26.67±9.94). Bivariate 
correlation analysis showed high correlations (r = 0.875) between percent body fat 
estimated by the BIA and BMI and the linear relationship was highly significant (p = 
.0001). However, data showed that there was moderate and highly significant 
correlations between the BIA and the four-site skinfolds (r = 0.691, p = .0001) and 
the skinfolds and the BMI (r = 0.751, p = .0001).  
 
Table 21: Between-groups percent body fat cut offs based on Jackson et al. (2002)  
Technique Group N ≤ 33% > 33% χ2 p-value phi 
 Frequency (%)  
BMI Naive 
ART 
211 62 (70.5) 
68 (55.3) 
26 (29.5) 
55 (44.7) 
4.990 .025* .154 
Skinfolds Naive 
ART 
211 51 (58.0) 
69 (56.1) 
37 (42.0) 
54 (43.9) 
0.072 .788 .018 
BIA Naive 
ART 
211 46 (52.3) 
49 (39.8) 
42 (47.7) 
74 (60.2) 
3.205 .073 .123 
Deuterium oxide 
solution 
Naive 
ART 
192 63 (77.8) 
80 (72.1) 
18 (22.2) 
31 (27.9) 
0.802 .370 .065 
*Statistically significant 
 
4.2.4 Percent body fat and the associated risk factors 
Age, time spent receiving ART, time with disease, being on medication and average daily 
activity level were assessed independently for any associations with the percent body fat 
estimated from the deuterium oxide dilution technique. Data showed a coefficient of 
determination (r
2
) of 0.109 and this indicates that only 10.9% of the variation in body fat 
could be explained by the variation in participant age (years). In addition, there was a 
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regression effect (p = .000). P-P plot of residuals showed that the resulting points lay 
roughly on a line with slope 1; hence having the same distributions, indicating the two 
data sets came from populations with a common distribution and so was with the random 
scattering about the horizontal line at level zero with no noticeable patterns in the 
standardised residual plot. In brief, only 11% of the variance in percent body fat could be 
explained by age and was highly significant (p = .000). A univariate regression revealed 
that for every 0.43 year increment in age, body fat increased by a percent (β = 0.430, see = 
0.089, p = .000).  
 
The study further assessed for an association with time on medication and results showed 
that only 3.5% of the variation in percent body fat was attributed to time receiving drugs 
(r
2
 = 0.035) and there was a regression effect (p = .048). The P-P plot of residuals showed 
that the resulting points lay roughly on a line with slope 1, hence having the same 
distributions, indicating the two data sets came from populations with a common 
distribution and this was so with the random scattering about the horizontal line at level 
zero with no noticeable patterns in the standardised residual plot. Independently, for every 
0.972 year increment receiving treatment, body fat increased by a percent (β = 0.972, see 
= 0.089, p < .006). More results showed a 3.3% variation in percent body fat attributable 
to time with the HIV infection (r
2
 = 0.033) and there was a regression effect as well (p = 
0.015). Both the P-P plot of residuals and the random scattering showed that the two data 
sets came from populations with a common distribution. In the end, data showed that for 
every 0.551 year increment with the HIV infection, body fat increased by a percent (β = 
0.551, see = 0.089, p = .000). In the same way, the study showed that only 2.1% variation 
in percent body fat could be attributed to being on ART (r
2
 = 0.021) and there was a 
regression effect as well (p = .043). Contrary, minimal (r
2
 = 0.003) and non-significant (p 
= .465) variation in percent body fat could be explained by average activity level.  
On using multivariable regression model, results (Table 22) indicated that only age was 
statistically significant (t = 4.295, p = .000) and consequently had a significant effect on 
the percent body fat.  
 
When time on ART was removed from the model, the time one had lived with the HIV 
infection became statistically significant (t = 2.066, p = .040) but with a smaller effect (β 
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= 0.458, see = 0.222). However, removing study group had no statistically significant 
effect on physical activity (t = -1.075, p = .284). The latter was so when physical activity 
was replaced with the group a participant belonged to (t = 0.243, p = .809). 
 
Table 22: Correlation coefficients before and after controlling for the other variables and 
the percent body fat 
N = 180 univariate multivariable 
Variable β (se) t-statistic sig β (se) t-statistic sig 
Age 0.430 (0.089) 4.810 .000* 0.435 (0.101) 4.295 .000* 
Time on ART 0.972 (0.348) 2.792 .006* - 0.071 (0.627) -0.113 .910 
Time with HIV 0.551 (0.225) 2.446 .015* 0.477 (0.281) 1.698 .091 
ART/ART-naive 2.940 (1.441) 2.040 .043* 0.396 (0.092) 0.189 .850 
Average daily 
activity level 
-0.380 (1.146) -0.732 .465 -1.176 (1.115) -1.055 .293 
*Statistically significant 
 
Associations with percent body fat and other life style factors revealed a statistically 
significant (F = 0.002, p = .001, R
2
 = 0.055) association with family medical history of 
diabetes, but not hypertension (F = 0.002, p = .968, R
2
 = 0.000) or average weekly 
consumption of high fat diet (F = 0.787, p = .502, R
2
 = 0.012). However, on modelling 
the above variables, results indicated that the overall model was statistically significant (F 
= 2.419, p = .008) and the effect size of partial Eta
2
 = R
2
 = 0.132 was large (Cohen, 
1988). Although highly significant, the model explained only 13.2% of the variation in 
the body fat and the life style factors [diabetes (F = .342, p =. 559), hypertension (F = 
1.627, p = .204) as well as the average weekly consumption of high fat diets (F = 1.651, p 
=. 180)]. Nonetheless, the interactions of these variables were significant. For example, 
history of diabetes and hypertension (F = 3.926, p =. 049), history of diabetes and average 
weekly consumption of high fat diet (F = 4.225, p =. 016) and that of hypertension and 
the high fat (F = 3.347, p =. 037). Despite significance in all these interactions, there was 
a very small effect size. Diabetes and hypertension explained only 2.2%. Diabetes and 
average weekly consumption of high fat diet explained only 4.6%, while only 3.7% of the 
variation was explained by a history of hypertension and high fat. 
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In brief, 211 patients were included in the nutritional status and body composition 
analysis. More than half (N= 123) were receiving ARVs. Only the average, a 
participant had lived for 34.1±7.65 years. Additionally, on average one had spent 
4.63±4.78 years with the HIV infection and close to three (2.8±1.9) years receiving 
therapy. Majority (91.9%) of the AIDs-treated participants were receiving first line 
drugs; 26% of whom had ever changed drug combinations. Of those who had ever 
changed drugs, 8.1% were receiving PIs and 15.5% changed drugs because of 
lipodystrophy.  
 
Although, mean BMI (24.85±4.96 kg/m
2
) was within the healthy range, many 
participants were malnourished; i.e. 7.1% were thin while 46.4% were overweight. 
Data showed acceptable mean WC (77.68±10.15), nevertheless, close to half were at 
some risk and there were no differences in all circumferences of the two study 
groups. Height and hip circumference considerations lowered the risk in this sample. 
Mean percent fat estimated from the BMI (31.30±7.37), the four-site skinfolds 
(31.82±7.05) and the BIA (34.24±6.75) independently correlated with ones’ age and 
the groups had similar percent body fat using those three techniques. In contrast, the 
criterion technique (26.67±9.94) established a difference in the two study groups (p = 
.045), although there was a small effect size (R
2
 = 0.021). Age (p = .000), time spent 
receiving ART (p = .048), time with disease (p = .000), being on ART (p = .000) 
were independently associated with patients’ body fat but age was the greatest single 
predictor (p = .000) after modelling these factors. Of the lifestyle indicators, only 
family medical history of diabetes was significantly (p = .001) associated with the 
body fat. 
 
4.3 Discussion 
4.3.1 Body mass and BMI 
The aim of this study was to establish the nutrition and body composition status of 
the group using a comprehensive anthropometric protocol. The latter included 
skinfold thickness and circumference (girth) measures. Anthropometric indices 
including the BMI and the ratios (WHR and WHtR) were also calculated. Body 
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weight, a relevant and an easy-to-use parameter for the follow-up of patients on ART, 
can indicate important clinical events including malnutrition (Mangili et al., 2006). 
Thus, taking body weight remains an important option in resource-limited facilities 
faced with high patient burdens, yet suffers shortages of staff and equipment scarcity. 
Using body weight, the present study found that on average, a participant weighed 
61.7 (13.6) kg, acceptable for an adult female. Most probably, it was because treated 
subjects had received ARVs for some time. The period on medication is relatively 
sound for the AIDs treatment to have stabilised the body mass, regardless of where 
one began, and consequently, the reason for the acceptable levels. In Uganda, one 
such occurrence is where patients who had been on treatment for 18 months recorded 
an average weight gain of 10.3 kg (Okongo et al., 2006). Moreover, treated 
participants of the current study had received ARVs longer (2.8±1.9) years than the 
18 months (1.5 years) of the 1996 study. 
 
On the other hand, 7.1% of participants were thin or considered underweight, a 
problem that could in part be because of HIV-associated wasting and inadequate 
nutrition. The two hasten disease progression and likely contribute to the strikingly 
high early mortality observed in several analyses (Johannessen et al., 2008). A 
decade ago, Forrester et al. (2001) revealed that principally, weight loss consists of 
fat loss in HIV-infected patients. This was confirmed a year later (Tang et al., 2002) 
and is ultimately related to survival and quality of life. Most recently, Mupere and 
team (2010) studied body composition among HIV-seropositive and HIV-
seronegative adult patients with pulmonary TB in Uganda. In the latter study, TB 
disease other than HIV infection was a dominant factor driving the wasting process. 
Current data cannot confirm this finding however, since medication for treating TB 
was one of the exclusion benchmarks. Participants with TB took longer to empty 
their bladders; the interpretation was lacking normal hydration.   
 
What is obvious is that underweight is a leading risk factor for preventable deaths 
and diseases. In developing countries like Uganda, maternal underweight is a leading 
risk factor for preventable deaths and diseases (WHO, 2002). Yet in Tanzania, 
patients with a BMI < 16.0 at ART-initiation had a double mortality rate compared to 
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those with a BMI ≥ 18.5. Thus, the 7.1% participants currently considered thin (based 
on BMI), are at risk for many reasons. Although the incidence of wasting syndrome 
has declined dramatically since the implementation of advances in ART, wasting still 
occurs, especially in individuals who are not receiving ART and who are of lower 
socioeconomic status - yet it often goes unrecognized, emerging subtly over a longer 
period of time (Tang et al., 2005). Together, these findings are supported by an 
analysis of 11 sub-Sahara African countries’ demographic and health surveys 
(Uthman, 2008). This analysis found that 10.3% of 15 - 49-year old HIV-infected 
women had BMI less than 18.5. Of particular note here is that, in the present study, 
like in Uganda (UDHS, 2006) and the rest of sub-Saharan Africa (Uthman, 2008), 
under nutrition still exists with or without HIV.  
 
Even when many researchers have questioned the usefulness of BMI compared to 
body mass alone, BMI still has a place in the clinic since BMI gives slightly better 
interpretation of one’s nutritional status than weight alone.. An extension to the 
usefulness of the BMI was the assessment of percent body fat per unit BMI, in which 
the mean ratio was 1.06 (0.346) (N = 192). The treated group was determined to have 
more percent body fat per unit BMI (1.11±0.31) compared to the group on 
prophylaxis (0.99±0.38), and there was a between-group difference (p = .024). 
Overall, this is a lower ratio than has been seen in other ethnic groups (Misra, 2003). 
Further analysis on the topic showed; firstly, that none among those considered thin, 
according to BMI, had excess body fat. With this, HIV-infected participants in the 
present sample with muscle wasting did not have extra fat. Secondly, 81.6% of those 
with excess fat were determined as overweight/ obese (according to the BMI). 
Moreover, this supports Morley et al. (2006), Forbes (2000) and Forbes (1987) who 
reported that pure starvation produces body composition in which weight loss goes 
along with more fat loss than lean tissues or sometimes in equal proportions. In 
response, there is neither sparing of lean tissue nor fat mass; since patients 
considered thin exhibited excess fat. Accordingly, BMI may reliably be used in a 
population from whom the present data was collected simply because the percent fat 
measures based on the deuterium oxide dilution approach did not alter the accuracy 
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of BMI as a measure for classifying individuals into the broad categories of 
underweight, normal and overweight. 
 
More data showed that BMI categories do not compare in some cases with the 
national outcomes (UDHS, 2006 and UDHS, 2011); in that, many (71.0% and 70%) 
women nationally are in the healthy range compared to the 46.4% of the present 
study. In other words, there are nearly three times as many overweight women in the 
current research than was reported, 17% and 19% nationally in the UDHS (2006) and 
UDHS (2011), even though UDHS data was not based on disease status. This may 
explain the changing ‘face’ of the HIV infection. During the early years, wasting was 
the hallmark of AIDs. For more than two decades now, isolating an HIV-infected 
individual was quick since the disease was associated with weight loss (Kotler et al., 
1989) at the time (and regarded as ‘slim’ for small in Uganda). Today, one may not 
easily isolate an infected person based on body weight alone. Early in the HIV 
epidemic, as people lived longer, weight loss and wasting was more of a problem. 
Currently, because of ARVs and better control of opportunistic infections, the longer 
PLHIV live, the more often weight becomes a problem. Therefore, the 46.4% 
overweight patients in the current study can be considered at risk of nutritional 
related conditions; associated with overweight and or obesity (Currier et al., 2008; 
Gallagher, 2007). Such risks include the metabolic syndrome and its associated 
effects.  
 
However, the issue of overweight and its associated health risks in African 
populations has not been in the lime light in the past. For a long period, African diets 
have been dependent on food from the original high-fibre meals to low carbohydrate 
meals (FAO, 1979). Overweight and obesity was previously not seen in Africa where 
people consumed unprocessed foods plus engaged in high physical workloads, 
especially women since there is less automation. In contrast to the traditional 
situation, current data revealed a high (84.8%) consumption of low fats and a rare 
(57.3%) consumption of whole grains and cereals. This may add to the explanation of 
the comparable trends of women’s nutritional status in the present study and 
generally in Uganda. Nationally, there has been minimal change in the percentage of 
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women with BMI < 18.5 reported more than 15 years ago (UDHS, 1995), but rather 
an increase in overweight, from 14 to 19% (through to 2011). Since there is an 
increase in overweight among the general population, there may be other general and 
or traditional risk factors contributing significantly to this overweight in Uganda. 
These general factors are, with and without the HIV infection. Nevertheless, those 
with the infection such as in the present data may be at three-fold risk for overweight, 
for reasons other than the traditional causes.  
 
There is a school of thought that the fear of being singled out as PLHIV and 
stigmatised in communities may be the reason that has led this population to hide 
behind a mask of overweight (Kaute, 2002). Moreover, this could be a potential 
explanation for the present data set. The masking may be due to ignorance of the fact 
that in the pre-ART era, extra weight may have been a good idea. At the time, the 
weight preserved one’s CD4 count and that they may feel it is right to have extra 
weight for protection from wasting and its associated health repercussions. Other 
reports suggest that PLHIV are gaining weight and beginning to approach weight 
levels seen in the general US population, in which approximately two out of every 
three adults are overweight and one in every four adults is obese (Ogden et al., 2006). 
Generally, there seems to be upward trend in weight gain in this population because a 
few years after more effective ART was introduced, 21% of women were obese and 
27% were overweight (Shevitz and Knox, 2001). Soon after, Hendricks et al. (2006) 
examined 321 HIV-infected adults in the years 2000 and 2003. The latter study 
reported that 29% of women were obese, and 34% were overweight, a tremendous 
obesity prevalence in that cohort. A decade now, close to half of women in the 
present HIV-infected sample is overweight/ obesity, nearly seven fold than wasting, 
as is found elsewhere (Amorosa et al., 2005). Latter researchers compared the 
prevalence of obesity and overweight among a large (N51, 689) urban population of 
HIV-infected participants on ART. Obesity (14%) and overweight (31%) were more 
common than wasting (9%). This signals a need for health workers to change caring 
approaches for PLHIV, as there seems to be a need to shift the focus to the 
prevention of overweight and obesity, to prevent the associated health risks. 
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Unfortunately, in light of these findings, as more efforts go into prevention of 
overweight and obesity, less effort could go in preventing the pandemic.  
 
Unlike current results, the above studies and observations by Hendricks et al. (2006), 
Justman et al. (2008) reported no indication of progressive obesity among an urban 
cohort of HIV-infected women followed over five years. While obesity remains a risk 
factor for disease(s) in many populations, some researchers have found that there is 
decreased risk of disease progression among overweight/ obese HIV-infected 
subjects. In a one study (Shor-Posner et al., 2000), over an 18-month follow-up 
period, investigators reported that BMI measurements among the HIV-infected 
cohort were inversely related to progression to death. Moreover, the measurements 
were also independent of CD4 cell count (< 200 cells/ mm
3
). In addition, the risk of 
declining CD4 cell counts was lower in overweight/ obese participants than in non-
obese participants; meaning that obesity did not impair immune functioning in this 
population. Shuter et al. (2001) also reported similar results among 189 HIV-infected 
subjects recruited from an urban HIV clinic. In that, overweight patients without 
AIDs experienced slower disease progression. They also had lower viral loads than 
participants who were not overweight. Yet this was regardless of similar time to the 
initiation of ART and similar baseline CD4 cell counts. In addition, the study 
reported that a lower baseline BMI and decreases in BMI over time were independent 
predictors of progression to AIDs. In a longitudinal study of 817 infected women 
(Jones et al., 2003), there was decreased risk of disease progression among 
overweight/ obese HIV-infected subjects, majority of whom were African American. 
 
4.3.2 Circumferences and ratios 
According to WC, 40.3% were centrally obese, and the treated were not different 
from the exposed group. However, this prevalence is five times greater than the 
prevalence (7.44%) reported in ART individuals by Geraix et al. (2008). Central 
obesity is attributable to central lipodystrophy (Schwenk et al., 2001). Increased 
trunk is because of VAT (Saint-Marc et al., 2000). In addition, this became a reality 
more recently (Brown et al., 2009) when after an average of six years of follow-up, 
WC increased at a faster rate in men with clinical evidence of lipodystrophy. On the 
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contrary, Justman et al. (2008) reported no indication of progressive obesity among 
an urban cohort of HIV-infected women followed over five years. At baseline 
(Justman et al., 2008), the HIV-infected group had greater WHR than the uninfected 
group (equivalent WC in both groups, with smaller hip circumference in the HIV-
infected than uninfected women did). Over the study period, waist and hip 
circumferences, and the WHR remained stable among HIV-infected women but 
consistently increased among uninfected women. Despite lower waist and hip 
measurements, HIV-infected women had higher WHR, most likely because of 
lipoatrophy associated with reduction at the buttocks. None the less, the current 
sample remains at risk of ill health regardless of the medication status, especially, the 
46.4% that were determined as overweight/ obese (according to BMI) plus a similar 
number (40.3%) considered to have had unacceptable WC, well knowing that other 
researchers have considered the latter as the best anthropometric correlate of 
metabolic complications. For instance, the latter was so in the prominent FRAM 
study (Scherzer et al., 2008) as was the case in another study (Panagiotakos et al., 
2009) where WC was the best predictor of hypertension. Furthermore, all the 
circumferences had a positive association with older age, even when the associations 
were very small.   
 
Central obesity problems are rising among HIV-infected populations. Although 
unacceptable levels of WHR may be high in PLHIV, the extent to which WHR 
compares with age-matched HIV-negative controls remains unclear (Lichtenstein et 
al., 2007). Presently, 43.1% participants have unacceptable WHR. Yet recently, 
Geraix and his colleagues (2008) reported unacceptable WHR in 38.3%, closely 
similar to the present findings.  Moreover, the problem of central obesity seems to be 
reducing once hip circumference effect is out. For instance, an Australian study 
reported a lower prevalence of newly diagnosed diabetes and dyslipidaemia in 
subjects with higher hip circumferences (Snidjer et al., 2004). The allegation is that 
people with high levels of fat around their abdomen have a large WC compared to 
the hips. In the present data, mean WC (77.68±10.2) and hip circumference 
(97.46±11.1) lowered the prevalence of unacceptable WHR, probably because only 
40.3% were determined with unacceptable WC. As such, it is most likely that PLHIV 
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perceive their hips to have decreased simply because they see extended waists. In 
support of this, a recent MACS publication (Brown et al., 2009) revealed that annual 
changes in hip and thigh circumferences were similar between groups of 33 men with 
clinical evidence of lipodystrophy. In the latter study, 23 HIV-infected men did not 
have clinical evidence of lipodystrophy, while 33 were HIV-uninfected. Another 
possibility is an underlying ethnicity influence, where in the Ugandan population you 
may find different body shapes from the populations that others have studied. Thus, 
even if there was an influence by disease or the medication, one may not rule out the 
influence of ethicinity in determining shape and where fat will be stored. There are 
no known studies on body shapes of women (15 - 49 years) in Uganda. However, 
ethnic differences can create a tendency to store fat and the variations in the sites of 
the fat storage exist between races. There would have been good insight had this 
study been a longitudinal observation showing changes over time, and much more 
better with comparison of races.  
 
Recently, scholars have proposed the WHtR as a common measure of central obesity. 
For instance, the cut-off level of 0.5 for both sexes is utilised in Asia (Ho et al., 
2003). In Europe, a higher range of 0.54 – 0.59 has more recently been suggested by 
Scheider et al. (2007) disqualifying that given by Ashwell and Hsieh (2005). The 
former urges differences in suggestions based on differences in methodologies for 
their studies. In the current data, a mean average of 0.49 (0.06) was obtained for the 
WHtR. Since the latter is from a diseased population in which the issue of obesity is 
currently causing debates, findings may be ‘safer’ than that of the Asian and 
European populations suggested above. 
 
4.3.3 Percent body fat 
Unlike with the deuterium oxide dilution approach, there was no between-group 
differences in percent body fat predicted by BMI, the usual four-site skinfold 
thickness measures and the BIA technique. Consequently, while BMI, skinfolds and 
the BIA are still largely applicable as routine clinical measures of body composition, 
the present study identified the limitation in detecting very small differences in body 
composition. To an extent, this finds support in deductions made by Moon and 
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colleagues (2008) that stable isotope techniques to measure TBW remain of large use 
in research context. The latter researchers also asserted that reliance on equations 
derived from such data might be of help should one require differences detected. 
Moreover, cut offs (> 33% at risk) in percent body fat predicted from the BMI were 
dependent on study group (p = .025) not the case with the other techniques. 
Particularly, many (67.9%) treated subjects than (32.1%) the exposed were 
determined obese (> 33% body fat); moreover, with a large effect (R
2 
= 0.154). This 
makes BMI a commendable technique in assessing obesity based on Jackson et al. 
(2002) recommendations; an unusual situation with the ordinary (WHO, 2000) cut 
offs. Based on WHO cut offs, current results showed that the two groups were not 
different (p = .764). Similarly, Joy et al. (2008) using the existing WHO BMI cut-off 
points, demonstrated similar levels of BMI (p = .60) among HIV-infected women and 
the control group. Presently, a critical explanation can be splitting data into more 
than two-way. Firstly, splitting data into six classifications of the BMI, three of the 
WC (WHO, 2000) and five of WHR (Jackson et al., 2002). Secondly, into the two 
study groups (the treated and exposed groups); thus, reducing the number of 
participants in each category, affecting significance. In addition, after splitting the 
BMI into the usual WHO classifications, there were > 33% cells with expected 
counts less than five meaning that these numbers were too small. However, when 
splitting data into only two divisions for obesity (≤ 33% healthy or > 33% at risk), 
there were still substantial participant numbers in each obesity category as not to 
reduce significance. This assumption can only be tested using larger sample sizes 
than presently considered. 
 
Moreover, according to Lohman (1992), for predictive techniques to be valid, the 
correlation coefficient must be greater than 0.80. In the present study, the medium to 
high correlations between techniques for predicting body fat are supported by 
findings form a study on HIV-infected persons in Thailand (Ludy et al., 2005). 
Moderate to high correlations were found between BIA and anthropometry (skinfold 
thickness and BMI). Additionally, the highest correlation (r = 0.860) was between 
BIA and skinfolds in the earlier study, but highest between BIA and BMI in our study 
(r = 0.875). We find support from another study by Shwenk and colleagues (2001) 
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who reported a high correlation between BIA and BMI (p < .001). Each of these 
bedside techniques may be  used interchangeably or individually in quantifying 
percent body fat. 
 
Repeated measures analysis revealed that BIA predicted highest percent mean body 
fat while the criterion technique predicted the least, and there was a between-group 
difference based on estimates by the reference technique. While we are aware that 
BIA’s capability in measuring total body fat is moderate (Snidjer et al., 2006), we 
can raise questions on whether the BIA machine (Body Stat 1500) and deuterium 
oxide dilution techniques can substitute for one another in predicting fat in the 
current sample. There was also a high disagreement in average fat determined by the 
single frequency BIA in the present research and recent one by Mupere et al. (2010). 
The latter reported an average percent body fat of 28 (10) in the 61 HIV-infected 
women with no TB, in Uganda. The potential reason for the differences could be the 
use of different equations.  
 
Despite similar mean values for skinfolds and BMI, there were no between-group 
differences, meaning that the two techniques may be used interchangeably in the 
clinical setting. In addition, they compared fairly well with results from the reference 
technique, whose capability in measuring total body fat has been demonstrated to be 
high (Snidjer et al., 2002). Despite this, we cannot ignore inaccuracies that may stem 
from the use of anthropometric measurements, including from inexperienced 
measurers. In the present study pilot work was undertaken to ensure that both TEM 
and percent TEM were within the recommended intra-tester limits (Gore et al., 
1996). The latter was true for both skinfolds (7.5%) and other anthropometric (1.5%) 
measurements. 
 
While time receiving treatment, time with the infection, being ART or not as well as age 
were independently associated with percent fat, age was the strongest predictor of body 
fat, remaining influential even in multivariate analyses. The influence of age on percent 
body fat earlier explained links BMI to older age. After all, BMI provides an 
approximation of relative total body fatness. Interestingly however, excluding time on 
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treatment from the model, with all the other variables intact, made time with HIV 
infection more informative, regaining influence on the body fat. Clearly, the longer people 
have HIV, the more likely they are to gain fat. Many more times, the latter happens with 
increased overall body weight. Most likely, this is because the issue of lipid abnormalities 
(including overweight and obesity)  has been said to occur in both HIV-infected 
individuals, whether they were on ART or not (Patella et al., 2004; Robinson et al., 2004; 
Miller et al., 2003; Huang et al., 2001). Therefore, HIV has a direct effect on nutritional 
status as suggested a decade ago (Kotler, 2000).  Nevertheless, while HAART is 
responsible for compounding any existing risk factors for lipid abnormalities (Villarroya 
et al., 2007), results of this sample did not find an influence of ARV use on percent fat 
when other factors are considered.  Probably, this is one of the concerns for whether the 
infection itself or the medication has the effect in these populations. Current findings 
contribute to this large debate.  
 
On the other hand, there was no influence by AIDs medication while in a model with 
other variables. Most likely, it is due to the fact that only 10 (8.1%) of the 123 participants 
on ART were receiving PIs. Yet PIs have been reported to have a greater impact on fat 
abnormalities (Caron-Debarle et al., 2010; Kovsan et al., 2009; Martinez et al., 2001), 
specifically fat accumulation (WHO, 2003). However, less representation of PIs most 
likely explains the lack of impact on this very matter. Less representation between those 
on first-line and second line combinations was not purposive but was related to the fact 
that, second-line regimens are often delayed unless the first-line drug combinations pose 
severe side effects including fat loss observed in NRTIs (Staszewski et al., 2003). In 
addition, drug combinations with PIs are more costly (NAM, 2009). Consequently, 
limiting quick initiation in addition to the fact that viral-load assessments upon which 
regimens find clinical alteration are limited in resource-poor settings (Ford et al., 2009). 
Elsewhere, we presume average daily activity level had no statistical significance in 
influencing percent body fat because as many 147 (69.7%) of the subjects did not engage 
in regular physical activity. Moreover, the small numbers that did exercise, took an 
average of less than two days per week (1.35±2.4), with a mean duration of 39.10 (98.3) 
minutes in exercise. Yet, many (45%) participants reported that engaging in physical 
activity would is extremely likely to kill boredom rather than reduce chances of illness. 
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Independently, medical family history of lifestyle diseases and high fat consumption did 
not influence the percent body fat.  Rather, there were interactions with very small effects. 
For example, diabetes and hypertension explained only 2.2%, diabetes and average 
weekly consumption of high fat diet explained only 4.6%, while hypertension and high fat 
diet explained 3.7% of the variation in the fat. 
 
In summary, a few patients were thin and this remains a problem nationally and 
across the Sub Saharan region. Many subjects were determined overweight, a 
problem reported by many other researchers. Unfortunately, the problem was three 
times higher than the general Ugandan population of women in the similar age group. 
The latter makes the present sample more risky - and may find explanation in other 
causes than the traditionally known. The BMI was considered a reliable technique 
since the approach maintained percent cut offs within the usual three broader 
categories, moreover, with a larger effect. Unfortunately, this was underscored when 
the usual classifications of WHO (2000) were considered which may be attributed to 
dividing the sample too finely. There was a between-groups difference in mean 
percent fat predicted by the reference technique although the difference was small. 
Lastly, while there were other indicators that were independently associated with 
percent body fat, older age was the strongest predictor.  
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Chapter 5:  LIPODYSTROPHY 
5. Introduction 
As the HIV pandemic continues, so is evidence building on other problems 
associated with the infection, including fat re-distribution (lipodystrophy). 
Lipodystrophy syndrome remains a problem (Villarroya et al., 2010; Villarroya et al., 
2007) with similar prevalence in the West, Africa, as well as Asia (Womack, 2009).  
 
Although the etiology of lipodystrophy remains poorly understood, in HIV-infected 
individuals, the problem occurs soon after the introduction of PI drugs in HAART 
regimens (Grinspoon and Carr, 2005; Martinez et al., 2001). Lipodystrophy is also 
present in some treatment-naive patients (Grinspoon and Carr, 2005; Dube, 2005; 
Patella et al., 2004; Miller et al., 2003; Huang et al., 2001). However, there is 
contemplation that HAART is responsible for compounding any existing risk factors 
(Villarroya et al., 2007; Saint-Marc et al., 2000; Carr et al., 1998). Clinical evidence 
links d4T and the development of lipoatrophy (Villarroya et al., 2010, Griensven et 
al., 2009; Wohl et al., 2006), but also to other factors. Problems of lipoatrophy have 
been previously associated with older age (Guaraldi and Baraboutis, 2009). Although 
equally linked to aging, long-term-treated adolescents or young adults perinatally 
HIV-infected display characteristics of lipodystrophy (Arpadi et al., 2009). Being 
female is another factor greatly associated with the problem (Chariyalertsak et al., 
2008; Homsanit et al., 2007; van Griensven et al., 2007; Jacobson et al., 2005). 
Others (Han et al., 2009; van Griensven et al., 2007) attribute the problem to longer 
time on AIDs treatment. 
 
Even when the problem exists, there is no single standardized method of defining or 
assessing lipodystrophy. While there is still an absence of a uniform definition (Tien 
and Grunfeld, 2004) and diagnosis (NAM, 2009) there is localized fat gain, a loss of 
subcutaneous fat, or the two conditions occurring in the same individual at the same 
time (NAM, 2009). Currently in use are objective measures such as anthropometry 
and skinfold measurement (Ketel et al., 2007), as well as DXA to assess the 
condition. Even then, self-report approaches combined with clinical examinations 
remain a necessity (Womack, 2009).   
  
107 
 
While the initial study determined that many participants were malnourished, with 
the problem of overweight/ obesity three times higher than the general Ugandan 
population of women in the similar age group, it becomes critical to assess the 
contribution of lipodystrophy to this form of malnutrition. Consequently, we assessed 
for presence and risk factors of lipodystrophy in the hope that the condition may be 
one of the non-traditional causes that explain the risk of over nutrition in this sample. 
Unfortunately, the most robust objective techniques considered as reference methods 
for quantifying lipodystrophy were not available in the current study. Accordingly 
and in line with the literature, the study assessed presence of lipodystrophy plus 
association with medication or disease status and/or, patient characteristics, through 
self-reports and body fat distribution by anthropometric (including the 
circumferences and skinfold thickness) measures and BMI. 
 
5.1 Methods 
5.1.1 Self-report data 
Self-reported changes in body shape included overall weight gain, size of the neck, 
breasts, abdomen, both upper and lower limbs and the face on a bi-directional scale. 
In addition, this gave chance to respondents to report any observed increased or 
decreased alteration at such body sites. Self-reports were an option because 
establishing the problem of lipodystrophy is frequently upon patient’s perception. For 
example, revelations show that patient’s perception correlates well with physical 
examination (Bacchetti et al., 2005). Recording of participant responses was in a 
format next (Table 23). 
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Table 23: Morphological alterations since HIV diagnosis 
Site Before start of ART (both groups) After start of ART 
(ART group only) 
Face   
Neck   
Breasts   
Abdomen   
Arms   
Legs   
Buttocks   
Overall weight 
change 
  
Other (specify)   
 
(Record increase, decrease or no change) 
 
5.1.2 Fat distribution measures 
To ascertain body fat distribution, the present study measured circumferences of the 
upper arm (relaxed) (maximum), calf (maximum), waist and abdomen as well as 
upper and the lower body skinfold thickness plus the calf (maximum) and iliac crest 
to the nearest two mm. Some experts have implicated PIs as the leading cause of 
lipodystrophy among HIV-infected persons (Grinspoon and Carr, 2005; Martinez et 
al., 2001; Saint-Marc et al., 2000). However, there is some evidence that long-term 
HIV infection could be implicated (Mondy et al., 2007). Therefore, we documented 
HAART profile, including if there had ever been change in medication(s) and 
consequently reasons for altering the drugs. Table 24 shows the ascertaining of 
information on medication from individual medical files. Additional information was 
the most recent CD4 counts and initial date at HIV diagnosis. 
 
5.1.3 Data analysis 
We examined the relationship of lipodystrophy with disease status, medication status 
as well as patient characteristics. Chi Square test and Pearson Chi-square tested the 
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degree of association of lipodystrophy and any categorical variables such as 
medication status. If there were any categorical outputs with many cells, with 
expected counts less than five, Fisher’s exact test became a choice. During analysis, 
association of lipodystrophy and any of the continuous variables (anthropometric 
measurements; time with disease; time on ART and recent CD4 counts; age) were 
examined with the independent-samples t-test between those who did and those who 
did not experience the problem of lipodystrophy. Significance was set at p < .050. A 
significant univariate analysis led to logistic regression analysis to assess the effect of 
independent variables. Hosmer and Lemeshow statistic method verified the 
goodness-of-fit. 
 
5.2 Results 
This sub-study aimed gained responses from participant self-reports on physical 
changes. Increased physical alterations included the appearance of a buffalo hump (at 
the back of the neck); increased fat deposition in the abdomen, breasts and visceral 
adipose tissue. In addition to decreased fat deposition on the face, arms, legs and 
buttocks; and ascertaining distribution of the fat around the body. Moreover, the 
study analysed data to assess for risk factors associated with the problem of 
lipodystrophy. 
 
5.2.1 Medications 
On average, patients had been on ART for 2.8 (1.9) y. Drug regimens varied greatly 
from one participant to the other. Many participants were receiving CBV/NVP 
(41.6%), followed by 3TC/AZT/NVP (14.4%), CBV/EFV (11.2%) and 7.3% on 
TDF/FTC/EFV (Fig. 5). The rest (27.4%) of the subjects on medication were 
receiving other combinations including, TDF/FTC/NVP, TDF/FTC/LPV/RTV, 
3TC/d4T/NVP, 3TC/TDF/LPV/RTV, 3TC/TDF/NVP. 
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Table 24:  Participant medication profile 
ART class Example (circle/write out) *HAART 
(Yes/no) 
Medication start date 
(DD/MM/YYYY) 
Time on medication 
(years) 
Reverse 
Transcriptase 
Inhibitor 
NNRTIs 
efavirenz- EFV, nevirapine – NVP, etravirine, 
delavirdine  
Atripla 
Kaletra 
Combivir 
Trizivir 
Epzicom 
Truvada 
  
NRTIs 
abacavir -  ABC, didanosine – ddi,  
lamivudine – 3TC, stavudine – d4T, tenofovir – 
TDF, zidovudine – AZT, emtricitabine - FTC 
 
Protease 
Inhibitor 
indinavir – IDV, lopinavir – LPV, nelfinavir – 
NFV, ritonavir – RTV, saquinavir – SQV, 
darunavir, atazanavir – ATV, fosamprenavir, 
tipranavir – TPV, kaletra 200/50- 
(lopinavir+novir) 
 
 
*Atripla – tenofovir + emtricitabine + efavirenz; *Kaletra – lopinavir + norvir; *Combivir – lamivudine + zidovudine; *Trizivir – 
abacavir + lamivudine + zidovudine; *Epzicom – lamivudine + abacavir; *Truvada – tenofovir + emtricitabine 
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41.6%
14.6%
11.2%
7.3%
27.4%
CBV/NVP 3TC/AZT/NVP CBV/EFV TDF/FTC/EFV others
P
ar
ti
ci
p
an
ts
 (
%
)
Drug combinations*
Fig. 5: Drug combinations in use
  
*Drugs: - efavirenz- EFV, abacavir -  ABC, didanosine – ddi, lamivudine – 3TC, 
stavudine – d4T, tenofovir – TDF, zidovudine – ZDV, emtricitabine – FTC, indinavir 
– IDV, lopinavir – LPV, nelfinavir – NFV, ritonavir – RTV, saquinavir – SQV, 
darunavir, atazanavir – ATV, fosamprenavir, tipranavir - TPV 
  
Moreover, as many as 113 (91.9%) patients in this group were on first line regimens. 
In the entire treated group, only 10 (8.1%) participants were receiving a second line 
regimen. The latter were on drug combinations that contained PIs. These include four 
participants that were receiving TDF/FTC/LPV/RTV, three on 3TC/TDF/LPV and 
one, each on CBV/LPV/RTV, ddi/KLT/EFV and TVD/LPV/RTV. Some of the 
reasons on record for having ever had to change drug regimens ranged from 
treatment failure (8.1%), lipodystrophy (4.1%), and severe side effects (8.9%). In 
addition, less than 1% for pregnancy related reasons, as well as being on drug 
holiday. Five (4.1%) patients were receiving regimens with d4T, 28 were receiving 
EFV (22.8%) and 90 (65%) were on other drugs. Protease inhibitors, d4T and EFV 
are associated with lipodystrophy. Actually, all present participants receiving PIs 
reported living with a problem of lipodystrophy. Therefore, were up to 22 
participants receiving EFV and three on d4T. 
 
Overall, 99 (46.9%) participants reported no lipodystrophy. However, 112 (53.1%) of 
all respondents had at least one morphological alteration, 98 (87.5%) of whom were 
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receiving treatment for AIDs and there was a between-groups difference (χ2 = 83.75, 
p = .000). Furthermore, 16 (7.6%) participants experienced lipohypertrophy, 23 
(10.9%) confirmed lipoatrophy, while 73 (34.6%) had mixed alterations. Each 
morphological alteration at a specific site was coded a value one and a sum of each 
subject obtained. Moreover, data shows that there was a mean of 1.38 (min - max, 0 - 
9) points for a gain fat and 1.72 (0 – 13) for the losses. There was a higher mean gain 
in fat among the treated (2.218; CI, 1.696 – 2.74) than did in the participants on 
prophylaxis (t126 = 8.415, p = .000). 
 
5.2.2 Presence of lipodystrophy ascertained through self-reports 
5.2.2.1 Fat gain 
More than half (56.1%) in the 
treated group reported a gain in 
body weight (Table 25), vs. only 
seven (8.0%) participants in the 
other group. In the former group, 
thirty-two (26.0%) treated 
participants reported an 
expanded abdomen (similar to 
photo next). It was a related 
complaint among 23.6% each that gained fat on the face, breast, arm as well as legs 
and 21.1% who gained at the buttocks. Very few participants in the naïve group 
reported fat gains.  
5.2.2.2 Fat loss 
Data showed that ten (11.4%) of the group on prophylaxis reported loss in overall 
body weight. Moreover, some participants lost fat on the abdomen (3.4%) and the 
breasts (3.4%), while a few (2.3%) also reported loss of fat on other parts 
(comparable to photos below). However, there were more fat losses among the 
treated group including the 18 (14.6%) participants that lost the overall weight.  
A participant with an 
increased trunk 
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A 42 year old participant with decreased buttocks (left) 
and another with a depression at the side of the knee 
(right) 
Some participants experienced both a gain and loss concurrently, many times with 
visual evidence of localized subcutaneous fat atrophy or fat redistribution (next 
photo). Data shows a higher mean sum of fat losses (2.456; CI, 1.811 – 3.101) in the 
treated group than in the group on prophylaxis, with a between groups difference (t164 
= 7.52, p = .000). 
 
 
 
 
 
 
Same person with 
decreased lower limbs 
(right) and an 
increased bust (left) 
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Table 25: Morphological alterations (%) reported by the participants 
 ART group N=123; ART-naïve N=88 
Site  Study groups Gains (%) Losses (%) No alteration (%) 
Face Treated group 
Naïve group 
29 (23.6) 
00 (0.0) 
08 (6.5) 
26 (2.3) 
86 (69.9) 
86 (97.7) 
Neck Treated group 
Naïve group 
24 (19.5) 
00 (0.0) 
06 (4.9) 
02 (2.3) 
93 (75.6) 
86 (97.9) 
Breasts Treated group 
Naïve group 
29 (23.6) 
00 (0.0) 
06 (4.9) 
03 (3.4) 
88 (71.5) 
85 (96.6) 
Abdomen Treated group 
Naïve group  
32 (26.0) 
00 (0.0) 
07 (5.7) 
03 (3.4) 
84 (68.3) 
85 (96.6) 
Arms Treated group 
Naïve group 
29 (23.6) 
00 (0.0) 
08 (6.5) 
02 (2.3) 
86 (69.9) 
86 (97.7) 
Legs Treated group 
Naïve group  
29 (23.6) 
00 (0.0) 
14 (11.4) 
02 (2.3) 
80 (65.0) 
86 (97.7) 
Buttocks Treated group 
Naïve group 
26 (21.1) 
01 (1.1) 
11 (8.9) 
02 (2.3) 
86 (69.9) 
85 (96.6) 
Overall weight Treated group 
Naïve group 
69 (56.1) 
07 (8.0) 
18 (14.6) 
10 (11.4) 
35 (28.5) 
71 (80.7) 
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5.2.3 Presence of lipodystrophy ascertained through body distribution 
5.2.3.1 Circumferences and other anthropometric measurements 
Detailed results on circumferences in the previous chapter revealed that mean WC 
was acceptable, with no between-groups differences. In addition, 126 (59.7%) were 
at low, 51 (24.2%) at increased, while 34 (16.1%) were at substantially increased risk 
for abdominal obesity consequences. More results showed a mean circumference of 
(97.46±11.06) at the hips, abdomen (83.29±12.73), calf (34.53±3.47) as well as 
AMC (29.41±4.30). Further data shows an average AMA of 1.83 (0.24) and that 
none of the circumferences was different among those who, ever experienced 
lipodystrophy and those who did not [WC (p = .110); hip (p = .390); abdominal (p = 
.223); Calf (p = .784) and AMC (p = .503)]. Other anthropometric measures not 
associated with the problem included WHR (p = .114), WHtR (p = .390), body 
weight (p = .176) and the BMI (p = .301). Contrary to these, associated with the 
presence of lipodystrophy was percent body (p = .014). In fact, 70 (68.6%) of the 
participants that reported to have the problem were determined to have < 33 percent 
body fat. Similarly, 32 (31.4%) participants were considered obese and the two 
groups were statistically different (χ2 = 3.92, p = .048). 
 
5.2.3.2 Skinfold thickness 
Results (Table 26) showed a mean skinfold thickness (cm) of 21.85 (10.94) at the 
abdomen; triceps (20.44±8.30); subscapular (19.71±10.51); medial calf (19.18±8.04); 
iliac crest (16.82±11.29) and 12.85 (7.20) at the biceps. Further data (Table 26) 
shows that only subscapular skinfolds were thicker (21.61±11.27) among those in 
whom lipodystrophy existed than those in whom there was no problem (17.55±9.17; 
p = .004). Other relationships showed no significant differences in the mean 
skinfolds thickness measures of the treated and naïve groups. 
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Table 26: Skinfolds thickness measures 
Skinfold 
site 
N=211 
Mean (SD) 
Std. Error Mean (SD) of  
Lipodystrophic participants 
Mean (SD) of  non-
Lipodystrophic 
participants 
P-  value Mean (SD) of the 
treated vs. naïve 
P-  value 
Triceps  20.44 (8.30) .57 21.25 (8.34) 19.53 (8.21) .134 20.69 (8.00) vs. 
20.09 (8.74) 
.603 
Biceps  12.85 (7.19) .49 12.77 (7.46) 12.93 (8.93) .868 12.12 (6.69) vs. 
13.87 (7.77) 
.081 
Subscapular  19.71 (10.52) .72 21.61 (11.27) 17.55 (9.17) .004* 20.65 (10.72) vs. 
18.39 (10.14) 
.125 
Iliac crest  16.82 (11.29) .78 17.98 (12.76) 15.51 (9.26) .107 17.24 (11.91) vs. 
16.24 (10.41) 
.525 
Medial calf  19.18 (8.04) .55 19.54 (8.71) 18.78 (7.23) .492 19.29 (8.44) vs. 
19.03 (7.49) 
.816 
Abdominal  21.85 (10.94) .75 22.71 (11.91) 20.87 (9.71) .220 22.41 (11.11) vs. 
21.05 (10.71) 
.376 
*statistically significant 
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5.3 Factors associated with lipodystrophy 
Analysis showed that the form of morphological alteration was highly dependent on 
receiving ARVs (χ2 = 94.482, p = .000). Specifically, while 25 (20.3%) treated 
participants did not, 11 (8.9%), 15 (12.2%) and 72 (58.3%) did experience 
lipohypertrophy, lipoatrophy and mixed alterations in that order. On the other hand, 
less for the majority (84.1%) that did not, five (5.7%), eight (9.1%) and one (1.1%) 
participant confirmed similar experiences in the exposed group. More data showed 
that the type of morphological alteration (lipohypertrophy, lipoatrophy or mixed 
presentations) experienced was dependent on receiving PIs (Fisher’s exact χ2 = 
113.591, p = .000). Moreover (Table 27), participants that had experienced 
lipodystrophy had been on ARVs for an extra 1.79 years than those who had not 
(0.71±1.44) and the two were different (t209 = 6.739 p = .000). In addition, those with 
lipodystrophy had the lower CD4 count (343.19±237.75) than did in the group with 
no lipodystrophy (465.45±239.6) and the two were different (t207 = 3.694, p = .000). 
At the end of it all, ART exposure was the strongest factor associated with the 
problem of lipodystrophy (Exp (β) = 0.040, p = .000), when other independently 
significant factors were considered in a single model. Removing the factors one at a 
time did not alter the effect of ART exposure nor was there an improvement on the 
status of the other variables. 
 
Table 27: Risk factors for lipodystrophy 
 Lipodystrophy exists 
Mean (SD) 
No lipodystrophy 
Mean (SD) 
t – test value p - value 
Time on ART 2.41 (2.10) 0.71 (1.44) t209 = 6.739 .000* 
CD4 counts 343.19 (237.75) 465.45 (239.6) t207 = 3.694 .000* 
Time with 
HIV 
10.89 (6.54) 8.74 (5.29) t125 = 1.915 .045* 
Age  35.09 (7.32) 32.98 (7.90) t209 = 2.013 .045* 
*statistically significant 
 
Lastly, exposure to treatment and anthropometric measurements that had an 
association with lipodystrophy was in another model. The former (Exp (β) = 0.046, p 
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= .000), but not the subscapular skinfolds (Exp (β) = 1.042, p = .050) and the percent 
body fat (Exp (β) = 1.010, p = .649) was associated with presence of lipodystrophy. 
 
5.4 Discussion 
The research examined the existence of lipodystrophy through self-reports and 
distribution of fat around the body by use of anthropometric measurements. It was 
important to quantify both fat losses and gains separately in our sample since this 
seems a problem elsewhere. Briefly, results showed that more than half of the 
participants had experienced at least one morphological alteration. Specifically, 7.6% 
reported to have lipohypertrophy, lipoatrophy (10.9%) and the mixed experiences 
(34.6%). Majority of the treated participants, moreover, all that were receiving PIs 
reported to have the problem. Additionally, time spent receiving the medication, 
receiving PIs, CD4 counts, time with the infection as well as older age were 
independently associated with lipodystrophy. Even then, receiving treatment was the 
greatest predictor of the problem.  
 
Present revelations find support in a recent review of articles and abstracts on the 
problem of lipodystrophy in Africa and Asia. In that review, Womack (2009) 
reported that the problem of lipodystrophy ranges between zero to 69.6%. Because of 
the high frequency (34.6%) of the mixed forms of morphological alterations in the 
present sample, higher than lipohypertrophy and lipoatrophy combined, one may 
suggest that the two may have some causal relationship. Actually, not all 
morphological alterations have to occur together in the same person or with the same 
frequency. To illustrate this, a number of studies (Villarroya et al., 2007; Grinspoon 
and Carr, 2005) have shown that subcutaneous loss of adipose tissue occurs relatively 
frequently, whereas the dorsocervical lipomatosis is more unusual. In short, the same 
patient may show lipoatrophy in the face and arms, and an enlarged fat pad in the 
dorsocervical area. Years back, display of mixed forms of the problem was in as 
many as 50% of patients observed by Miller and group (2003). In addition, data 
showed that up to 56.1% in the treated group reported gain in overall body weight. 
Although it is the group in which obesity and overweight have been said to be more 
common than wasting (Amorosa et al. (2005), this weight gain may or may not 
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necessarily be regarded as lipohypertrophy. It is for the fact that three decades ago, at 
the start of the epidemic, PLHIV were likely to die much younger, but with ART, 
they can now have longer, improved lives and this may not mean lipohypertrophy 
unless proven otherwise.  
 
Nearly all patients started on ART, once after stabilizing, will gain weight (Okongo 
et al., 2006). Weight gain is typically a contribution of weight from all the other body 
parts Furthermore, it is likely that before the start of ART, patients may not be able to 
afford regular high-protein and high-calorie meals needed for weight gain and for 
restoration of lost BCM. Often, this may be due to poor health and reduced energy 
depending on clinical staging of the HIV disease. Nonetheless, it can be the reverse 
once one’s health and quality of life improves, while on AIDs treatment (Wools-
Kaloustiana et al., 2006). There is no doubt that additional food contributes to weight 
gain among HIV-infected Ugandans (Rawal et al., 2010). Current data was collected 
through a cross sectional design rather than a longitudinal approach, therefore 
explanations to the likely causes of the reported gain in fat can only be assumed. On 
the other hand, weight gain before start of ART among newly HIV diagnosed cases is 
in many times because they generally must start on cotrimoxazole/ septrin 
prophylaxis. Sometimes one may need to take isoniazid to prevent TB, and other 
opportunistic infections in patients with low CD4 counts. An earlier study established 
correlations between low CD4 cell counts and weight loss (Wanke et al., 2000), yet 
the reverse prevents attacks and or any other opportunistic infections that would have 
otherwise subjected the body to higher demands for nutrient intake. Inevitably, a 
patient stops losing weight or in many times gains, some weight. In addition, there 
are many other services aimed at providing holistic care that generally improves a 
person’s quality of life and consequently better health even when they have not 
started on ARVs. At the time of study and at the site of the present study, such 
services included pastoral care, social work and counseling, nutritional advice, 
physiotherapy, occupational therapy and children's rehabilitation within its palliative 
care package. There were other clinical services like diagnostic laboratory 
investigations, electrocardiography, eye specialist care, dental care and ultrasound 
among others. On a whole, all such services contribute to good quality holistic and 
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comprehensive care. In the end, any recipient gains an improved general wellbeing, 
especially among the PLHIV.  
 
Although more than half of the participants reported an gain in overall body weight, 
there were no differences in all circumferences and skinfolds (less for subscapular) 
thickness measures among the lipodystrophic and those who did not have the 
problem. Similarly, there were no differences in all skinfolds thickness measures 
between the treated and naïve groups. The discrepancy in the reported gain in fat 
between the lipodystrophic and their counter parts and the treated and the naïve and 
the anthropometric measures is most likely because the problem of lipodystrophy had 
receded at the time of undertaking the research. Thus, concerns of diagnosing 
lipodystrophy problems through cross sectional research designs become 
questionable. Moreover, this can be worse upon use of rudimentary methods for 
assessing the problem. However, present responses on overall weight gain were not 
necessarily surprising. Simply because, there are reports of frequent fat accumulation 
(Jacobson et al., 2005; Galli et al., 2003) in women. Particularly, women gain more 
fat in the central areas (McComsey et al., 2009). Indeed, since start of treatment, 26% 
had increased on the abdomen. Nevertheless, since the weight gain experienced 
during fat distribution may not necessarily come with corresponding gain in body 
mass (Silva et al., 1998), there is need for alternate methodological approaches for 
patients who report a gain in overall weight. Because, mean BMI (24.85±4.960), WC 
(77.68±10.15), WHR (0.80±0.07) as well as percent body fat (26.67±9.94) were 
within acceptable levels. Yet, the means were not different among those who 
experienced lipodystrophy and those who did not. Only percent body fat and the 
subscapular skinfold thickness were different in such categorisation. 
 
Breast enlargement, another manifestation of lipohypertrophy, exists in 24% of the 
treated subjects. This problem, infrequently seen in both men and women is expected 
once glandular fatty tissue increases (Mauss, 2000). Earlier explanations show central 
enlargement seen in 26% of the treated patients as central lipohypertrophy (Bacchetti 
et al., 2006). The latter usually occurs after two months of ART initiation (Kratz et 
al., 2008). Although the WHR is becoming of interest in these populations; in 
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showing morphological alterations (since reduction in the hip circumference is said 
to be accompanied by an increase in WC), the present study has reservations 
supporting this theory, because the present data showed no differences among those 
who reported to have the problem and those who did not. Probably, this is because 
even if a patient has a mixed experience, fat from the periphery does not necessarily 
move to the central stores (NAM, 2009). Another suggestion could be to the fact that 
patients with higher total body fat prior to HAART and a positive energy balance 
may present with further increases in trunk, breast, and dorsocervical fat. Whereas, 
patients with lower total body fat and neutral or negative energy balance may present 
with decreased limb or facial fat (He et al., 2005). If the latter holds, present findings 
may suggest that PLHIV in countries, whose prevalence for obesity is high for the 
general population, may be ─ determine higher prevalence’s of more fat gains. 
Particularly, at body sites affected by lipohypertrophy, because they are starting off 
with higher total body fat prior to HAART or even before acquiring the infection. It 
might then be the reason that there are presently fewer lipohypertrophy 
lipohypertrophic cases, since means of measures of the BMI, WC, WHR and percent 
body fat are healthy.  
 
Other results showed that 23% of participants receiving ART observed 
lipohypertrophy in the legs since the start of treatment. Moreover, since initial 
increases in fat of limbs can predict long-term peripheral lipoatrophy (Calmly et al., 
2008); it is likely that the prevalence of the latter will be higher as the patients 
continue to live. This becomes more than predictable because problems of 
lipoatrophy have been associated with older age, being female (Chariyalertsak et al., 
2008), as well as length of time on AIDs treatment (Han et al., 2009). In a 24-month 
cohort study to assess correlates of risk of lipodystrophy over time, Galli et al. (2003) 
found that about 55% of women on treatment developed ATAs. The ATAs were 
independently correlated with use of PIs in the initial 12 months (OR 2.81, p = .002) 
but by the end of 24 months, ATAs significantly related to overall duration of ART 
(OR 1.85, p = .041). Present findings draw from such revelations for a potential for 
the current sample to meet the criteria for the lipodystrophy as long as they enjoy 
increased chances of survival because of receiving medication. However, even when 
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lipodystrophy is currently associated with older age, further analysis indicated that 
some cases (3.6%) with the problem were < 21 years of age; which could mean that 
adolescents and young adults are neither any safer. Actually, long-term-treated 
adolescents or young adults perinatally HIV-infected do also display characteristics 
of lipodystrophy (Arpadi et al., 2009). In addition, in Western countries, long-term 
HIV-infected patients recently encountered several age-related co-morbidities earlier 
than the general population (Guaraldi and Baraboutis, 2009). It is known that aging 
adipocytes release more pro-inflammatory cytokines than young ones (Wu et al., 
2007) and consequently risk much more than the young ones do, in depositing body 
fat. It is also certain, that individual genetic makeup is responsible for influencing the 
occurrence of lipohypertrophy. Not long ago, genetic polymorphisms were a 
significant link to ART-associated lipodystrophy (Zanone et al., 2008).  
 
While gains in fat were evident, lipoatrophy existed in the present sample. This 
problem is associated with (recent) weight loss (Tien et al., 2007; van Griensven et 
al., 2007; Lichtenstein et al., 2001; Carr et al., 2000). In the present research, data 
showed that at localized sites, the problem was lower than fat gains reported at those 
very body locations. Women do suffer less fat loss (McComsey et al., 2009) and 
actually, only 23 (10.3%) women had lipoatrophy in the entire sample. Supporting 
our findings is the FRAM study where loss of subcutaneous fat, clinically apparent 
was primarily in the face, limbs and the buttocks and was generalized (Bacchetti et 
al., 2006). However, the prevalence is generally less than what others have reported. 
One such report is the fat loss problem in HIV-1 male patients on HAART assessed 
using a questionnaire and clinical examination that was in 14% of the 168 patients 
who had been on HAART for a median length of 17 months (Worm et al., 2002). 
However, the 14% prevalence is actually in men who by gender differences do 
experience less of the problem than in the women. Moreover, the latter finding was 
consistent with an earlier study where lipoatrophy was in 14% of the patients who 
had been on HAART for a median of 18 months (Martinez et al., 2001). Nearly twice 
as high was a 29.1% prevalence reported among Serbians (Jevtović et al., 2009); in 
which study the probability of developing lipodystrophy reached 100% by 10 years of 
medication and the median time was seven years. Nevertheless, our data showed a 
  
123 
 
much lower median time (2.2 years) on AIDs treatment, which could in part explain 
the lower prevalence. Elsewhere (Mutimura et al., 2007) in the region, a much higher 
prevalence of the problem has been reported; in their study, lipodystrophy was 
determined in 34% among 571 individuals placed on WHO-recommended first line 
ART in Rwanda. This prevalence (34%) went as far up as 70% after 72 weeks on 
ART. Seventy-two (72%) percent of whom presented with peripheral lipoatrophy 
combined with abdominal lipohypertrophy. Lipoatrophy is most commonly in 
patients responding well to therapy (Grinspoon and Carr, 2005). Majority (65.2%) of 
the present participants with lipoatrophy were receiving ART.  
 
There is mounting evidence on classes or individual ARV drugs in causing 
lipoatrophy. Firstly, there is clinical evidence linking d4T (NRTI) and the 
development of lipoatrophy (Villarroya et al., 2010; Griensven et al., 2009; Wohl et 
al., 2006). There was evidence when patients switched from d4T to TDF or NVP plus 
LPV/r; there was an improved fat mitochondrial function and decreased oxidative 
stress (Gerschenson et al., 2009; Negredo et al., 2009). Despite this evidence, only 
five (4.1%) patients on HAART were using d4T in the present research. In addition, 
none of these experienced lipoatrophy per se, contrary to a review on implications of 
d4T by Villarroya et al. (2010), but three of them reported lipodystrophy. On the 
other hand, since two patients experienced mixed alterations, it is likely that the fat 
losses attributed to d4T can be in part, explained in the two cases. Secondly, although 
initial studies revealed no role for EFZ (NNRTI) in lipodystrophy (Miller et al., 
2003), much recently the ACTG A5142 study reported that lipoatrophy was more 
frequent with EFZ than LPV/r (PI) when combined with NRTIs (d4T or AZT) 
(Haubbrich et al., 2009). In the current data, 28 subjects were receiving EFV, 22 of 
these had lipodystrophy, five of whom reported lipoatrophy. Accordingly, there is 
need to reconsider drug combinations with EFZ while treating AIDs. Thirdly, in the 
present data, all the ten patients on PIs had lipodystrophy. There were equal numbers 
of patients with lipoatrophy (20%) and lipohypertrophy (20%) but many (60%) had 
mixed experiences. In 1996, soon after the introduction of PIs, patients developed a 
syndrome of fat redistribution with peripheral loss and central gain (Grinspoon and 
Carr, 2005). In fact, this should explain the majority that exhibited mixed alterations 
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in the current data. PIs are responsible for impairment in the ability of certain 
enzymes responsible for mopping up excess fat and keeping fat cells functional, an 
explanation why fat accumulates (Caron-Debarle et al., 2010).  
 
Current data finds support in the affirmation that women lose less limb fat 
(McComsey et al., 2009); because almost none of the naïve patients experienced 
lower limb fat loss. Even though abdominal fat loss was reported in very few 
participants (5.7% in ART vs. 3.4% in the naïve group), it is difficult to confirm if 
that was all since truncal subcutaneous fat atrophy is often less noticeable than fat 
atrophy elsewhere, especially if there is concomitant visceral fat deposition, keeping 
the waist circumference unchanged. Information on visceral fat deposition is lacking 
because it requires equipment that was not available to the researchers. 
Unfortunately, there is also less information from studies in the region, on patterns of 
lipoatrophy; which seems to be a general trend in poorly resourced settings (Boulle et 
al., 2006; Forna et al., 2006; Kim et al., 2005). Where documentation has been 
performed, it has been based on diagnosis of exclusion, retained as an explanation for 
(subcutaneous) fat loss after alternative explanations have been ruled out (Griensven 
et al., 2008 ). However, the eight (6.5%) treated patients who reported facial fat loss; 
18 (14.6%) in general weight, legs (11.4%) and buttocks (8.9%) are to an extent 
attributable to generalized fat loss that is because of HIV infection itself. 
Alternatively, due to HIV-associated wasting syndrome commonly observed in this 
population since the methodology employed could not rule out the substantial loss of 
lean tissue mass. HIV wasting syndrome is involuntary weight loss greater than 10% 
of baseline weight (CDC, 1992). It is usually associated with either chronic diarrhoea 
for at least 30 days, chronic weakness, or documented fever for at least 30 days in the 
absence of a concurrent illness or condition other than HIV infection that could 
explain that. Unfortunately, participants were not asked in how many days back fat 
loss was observed, but rather what was seen since HIV diagnosis until the day a 
patient underwent study activities for the naïve group while those in the ART group 
were asked about the pre and post ART eras separately. Generally during primary 
HIV infection – which may be asymptomatic or experienced as acute retroviral 
syndrome; at the clinical stage two, HIV-infected persons go through a phase of 
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physiological changes including minor weight loss (WHO, 2005). This only gets 
worse during clinical stage three of this infection – that includes unexplained chronic 
diarrhoea, unexplained persistent fever, oral candidiasis or leukoplakia, severe 
bacterial infections, pulmonary tuberculosis, and acute necrotizing inflammation in 
the mouth (WHO, 2006). Some persons with clinical stage three have developed 
AIDs already; otherwise, weight loss becomes inevitable during clinical stage four – 
that includes 22 opportunistic infections or cancers related to HIV. There are many 
other factors associated with weight losses in this population. Other losses can be due 
to poor nutrition, nutrient malabsorption, and disturbances in metabolism (Mangili et 
al., 2006). Others may include lack of safe and potable water, poor hygiene and 
sanitation, psychological stress because of fear for death, neglect and discrimination 
as well as the influence of poor social and economic status. With or without HAART, 
weight loss remains inevitable in HIV-infected patients (Tang et al., 2002). Being on 
ART and still experiencing weight loss can be due to the persistence of HIV in 
peripheral blood monocytes and macrophages (Shikuma et al., 2005). Subcutaneous 
fat losses of 20% are the criterion for fat loss (Haubrich et al., 2007). Other 
researchers have thought it should range between 40 – 50 % (McComsey et al., 2004; 
Moyle et al., 2005). However, in poorly developed countries, problem diagnosis is 
after the patient presents a complaint. By the time, there is probably limited 
estimation of how quickly and how much subcutaneous fat has occurred, due to lack 
of baseline information. Actually, there was no proper estimation in the current cross 
sectional study of how much fat had been lost, thus, the study relied on getting self-
reports of whether one had noticed any loss or not, at localized body sites. Self-
reports were an option because they are recommended where other priority 
equipment cannot be used (Womack, 2009). For consenting patients, a record is in 
place of photos whose expression does not substitute for serial photography used to 
calculate a longitudinal score of the problem. 
 
Less for self-reports, lipodystrophy was assessed by anthropometric measures, 
including skinfolds measurements that have an advantage over other anthropometric 
methods since they can analyze fat according to body segments. Results showed that 
patients were mostly thicker at the abdomen, triceps, subscapular, calf, iliac and the 
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biceps in that order. Yet, there were no significant differences in the mean skinfolds 
measures at all these body sites between the treated and the naive group. 
Accordingly, whether the subjects had been taking treatment for AIDs or not, 
skinfolds measures remained the same on comparison of similar sites. This is in 
consistence with a study in Thailand that used an approach similar to what we used, 
although did not evaluate anthropometrics, and found no differences in central fat 
mass among patients in the different antiretroviral groups (Homsanit et al., 2007). 
The first school of thought for the lack of difference in the current data could be 
because the trigger that turns on the metabolic cascade, which results in fat 
redistribution, has been reported to be specific to the drugs. To an extent that some 
body fat changes may ameliorate after switching to newer therapies (Arranz Caso et 
al., 2005; Shlay et al., 2005). Since only a few (8.1%) in the current data have ever 
changed medication, probably there had been no life threatening reasons requiring 
majority (91.9%) of the subjects in the ART group to switch drugs; moreover 
minimal numbers (4.1%) of those that had ever switched medication did so for 
reasons related to fat redistribution. We also found no differences in the means of 
skinfolds at all the sites among those who, ever, or never switched medication (p-
value at: the triceps = .141; biceps = .992; subscapular = .674; iliac crest = .582; 
medial calf = .975 and abdominal site = .508). The second school of thought could be 
the fact that simple obesity is associated with increased subcutaneous fat while 
visceral deposition is in fact associated with maintained subcutaneous fat. If the latter 
was the case in the patients we examined, the current study is unlikely to have 
established any difference whatsoever due to lack of objective measures. If there 
were no depositions to cause greater risk, it was because the sample had no gender 
bias but also very few subjects had unacceptable triglycerides. The latter relates to a 
cohort of 452 individuals assessed at baseline and again one year later, where the risk 
of developing new fat deposition during the year of follow-up was higher among 
women (p < .001) and among participants with greater body fat levels (p = .005) and 
higher triglyceride levels (p < .001). While lipodystrophy per se is not necessarily 
physically harmful, the images of those who had experienced changes lamented it 
was unpleasant. Indeed, Power et al. (2003) using grounded theory found that 
patients are often in distress over the physical changes in their appearance, especially 
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if they developed facial lipoatrophy. We do not present any significant results on how 
many patients with body fat redistribution had low self-esteem. The latter was not an 
aim of the study; nevertheless, several participants mentioned so while study 
activities were in progress. 
 
In summary, lipodystrophy exists in this sample. The problem is represented by fat 
gain(s), loss(es) and mixed alterations with ascending prevalence in that order. The 
problem occurred in majority of the treated patients and in all subjects receiving PIs. 
The prevalence is similar to ranges reviewed in other countries in Africa and many 
other regions. More than half of the participants had gained weight, even when the 
average BMI, all the circumferences and skinfolds (less for subscapular) were not 
different among those who had lipodystrophy and those who did not. Subjects with 
lipodystrophy were determined to have extra percent body fat. Subscapular skinfold 
was a stronger predictor of lipodystrophy than percent body fat did. Protease 
inhibitors, time with disease, CD4 counts, age, and time on ART as well as receiving 
the medication were independently associated with lipodystrophy but only 
medication was the greatest single predictor when all these factors were in a model. 
Contrary to published information, none of the participants receiving d4T did 
experience lipoatrophy per se, but fat losses among those who received the drug and 
had experienced mixed alterations. Related to other findings was the 33.3% with 
lipodystrophy that received EFV and the fact that there were less lipoatrophic 
experiences, which is said to occur less frequently in women. The study is likely to 
have had more accurate findings had it not been the use of a cross sectional approach 
and lack of better equipment to ascertain presence of lipodystrophy.  
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Chapter 6: METABOLIC SYNDROME AND ASSOCIATED RISK FACTORS 
6. Introduction 
Metabolic syndrome is an agglomeration of interrelated risk factors that indicate 
individuals at increased risk for type 2 DM and CAD (Rosenson, 2005). The 
syndrome attributes to a double risk for death (Isomaa et al., 2001) and a number of 
other obesity-related diseases. These diseases include non-alcoholic fatty liver 
disease (Saito et al., 2007), chronic kidney disease (Lastra et al., 2006), polycystic 
ovary syndrome (Rader, 2007) and obstructive sleep apnea (Alam et al., 2007). The 
syndrome has been variously defined with the IDF (2006) classification being the 
most appropriate (Alberti et al., 2005).  
 
Reaven (1988) first suggested the cluster of metabolic abnormalities more than two 
decades ago in which, insulin resistance, visceral adiposity, dyslipidemia and a 
systemic pro-inflammatory and pro-coagulant state characterize the abnormalities. 
Other associated abnormalities include – elevated levels of triglyceride-rich 
lipoproteins along with low levels of HDL cholesterol (Reaven, 2005). Body fat is 
often identified as underpinning the syndrome, particularly via several mediators as 
being the pathologic impetus behind metabolic syndrome (Sattar et al., 2003). 
Furthermore, a large body of evidence reports that central fat is associated with 
increases in triglycerides and decreases in HDL cholesterol (Wohl et al., 2008) and 
reports that the metabolic syndrome is more prevalent in HIV-seropositive than HIV-
seronegative women (Sobieszczyk et al., 2008). Treatment for AIDs is identified as a 
concern, for instance, earlier researchers reported an association between the 
syndrome and HAART (Jerico et al., 2005). Nevertheless, the syndrome is also seen 
in untreated HIV-infected persons. One such example is where both HIV disease and 
demographic characteristics influenced lipid values and glucose homeostasis in the 
absence of ART (El-Sadr et al., 2005). Consequently, whereas some researchers 
attribute the existence of the syndrome to ARVs, others report similar findings in 
treatment-naïve HIV-infected persons and sometimes in the general population.  
 
Similarly, there is a link of the problem of lipodystrophy to the metabolic syndrome. 
Studies show that patients with lipodystrophy have metabolic alterations similar to 
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those in the metabolic syndrome (Samaras et al., 2007) and are consequently at a 
similar risk. In some studies, lipoatrophy is associated with high triglyceride levels 
(Villarroya, et al., 2010; Wohl et al., 2008). Both lower limb lipoatrophy, which 
reduces the amount of a fat depot with protective potential at the metabolic level 
(Snidjer et al., 2004) and central fat hypertrophy, probably contribute to the 
cardiovascular and hepatic complications that lead to increased morbidity and 
mortality. Also established is that HIV-linked lipodystrophy associates with 
subclinical atherosclerosis, hypertension and increased CVD risk (Grinspoon and 
Carr, 2005). In line with the literature, the present study assessed for presence of the 
components that when characterized together define the metabolic syndrome. In 
addition, the study assessed for presence of the syndrome plus associated risk factors; 
not limited to AIDs treatment or disease status and or, patient characteristics. The 
IDF (2006) definition was the preference for ascertaining presence of syndrome. 
 
6.1 Methods 
This final sub-study sought to examine the existence of the metabolic syndrome and 
its components and if older age, disease and ARV status as well as increased percent 
body fat was a likelihood of the syndrome. In addition, the study sought to ascertain 
any relationships between subjects’ nutritional status; circumferences at the waist, 
abdomen and hips; weight and influence of height on the weight; and the skinfolds 
thickness measures. An extension to these aims was a hypothesis that bigger arm 
(AMC or AMA) anthropometric measurements are associated with components or 
presence of the metabolic syndrome. In a bid to develop easier methods for assessing 
metabolic syndrome, the study went further to explore the influence of additional 
scores of height, square and cubic height and hip circumference on the performance 
of WC in predicting components of the syndrome. An additional imperative was to 
seek for relationships between the syndrome and lifestyle characteristics. 
 
Preliminary records scrutiny conducted at Mildmay Uganda between January and 
March 2009 revealed that lipid profile was not a routine clinical test at the study site. 
Yet there is need for simpler methods in predicting disease risk in such settings. The 
latter need is consistent with one scholar who has argued that the metabolic schemes 
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that have emerged have proved useful for statistical analysis and epidemiological 
comparison, but not for clinicians, who hardly ever record the diagnosis (Ford, 2005). 
It was more than likely that where information on record showed results on 
components of the syndrome, the basis for the test was because of patient complaint 
or suspicion from a Practitioner. If either were true, conclusions based on such 
information would reflect bias. Therefore, it was not feasible and logical using 
secondary data to address the aims of the study. What therefore happened was to 
incur an extra cost in collecting plasma samples for this purpose.  
 
Every subject underwent laboratory tests following the drawing of plasma after an 
overnight fast; and subjected to enzymatic methods performed with a fully automated 
Cobas Mira Plus chemistry-analyzer (Roche Diagnostics) in addition to 
manufacturer’s reagent kits. Moreover, in a quiet room after the participant had 
rested for a minimum of ten minutes in a sitting position, blood pressure was 
measured in the left arm with the elbow flexed at heart level using a digital electronic 
device (OSZ5 easy, Welch Allyn, Art. -Nr. 5595127_02-2003). Individuals 
automatically met the criterion for high blood pressure or high fasting glucose 
concentration if they were receiving antihypertensive or oral hypoglycaemic 
therapies, respectively. A criterion (Table 3) based on IDF (2006) definition of 
metabolic syndrome was adopted in presently defining the syndrome. Central obesity 
was preferred because lipodystrophic changes with central fat accumulation and loss 
of peripheral subcutaneous fat may under-estimate the prevalence of metabolic 
syndrome.  Patients with central lipohypertrophy may have a normal BMI (Worm et 
al., 2009). This is to emphasize the central role obesity plays in the definition of the 
metabolic syndrome (Cameron et al., 2008). The latter noted that, central obesity 
precedes deterioration in each of the components that constitute the metabolic 
syndrome. 
6.1.1 Laboratory tests (details in appendix 5) 
i) Triglycerides liquicolor
mono 
To determine triglycerides levels, a GPO-PAP method, which is an enzymatic test for 
triglycerides with lipid clearing factor-LCF, was the prime technique. This method 
involves determining triglycerides after enzymatic hydrolysis with lipases. The 
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indicator, formed from hydrogen peroxide, 4-aminoantipyrine and 4-chlorophenol 
under the catalytic influence of peroxidase is quinoneimine. 
References 
Schettler G, Nussel E. Arc. Med. Soz. Med. Prav. Med. 1975; 10: 25 
Jacobs NJ, VanDenmark PJ. Arc. Biochem. Biophys. 1960; 88:250-255 
Koditschek LK, Umbreit WW. J. Bacterial. 1969; 68:1063-1068 
Trinder P. Ann. Clin. Biochem. 1969; 6:24-27 
ii) HDL Cholesterol liquicolor 
To determine HDL-cholesterol, direct homogeneous test for the determination of 
HDL-cholesterol was, and the latter is an enzymatic colorimetric test. The assay 
combines two specific steps. Initially are chylomicrons, VLDL and LDL cholesterol 
specifically eliminated and destroyed by enzymatic reactions. Finally is the 
verification of the remaining cholesterol from the HDL fraction by well-established 
specific enzymatic reactions in the presence of specific surfactants for HDL.  
References 
Gordon T et al. Am. J. Med. 1977; 62:707 
Izawa S et al. J.Med. and Pharm. Sci. 1997; 37:1385-1388 
iii) Glucose liquicolor 
Another step is glucose analysis using the GOD-PAP method, which is an enzymatic 
colorimetric test for glucose without deproteinisation, a method determined after 
enzymatic oxidation in the presence of glucose oxidase. The formed hydrogen 
peroxide reacts under catalysis of peroxidase with phenol and 4-aminophenazone to a 
red-violet quinoneimine dye as indicator. 
References 
Barham D, Trinder p. Analyst. 1972; 97 
Teuscher A, Richterich P. Schweiz. Med. Wschr. 1971; 101:345 and 390 
 
Lastly, the study included brief questions (Appendix 6) on use of coffee, smoking, 
alcohol, physical activity level and exercise, as well as current meal patterns and the 
usual food consumption frequency. Responses reflect participants’ average lifestyle. 
In addition, was the data on presence of medical or family history to diseases of the 
lifestyle. Collecting information on lifestyle accrued from the fact that smoking is 
  
132 
 
one of the most notable factors associated with higher prevalence of metabolic 
syndrome among HIV-infected women (Sobieszczyk et al., 2008). Much more closer 
to the Ugandan population, Mutimura et al. (2008) showed that six months of cardio-
respiratory exercise training reduced WC (-7.13 +/- 4.4 cm, p < .0001), WHR (-0.10 
+/- 0.1, p < .0001), sum of skinfold thickness (-6.15 +/- 8.2 mm, p < .0001) and 
percent body fat mass (-1.5 +/- 3.3, p < .0001) in HIV-infected Rwandese. In 
addition, the exercise reduced fasting total cholesterol (-0.03 +/- 1.11 mM, p < .05), 
triglycerides (-0.22 +/- 0.48 mM, p < .05) and glucose levels (-0.21 +/- 0.71 mM, p < 
.05). This is an indication that physical activity and other possible modifiable risk 
factors might play a great role in the HIV-infected population where alteration of 
biochemical metabolites by the disease and the medication is. 
 
6.1.2 Data analysis 
During analysis, association of the syndrome and any of the continuous variables 
(age, time and disease status as well as outcomes of nutritional status) was throough 
an independent-samples t-test between those who did and those who did not live with 
the syndrome. Chi square test was used to compare the prevalence of metabolic 
syndrome with the sum of each of the components of the metabolic syndrome (one 
point for each of the unacceptable components), categorical age, and cut offs for 
percent body fat, BMI, WC, WHR and the lifestyle characteristics of the subjects. In 
addition, we explored the influence of height, square and cubic height and hip 
circumference on the performance of WC in predicting components of the syndrome. 
Significant univariate factors (p < .050 with the outcome variable), were included in 
the logistic regression analysis. Hosmer and Lemeshow statistic method verified the 
Goodness-of-fit. 
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6.2 Results 
6.2.1 Participation 
Like was in the previous two sub-studies, 211 participants were included in the 
analysis for the metabolic syndrome and risk factors associated with the syndrome. 
Again, 123 (58.3%) of the participants were receiving ARVs. During this analysis, 
responses of family medical history of disease that were captured as ‘don’t know’, 
were classified as missing values because there were no meaningful analyses before 
this alteration was made. 
 
6.2.2 Metabolites and components of the syndrome 
6.2.2.1 WC (cm) 
A WC that was ≥ 80 cm reflected risk(s). Overall, mean WC (cm) was 78.11 (9.77), 
demonstrating acceptable circumference in the entire sample. However, there was 
somewhat a high prevalence of central obesity (WC > 80 cm), determined in 85 
(40.3%) subjects. Furthermore, the coefficient of determination (r
2
) of 0.770 
indicates that 77.0% of the variation in WC could be explained by the variation in 
body weight and this was highly significant (p = .000), inferring that there is a 
regression effect. Moreover, subjects in whom central obesity was determined were 
20 kg heavier (CI, 18.384 – 23.607) than those determined to have no central obesity 
(t209 = 15.849, p = .000). In addition, subjects in whom central obesity was diagnosed 
were 18.89 cm (CI, 15.817 – 21.970; t209 = 12.193, p = .000) wider at the waist. They 
were also 15.458 cm (CI, 12.833 – 18.083; t209 = 11.668, p = .000) wider at the hips; 
5.787 cm (CI, 4.85 – 6.723; t209 = 12.181, p = .000) wider at AMC and had 4.056 cm 
(CI, 0.416 - 3.236; t209 = 9.754, p = .000) greater calf circumference than subjects 
without central obesity.  
 
Central obesity was shown to be significantly associated with older age (χ23 = 16.039, 
p = .001). Subjects with central obesity were 5.28 (CI, 3.22 - 7.34) years older than 
those in whom central obesity was not determined (t209 = 5.05, p = .000). Participants 
< 21 years of age lived with the least risk (1.4%) to central obesity. The risk 
increased through the 21 - 30- year-olds (20.3%), > 40 years (35.1%) and was most 
evident among the 31-40-year-olds (43.2%). Additional analysis revealed that the 
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larger at the waist were also heavier. According to body mass (kg), the larger at the 
waist were 73.80 (11.07) kg heavy, compared to 53.85 (8.28) kg of those that were 
considered narrower and the two groups were different (p = .000). Based on the BMI, 
the larger at the waist were 29.08 (4.28) kg heavier compared to 2.70 (6.86) kg of 
those considered narrow, and the two groups were different (p = .000). More results 
showed no differences between those who were receiving ARVs and those who did 
not (Table 28). Neither was there an association with receiving PIs (p = .383) nor 
CD4 counts (p = .490). However, BMI was the most influential (CI = 1.12 - 1.62, β = 
1.34, p = .002) when the all the significant factors were considered at once. 
 
Table 28: Means of components of the syndrome among the treated and ART-naive 
groups (ART-naïve N = 88; treated group N = 123; df = 209) 
Syndrome components Group Mean (SD)  Sig. 2 tailed 
WC (cm) Treated 
Naïve-group 
79.18 (9.66) 
76.67 (9.81) 
 .066  
BMI (kg/ m
2
) Treated 
Naïve-group 
25.04 (4.80) 
25.45 (8.78) 
 .663  
Total cholesterol (mg/ dL) Treated  
Naïve-group 
202.44 (67.73) 
178.51 (52.76) 
 .004* 
 
Triglycerides (mg/ dL) Treated  
Naïve-group 
54.05 (30.62) 
51.65 (26.91) 
 .556  
HDL cholesterol (mg/ dL) Treated 
Naïve-group 
88.57 (37.89) 
69.45 (25.14) 
 .000* 
 
LDL cholesterol (mg/ dL) treated 
naïve-group 
101.76 (46.62) 
87.97 (33.35) 
 .013* 
 
Systolic BP (mm Hg) Treated 
Naïve-group 
117.96 (18.10) 
121.32 (17.29) 
 .177  
Diastolic BP( mm Hg) Treated 
Naïve-group 
76.78 (12.16) 
78.88 (12.39) 
 .268  
Fasting plasma glucose 
(mg/dL) 
Treated 
Naïve-group 
93.83 (23.40) 
90.34 (12.61) 
 .204  
*significant results 
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6.2.2.2 BMI (kg/ m
2
) 
General BMI mean was 25.21 (6.74) kg/ m
2
 and this is more or less at the margin of 
the acceptable range. Moreover, there were no statistical differences between the 
treated (25.04±4.80) and the ART-naïve group (25.45±8.78; p = .663) for the other 
group. Additional classification for presence of BMI obesity (> 30 kg / m
2
) among 
the participants revealed that up to 177 (83.9%) did not have BMI obesity. However, 
the problem of BMI obesity was determined in 34 (16.1%) participants. Among the 
34 subjects with BMI obesity, statistical analysis revealed association with older age. 
Specifically, no BMI obesity was determined among those < 21 years but rather, in 
20.6% of the 21 - 30 –year-olds, 38.2% of those above 40 years and was highest 
among the middle aged (31 - 40 years). Further analysis showed that those who were 
diagnosed with BMI obesity were 17.35 cm (CI, 14.436 – 20.270) wider at the waist 
than those who were not obese (t209 = 11.728, p = .000). Additionally, they were also 
21.947 cm (CI, 18.308 – 25.586; t209 = 11.889, p = .000) wider at the abdomen and 
17.3 cm (CI, 12.464 – 22.154; t209 = 7.235, p = .000) at the hips than those without 
BMI obesity. So was the case with the AMC in which results revealed that the obese 
(based on the BMI) had 6.482 cm (CI, 5.161 – 7.803, t209 = 9.673, p = .000) wider at 
the AMC as well as 4.198 cm (CI, 3.049 – 5.347, t209 = 7.203, p = .000) greater at the 
calf circumference. A multiple regression analysis model (age, circumferences of the 
waist, abdomen, hip and mid-upper arm plus percent body fat, time on ART and time 
with infection) indicated that 37.6% (r
2
 = 0.376) of the variation was explained by 
the variation in the above mentioned predictor variables and there was a regression 
effect (p = .000). However, AMC proved the greatest predictor of the BMI in that 
equation (β = 0.225, p = .028) and percent body fat was only near prediction (β = 
0.142, p = .060). There were some medium linear relationships with BMI, noted is 
that with circumferences of the waist (r = 0.522), abdomen (r = 0.519), hip (r = 
0.558) as well as the AMC (r = 0.549). 
 
6.2.2.3 Total cholesterol (mg/ dL) 
Mean total cholesterol was 192.46 (62.92) mg/ dL, with an obvious between- groups 
differences (p = .004). Consequently, the treated group had greater mean total 
cholesterol (202.44±67.73) than the naïve group 178.54 (52.76). Moreover, 74 
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(35.1%) participants (Fig. 6) had a substantiated prevalence of lipid disturbance as 
determined by total cholesterol (> 199 mg / dL). Furthermore, total cholesterol 
exhibited a moderate relationship with age (r
2
 = 0.051, p = .000). 
 
acceptable
65%
unacceptable
35%
Fig. 6: Prevalence of unacceptable levels of total 
cholesterol
 
 
Additionally, the coefficient of determination (r
2
 = 0.048) indicates that only 4.8% of 
the variation in total cholesterol could be explained by the variation in body weight. 
In addition, the latter was highly significant (p = .000), inferring that there was a 
regression effect. Particularly, participants with unacceptable total cholesterol were 
4.3 kg heavier (CI, 0.175 – 8.566, t209 = 2.063, p = .041) with 1.798 kg
-2 
(CI, 0.405 – 
3.191, t209 = 2.545, p = .012)
 
greater BMI than those who presented with acceptable 
total cholesterol respectively. More results revealed that those with unacceptable total 
cholesterol were 3.958 cm larger at the waist (CI, 0.741 – 7.176, t209 = 2.439, p = 
.016). Moreover, they were also 4.802 cm larger at the abdomen (CI, 0.806 – 8.798, 
t209 = 2.381, p = .019), 4.457 cm at the hips (CI, 1.364 – 7.55, t209 = 2.84, p = .005) 
and 2.158 cm extra at the upper arms (CI, 0.969 – 3.347, t209 = 3.579, p = .000). 
There were no significant differences in the calf circumference (p = .405) and WHR 
(p = .320) in participants with unacceptable and those with normal total cholesterol 
levels. 
 
A multiple regression analysis illustrated variation in total cholesterol (mg/dL). The 
model indicates that only 12.9% (r
2
 = 0.129) of the variation in total cholesterol (mg/ 
dL) was explained by the variation in body mass, BMI and the circumference 
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measures- at the waist, abdomen, hips and AMC. Yet, there was a regression effect (p 
= .000). Like was with BMI, AMC (β = 0.339, p = .003) and the WC (β = 0.08, p = 
.017) were the most influential predictors of total cholesterol in that equation and the 
model was significant (p = .000). Other predictor variables (age, time with HIV and 
time on AIDs medication) were modelled in a separate equation as a group, and 
results showed that the model explained only 4.4% (R
2
 = 0.044) of the variation in 
total cholesterol and the model was significant (p = .033). Older age (β = 0.179, p = 
.018) was the greatest predictor of the cholesterol in that model. Relationships of the 
predictor variables with the total cholesterol were weak (r < 0.2 for all variables 
mentioned). 
 
6.2.2.4 Triglycerides (mg/ dL) 
Generally, total triglycerides mean score was 53.05 (29.09) mg/ dL and there were no 
significant between-groups differences in the lipid disturbance of triglycerides (p = 
.556). Further analysis showed that only three (1.4%) participants had a disturbance 
(> 149 mg/ dL) in plasma triglycerides. Triglycerides were positively correlated with 
ones’ age (r2 = 0.039, p = .004). Actually, participants that lived with unacceptable 
triglyceride levels were 10.04 (1.36 – 18.73) years older than those who presented 
with normal triglycerides (t209 = 2.28, p = .024). Moreover, the coefficient of 
determination (r
2
 = 0.053) indicates that only 5.3% of the variation in triglycerides 
could be explained by the variation in body weight and was highly significant (p = 
.001). More data showed that those with unacceptable triglycerides were 19.319 cm 
wider at the abdomen (CI, 4.925 – 33.712, t209 = 2.646, p = .009) and had 5.842 cm 
extra AMC (CI, 0.97 – 10.713, t209 = 2.364, p = .019). There were no significant 
differences in the BMI (p = .251), WC (p = .525), hips (p = 0.329) and calf (p = .079) 
circumferences. Nor, with the rations - WHR (p = .748) or WHtR (p = .475), among 
those participants with unacceptable triglycerides levels and those who did not. A 
multiple regression analysis (age, body mass, all circumference measures, time with 
the infection and the time on treatment) indicates that only 8.9% (r
2
 = 0.089) of the 
variation in triglycerides was explained by the variation in the above mentioned 
predictor variables and the model was significant (p = .006). However, only 
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abdominal obesity stood out as the greatest predictor (β = 0.307, p = .022) of the 
triglycerides in that equation.  
 
6.2.2.5 HDL cholesterol (mg/ dL) 
Mean HDL cholesterol was 80.60 (34.42) mg/ dL, and was considered acceptable.  
While 178 (84.4%) participants were determined with acceptable (> 50 mg/ dL) 
levels of HDL cholesterol, 33 (15.6%) were considered at risk. Furthermore, the 
treated group were determined to have 19.115 mg/ dL (CI, 10.554 – 27.675) extra 
HDL cholesterol than did the non-treated group (t209 = 4.402) and the two were 
different (p = .000). On the contrast, data showed no differences in body mass (p = 
.106), BMI (p = .137), WHR (p = .7387), WHtR (p = .051), circumferences of the 
waist (p = .051), abdominal (p = .080) and calf (p = .05) among participants with and 
without unacceptable HDL cholesterol. Rather, relationships existed with hip 
circumference (CI, -8.494 to – 0.299, t209 = -2.115, p = .036) and AMC (CI, -3.36 to -
0.834, t209 = -2.323, p = .021) with HDL cholesterol. A multiple regression analysis 
(circumferences of the arm and hips, time on ART and the time with the infection 
and age, showed that only 4.6% of the variation in  HDL cholesterol was explained 
by these predictor variables and the model was significant (p = .105).  
 
6.3.2.5 LDL cholesterol (mg/ dL) 
Mean LDL cholesterol (96.01±42.07) was generally within acceptable (< 130 mg/ 
dL) plasma levels. However, only 37 (17.5%) participants were determined to have 
acceptable levels of the LDL cholesterol. Furthermore, there was no statistically 
significant association of one’s age and the LDL cholesterol (p = .075). Moreover, 
the coefficient of determination (r
2
 = 0.031) indicates that only 3.1% of the variation 
in the LDL cholesterol could be explained by the variation in body mass and the 
relationships was highly significant (p = .010). The group on medication were 
determined to have higher levels of the LDL cholesterol (101.76±46.62) than the 
non-treated group (87.97±33.35), and the two were significantly different (p = .013). 
Further data showed 0.027 (CI, 0.005 – 0.050, t209 = 2.412, p = .017) extra WHtR in 
those with higher LDL cholesterol than those in whom LDL cholesterol was 
acceptable. A multiple regression analysis indicates that only 5.8% (r
2
 = 0.058) of the 
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variation in LDL cholesterol (mg/ dL) was explained by the variation in the predictor 
variables and the model was not significant (p = .730).  
 
6.2.2.6 Blood pressure (mm Hg) 
Generally, the average blood pressure levels were within acceptable levels (Table 
29). In the entire sample, results showed a mean systolic blood pressure of 119.36 
(17.80) and a diastolic mean pressure of 77.77 (12.26) mm Hg.  
 
Table 29: Participants’ blood pressure levels (mm Hg) 
 Systolic blood pressure Diastolic blood 
pressure 
 
general sample 119.36 (17.80) 77.77 (12.26)  
acceptable levels  159 (75.4%) 154 (73.0%)  
unacceptable levels  52 (24.6%) 57 (27.0%)  
ART group mean  117.96 (18.10) 76.98 (12.6) p = .177 
ART naive mean  121.32 (17.29) 78.88 (12.39)  
 
An extension of this revealed no between-groups differences. Moreover, that there 
was no influence by one’s age on the systolic blood pressure (p = .118). The 
coefficient of determination (r
2
 = 0.044) indicates that only 4.4% of the variation in 
blood pressure could be explained by the variation in body mass and this was highly 
significant (p < .002). Indeed, those found with high blood pressure were 4.89 kg (CI, 
0.659 – 9.137, t209 = 2.278, p = .024) heavier than those with normal blood pressure. 
Therefore, was with the BMI, where by, participants with unacceptable blood 
pressure possessed 2.19 kgm
-2 
(CI, 0.56 – 3.639, t209 = 2.6881, p = .008) extra BMI 
than those with normal pressure. Particularly, none among the participants considered 
thin, but 44.2% among the healthy and 55.8% among the overweight (χ22 = 6.27, p = 
.043), were determined with unacceptable blood pressure. Furthermore, participants 
with high blood pressure had 0.027 (CI, 0.06 – 0.047; t209 = 2.58, p = .011) extra 
WHR and 0.01 (CI, 0.008 – 0.048; t209 = 2.79, p = .006) extra WHtR. They were also 
4.691 cm (CI, 0.659 - 9.137, t209 = 2.278, p = .004) larger at the waist and 4.679 cm 
(CI, 0.710 - 8.648, t209 = 2.324, p = .021) abdomen. However, they presented with 
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similar hip (p = .086), AMC (p = .050) and calf (p = .319) circumferences. Age (p = 
.248), time with the infection (p = .093) and the time spent receiving treatment (p = 
.260), were not associated with higher blood pressure. A multiple regression analysis 
indicates that only 7.1% (r
2
 = 0.071) of the variation in blood pressure was explained 
by the variation in the influential predictor variables and the model was significant (p 
= .020). Nevertheless, none of these predictor variables showed greater influence 
while in a single equation.  
 
6.2.2.7 Fasting plasma glucose (mg/ dL) 
Mean fasting plasma glucose (92.38±19.67) was generally acceptable (< 99 mg/ dL). 
In addition, there was no between-groups differences (p = .505) (Fig. 7). However, 
further details showed that 43 (20.4%) subjects had a disturbance in fasting plasma 
glucose levels. 
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Fig. 7: Mean fasting plasma glucose (mg/dL) among 
the groups
 
 
Of the 43 participants determined with unacceptable fasting plasma glucose levels, 
46.5% were those determined to have unacceptable WC. Specifically, participants 
classified as having a disturbance in fasting plasma glucose were 4.94 cm (CI, 1.057 
– 8.824, t209 = 2.548, p = .014) larger at the waist. Moreover, they also possessed 1.73 
cm (CI, 0.308 – 3.171) extra AMC, than did the participants that were determined to 
be have no disturbance. Similarly, WHR (CI, 0.015 – 0.058; t209 = 3.279, p = .001) 
and WHtR (CI, 0.006 – 0.049; t209 = 2.557, p = .011) were significantly associated 
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with the disturbance in the fasting plasma glucose. However, body mass (p = .062), 
the BMI (p = .053), hip (p = .835) and the calf circumferences, as was with the time 
one had lived since birth (p = .095), were not significantly associated with the 
glucose disturbance. In a multiple regression equation, the model indicates that only 
7.4% (r
2
 = 0.074) of the variation in fasting plasma glucose was explained by the 
variation in these predictor variables and this model was significant (p = .007). 
However, only WHR proved the greatest single predictor of fasting plasma glucose 
when all the influential variables were in a single equation (β = 0.245, p = .004). 
 
6.2.3 Presence of the syndrome 
Overall, in 146 (69.2%) participants was ≥ 1 feature(s) that define the metabolic 
syndrome. Two or more features were determined in 67 (31.8%) of them, while ≥ 3 
features were seen in 25 (11.8%) participants. Additionally, five (2.4%) participants 
lived with ≥ 4 of the features that define the syndrome. From the data, > 0.5 lived 
with at least one feature that defines the metabolic syndrome (Fig. 8). In such 
occurrence, 82 (66.7%) subjects lived with at least such a feature in the ART group 
and the groups were not different (Pearson Chi-square, χ 21 = 0.884, p = .347).  
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Fig. 8: Prevalence of ≥ 1 feature(s) defining 
metabolic syndrome among study groups
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Despite having more than half of the participants living with at least a single feature 
that defines the metabolic syndrome, a diagnosed for the syndrome was established in 
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only 32 (15.2%) participants. Specifically, in 19 (15.4%) subjects among the treated 
and 13 (14.8%) in the ART-naïve group respectively and there was no between-
groups difference (χ 21 = 0.018, p = .893). 
6.2.4 Metabolic syndrome and associated risk factors 
6.2.4.1 Association with age, percent body fat, time with infection, time receiving 
ARVs, CD4 counts and use of HAART 
For each study participant, an existing component of the metabolic syndrome was 
assigned a value—one (1). The sum obtained showed a maximum of four points 
among those who existed with the problem, with an average of 1.15 (1.043) points 
for the entire sample. Further analysis revealed that participants who were diagnosed 
with the metabolic syndrome had 1.927 points higher (CI, 1.631 – 2.222) than those 
in whom the syndrome was not confirmed (t209 = 12.842, p = .000). The weight of the 
components of the syndrome were irrespective of being treated for AIDs or not (p = 
.832). Furthermore, presence of the metabolic syndrome was associated with older 
age. In that participants living with the syndrome were 3.16 (95% CI, 0.291 to 6.031) 
years older than those in whom the syndrome was not observed (t209 = 2.171, p = 
.031). Additionally, the prevalence of the syndrome was lowest among younger than 
21 (3.1%) – year old participants, followed by those aged between 21 – 29 (25.0%), 
then the > 40 (31.3%) and was highest among the 31 – 39 year olds (40.6%). 
However, this difference was not statistically significant (Likelihood ratio χ 23 = 
2.155, p = .541). Moreover, presence of the syndrome was associated with higher 
percent body fat. Specifically, participants with the metabolic syndrome had 5.0% 
extra percent body fat (CI, 1.089 to 8.887) than did in those without the syndrome 
(t190 = 2.523, p = .012). Actually, the metabolic syndrome was determined in 26.5% 
of the participants that had > 33% body fat and was significantly higher (p = .022) 
than that in the 12.6% among those that had < 33% body fat. The other predictor 
variables considered showed no association with presence of the syndrome (Table 
30). After mutual adjustment for these variables, previously significant variables like 
older age (CI, 0.981 – 1.099; β = 0.038; p = .195) and higher percent body fat (CI, 
0.999 – 1.089; β = 0.043; p = .058) ceased to be strong risk factors for metabolic 
syndrome. However, percent body fat showed a near significant modest influence. 
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Table 30: Metabolic syndrome and associated risk factors 
 Patient with metabolic 
syndrome 
Patients without 
metabolic 
syndrome 
 
P 
Age (years) 36.78 (7.95) 33.62 (7.52) .031* 
Percent body fat 30.90 (11.29) 25.92 (9.53) .012* 
Time (years) with HIV 
(recall) 
5.95 (5.41) 4.39 (4.26) .130 
Time (years) on ART 1.92 (2.51) 1.56 (1.91) .442 
CD4 count 408.25 (201.82) 398.43 (253.78) .836 
Exposure to protease inhibitors 
 
1. On PIs 
2. No PIs 
02 (10.5%) 
08 (7.7%) 
17 (89.5%) 
96 (92.3%) 
.678 
*statistically significant 
 
6.2.4.2 Metabolic syndrome and nutritional status 
The syndrome was associated with WC, in that subjects with the syndrome were 13.64 
cm (CI, 10.265 to 17.007) larger than those without the syndrome (t209 = 7.974, p = .000). 
Like would be expected, the syndrome was lowest (3.1%) among participants at low 
central obesity risk but more or less similar among those with increased risk (50.0%) and 
in 46.9% of those at substantially increased risk (Likelihood ratio χ 22 = 52.79, p = .000). 
Similarly, there was an association of the metabolic syndrome and abdominal 
circumference. Participants in whom the metabolic syndrome was determined were 14.47 
cm (CI, 8.338 - 20.61) larger than those in whom the syndrome was absent (t209 = 4.785, p 
= .000). A similar was seen in participants with the syndrome, whereby they were 10.55 
cm (CI, 6.613 - 14.492) wider at the hips than did their colleagues (t209 = 5.281, p = .000). 
Apparently, so was with WHR (p = .000) and the WhtR (p = .000). Furthermore, 
participants diagnosed with the syndrome were 15 kg (CI, 10.967 – 20.35, t209 = 6.579, p 
= .000) heavier (body mass). However, independently height, height squared and height 
cubed showed no statistical influence (p > .05) on presence of the syndrome. When this 
was extended to the BMI, data revealed that those with the syndrome had 5.887 kg/m
2 
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(CI, 4.186 - 7.589, t209 = 6.82, p = .000) extra BMI. To demonstrate this further, the 
problem did not exist among participants considered as thin and was less prevalent 
among the ones in the normal range (6.3%). Yet, the prevalence of the syndrome was 
seen to be highest among participants with extra BMI (93.8%) and these prevalence were 
different (Likelihood ratio χ 22 = 39.338, p = .000). When the indices above were 
considered in a multivariable logistic regression model, the model was not significant 
(Homer and Lemeshow test χ 28 = 12.643, p = .125) and only WC contained its influence 
(CI, 1.082 – 1.397; Exp (β) = 1.23; p = .001) on the existence of the syndrome. 
 
Additionally, fat deposition based on skinfolds thickness measures showed that there 
was an association between each of the thickness measures and presence of the 
metabolic syndrome. One such example is the fat deposited at the triceps, where, 
subjects in whom the syndrome existed had an average of 27.19 (8.14) cm unlike 
patients with no syndrome (19.14±7.68) and the two were statistically different (p = 
.000). Another example was at the biceps where those who lived with the syndrome 
had a mean of 18.13 (7.13) cm compared to subjects with no syndrome (11.83±6.77) 
cm and these were different (p = .000). Like was with the subscapular (30.44±9.96 
vs. 18.65±9.320, p = .000) and the iliac crest (28.34±9.10 vs. 14.61, p = .000). 
However, only the iliac crest remained significantly influential (CI (β) = 1.000 – 
1.114, p = .050) when all the skinfolds thickness sites were regressed in one 
equation. Lastly, subjects who were determined to have the syndrome were 4.99 cm 
(CI, 3.413 – 6.39, t209 = 6.59, p = .000) larger at AMC and had 0.195 cm
2 
(CI, 0.110 -
0.28, t209 = 4.515, p = .000) extra AMA. However, when the two arm variables were 
put in a model, only AMC remained significantly influential (CI, 1.178 – 1.649; Exp 
(β) = 1.394; p = .000). In a later analysis, WC sustained significant association with 
the syndrome over and above AMC when the two were modelled (CI, 1.056 – 1.216; 
Exp (β) = 1.133; p = .000) and the model was significant (Exp (β) = 0.179; p = .000).  
 
6.2.4.3 Presence of the syndrome and lifestyle characteristics 
When lifestyle was considered, participation in regular physical activity (Pearson Chi 
square, χ 21 = 1.277, p = .259), average physical activity level (χ 
2
2 = 4.223, p = .121) and 
duration of exercise (t209 = -1.215, p = .226) showed no statistical influence on existence 
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of the syndrome. This was similar to the estimated average consumption of foods in the 
groups of fruits (χ 22 = 2.634, p = .268), vegetables (χ 
2
2 = 0.443, p = .801), low fat (χ 
2
2 = 
1.297, p = .523), high fat (χ 23 = 3.362, p = .339) plus the whole grains and cereals (χ 
2
3 = 
3.883, p = .274). Lastly, the syndrome was neither influenced by medical family history of 
diabetes (p = .145) nor with hypertension (p = .422) and the problem of lipodystrophy 
was not different among participants with the metabolic syndrome compared to those 
without the syndrome (p = .439). 
 
6.3 Discussion 
6.3.1 Metabolites and components of the syndrome 
For a while now, studies have demonstrated that HIV-related lipodystrophy is 
associated with adverse metabolic variables (Currier et al., 2008; Wohl et al., 2008; 
Sobieszczyk et al., 2008). However, much more recent reports (Jevtović et al., 2009) 
reveal that hyperlipidaemia precedes lipodystrophy, and that after its appearance 
there is a significant probability of developing lipodystrophy.  Because the use of 
body weight alone does not provide much detail regarding the relative contributions 
of body fat and muscle (Heitmann and Garby, 2002), it becomes inevitable to know 
plasma metabolite status of PLHIV. Actually lately, the latter are considered an at-
risk-population. Among the components that define the syndrome (IDF, 2006), 
presence of central obesity is presently seen in 85 (40.3%) of the 211 subjects. This 
finding is far (five times) higher in the present sample than was reported nearly a 
decade ago in ART subjects in Cameroon (Geraix et al., 2002). In spite of having no 
significant differences in central obesity between the treated and naïve groups, time 
spent receiving ARVs was statistically significant, both independently and while in a 
regression model. This relates to longitudinal studies, such as ACTG 5005s (a sub 
study of ACTG 384), that demonstrated an increase in truncal adiposity with 
prolonged ART (Mulligan et al., 2005). Even when mean BMI was determined to be 
just at about the margin of healthy range and overweight, present results show that 
participants diagnosed with BMI obesity (> 30 kg/ m
2
) were also larger at the waist. 
In light of this, there is demonstration for justification of the recommendation by IDF 
(2006); that BMI can predict the metabolic syndrome. Correspondingly, participants 
with BMI obesity were larger at all the other circumference measures, more so at the 
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AMC which proved the greatest predictor of the BMI. There is need to validate the 
latter findings in related populations, which if proven true may become imperative to 
future research on the topic.  
 
Metabolic variables do include elevations of the total triglycerides, raised levels of 
VLDL and low levels of HDL (Nair, 2005). Firstly, total cholesterol is not among the 
components that define the syndrome, according to the criteria of the present study. 
However, 35% of the subjects presented with unacceptable levels of total cholesterol. 
Moreover, there was a between-groups difference (AIDs-treated vs. nave group). The 
former group that was heavier and larger at all the circumferences, less for the lower 
limbs. Besides the BMI, AMC stood out as a strong predictor for the total 
cholesterol, thus, AMC deserves special consideration in future studies ─ in related 
populations. Secondly, even when subjects with unacceptable triglyceride levels were 
very few, the study could not distinctly attribute this finding to disease or medication 
status.  
 
Contrary to the present findings, nearly every participant (95.5%) of those with the 
metabolic syndrome in the reknown DAD study (Worm et al., 2009) had elevated 
triglycerides. What is clear is that reduced lipoprotein lipase activity stimulates 
hepatic lipid synthesis, thereby producing hypertriglyceridemia in this kind of 
population. Where triglyceride levels were unacceptable, all the other predictors 
mentioned above in other components of the syndrome showed influence, but most 
importantly was the abdominal obesity that stood out as having the greatest 
association. Indeed, in the metabolic syndrome definition not adapted by the present 
study, definition for the syndrome encompasses disturbances in other factors but also 
in lipid metabolism associated with abdominal obesity (Grundy et al., 2004). 
Accordingly, abdominal obesity should be part of components that define the 
metabolic syndrome, in particular, when dealing with presence of raised triglycerides. 
Although most PIs are associated with high triglycerides, presently, with < 10% 
participants receiving PIs lacked such an association, a finding that may be attributed 
to the small numbers of PI-treated. Thirdly, although 15.6% of the subjects lived with 
much lower HDL cholesterol than is said to impart a protective effect, it was 
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surprisingly higher (and hence considered protective) in the treated group than did in 
their counter parts. The hip and AMC that were independently associated with HDL 
cholesterol lost the influence when all other predictor variables were pulled in the 
model as a group. We need to note that in the infected population in the USA 
(Mondy et al., 2007); the most prevalent factor responsible for the diagnosis of the 
metabolic syndrome was dyslipidaemia (involving triglycerides and HDL 
cholesterol). However, in Uganda, raised triglycerides were not a concern, and this 
further stresses a difference in populations found in the first and the third world 
countries. The fourth metabolite was LDL cholesterol, which was significantly but 
unfortunately higher in the treated group. Nevertheless, there was lack of a single 
most outstanding predictor associated with this component when predictor variables 
were in a collection. However, independently, LDL cholesterol was associated with 
the circumferences at the waist, hips and AMC as well as WHtR. On a fifth note, 
results indicated a similarity in the blood pressure levels among the study groups and 
there was no single factor associated with this component, while predictors were in a 
group, but rather independently associated with body mass, the BMI and the 
circumferences (waist and the abdomen), plus both the ratios. Fuchs et al. (2005) 
found similar associations with blood pressure except for the BMI. Lastly, among the 
components of the syndrome was the fasting plasma glucose, where more than 20% 
lived with unacceptable levels even when the study groups compared similarly. On 
the other hand, Blass and team (2008) reported impaired fasting glucose as one of the 
components of the metabolic syndrome in 28% of HAART-treated patients. 
However, present data determined the syndrome in 15.4% in the treated group alone, 
a lower prevalence than the former researchers did. Other scholars (El-Sadr et al., 
2005) demonstrate that both HIV disease and demographic characteristics influence 
lipid values and glucose homeostasis in the absence of ART. The latter implies that, 
whereas some researchers attribute the existence of risk factors for the metabolic 
syndrome to ARVs, others report similar findings in treatment-naïve HIV-infected 
persons and the general population, a situation similar to the present study. 
 
Independently however, circumferences at the waist, abdomen and the AMC, plus the 
two ratios, had a significant association with the fasting sugar levels. The WHR stood 
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out as the greatest influential predictor variable while in the model. Current findings 
do partly agree and to some degree support an earlier study on HIV-infected women 
by Dolan et al. (2005). The latter researchers revealed a higher triglyceride level (163 
vs. 75 mg/ dL, p = .0002), fasting glucose (81 vs. 45 mg/ dL, p = .0003) and lower 
HDL (45 vs. 56 mg/dL, p < .0001) compared to their control counterparts. In their 
study (Dolan et al., 2005), the same participants had increased WHR (0.92 vs. 0.83, p 
< .0001). Moreover, WHR significantly related to CVD risk indices in both the study 
and control groups. A year later, Torriani et al. (2006) supported Dolan and 
colleagues’ findings (2005) after reporting an increased triglyceride (131.1 vs. 66.3 
mg/dl, p = .0003) level in a study of 46 women and 21 controls, respectively. Current 
data show mean fasting plasma glucose over and above 90 mg/dL in each of the 
study groups. In addition, up to 22% of the treated participants had unacceptable 
glucose levels. Nevertheless, the latter remains lower than the prevalence of 35% of 
impaired glucose tolerance reported by Hadigan et al. (2001), in a cohort they carried 
out on HIV-infected patients on HAART. From the present data and that of previous 
researchers, it seems that metabolic indicators increase with the degree of obesity and 
that there are higher triglyceride cholesterol levels in other populations than the 
present sample. In exceptional cases, adverse metabolic profile at ‘normal’ BMI 
category existed including 23.5% with high systolic (p = .243) and 24.5% with 
unacceptable diastolic blood pressure (p = .080).     
 
6.3.2 Presence of the metabolic syndrome  
As far as a decade ago, there have been reports of metabolic abnormality in HIV-
infected populations. For instance, Thiebaut et al. (2000) revealed that 45% of 
females in their sample of patients had some form of lipid or glucose abnormality. In 
our data, nearly 70% of the subjects were determined to have at least one feature that 
defines the metabolic syndrome; a problem diagnosed in only 15.2% subjects using 
the IDF (2006) criteria and there was statistical similarity across the two study 
groups. This estimate of the problem is somewhat similar to the 17% prevalence 
reported for HIV-infected patients in Barcelona (Jerico et al., 2005) although these 
researchers used ATP III criteria for their definition. Samaras and team (2007) who 
used the IDF criteria (like did in our study) in Australia reported the prevalence of the 
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syndrome in 25% of all HIV-infected women. While there was similarity in criteria 
used to define the metabolic syndrome, the Australian authors collected data among 
many participants that already presented with the problem of lipodystrophy. 
However, we learn from Jevtović and team (2009), that, hyperlipidaemia precedes 
lipodystrophy and consequently could have been the reason for the high prevalence 
of the syndrome. Our study did not put a precedence of lipodystrophy as entry criteria 
into the study. Besides, diagnosis of the metabolic syndrome enhances prediction of 
diabetes and CVD, if these are not already present.  
 
As such, Worm and team (2009) found that there was a strong association between 
presence of an increasing number of the components of the metabolic syndrome in 
HIV-infected patients and an increased CVD risk. Based on this, we may predict 
diabetes and CVD (if none exists already) in about 15% of the patients in the current 
sample; simply because the grouping of the components of the metabolic syndrome 
was first described in patients with type 2 DM (Gale, 2005). After all, an increasing 
number of HIV-infected patients are starting to develop diabetes (Glass et al., 2006). 
Not limited to diabetes and the double risk of death (Isomaa et al., 2001), the 
metabolic syndrome has also been associated with a number of other obesity-related 
diseases. Among which is the non-alcoholic fatty liver disease (Saito et al., 2007), 
chronic kidney disease (Lastra et al., 2006), polycystic ovary syndrome (Rader, 
2007), and obstructive sleep apnea (Alam et al., 2007) which could all overburden 
health care systems in resource-poor settings like Uganda where the HIV pandemic 
has already done more than harm. While not all those who lived with features of the 
syndrome had the syndrome, the presence of one or more features leaves this sample 
at risk irrespective of the HIV therapeutic status. But we see that in a related cross-
sectional analysis (Mondy et al., 2007), a high prevalence of the metabolic syndrome 
in HIV-infected patients was reported (25.6%), although this was no higher than that 
of a matched sample from the general US population (26.5%) generated in NHANES 
2001–2002 cohort. Yet, in the recent FRAM study (Currier et al., 2008); the authors 
reported that HIV-infected white women were more likely to have proatherogenic 
lipid profiles than HIV-infected African American women were. What we learn here 
is that the prevalence of metabolic syndrome remains lower in races or populations 
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from poor settings. Thus, suggest that there could be other traditional risk factors 
putting populations in well-to-do nations at a much higher risk than their counter 
parts in other parts of the world.  
 
6.3.3 Metabolic syndrome and associated risk factors 
In our sample, metabolic syndrome in the 32 subjects is associated with age just like 
seronegative adults reported by Ford et al. (2002), and not the period they have been 
with neither the infection nor the time on treatment for AIDs. Actually, Samaras et 
al. (2007) reported that subjects classified as having metabolic syndrome were 
slightly older. A year later, Sobieszczyk et al. (2008) found that the notable factors 
associated with higher prevalence of metabolic syndrome among HIV-infected 
women included older age (OR = 1.38 per five year increase, p < .0001). The trend 
seems to have followed as the re-known DAD study of HIV-infected individuals 
across Europe, Australia and America reported that those with the metabolic 
syndrome at enrolment into their study were significantly older among other factors 
(Worm et al., 2009). Back, data from a cohort of 50 men in the prospective MACS 
who later initiated HAART showed notable declines in mean total, HDL and LDL 
cholesterol levels from the time of seroconversion (Riddler et al., 2003). More than a 
decade down the journey, the increase in total cholesterol levels was consistent with 
expected age-related changes, irrespective of HIV or medication status. With due 
respect to the shortcomings of cross-sectional studies, our findings suggest that 
neither being on ART nor the use of protease inhibitors did put the subjects at any 
greater risk than those in the ART-naïve group. However, this finding contradicts 
earlier researchers who reported an association between the metabolic syndrome and 
HAART among HIV-infected individuals (Samaras et al., 2007; Jerico et al., 2005). 
Specifically, the syndrome was more common in those receiving PIs (p = .040).  
 
Considerably, PIs amplify the effect of NRTIs. In a sense that first-generation PIs 
alter lipid and glucose parameters including increased triglycerides, decreased high-
density lipoprotein cholesterol and increased insulin resistance (Mallon et al., 2007). 
They are also probably involved in central hypertrophy and less probably in 
peripheral lipoatrophy. Current data neither has evidence that central obesity and PIs 
  
151 
 
are linked in anyway (χ2 = 4.15, p = .125). In another setting, Worm et al. (2009) 
revealed that those with the syndrome at entry into the study were significantly more 
likely to have lipodystrophy, while Samaras et al. (2007) had also reported that 
lipodystrophy was more common among participants with the metabolic syndrome, 
contradictory to our findings. Researchers before that had reported that soon after the 
introduction of PIs in 1996, patients developed a syndrome of fat redistribution with 
peripheral loss and central gain, generally associated with metabolic abnormalities 
and insulin resistance (Grinspoon and Carr, 2005). However, there is an 
understanding that long-standing lipoatrophy is partially and slowly reversible. 
Presently, it is likely that participants receiving PIs had not developed central 
lipohypertrophy at the time of the study. If at all they did have abdominal 
lipohypertrophy, but did not have enough of the other features of the IDF (2006) 
criterion, they possibly were missing among participants that were determined to 
present with the syndrome. However, it is no doubt that even without any other forms 
of lipodystrophy, abdominal lipohypertrophy alone can still pose risk to the 
individual. 
 
Other than PIs, the present study also lacks evidence on whether living with HIV, 
less or more years, did contribute to a greater risk of the metabolic syndrome. The 
present average time (years) with HIV infection of 3.95 (3.67) is much less than that 
reported (8.1±4.0) by Samaras and colleagues (2007). Given the widespread use of 
HAART but with lacking data especially on PLHIV in Uganda, the present study is 
still unable to have comparisons from the region. Even when using the WC in HIV-
infected populations, as definitions of the metabolic syndrome adapted for the 
general population has been said that could lead to underestimation of the metabolic 
risk in some patients (Mondy et al., 2007), the syndrome was highly associated (p = 
.000) with WC. In that, participants with the syndrome had 13.64 cm greater at the 
waist in this Ugandan-infected-female sample. As demonstrated in previous lines, 
present data suggests WC as the most influential factor in determining metabolic 
syndrome. Moreover, this emphasizes the central role obesity plays in the definition 
of the metabolic syndrome as is demonstrated by Cameron et al., (2008). The latter 
noted that central obesity precedes deterioration in each of the components that 
  
152 
 
constitute the syndrome. Actually, fat itself (not ruling out that around the waist) via 
different mediators is thought to be the pathologic impetus behind metabolic 
syndrome (Sattar et al., 2003). And Samaras et al. (2007) reported that subjects with 
the metabolic syndrome had significantly greater adiposity, including that at the 
circumference of the waist. So was the case with other populations whose HIV status 
was not a central role, such as a study in German (Schneider et al., 2007) and the 
American adult population (Ford et al., 2002). Although Samaras et al. (2006) noted 
that the WC and WHR criteria for the IDF definition of the syndrome is set too high 
and therefore too insensitive for maximal detection of CVD and diabetic risk factors 
in HIV-infected adults. If this were the case, it would mean the prevalence for the 
syndrome is lower than presently determined owing to adoption of the IDF criterion. 
The latter presumes that, in the infected populations, an increase in WHR could be 
attributable to a relatively lower increase in hip circumference rather than an 
increased rate of change in WC (Brown et al., 2006). There is need to appreciate that 
measurement of the hip circumference presents greater potential error (Lohman, 
1992); which together with observations by Brown et al. (2006) were not confirmed 
in the present data. Because HIV-negative controls were not part of the present study. 
On the other hand, there is need to rule out the under or over-estimation of the 
frequency of the components to the syndrome since measurements of these 
components were specifically obtained through standard procedures of the study. In 
addition, there was no reliance on data generally obtained through routine clinical 
care. The latter may not necessarily adhere to standardized protocols.   
 
Although prospective studies with WHtR and the hip circumference are scarce 
(Snidjer et al., 2004), elsewhere (Can et al., 2008; Schneider et al., 2007), WHtR, 
which takes differences in body height into account proved a better independent 
predictor of the metabolic syndrome. However, WC, considered as a measure of 
abdominal obesity became more superior after adjusting for other influencing factors 
among our sampled women. However, there is need for consideration of the fact that 
WC measure does not distinguish between visceral and subcutaneous fat. Yet, it is 
the excess visceral fat that is important in the etiology of the chronic diseases given 
its association with circulating free fatty acids, insulin resistance, hyperinsulinemia, 
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dyslipidemia, and atherosclerotic inflammatory markers (Bjorntorp, 1991). Stewart et 
al., (2003) have shown WC to be a better marker of visceral fat. In addition, WC 
suggests visceral fat mass ─ directly related to insulin resistance (Samaras et al., 
2007). Additional scores of skinfold thickness, percent body fat, AMC, AMA, height, 
height square, cubic height as well as disease and medication status were not superior 
to the WC. Pursuing the syndrome further, other scholars (Sobieszczyk et al., 2008) 
report that increased prevalence of the problem was due to dyslipidemia rather than 
higher blood pressure, glucose, or WC. Similarly, Jerico and colleagues (2005) found 
that hypertriglyceridemia was the most frequent trait of the metabolic syndrome in 
their data set on the metabolic syndrome among HIV-infected patients, unlike in the 
present findings. All this proves to us that differences in criteria and definitions are 
only making it difficult to compare study outcomes. Further, into the risk factors, 
none of the life style characteristics was significantly associated with metabolic 
syndrome, presently. In contrast, adjusting for demographics, physical activity and 
diet lowered the prevalence of the metabolic syndrome in HIV-infected patients than 
in the general US population, HAART-treated or not (Mondy et al., 2007). Owing to 
differences in these findings, we cannot under estimate the contribution of not using 
standardized methodologies in collecting information related to lifestyle and 
demographic characteristics in research on the topic. Consequently, differences in 
study designs, methodological aspects as well as reporting data on unrelated 
populations may in part have contributed to the difference in the findings. 
 
Overall, present data shows that majority of the participants lived with at least one 
feature that defines the syndrome. While the prevalence was close to some previous 
reports, it was many times less than reported in most others. Furthermore, that the 
syndrome was mostly subjective to central obesity and that the problem existed 
highest among those who were older. Additionally, the older lived with the highest 
amount of fat in their bodies; specifically, subjects with > 33% body fat were on 
average 38.10 (7.14) years old compared to 32.90 (7.35) - years olds, in whom the 
body fat was < 33% and the two were different (p = .000). These results remind us 
that HAART although not a cure to AIDs prolongs one’s life. Consequently, turns 
HIV into a chronic disease. The latter situation may come with consequences and 
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other associated risks related to living longer, including adverse metabolic profile. 
The present study also observed an independent significant association between thick 
skinfolds thickness measures and presence of the metabolic syndrome, at all the usual 
four sites, but that the syndrome was only significantly associated with iliac crest 
once the four-site measurements were in a single equation. The latter defies the 
rationale of inclusion of truncal subcutaneous fat in candidate definitions of 
metabolic syndrome some experienced investigators (Misra et al., 2004) suggest. 
Lastly, the lack of the link between PIs, lipodystrophy and the metabolic syndrome 
was surprising, because, others (Samaras et al., 2007; Jerico et al., 2005; Carr, 2003) 
have exclusively reported of this association. Of the 123 participants receiving 
ARVs, only ten (8.1%) reported were using PIs. This is considered a small number 
for comparison reasons; thus could have been a potential factor for lack of 
significance with the PIs. Alternatively, because there is an understanding that long-
standing lipoatrophy is partially and slowly reversible but not abdominal 
lipohypertrophy, this could mean that even without any other forms of lipodystrophy, 
abdominal lipohypertrophy alone can still put such a patient at risk. Thus, present 
revelations might as well concur with Pao et al. (2008); that metabolic abnormalities 
in PLHIV are part of discrete conditions not linked to a single underlying etiology; 
rather, they reflect individual responses to HIV infection and its treatment. 
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Chapter 7: SUMMARY AND CONCLUSIONS 
7.1 Overview, conclusions and recommendations 
7.1.1 Nutritional status and body composition 
HIV continues to be a serious health problem, yet there is limited information on the 
nutritional status of PLHIV in Uganda. Thus, the overall objective of the study was to 
assess nutrition and body composition of the participants. Specifically, this initial 
sub-study aimed at establishing the nutrition and body composition status using a 
comprehensive anthropometric protocol that included skinfold thickness and 
circumference (girth) measures, and calculated anthropometric indices including the 
BMI and the ratios (WHR and WHtR). Furthermore, the study aimed at assessing 
TBW, and subsequently FFM and FM, using the BIA and deuterium oxide dilution.  
A second aim was to compare percent body fat predicted from the anthropometrics (BMI 
and skinfold thickness measures) and the BIA techniques against that estimated by 
deuterium oxide dilution technique. In a cross sectional design, anthropometry, body 
composition, demographic and lifestyle characteristics were assessed on 211 of the 15 - 
49 year old HIV-infected women based at Mildmay Uganda. More than half (58.3%) 
were receiving ARVs.  
 
General demographic data showed that the mean age of participants was 34.1±7.65, had 
lived for 4.63±4.78 years with HIV infection, 2.8±1.9 years of which, they were using 
ARVs. More than a quarter (26%) of the participants receiving ARVs had ever changed 
drug combinations. Some (15.5%) participants had ever changed drugs due to 
lipodystrophy. Only 8.1% of the participants on AIDs treatment were using PIs. On 
nutritional status and body composition, data revealed that the average BMI (24.85±4.96) 
was considered acceptable and data showed no between-groups difference (p = .522). 
Only a few (7.1%) participants were categorised as thin and many (46.4%), were 
determined as overweight/ obese. Mean WC (77.68±10.15) was regarded acceptable and 
the study groups faired similarly (p = .118). More than half (56.9%) of the subjects were 
determined to have acceptable WHR. Mean percent fat estimated from the BMI 
(31.30±7.37), the four-site skinfolds (31.82±7.05) and the BIA (34.24±6.75) were 
independently associated with age and was similar in the two study groups. The criterion 
technique predicted the lowest percent body fat levels (26.67±9.94) with between-groups 
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differences (p = .045). Participant age, time neither spent receiving ARVs nor with the 
infection plus being treated, but not daily activity, were independently associated with 
percent body fat. Older age was the greatest single predictor while these factors were in a 
single model. Only family medical history to diabetes, but not history to hypertension or 
the average weekly consumption of high fat diet, was significantly associated with the fat. 
 
To explain the nutritional status of the 7.1% of the participants with an underweight 
problem, HIV-associated wasting and inadequate nutrition were initially an issue. 
The two effects do hasten disease progression and are likely to contribute to the 
strikingly high early mortality observed in several analyses (Johannessen et al., 
2008). More recently, this kind of wasting, in HIV, is attributable to TB and not HIV 
infection in Ugandans (Mupere et al., 2010). This remains an unconfirmed finding 
since receiving TB medication was an exclusion criterion in the present sample. 
Although dramatically declining, wasting syndrome still occurs (Tang et al., 2005). 
Among Ugandans, the problem occurs higher with or without considering disease 
(UDHS, 2007). A similar observation is, but, in many other countries in the region 
(Uthman, 2008). What these findings emphasise is that, presently, is in the Ugandan 
situation and the rest of sub-Sahara (Uthman, 2008), under nutrition still exists, with 
or without HIV.   
 
More of the nutritional status revealed that nearly thrice (46.4%) as many women 
were overweight compared to the 17% nationally reported. This revelation may partly 
explain the changing ‘face’ of the HIV infection. Previously, wasting was the brand 
of AIDs─ an HIV infected individual weight loss was strongly associated with the 
disease (Kotler et al., 1989). Today, because of ARVs and better control of 
opportunistic infections, PLHIV live longer. The longer PLHIV live, the more often 
weight becomes a problem. Overweight/ obesity is previously (FAO, 1979) not seen 
in Africa where people consumed unprocessed foods and high-energy expenditure 
because of energy intensive workload, especially among women, since there is less 
automation. However, since there is a high consumption of low fats and a rare 
consumption of whole grains and cereals in the present study, there is no doubt in the 
trends of women’s nutritional status. Nevertheless, there is an increase in overweight, 
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from 14 to 19% in the general Ugandan women as well which may mean that there 
may be other general and traditional risk factors contributing significantly to this 
overweight in the country, with and without the HIV infection. However, among the 
infected, there could be additional reasons other than the traditional causes leading to 
the problem of overweight. One such reason(s) is the fear of pinpointing PLHIV and 
stigmatisation in communities. This can lead this population to hide behind a mask of 
overweight (Kaute, 2002); forgetting that in the pre-ART era, extra weight may have 
been a good idea since it was indicated to preserve one’s CD4 count and that they 
may feel it is right to have extra weight to be protected from wasting and its 
associated health repercussions. Elsewhere, PLHIV are equally gaining weight 
(Ogden et al., 2006) even soon after introduction of ARVs (Shevitz and Knox, 2001; 
Hendricks et al., 2006; Amorosa et al., 2005; Hodgson et al., 2001). Presently, BMI 
gives better information than weight alone. In one example, mean body fat (%) per 
unit BMI in 192 participants is significantly higher in the group receiving ARVs 
(1.11±0.31) vs. the naïve group (0.99±0.38); but on a whole is a lower ratio than has 
been seen in other ethnic groups (Misra, 2003).  
 
Other than the overweight, a significantly similar between-groups abdominal obesity 
is equally in many (40.3%). This prevalence is five times greater than that (7.44%) 
reported in ART individuals (Geraix et al., 2008). Abdominal obesity here is 
attributable to central lipodystrophy common in related populations (Brown et al., 
2009; Justman et al., 2008; Schwenk et al., 2001). This is because; an increased 
trunk is due to VAT (Saint-Marc et al., 2000). This problem puts the current sample 
at an increased risk of ill health since WC is a better predictor of hypertension 
(Scherzer et al., 2008; Panagiotakos et al., 2009). A study in Africa (Geraix et al., 
2008) reported unacceptable WHR in 38.3%, closely similar to the current findings.  
In either case, the problem remains lower than that seen with WC alone. On 
accounting for hip circumference, the high problem of central obesity seems to be 
reducing. For instance, a lower prevalence of newly diagnosed diabetes and 
dyslipidemia was in subjects with higher hip circumferences (Snidjer et al., 2004). 
Nevertheless, PLHIV are likely to perceive their hips to have decreased simply 
because they see extended waists. To support this, Brown et al. (2009) revealed that 
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annual changes in hip and thigh circumferences were similar between a group of 33 
men with clinical evidence of lipodystrophy, 23 HIV-infected men without clinical 
evidence of lipodystrophy and 33 HIV-uninfected men. It is also likely that the 
Ugandan population has different body shapes from the populations that others have 
studied. The latter assumption may add to the influence by disease or the medication 
status. Furthermore, WHtR in this diseased population in which the issue of obesity 
is currently causing debates can be considered ‘safer’ than that of the Asian and 
European populations suggested by others (Scheider et al., 2007; Ashwell and Hsieh, 
2005); Ho et al., 2003). What these results mean is that when hip circumference and 
height are accounted for, abdominal obesity problem is decreased.  
 
Unlike the criterion technique, the BMI, skinfolds and the BIA methods did not 
detect differences in fat between the treated and naïve groups. However, cut offs (> 
33% at risk) in percent body fat predicted from the BMI are dependent on study 
group (p = .025) not the case with the other techniques. Therefore, the BMI becomes 
a commendable technique in assessing obesity based on Jackson et al. (2002) 
recommendations. This is an unusual situation with the ordinary BMI cut offs based 
on WHO (2000). Actually, based on the latter, there was no between-groups 
differences (p = .764). A finding that supports Joy et al. (2008) who found similar 
levels of BMI (p = .60) among HIV-infected women and the control group. A crucial 
explanation can be because of splitting the data into more than two-way. Firstly into 
the six classifications (WHO, 2000) ─ of the BMI, three of WC and five of WHR 
and secondly into the two groups (treated and naïve). This kind of splitting may have 
reduced the absolute numbers of participants in each category, affecting significance. 
However, once less finely divided, splitting data into only two divisions for obesity, 
≤ 33% (healthy) or > 33% (at risk), there are still substantial absolute numbers in 
each category, thus less likely to reduce significance. This assumption can only be 
tested using larger sample sizes. Thus, BMI may reliably be used in a population 
from whom data was collected because percent fat measures do not greatly alter the 
accuracy of the approach as a measure for classifying individuals into the broad 
categories of underweight, normal and overweight.  
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The medium to high correlations (highest between BIA and BMI) for predicting 
percent body fat are related to other studies on HIV- infected persons (Ludy et al., 
2005; Shwenk and colleagues, 2001). Hence, BIA and skinfolds or skinfolds and 
BMI may, but BIA and BMI can; substitute for one another to predict percent body 
fat. The present study also observes that the bedside techniques individually or 
interchangeably can estimate body fat. The BIA’s capability in measuring total body 
fat is previously rated moderate (Snidjer et al., 2006). Meaning that the present 
findings raise questions on whether the BodyStat 1500 machine and deuterium oxide 
dilution techniques can substitute for one another in predicting fat. This is because 
there is a difference between estimated amounts of fat by the two techniques. A 
similar case has been reported most recently in Uganda (Mupere et al., 2010), who 
insist that the potential reason for the differences could be the use of different 
equations. Other than that, fat estimated from the four-site skinfolds thickness 
measures and the BMI faired closely with the standard technique. The latter’s 
capability in measuring total body fat has for a while been demonstrated to be high in 
other populations (Snidjer et al., 2002).  
 
While time on spent receiving ARVs or with HIV, being treated and older age are 
independently associated with one’s body fat; age is the greatest independent 
predictor, remaining influential even in multivariate analyses. However, once time-
spent receiving ART was out of that model, time with the infection became 
statistically informative. Meaning that the longer people have HIV, the more likely 
they are to gain fat, and many times with increased overall body weight. Because of 
this finding, indeed HIV has a direct effect on nutritional status as suggested a decade 
ago (Kotler, 2000).  This has been reported true whether patients are on ART or not 
(Patella et al., 2004; Robinson et al., 2004; Miller et al., 2003; Huang et al., 2001). 
HAART is a responsible factor for compounding any existing risk factors for lipid 
abnormalities (Villarroya et al., 2007); conversely, results of this sample do not find 
an influence of ARV use on percent fat, when other factors are considered. This 
becomes a concern for whether the infection itself or the medication has the effect in 
these populations. On the other hand, lack of the influence by AIDs medication when 
modelled with other variables could be because only 8.1% were receiving second-
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line regimens (that comprises of PIs). The latter pose a greater impact on fat 
abnormalities, specifically fat accumulation (WHO, 2003) and since they are less 
represented, most likely this explains the lack of effect here. There is an intentional 
delay in introducing second-line regimens unless the first-line drug combinations 
pose severe side effects including fat loss observed in NRTIs (Staszewski et al., 
2003). Additionally, drugs with PIs are more costly (NAM, 2009), especially for the 
setting in which the present study was conducted.  
 
There was no significant association with the average daily activity level and the 
estimated percent body fat. Most likely, it is because the majority (69.7%) of the 
participants did not engage in regular physical activity. They reportedly spent < 2 
days per week, with a mean duration of 39.10 (98.3) minutes in exercise among those 
who did. Many (45%) reported that physical activity becomes a solution in reducing 
boredom, rather than illness. Other lifestyle indicators explain minimal but 
significant variation in the body fat. 
 
Based on the nutritional status and body composition findings, the present sample has 
more malnourished participants, many of whom are overweight, with some obese 
individuals. While the sample remains at disease risk, older age and disease factors 
significantly influenced the participants’ nutritional status. Accounting for hip and 
height measures lowered the problem of central obesity to an extent. Although the 
standard reference technique established between-groups in percent body, deuterium 
oxide dilution technique as a method of measuring TBW remains costly, less 
available, and consequently difficult to apply to large populations. Luckily, the 
alternate - the BMI that is cheaper, quicker and simpler, can give meaningful 
interpretation of nutritional status and to an extent body composition. Because a 
larger sample is unhealthy, firstly, the present study encourages that all overweight/ 
obese HIV-infected patients join weight reduction programmes. This should aim at 
achieving normal weight, taking regular screening to detect any faulting from the 
normal, as guided by health care takers. This is because overweight/ obese puts one 
at higher risk of other complications. Exercise is preferred since Mutimura and 
colleagues (Mutimura et al., 2008) recently demonstrated that exercise might be of 
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benefit in HIV populations in the region. There are also views that resistance exercise 
may reduce central fat accumulation. Bearing in mind the high pill burden that comes 
with management of HIV/AIDs; programmes in care for the infected persons may 
need to include fitness and wellness activities to avert consequences of poor health 
resulting from overweight and obesity. Whereas fitness and wellness programmes 
pose no known risks in the general population, other techniques to reduce weight 
such as use of growth hormone and Metformin come with some risks. One such 
occurrence is that growth hormone may reduce visceral adiposity and some lipid 
parameters; but may also produce glucose intolerance (Falutz et al., 2007; Lo et al., 
2008). Metformin may promote weight loss, but can also promote loss of 
subcutaneous fat and lean body mass (Kohli et al., 2007). Tissue re-growth and 
surgical complications such as infection and bleeding may offset surgery in removing 
excess adipose tissue (Moyle, 2005). All these other interventions can also come at a 
higher cost than is affordable in economically constrained set ups. All programmes, 
including resource-constrained settings such as Mildmay Uganda and the likes in the 
region, should embrace the concern for moderate fitness activities, bearing in mind 
that high intensity exercise may put further strain on patients that are already immune 
suppressed. Ignoring fitness and wellness activities in these programmes may groom 
a generation that combines both the under and over nourished, consequently 
stretching the already burdened health care systems since there will be overwhelming 
need for healthcare utilization and costs. Finally, the study aimed to establish the 
validity of the usual techniques in ongoing field and clinical assessments of body 
composition where the use of the deuterium method may be prohibitive. Thus, the 
present study proposes that BMI and WC routinely assess status of obesity in these 
populations. Since a number of PLHIV may have abdominal obesity, it is therefore 
helpful to distinguish whether other characteristics of lipodystrophy or dyslipidemia 
accompany increased WC. However, given that WHR may under or overestimate 
WC in HIV (Wohl et al., 2006), it may remain unhelpful in places that cannot 
estimate VAT. 
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7.1.2 Lipodystrophy and medication profile 
The research examined the existence of lipodystrophy by finding either a gain or loss 
in fat or, experience of mixed morphological alterations. Briefly, > 50% of the 
participants had experienced ≥ 1 morphological alteration, with more fat gains than 
the losses. Of all the participants, 7.6% had lipohypertrophy; lipoatrophy (10.9%) and 
mixed alterations (34.6%) in that order. Majority (90%) of lipodystrophic participants 
were receiving ARVs. Accordingly, the prevalence of the problem is similar to that in 
the West, Africa and Asia (Womack, 2009) and shows that indeed, not all the 
alterations have to occur together in the same person or with the same frequency.  
 
Other than establishing if the problem exists, the study sought for risks factors 
associated with the problem of lipodystrophy.  Data shows that the period spent 
receiving AIDs medication(s), receiving PIs, recent CD4 counts, time with HIV as 
well as older age are independently associated with the problem. However, receiving 
ARVs is the greatest predictor of them all. Moreover, up to 56.1% in the treated 
group reported gain in overall body weight. This is the very group in which obesity 
and overweight are more common than wasting is (Amorosa et al., 2005). From 
literature, starting ART stabilises patients and later leads to weight gain ─ including 
Ugandans (Okongo et al., 2006). Before start of HAART, patients may not be able to 
afford regular high-protein and high-calorie meals needed for weight gain and for 
restoration of lost BCM. This may be due to poor health and reduced energy 
depending on clinical staging of the HIV disease, which condition that reverses once 
one’s health and quality of life improves while on AIDs treatment (Wools-
Kaloustiana et al., 2006).  There is no doubt that additional food contributes to 
weight gain among HIV-infected Ugandans (Rawal et al., 2010). While ART comes 
with longer survival, there is also a generally improved quality of life.  
 
Weight gain is also among patients on prophylaxis. Among the ART-naïve, weight 
gain is because they generally must start on cotrimoxazole/ septrin prophylaxis. Once 
on prophylaxis, the diseases prevented and or any other opportunistic infections, 
which would have otherwise subjected the body to higher demands for nutrient 
intake, are under control (Wanke et al., 2000). In such an instance, a patient stops 
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losing weight or in many times gains, some weight. Holistic care, an approach for 
HIV/AIDs at the study site, generally improves a person’s quality of life and 
consequently better health even before the start of ARVs.  
 
Less for self-reports, anthropometric measurements were conducted to examine 
distribution of fat around the body. Data shows that when circumferences and nearly 
all the skinfolds, less for subscapular, are used, there are no differences between 
participants with lipodystrophy and those without. Moreover, there are no differences 
in all skinfolds thickness measures between the treated and the naïve participants. 
One reason for this kind of revelation can be that lipodystrophy had receded at the 
time of undertaking the study. Moreover, this becomes a big concern for diagnosing 
lipodystrophy problems through cross sectional research designs. Higher reports of 
overall weight gain than any other forms of lipodystrophy is not surprising since 
women have been reported to frequently show fat accumulation (Jacobson et al., 
2005; Galli et al., 2003); particularly, central fat (McComsey et al., 2009). 
Nevertheless, this weight gain may not necessarily come with corresponding gain in 
body mass (Silva et al., 1998) and we see that mean BMI (24.85±4.960) and WC 
(77.68±10.15) and the percent body fat (26.67±9.94) are presently within acceptable 
levels. However, only the latter and subscapular skinfolds are different in the two 
study groups. Central enlargement seen in the 26% of the presently treated patients is 
central lipohypertrophy (Bacchetti et al., 2006). Accordingly, in lipoatrophic ART-
treated patients, who were mostly naive at inclusion, the expression of some 
adipogenic transcription factors increases in abdominal SAT after two months, 
whereas these same factors decrease in thigh-level SAT (Kratz et al., 2008)). 
Although the WHR is becoming of interest in these populations, in showing 
morphological alterations since an increase in WC accompanies a reduction in the 
hips circumference, the present study has reservations supporting the theory. This is 
because data showed no differences among those who reported the problem and those 
who did not; even if one has mixed morphological alterations at the same time, fat 
from the periphery is not necessarily moving to the central stores (NAM, 2009).  
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Higher total body fat prior to HAART and a positive energy balance may present 
with further increases in trunk, including visceral, breast, and dorsocervical fat, 
whereas those with lower total body fat and neutral or negative energy balance may 
present with decreased limb or facial (He et al., 2005). Since reports show that 
obesity is high in infected populations, they may be starting with higher total body fat 
prior to HAART or even before acquiring the infection. It might then be the reason 
that presently there is a record of fewer than reported cases with the problem than has 
been in these places ─ mean BMI, WC, WHR and percent body fat are presently 
acceptable. Unfortunately, because of the 23% reporting lipohypertrophy in the legs, 
future atrophy may be higher as the patients continue to live. For a reason that initial 
increases in limb fat can predict long-term peripheral lipoatrophy (Calmly et al., 
2008).  
 
Problems of lipoatrophy have been associated with older age, being female 
(Chariyalertsak et al., 2008), as well as length of time on AIDs treatment (Han et al., 
2009). The problem among patients younger than 21 years (3.6%) could mean that 
adolescents and young adults are not any safer. Indeed, long-term-treated adolescents 
or young adults perinatally HIV-infected recently displayed characteristics of 
lipodystrophy (Arpadi et al., 2009). In addition, long-term HIV-infected patients have 
been much recently reported to encounter several age-related co-morbidities earlier 
than the general population (Guaraldi and Baraboutis, 2009) because aging 
adipocytes release more pro-inflammatory cytokines than young ones (Wu et al., 
2007), depositing fat more. Moreover, genetic polymorphisms of genes involved in 
apoptosis and adipocyte metabolism are to an extent linked to ART-associated 
lipodystrophy (Zanone et al., 2008). Only 10.9% women presently have lipoatrophy; 
a  problem that has been shown to be associated with (recent) weight loss (Tien et al., 
2007; van Griensven et al., 2007; Lichtenstein et al., 2001; Carr et al., 2000) 
although less often in women (McComsey et al., 2009). Closely in support of present 
findings is the landmark FRAM study (Bacchetti et al., 2006). There is another 
earlier one in which fat loss problem in HIV-infected male patients on HAART using 
a questionnaire and clinical examination was 14% of the 168 patients who had been 
on HAART for a median length of 17 months (Worm et al., 2002). A decade ago, 
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Martinez et al. (2001) revealed a similar problem among 14% of patients on HAART 
for a median of 18 months. However, a revelation of more than a quarter (29.1%) in 
Serbia (Jevtović et al., 2009); and 34% in Rwanda (Mutimura et al., 2007) are on the 
upper side.  
 
Presently, 65.2% with lipoatrophy are receiving ARVs. Lipoatrophy is a problem 
commonly documented in patients responding well to therapy (Grinspoon and Carr, 
2005). Of the ARVs, d4T (NRTI) is associated with development of lipoatrophy 
(Villarroya et al., 2010; Griensven et al., 2009; Gerschenson et al., 2009; Negredo et 
al., 2009; Wohl et al., 2006). Currently, only a few (4.1%) participants receiving 
HAART do use d4T. Moreover, none among the latter experienced lipoatrophy, a 
finding that is contrary to a review on implications of d4T by Villarroya et al. (2010). 
However, since two (40%) of them reported mixed alterations, it is likely that the fat 
losses attributed to d4T have been explained in these two cases.  
 
Efavirenz (NNRTI) not implicated in lipodystrophy much earlier (Miller et al., 
2003), has recently been associated with lipoatrophy (Haubbrich et al., 2009). 
Presently, 17.9% of the 28 participants that are receiving EFV have lipoatrophy. All 
those receiving PIs reported lipodystrophy; 20% of whom have lipoatrophy, while a 
similar number have lipohypertrophy. The rest (60%) of those receiving PIs 
complained of mixed experiences. Nevertheless, we know that soon after the 
introduction of PIs in 1996, patients developed a syndrome of fat redistribution ─ 
with peripheral fat loss and central fat gain (Grinspoon and Carr, 2005). Moreover, 
this can be a potential explanation for the high prevalence of the mixed alterations in 
the present data. With almost none, among the ART-naïve patients; reporting fat loss 
of the legs; present data finds support of a recent publication (McComsey et al., 
2009), which revealed that women lose less limb fat. Nevertheless, since the present 
data shows that participants receiving treatment have a higher mean sum of fat loss 
(decreases) experiences [2.456 (CI, 1.811 – 3.101)] than participants on prophylaxis 
(t164 = 7.52, p = .000), it is much likely that lipoatrophy exists. Thus, with or without 
HAART, weight loss remains inevitable in PLHIV (Tang et al., 2002). Among the 
treated, weight loss has been attributed to the persistence of HIV in peripheral blood 
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monocytes and macrophages (Shikuma et al., 2005). Other factors associated with 
weight losses in this population include poor nutrition, nutrient malabsorption and 
disturbances in metabolism (Mangili et al., 2006). In addition to lack of safe and 
potable water, poor hygiene and sanitation, psychological stress because of fear for 
death, neglect and discrimination as well as the influence of poor social and 
economic status.  
 
The other complaint was the abdominal fat loss in 5.7% treated participants vs. 3.4% 
of the ART-naïve group. The latter problem is difficult to confirm since truncal 
subcutaneous fat atrophy is often less noticeable than fat atrophy of other body parts. 
This becomes worse once there is concomitant visceral fat deposition, which keeps 
the WC unchanged. With lack of standard equipment to confirm lipodystrophy, facial 
fat losses in 6.5% treated patients; 14.6% in the general weight, legs (11.4%) and 
buttocks (8.9%) to an extent can be attributable to generalized fat loss that is because 
of HIV infection itself or, HIV associated wasting syndrome. According to CDC 
(1992), HIV wasting syndrome is involuntary weight loss greater than 10% of 
baseline weight associated with chronic illness. Unfortunately, there is no present 
validation on the latter. Participants did not respond to how many days prior to data 
collection fat losses had in existence. Persons infected with the virus go through a 
phase of physiological changes, including minor weight loss (WHO, 2005). The latter 
gets worse in later stages of the disease (WHO, 2006). Although subcutaneous fat 
loss of 20% (Haubrich et al., 2007) or 40 – 50 % range (McComsey et al., 2004; 
Moyle et al., 2005) is the criterion for fat loss, diagnosing the problem in follows 
patient complaints. By then, there is probably limited estimation on how quickly and 
how much subcutaneous fat has occurred due to lack of baseline information. There 
are can only be much done in cross sectional studies either, but self-reports have been 
recommended as the best option where other priority equipment cannot be used 
(Womack, 2009). The capture or expression of the photos does not substitute for 
serial photography used to calculate a longitudinal score of the problem.  
 
Among the readily available techniques, skinfolds measurements have an advantage 
over other methods since they can analyze fat according to body segments. Presently, 
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highest measures occurred at the abdomen, triceps, subscapular, calf, iliac and the 
biceps in that order with no between-groups differences in all these mean measures. 
On the contrary, the experience of suffering any morphological alteration is 
dependent on receiving ART. One explanation for the difference here can be the fact 
that the trigger that turns on the metabolic cascade that results in fat redistribution 
has been reported to be specific to the drugs, to an extent that some body fat changes 
may ameliorate after switching to newer therapies (Arranz Caso et al., 2005; Shlay et 
al., 2005). Since only a few participants ever changed medication, moreover, much 
less, for reasons related to lipodystrophy, probably there has been no life threatening 
reasons requiring majority (91.9%) of the treated patients to switch drugs. Indeed, we 
find no differences in skinfolds thickness means, at all the skinfolds sites, among 
participants who ever or never switched medication. In that the corresponding p-
values were all > 0.050 i.e. at the triceps = .141, biceps .992, subscapular = .674, iliac 
crest = .582, medial calf = .975 and the abdominal site = .508. However, the present 
study cannot guarantee that all the findings on lipodystrophy are due to regimens 
participants were receiving at the time of study. This is because effects of prior 
regimens (for participants who had ever switched medication) may have been 
persistent. 
 
In conclusion, lipodystrophy exists in this sample. There were more fat deposits than 
losses or mixed. Furthermore, the prevalence is within ranges of other countries, 
including neighbouring countries to Uganda. In addition, more than half of the 
participants had experienced weight gain. However, the mean body mass, BMI, all 
circumferences and the skinfolds thickness measures (less for subscapular skinfolds) are 
not different among participants that reported lipodystrophy and those who did not. A 
finding that indicates a weakness in the usual anthropometric approaches in assessing 
lipodystrophy because the standard technique established extra percent body fat in 
participants with lipodystrophy. However, subscapular skinfolds thickness is a stronger 
predictor of lipodystrophy than percent body fat. Use of PIs, longer time with disease, 
lower CD4 counts, older age and longer time on ART were independently associated with 
existence of lipodystrophy. The latter proved the greatest single predictor when all these 
factors were in a model. Contrary to published data, none of the participants receiving 
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d4T-experienced lipoatrophy per se, although the fat losses could be explained among 
those who experienced mixed alterations. Related to other findings, is the 33.3% with 
lipodystrophy that were receiving EFV and the fact that all the subjects on PIs 
experienced the problem. Consequently, based on the findings the present study is less 
hesitant to recommend a need to introduce more ‘lipid friendly’ ARVs like Mallolas et al. 
(2009) recently has indicated. This is because; treated individuals in low-income 
countries are frequently receiving relatively toxic drugs ─ almost no longer in use in the 
Western world (Gatell, 2010). Accordingly, there is need to reconsider drug combinations 
with EFZ while treating AIDs. In addition, to consider use of more friendly PIs since all 
participants receiving PIs are presently lipodystrophic. 
 
7.1.3 Metabolic syndrome and associated risk factors 
The study assessed presence of metabolic syndrome and sourced for risk factors 
associated with the syndrome. This was because close to a decade, Thiebaut et al. (2000) 
revealed that 45% of females in their sample had some form of lipid or glucose 
abnormality. Presently in brief, many (69.2%) patients live with ≥ 1 feature(s) that defines 
the metabolic syndrome. Additionally, there is lack of a single and unique anthropometric 
predictor for the components to the syndrome. Thus, the best anthropometric index varies 
as the component is varied. Central obesity in the nearly 40% of the participants is far 
higher than earlier seen in subjects receiving ARVs in Cameroon (Geraix et al., 2002) 
almost a decade ago. The problem of central obesity is presently similar in the two study 
groups. Moreover, longer time receiving ARVs is the greatest predictor for the central 
obesity problem. More data on nutritional status shows that mean BMI is acceptable. 
Sadly, participants diagnosed with BMI obesity are also wider at the waist and all the 
other circumference sites, less for the lower limbs. The AMC was the most influential 
factor for the BMI.  
 
On lipid components to the syndrome, more than quarter (35%) have unacceptable levels 
of total cholesterol and is greater in the AIDs treated group. The latter component was 
highly influenced by AMC. In addition, majority of the subjects lived with acceptable 
triglyceride levels, and the prevalence is similar across the study groups. Furthermore, the 
present study lacks sufficient evidence to attribute unacceptable levels of triglycerides to 
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disease or therapy. Nonetheless, it is mainly associated with abdominal obesity, a finding 
that compares with Dolan et al. (2005) and Torriani et al. (2006). Interestingly, about 
16% have low levels of HDL cholesterol, and is much lower in the untreated participants. 
Further data shows that LDL cholesterol is independently associated with the 
circumferences at the waist, hip, arm but also with the WHtR. Additionally, there is 
similarity in the blood pressure levels among the two study groups. The latter is 
independently associated with participants’ body weight, the BMI and the circumferences 
measured at the waist and the abdomen, plus both the ratios. Further on plasma findings 
shows that 20% of the participants have unacceptable fasting glucose levels and the two 
groups are similar. Blass and team (2008) who reported unacceptable fasting glucose 
levels in 28% of HAART-treated patients closely relate the latter revelations. 
Independently however, circumferences at the waist, abdomen and AMC plus the two 
ratios have are significantly associated with the fasting sugar but WHR stands out as the 
greatest influential predictor variable while in the model. Latter results support an earlier 
study on HIV-infected women by Dolan et al. (2005). Unfortunately, the present study 
has misgivings on the contributions of WHR as a predictor of CVD risk factors in HIV 
attributable to increased WHR. The latter is said to result from low hip circumference 
(from atrophy); because the present data shows similar hip sizes among the two study 
groups. Moreover, there is also lack of a comparison group from the HIV-negative 
population. Besides, a research that compared infected women and negative controls 
demonstrated a higher WHR among the infected than the control population (Dolan et al., 
2005).   
 
Other than a brief on the components above, the problem of metabolic syndrome is 
presently among 15.2% of the sample. That prevalence is close to 17% prevalence in 
HIV-infected patients in Barcelona (Jerico et al., 2005) the researchers in Barcelona 
used ATP III definition criteria. On the other hand, the present findings and that in 
Barcelona remain lower than 25.6%, which was no higher than the 26.5% of a 
matched sample from the general US population (Mondy et al., 2007). As well as the 
25% prevalence in infected women in Australia, in which IDF criteria was used 
(Samaras et al., 2007). Some of the participants in the Australian study already 
presented with the problem of lipodystrophy at the time of recruitment. Hitherto, 
  
170 
 
Jevtović and team (2009) report that hyperlipidaemia precedes lipodystrophy. The 
2009 emphasis by Jevtović et al. could partly be the reason for the high prevalence of 
the syndrome in the study of Samaras et al. (2007). Moreover, in the recent FRAM 
study, authors (Currier et al., 2008) show that HIV-infected white women were more 
likely to have proatherogenic lipid profiles than HIV-infected African American 
women. What we learn here is that the prevalence of metabolic syndrome remains 
lower in races or populations from poor settings. However, we want to suggest that 
there could be other traditional risk factors putting populations in well-to-do nations 
at a much higher risk than their counter parts in other parts of the world. 
Furthermore, it is likely that 15% in the present sample are diabetic. For the reason 
that the grouping of the components of the metabolic syndrome was first described in 
patients with type 2 DM (Gale, 2005). After all, an increasing number of HIV-
infected patients are starting to develop DM (Glass et al., 2006). While 32 (15.2%) 
participants have the syndrome, it is highly associated with older age just like in the 
seronegative adults (Ford et al., 2002). Other Scholars (Worm et al., 2009; 
Sobieszczyk et al., 2008; Samaras et al., 2007; Riddler et al., 2003) have also 
reported that individuals classified as having metabolic syndrome were slightly older. 
Older age was, but not receiving ARVs or length with the infection linked to the 
metabolic syndrome. Despite these findings, earlier researchers have reported an 
association between the metabolic syndrome and HAART among HIV-infected 
individuals (Samaras et al., 2007; Jerico et al., 2005). In fact, among patients 
receiving PIs (p = .040).  
 
First-generation PIs alter lipid and glucose parameters including increased 
triglycerides, decreased HDL cholesterol and increased insulin resistance (Mallon et 
al., 2007) and are probably involved in central hypertrophy and less probably in 
peripheral lipoatrophy. Current data neither has evidence that central obesity and PIs 
are linked in anyway (χ2 = 4.15, p = .125). In another setting, Worm et al. (2009) 
revealed that subjects with the syndrome at entry into their study were significantly 
more likely to have lipodystrophy. Samaras et al. (2007) had earlier reported that 
lipodystrophy was more common among individuals with the metabolic syndrome, 
findings that are contradictory to the present data. Researchers before that had 
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reported that soon after the introduction of PIs in 1996, patients developed a 
syndrome of fat redistribution with peripheral loss and central gain, generally 
associated with metabolic abnormalities and insulin resistance (Grinspoon and Carr, 
2005). However, there is an understanding that long-standing lipoatrophy is partially 
and slowly reversible; hence, it is likely that patients receiving PIs had not developed 
central lipohypertrophy at the time of the present research. In addition, if the 
participants had abdominal lipohypertrophy, they may not have had enough of the 
other features that are included in the IDF (2006) criterion ─ thus, purposely left out. 
There is also lack of confirmation on whether living with HIV, less or more years, 
did contribute to a greater risk of the metabolic syndrome. A contribution made by 
the shorter mean period with the disease, the present sample had lived, unlike in the 
research by Samaras et al. (2007), who had lived for about twice (8.1 ± 4.0) as long. 
Similarly, the present study is inept to compare findings to the general Ugandan 
population since no data is available to date. 
 
In some infected individuals, WC for defining the metabolic syndrome adapted for 
the general population is pinned for underestimating the syndrome risk (Mondy et al., 
2007). On the contrary, the syndrome is highly associated (p = .000) with WC. 
Particularly, participants with the syndrome are 13.64 cm wider in the present 
Ugandan-infected-female sample. This could emphasize the central role obesity plays 
in the definition of the metabolic syndrome. Cameron et al., (2008) noted that central 
obesity precedes deterioration in each of the components that constitute the 
syndrome. If the latter argument be true, as many as 40.3% with central obesity may 
be at as much risk as there is in the 32 patients that were determined with the 
metabolic syndrome. Actually, fat itself (not ruling out that around the waist) via 
different mediators is thought to be the pathologic impetus behind metabolic 
syndrome (Sattar et al., 2003). Many argue that individuals with the metabolic 
syndrome have significantly greater adiposity, including that at the WC (Samaras et 
al., 2007; Schneider et al., 2007; Ford et al., 2002). Samaras et al. (2006) had earlier 
noted that central obesity criteria for the IDF definition of the syndrome is set too 
high and therefore too insensitive for maximal detection of CVD and DM risk factors 
in HIV-infected adults. If this were the case, it would mean the prevalence for the 
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syndrome is lower than determined. On the other hand, we might rule out the under 
or over-estimation of the frequency of the components to the syndrome since 
measurements of these components were specifically obtained through standard 
procedures of the study. In other words, there was no reliance on data generally 
obtained through routine clinical care. Collection of such data may not necessarily 
adhere to standardized protocols.   
 
Furthermore, details on girths shows that data on WHtR and the hip circumference 
are scarce (Snidjer et al., 2004). However, the former, which takes differences in 
body height into account, is a better independent predictor of the metabolic syndrome 
(Can et al., 2008; Schneider et al., 2007)). Presently, WC became more superior after 
adjusting for other influencing factors in the present sample of women. Additional 
scores of skinfold thickness, percent body fat, AMC, AMA, height, height square, 
cubic height as well as disease and medication status were not superior to the WC. 
Yet, there is need for consideration of the fact that WC measure does not distinguish 
between visceral and subcutaneous fat. But rather, that excess visceral fat is 
important in the etiology of the chronic diseases given its association with circulating 
FFAs, insulin resistance, hyperinsulinemia, dyslipidemia and the atherosclerotic 
inflammatory markers (Bjorntorp, 1991). However, Stewart et al. (2003) have shown 
WC as a better marker of visceral fat. Consequently, WC does more closely reflect 
visceral fat mass directly related to insulin resistance (Samaras et al., 2007).  
 
Despite all evidence on WC and its association with the metabolic syndrome, other 
scholars (Sobieszczyk et al., 2008; Jerico and colleagues, 2005) report that increased 
prevalence of the syndrome was due to dyslipidemia rather than higher blood 
pressure, glucose, or WC. Other studies, however, found that total body fat or the 
BMI, rather than its distribution, is the stronger predictor of the metabolic risks 
(Boyko et al., 1995; Mykkanen et al., 1992). Pursuing risk factors further, none of 
the included life style characteristics is associated with the syndrome, which is 
contrary elsewhere (Mondy et al., 2007), who after adjusting for demographics, 
physical activity and diet, lowered the prevalence of the metabolic syndrome in HIV-
infected patients than in the general US population, whether they were treated with 
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HAART or not. This and many other findings prove the difficulty differences in 
criteria and definitions are making in comparing study outcomes.  
 
Overall, majority of the patients live with ≥ 1 feature(s) that defines the metabolic 
syndrome. While the prevalence of the syndrome is close to some previous reports, it 
is in many times less than reported by many other Scholars. Most influential is 
central obesity and that the problem existed highest among participants who were 
older; and the latter lived with the highest amount of percent body fat. These results 
remind us that HAART although not a cure to AIDs prolongs one’s life, turning into 
chronic disease and this may come with consequences and other associated risks 
related to living longer, including adverse metabolic profile. We also observed an 
independent significant association between thick skinfolds thickness measures and 
the presence of the syndrome, at all the usual four sites, but that the syndrome was 
only significantly associated with iliac crest. The latter defies the rationale of 
inclusion of truncal subcutaneous fat in candidate definitions of metabolic syndrome 
(Misra et al., 2004). Lastly, the lack of the link between PIs, lipodystrophy and the 
metabolic syndrome was surprising, because others (Samaras et al., 2007; Jerico et 
al., 2005; Carr, 2003) have exclusively reported of this association. Present findings 
might as well concur with Pao et al. (2008) who concluded that metabolic 
abnormalities in PLHIV are part of discrete conditions that are not linked to a single 
underlying etiology; rather, they reflect individual responses to HIV infection and its 
treatment. 
 
From present findings, it appears that HIV-infected patients live with the metabolic 
syndrome and many, are living with some features that define this syndrome. The 
latter risk getting the complexities of the syndrome because the risk factors 
associated with the syndrome and the prothrombotic state associated with them that 
predisposes an HIV-infected patient to premature CVD (Wohl, 2005). Additionally, 
BMI obesity may not be a big problem presently, but central obesity is; and the latter 
is highly associated with the period a participant has spent receiving AIDs treatment. 
Backed by elevated levels of total cholesterol, LDL cholesterol, fasting sugar levels 
as well as reduced HDL cholesterol and without proof of association with life style 
  
174 
 
characteristics but rather with older age, these data provide additional support for the 
need for health and other supportive programs. There is also need to consider 
assessing for components and consequently determining the syndrome in individual 
patients as a routine measure. Especially, as one takes ARVs longer since patients 
receiving HAART appear to be at risk for CVD (Stein, 2006), but also because they 
are currently living longer. This is because some HIV-infected persons even at 
normal BMI may still be at risk of adverse metabolic outcomes, yet an increase in all 
or some of the components of the metabolic syndrome pause much more risk than 
those in whom these components absent. Consequently, support the recommendation 
that such patients should undergo CVD risk evaluation at least annually (Lundgren et 
al., 2008).  
 
Furthermore, routinely ascertaining lipid profile especially in adults is beneficial for 
all PLHIV, treated or not, well knowing that there is a potential human and economic 
cost of ill health. It has also been stated lately, that > 90% of HIV-infected people 
live in low-income countries and many will actually die of AIDs-defining events 
(Ferry et al., 2009). Consequently, in Uganda like should be in the other countries at 
most risk, programmes should strive to know one’s disease risk and move quickly to 
prevent further deterioration. The rationale here is that development of health 
problems is an imperative to long-term survival. The easiest and cheapest indicator to 
assess for risk in this population should be WC if routine laboratory services are not 
feasible. Although greatly associated with the metabolic syndrome in the present 
sample, WC is also commended as more sensitive to diet and training than the BMI 
since any increase of muscle mass may lead to minimal change of BMI but clearer 
changes in WC (Schneider et al., 2007). 
 
7.2 Overall strengths and limitations 
On a whole, pilot results indicate that anthropometric data are sufficiently reliable. 
The reliability of the measurements, thus, the indices including the BMI as well as 
body composition, is reassuring since BMI and WC can give meaningful 
interpretations based on the present data. While there were such strengths, limitations 
to the study also exist. Firstly, the cross sectional design could not allow the study to 
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shed light on how quickly participants experienced fat gains or losses or even 
developed the metabolic syndrome. In addition, the methodology did not extend 
observations to include a seronegative sample to rule out the absolute contribution of 
the infection. Secondly, while all possible steps ensured maximum participant recall 
of the study procedures, experience during data collection shows that some 
participants may not have complied with the instructions for ‘heavy water’. The lack 
of adherence to the latter procedure, which required recall from one’s memory, can 
be difficult in poor settings like Uganda. The use of stable isotopes may not only be a 
new procedure to participants but also pauses difficulty in translating the research 
into a lay and practical language due to the very low literacy levels of these 
populations.  
 
For instance, more than 19% of women aged 15 - 49 years have only attended 
primary school education (UDHS, 2006). Another issue that may have caused lack of 
adherence among some participants could have been prior experience on ART or anti 
TB drugs─in many times associated with very severe side effects (Table 1). Thus, 
causing fear that anything unusual and external to the body including ‘heavy water’ 
could result in related inconveniences. Thirdly, while it was intended that each 
eligible patient had an equal probability of being selected, a recruitment strategy 
aimed at minimizing influences in study outcomes, data was collected from 
volunteers as there was an overwhelmingly un-foreseen ‘cost’ of inviting randomly 
selected patients.  Unfortunately, voluntary recruitment determines characteristics of 
study groups. One such example is where Womack (2009) noted that voluntarily 
recruiting participants for clinical care (which was done), characterizes the 
population by those qualities or attributes found in the type of person who presents 
for care. The latter instance ordinarily excludes persons that do not present or those 
that present less frequently. Additionally, because of fewer participants which mainly 
affected the study on lipodystrophy and the medication profile, it was not easy 
interpreting findings of the association of so many variables on this very outcome, 
consequently lacked conclusive findings on the topic. Moreover, use of some of the 
most robust and provable objective techniques (such as the DXA machine) 
considered as reference methods for quantifying fat loss due to lipoatrophy were not 
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feasible. The techniques were not available within means of this study – both in 
Uganda and at the study site then. In addition, significant lipoatrophy can be present 
in HIV-infected persons without clinical evidence of fat wasting, and this more than 
highlights the limitations of using a bi-directional definition of lipoatrophy (Brown et 
al., 2009) based on self-reports where mimicking of conditions is difficult to rule out. 
Therefore, this remains clear that performing studies addressing lipoatrophy in Africa 
will remain challenging until technical measurements that confirm the problem are in 
place.  
 
Furthermore, we cannot under estimate the contribution of not using standardized 
methodologies in collecting information related to lifestyle and demographic 
characteristics. Consequently, differences in study designs and methodological 
aspects as well as reporting data on unrelated populations may in part have 
contributed to the difference in the findings. 
 
7.3 Future research directions 
It was an oversight for the present study not to investigate levels of physical and 
cardiorespiratory fitness, yet these have been considered to be associated with the 
prevalence of the metabolic syndrome, even among women (Farrell et al., 2004; LaMonte 
et al., 2005). Thus, investigating physical and cardiorespiratory fitness of the infected 
population, may well add an understanding of appropriate healthy programs. In addition, 
undertaking a well-designed, standardised and detailed dietary intake assessment can 
merit investigations and thus further insight in interpreting results on body composition in 
the kind of population. 
 
7.4 Contribution and significance of this study 
The present study underlines the potential importance of evaluating usual anthropometrics 
and the BIA for prediction of body composition. The study has shown that BMI can give 
meaningful interpretations since the three usual categories were maintained when BMI 
was subjected to assess obesity. In addition, findings contribute to the debate on the 
existence of lipodystrophy in the infected population, since results showed less than the 
reported prevalence of the problem. Furthermore, the research has supported other reports 
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from which WC has been recommended as the best predictor for the metabolic syndrome. 
Otherwise, with progressing aging of the HIV-infected population yet no doubt the 
continued use of ART, it will be inevitable to continue recording cases of overweight and 
obesity, lipodystrophy and the metabolic syndrome. Collectively, ARVs introduce this 
population to future risk for poor health. Thus, an overwhelming demand for health 
services which has a significant implication on the health care systems─mainly in 
resources-limited set-ups. Consequently, it might be helpful in clinical practice to 
thoroughly, investigate all risk factors at the time of diagnosing HIV and before initiating 
ARVs and continued routinely thereafter. Results of the present study are important to 
inform nutritionists and clinicians on the relative value of various measurements in 
assessing nutritional status and body composition of PLHIV and consequently assist in 
the provision of improved care. Results also highlight the relationship between AIDs 
medication and morphological alterations as well as the metabolic syndrome. 
Applicability of results to older adults may be limited and may not be generalized to the 
Ugandan HIV-infected population since sex-related differences might exist because 
metabolic risk factors appear in women at lower WC thresholds than in men.  
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9. APPENDICES 
9.1: Sample size calculation 
Krejcie & Morgan (1970) produced a table for determining sample size. They did this 
in response to an article called "Small Sample Techniques" issued by the research 
division of the National Education Association. In this article, a formula was 
provided for the purpose, but, according to Krejcie & Morgan, regrettably an easy 
reference table had not been provided. They therefore produced such a table based on 
the formula.  
N - n  N - n N - n N - n  N - n 
 10 - 10 100 - 80  280 - 162  800 - 260  2800 - 338  
 15 - 14 110 - 86 290 - 165 850 - 265 3000 - 341 
 20 - 19 120 - 92 300 - 169  900 - 269  3500 - 346 
 25 - 24 130 - 97  320 - 175 950 - 274 4000 - 351  
 30 - 28 140 - 103  340 - 181 1000 - 278 4500 - 354 
 35 - 32 150 - 108 360 - 186 1100 - 285 5000 - 357 
 40 - 36 160 - 113 380 - 191 1200 - 291 6000 - 361 
 45 - 40 170 - 118 400 - 196 1300 - 297 7000 - 364 
 50 - 44 180 - 123 420 - 201 1400 - 302 8000 - 367 
 55 - 48 190 - 127 440 - 205 1500 - 306 9000 - 368  
 60 - 52 200 - 132 460 - 210 1600 - 310 10000 - 370 
 65 - 56 210 - 136 480 - 241 1700 - 313 15000 - 375 
 70 - 59 220 - 140 500 - 217 1800 - 317 20000 - 377 
 75 - 63 230 - 144 550 - 226 1900 - 320 30000 - 379 
 80 - 66 240 - 148 600 - 234 2000 - 322 40000 - 380 
 85 - 70 250 - 152 650 - 242 2200 - 327 50000 - 381 
 90 - 73 260 - 155 700 - 248 2400 - 331 75000 - 382 
 95 - 76 270 - 159 750 - 254 2600 - 335 100000 - 384 
Adapted from Krejcie & Morgan, 1970, p.608 
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No calculations are required to use the table above. According to Krejcie & Morgan, 
if one wished to know the sample size required to be representative of the opinions of 
9,000 specified electronic users, then one enters the table at N = 9,000. In the this 
study, the sample size was 1,200 for those on AIDs medication and 633 for those in 
care but not yet on medication and which gave about 915 (50% of them all) eligible 
participants in general. The table is applicable to any population of a defined (finite) 
size. Required sample size, given a finite population, where N = population size and 
n = sample size. Krejcie and Morgan state that, using this calculation, as the 
population increases the sample size increases at a diminishing rate (plateau) and 
remains, eventually constant at slightly more than 380 cases. There is little to be 
gained to warrant the expense and energy to sample beyond about 380 cases. 
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9.2: Pilot study findings 
9.2.1 Background and pilot summary 
The pilot study aim was to inform on the feasibility and practicality of the initially 
proposed study activities and consequently, improving quality of the expected 
outcomes. Firstly, the pilot study hypothesized that there would be no difference in 
percent body fat derived from four techniques, with minimal bias. Secondly, that 
lipodystrophy would exist, with highest prevalence among participants with known 
HIV status and mainly persons receiving ARVs and that presence of lipodystrophy 
would be dependent on the time a patient had lived with HIV infection from initial 
diagnosis. Thirdly, that metabolic syndrome would exist, with worst prevalence 
among the HIV-infected. A final aim was to test precision of anthropometric 
measurements that had a central role to the major study. In all, ten HIV-infected and 
ten control women (15 - 49 years) at Mildmay-Uganda participated in the pilot 
between July and August 2009. Body composition status using a comprehensive 
anthropometric protocol included skinfolds thickness and circumference (girth) 
measures. Total body water and subsequently FFM and FM, estimated using the BIA 
technique was adopted in establishing the relationship between percent fat mass and 
participant disease and medication profile. Data was analysed using SPSS (16.0. Inc, 
Chicago, IL, USA). 
 
In brief, results showed that the mean body mass (kg) was 62.19 (10.2) for the HIV-
infected and 67.91 (12.18) for the group with unknown HIV status and there was 
between-groups difference (p < 0.05). In addition, none of the participants was 
considered underweight, however more than half (55%) were overweight (BMI > 
24.9 kg/m
2
). Furthermore, the latter finding was independent of ones’ HIV status (p = 
.228). More data showed that half of the participants in the pilot study were at low 
risk for abdominal obesity-related diseases, with 20% at a substantially increased 
risk. An estimated 39.2% of the variation in percent body fat predicted by BIA could 
be explained by the variation in WHtR and this variation was highly significant (p = 
.002). Results revealed that the BIA technique predicted the highest mean percent 
body fat (37.0±5.18), followed by the usual 4-site skinfolds (34.84±5.47) and the 
BMI (32.87±5.63) in that order. Significant mean differences were only observed 
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between percent fat predicted by the BIA technique and the BMI (p = .000). In 
addition, there was a significant difference in percent body fat of the HIV-infected 
group (38.9%) and the group made up of unknown HIV status (35.5%). And 24.3% 
variation in the percent mean body fat predicted by the BIA was explained by the age. 
Among the infected group, lipodystrophy at different body sites was independent of 
disease and the medication status. To test precision of generalized anthropometric 
measurements, results showed that both TEM (Ulijaszek and Kerr, 1999; Norton, 
1996) and %TEM were within the recommended limits for intra-tester %TEM for the 
skinfolds thickness measures (7.5%) as well as for the other measurement sites on the 
body (1.5%).  
 
Thus, there was between-groups difference for most anthropometric and body fat 
variables. Based on the experience during the pilot study, the actual study activities 
proceeded with some adjustments of the steps that had been stated in the study 
proposal. For example, while it was intended that each eligible patient had an equal 
probability of being selected (a recruitment strategy aimed at minimizing influences 
in study outcomes), data was instead collected from volunteers. This was because 
there was an overwhelmingly un-foreseen ‘cost’ of inviting randomly selected 
patients. In this, a phone call was required and a prospective participant had to arrive 
for a briefing and then return another day for actual data collection. Phone call and all 
the travels were attracting an expense, which the proposal had not factored in. 
Another adjustment was exclusion of all known active patients on medication for 
treating TB. Such participants filled their bladders at a much slower rate than any 
other participants did. Thus, they neither were in position to provide sufficient 
amounts of urine nor urinated at such hours for which urine samples were required. 
 
9.2.2 Pilot study methodology 
9.2.2.1 Pilot study participation 
The pilot involved women of childbearing age (15-49 years) living with HIV/AIDS 
attending Mildmay-Uganda and their counterparts that comprised of a similar age 
range whose HIV status was not known. Data was collected in a cross-sectional study 
employing anthropometry, along with study of the secondary information on 
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participant medication profile and time with HIV from initial diagnosis. One was 
included if they gave consent but excluded if they were pregnant, metal(s) or very 
weak, bedridden and unable to complete study activities. The study group was made 
up of a patient receiving care for HIV/AIDs at Mildmay Uganda, while the 
comparison group was made up of Mildmay Uganda employees who were known to 
have no HIV infection or had an unknown HIV status on the date of engaging in the 
study. A convenient sample of ten participants in each of the above categories was 
used. The initial study sought to assess for nutritional status and estimate body 
composition of the pilot subjects through the following steps: 
9.2.2.2 Anthropometric measurements 
Anthropometric measurements were undertaken according to the protocols of ISAK 
(2001) including body mass (kg) and stature (cm). Skinfolds thickness measurements 
(mm) including triceps, biceps, subscapular and suprailiac plus two girth 
measurements (cm) at the waist and hips using a flexible girth tape measured to the 
nearest 1.0 mm and 0.1 cm, respectively. 
i. Estimating body composition from anthropometric measurements 
a. Body Mass Index 
Body Mass Index was calculated by dividing weight (in kg) by height squared (in 
meters): BMI = weight (kg) / Height (m
2
) and the standard cut-off points (WHO, 
2000; Seidell and Flegal, 1997) were retained. An estimation of body fat derived 
from BMI was made using of formulae developed elsewhere (Jackson et al., 2002) 
adapted for age and sex, as: Adult %BF (see, 4.6%) = (1.39 x BMI) + (0.16 x Age) – 
(10.34 x gender) - 9 (female gender coded as zero). 
b. Skin fold thickness measurements 
An estimation of body composition was made by calculating body density in gm/cc 
based on the mean sum of four sites and FFM according to the table developed by 
Durnin and Womersley (1974), adapted for age and sex. Body density was calculated 
to be equal to 1.1567 - 0.0717 (logX) where X was sum of four skinfolds (triceps, 
biceps, subscapular and suprailiac [which is equivalent to iliac crest using the ISAK 
protocol]). Fat mass content was then estimated from the body density values above 
using the Siri equation (1954), namely, percent body fat (see, depending on age 
group) = (4.95/body density – 4.50) x 100. 
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ii. Estimating body fat distribution 
a. Waist: Hip ratio 
Waist: Hip ratio was calculated by dividing the waist girth with the hip girth and the 
WHR = Gw / Gh; where Gw = waist girth, Gh = hip girth and with the use of table 
below which outlines the general guidelines for acceptable levels for WHR (adapted 
from Janssen et al., 2002), placed a participant in the appropriate category. 
 
Waist-to-hip ratio cut-off points for women 
Acceptable  Unacceptable  
Excellent  Good  Average  High  Extreme  
< 0.75  0.75 - 0.80  0.80 - 0.85  0.85 - 0.90  > 0.90  
 
As no definitive cut-off points have been validated for HIV patients, this pilot study 
adopted 0.80 as the normal limit based on Molarius and Seidell (1998). 
 
9.2.2.3 Assessment of TBW (and body composition) 
i. The BIA technique 
The aim was to assess TBW by the BIA technique and subsequently derive body 
composition values (FFM and FM). The technique is based on the difference in 
resistance to current flow between the FFM and FM. The method is non-invasive, 
rapid, portable, convenient, technically precise, and highly reproducible (National 
Institutes of Health, 1996). The BODYSTAT
®
 1500 body composition monitoring 
unit (British Isles, UK) was adopted using a standardized protocol that is provided by 
the manufacturers. This machine works by passing a safe battery generated signal 
through the body and measuring the impedance at a fixed frequency of 50 kHz. 
Recommended standard conditions of the NIH in clinical practice (Kyle et al., 2004) 
were followed. The following equation was used to predict TBW (see, 2.50) = 0.830 
+ 0.714(Ht
2
/R) and FFM (Dioum et al., 2005; Schoeller & Luke, 2000; Zillikens & 
Conway, 1991; Kushner & Schoeller, 1986). R was selected over impedance based 
on the assumption that < 90% of the measured impedance in the human body is 
composed of R (Sun et al., 2003). Assuming that approximately 73% of FFM is 
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water, FFM was then calculated as TBW/0.73, and FM calculated as body weight - 
FFM (Forbes, 1996; Miranda da Cruz et al., 2003). Finally FM defined as percentage 
body fat was calculated as (Weight - FFMTBW)/ Weight X 100 (Ellis, 2001). In other 
words TBW (see, 2.50) = 0.830 + 0.714(Ht
2
/R); FFM = TBW/0.73; BF = Weight – 
FFM. 
iii. Deuterium oxide dilution technique 
Here, the aim was to assess TBW by the deuterium oxide dilution technique and 
subsequently calculate FFM and FM. On completion of analysis of the urine samples, 
the pre-dose urine sample that was obtained by voiding the bladder was used to 
determine the level of naturally occurring deuterium oxide. After collection of the 
pre-dose urine sample, each participant consumed a 10% solution of an oral bolus 
equating to 0.05 g/kg body weight of the stable, non-radioactive, non-toxic isotope, 
99.9% deuterium oxide atom. Four and six hour post dose urine samples were 
collected and the samples were then sealed, refrigerated and frozen below 18
0
C 
immediately after collection, and later prepared for delivery by DHL Courier 
Company to IHBI (QUT), Brisbane, Australia where enrichment of deuterium oxide 
dilution in the pre-dose and post-dose samples was assessed using IRMS. 
a. Preparation of deuterium oxide solution dose 
The researcher weighed 0.5 g per kg body weight of a 10% solution of the 99.9% 
deuterium oxide atom after assessing the total weight to be dosed. To make a 10% 
solution of deuterium, 100 mL of 99.9% 
2
H2O was added to 900 mL tap water in a 1 
L volumetric flask and mixed very well. The solution was then divided evenly into 
four Schott bottles and autoclaved (2340MK N/B 136007, Tuttnauer autoclave steam 
steriliser 2340MK N/B 136007, Tuttnauer autoclave steam steriliser) for ten minutes 
at 134
o
C to sterilise. Six urine sample bottles were clearly labelled with the 
participant code and date of assessment. Additionally, the same bottles were marked 
with pre, 4-hour and 6-hour in duplicate.  
b. Administration of dose 
The deuterium oxide dose was calculated as 0.5 g per kg body weight. Participants 
were fasted for a minimum of four hours and assumed to have been in a state of 
normal hydration. A baseline (pre-dose) urine sample was collected from each 
participant. Data collector weighed a sterile bottle and its cover using a Shimadzu 
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electronic balance (BL3200HL) and tared the scale reflected values. The total weight 
was the sum of the bottle + cover + calculated dose; then weighed the bottle and 
cover after the participant drunk the dose to account for any leftover dose in the cup; 
that leftover value was subtracted from the total bottle +cover + calculated dose to 
determine the actual dose that was consumed as exampled below: 
c. Administration of the 10% solution of 99.9% deuterium oxide 
Subject 
ID  
Weight 
(kg) 
Required dose 
(0.5 x 86.6 kg) 
bottle + 
cover (g) 
bottle + 
cover + 
Dose (g) 
bottle + 
cover (post 
drink) (g) 
Actual dose 
(g) 
e.g. 101 86.6  43.3 g 4.15 g 47.66 4.23 g 43.43  
 
d. Instructions that were given to the participants 
Participants were requested to avoid strenuous physical activity during the 
measurement period. This was to avoid fractionation due to water vapour loss 
because of increased breathing and transdermal evaporation. Moreover, this was 
assumed to be best achieved by keeping the participants at the study site, Mildmay 
Uganda, until the end of the study activities. Unexpectedly, it was nearly impossible 
keeping participants in one place for the required time of urine sample collection. 
Additionally, if a participant took any foods or drinks at the time they took their 
medications, they were asked to provide a sample or make a record of what the foods 
and amounts were. By the end of the pilot, all HIV-infected participants indicated to 
have taken a meal in favour of their medication(s). 
e. Urine sample collection timeline 
Time (hh: mm) Urine sample Received duplicate (tick) remark 
 Pre-dose   
 4-hour   
 6-hour   
 
f. Estimating body composition 
The concentration of deuterium oxide in urine will be calculated as the deuterium 
oxide enrichment being equal to 6-hour deuterium oxide - baseline deuterium oxide 
and the concentration used to calculate the TBW as: 
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TBW (kg) = [(W x A/a) x (Ea – Et)/ (Es – Ep)/ (1000 x 1.041)] (adapted from 
Abrahams and Wong, 2003) where; 
W = volume of tap water (mL) that (a) diluted in (200 mL) – shall use 200 mL 
A = dose given in grams (cup + straw + dose minus cup and straw) 
a = amount of dose diluted in 200 mL 
Ea = delta value of (a) the dose given in tap water 
Et = delta value of tap water 
Es = 6-hour delta value 
Ep = delta value of pre dose sample (baseline sample). Assuming that approximately 
73% of FFM is water, the FFM = TBW/0.73, while FM = body weight - FFM 
(Forbes, 1996; Miranda da Cruz et al., 2003). Alternatively, fat mass can be 
represented as percentage body fat defined as (body weight - FFMTBW)/ body weight 
times 100 (Ellis, 2001). 
 
9.2.2.4 Data management and analysis 
SPSS for windows (18.0 Inc, Chicago, IL, USA) was used for data entry, exploration 
and analysis for all the pilot data. Chi square was used to analyse categorical 
variables like demographic values, percent BFBMI, BFSF, BFBIA, BF
2
H2O as well as 
indices of BMI, WC and WHR (less or equal and greater or equal reference cut-off 
points). A two-sample student’s t-test was used for continuous variables between the 
infected and the comparison groups at p < .05 significance 2-tailed level. A (2x3) 
factorial ANOVA followed by Turkey's post hoc was applied to examine percent 
mean BFBMI, BFSF, BFBIA between HIV-infected and the pilot group with an unknown 
HIV status. 
 
The second study assessed for presence and risk factors of lipodystrophy.  Firstly, 
though some experts have implicated PIs as the leading cause of lipodystrophy 
among HIV-infected persons (Saint-Marc et al., 2000; Carr et al., 1998), there is 
some evidence that long-term HIV infection could be implicated (Mondy et al., 
2007). The pilot study documented the HAART profile of all HIV-infected 
participants and time with HIV since diagnosis with data ascertained from individual 
medical files except where there was no proof of record.  
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Participant medication profile and lipodystrophy report 
ART class Example 
(circle/write out) 
*HAART 
(Yes/no) 
Medication start 
date 
(DD/MM/YYYY) 
Time on medication 
(years) 
Reverse 
Transcriptase 
Inhibitor 
NNRTIs 
efavirenz 
nevirapine 
etravirine 
delavirdine 
Atripla 
Kaletra 
Combivir 
Trizivir 
Epzicom 
Truvada 
  
NRTIs 
abacavir  
didanosine  
lamivudine 
stavudine  
tenofovir 
AZT; zidovudine 
emtricitabine 
 
Protease 
Inhibitor 
indinavir 
lopinavir  
nelfinavir 
ritonavir 
saquinavir 
darunavir 
atazanavir 
fosamprenavir 
tipranavir 
kaletra 200/50- 
(lopinavir+novir) 
 
*Atripla – tenofovir + emtricitabine + efavirenz; *Kaletra – lopinavir + norvir; 
*Combivir – lamivudine + zidovudine; *Trizivir – abacavir + lamivudine + 
zidovudine; *Epzicom – lamivudine + abacavir; *Truvada – tenofovir + 
emtricitabine 
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Secondly, self-reported changes in body shape were adapted from Karmon et al. 
(2005) and included changes in the overall weight gain, size of the neck, breasts, 
abdomen, arms, legs and face on a bi-directional scale that allowed respondents to 
report an increase or decrease in any of the parameters. After all, diagnosis of 
lipoatrophy is frequently based on patient’s perception and this has been shown to 
correlate well with physical examination (Bacchetti et al., 2005). Another step was to 
ascertain fat distribution by considering circumferences of the upper arm (relaxed) 
(maximum), calf (maximum), abdomen as well as lower body SF, calf (maximum) 
and iliac crest were taken to assess fat distribution pattern across the body. Arm 
muscle circumference and AMA were calculated using a standard formula 
(Frisancho, 1990). AMC = MAC (cm) minus  × TSF
1
 (mm)/ 10 and AMA (cm
2
) = 
(AMC (cm
2
))/ 4 . Arm measurements were proposed to examine the difference 
between the infected and their counterparts. An earlier study reported that measured 
WC and WHR increased in HALS patients (Andersen et al., 2003). In their study, 
HALS patients were also slightly heavier than control subjects, which the reporters 
thought could be ascribed to an increased lean body mass in the former group. 
Andersen et al. (2003) also reported that limb fat (%) was significantly reduced in 
HALS patients compared with patients without lipodystrophy (36% vs. 46%; p = 
.0002). An important fraction of participants in another major but related study 
reported that participants were either diagnosed by peripheral lipoatrophy (25% to 
34%) or central obesity from 13% to 34% (Saint-Marc et al., 2000). In addition, most 
recently, Torriani et al. (2006) reported reduced calf subcutaneous fat area (17.8 vs. 
35 cm
2
, p < .0001) and extremity fat by DXA (11.8 vs. 15.6 kg, p = .024) but 
increased VAT (125.2 vs. 74.4 cm
2
, p = .004) among 46 women (25 of whom 
displayed fat redistribution) and 21 controls, respectively. 
 
 
 
 
                                                          
 
1
 TSF is Triceps Skinfold 
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9.2.2.5 Results for the pilot study 
i. Participants’ characteristics 
Generally, there were 20 participants, ten in each group and were on average aged 
37±8 and the infected group was 9.30 years older (p = .007). Further results showed 
that mean body mass (kg) was 62.19±10.20 for the infected and 67.91±12.18 for 
group with unknown HIV status respectively and the two groups were not different (p 
= .266). The mean BMI was 25.88 (3.63) kg/m
2 
and the two groups were not different 
(p = .804). However, more than half (55%) were in the overweight category, 
followed by those considered to have a normal BMI (35%) and the obese (10%) in 
that order. Analysis was extended to the girths and data showed that the mean WC 
(79.56±8.45) was acceptable (< 80 cm) and the two groups were not different (p = 
.388). Based on WHO (2000), 47.6% of the subjects were determined to be at low 
risk, 28.6% at an increased and 19.0 at a substantially increased risk for abdominal 
obesity. Mean WHR was generally acceptable (0.79±0.06) and the infected group 
was determined with a greater ratio than the group with unknown HIV status (p = 
.003). 
Table showing variable means and the comparison between the two pilot groups 
Variable Overall mean (SD) Group comparison 
Age (years) 37 (8) p = .007* 
Body mass (kg) 65.05 (11.23) p = .266 
BMI kg/m
2
 25.88 (3.63) p = .804 
WC (cm) 79.56 (8.45) p = .388 
WHR 0.79 (0.06) p = .003* 
*Statistically significant 
 
ii. Estimating percent body fat 
Greenhouse-Geisser correction indicated a significant difference (p = .015) in at least 
two of the mean percent body fat estimated from the four techniques. Post hoc 
comparisons were performed using the Bonferroni adjustment for multiple 
comparisons. Percent body fat was estimated highest by the BIA technique 
(37.05±5.18), followed by the four-site skinfold thickness measures (34.78±5.53), the 
BMI (32.87±5.63) and the criterion technique (28.94±11.41). And there was a clear 
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difference between that estimated by the BIA and the BMI (p = .001) as well as the 
BIA and the criterion technique (p = .021). 
 
iv. Presence of lipodystrophy 
Lipodystrophy existed in nine (45%) of all the subjects that participated in the pilot. 
Four participants reported to have experienced lipohypertrophy, while five reported 
lipoatrophy. All lipodystrophic cases were HIV-infected (Fisher’s Exact, p = .000).  
 
v. Technical Error of Measurements 
Using a sample of ten HIV-infected and ten others with an unknown HIV-status, 
TEM was calculated as being equal to √∑d2/2n. Where ∑d was the sum of the 
anthropometric differences while n was the number of participants that constituted 
the anthropometry. In this pilot study, differences were calculated as the two closest 
two measured values. TEM above was converted into relative values of percent TEM 
(%TEM) as %TEM = TEM/mean * 100. And here, the mean was the mean of 
duplicate measurements i.e. (mean1 + mean2)/2. This process was performed for each 
measured anthropometry. Recommended limits for intra-tester %TEM are 7.5% for 
skinfolds and 1.5% for the other measurement sites (Gore et al., 1986). Table 20 
below shows the measurement sites, TEM and %TEM that was seemingly within the 
recommended limits. 
TEM calculated from the anthropometry of the pilot sample 
Anthropometry TEM % TEM 
Weight (kg) 
Height (cm) 
0.007 
0.024 
0.011 
0.015 
Skinfolds (mm) 
Triceps 
Biceps 
Subscapular 
Iliac crest 
Medial calf 
Abdominal 
 
0.061 
0.129 
0.116 
0.139 
0.061 
0.055 
 
0.253 
0.841 
0.512 
0.668 
0.247 
0.204 
   
  
225 
 
Girths (cm) 
Arm 
Calf 
Waist 
Abdominal 
Hip 
 
0.031 
0.046 
0.132 
0.077 
0.066 
 
0.106 
0.129 
0.169 
0.091 
0.066 
 
vi. Discussion of the results 
Although this pilot study found that mean body mass (Kg) of the two groups was not 
significantly any different, Visnegarwala et al. (2007) previously reported that non-
infected men were heavier (+17.8kg, p < .001) than the ART naïve counter parts. 
Similarly, an earlier study revealed lowered weight in patients on HAART (Worm et 
al., 2002). The explanation for results of this pilot study could be probably because 
there was no random sampling of the participants but rather an advert was put was by 
email and word of mouth and anyone who thought they wanted to know about their 
nutritional status willingly volunteered to be part of the study. However, more than 
half (55%) were found to be in the overweight category, followed by those 
considered to have a normal weight for their square height (35%) and 10% found to 
be obese respectively. Overweight could be because participants are generally from 
urban settings which is evident as people’s lifestyles change. Recently in the national 
survey report, more than 22% of women in the reproductive age have been reported 
to be overweight (UDHS, 2007). It is very difficult to do a Meta-analysis and single 
out the contribution of the urban population to this prevalence as no details about this 
were published. 
 
Percent body fat between the HIV-infected and the pilot group with an unknown 
infection status differed. For instance, the former group had lower 4-site sum of 
skinfold. This can be attributed to lipoatrophy, which is said to be a problem in the 
populations infected with HIV. This has been justified elsewhere (Bacchetti et al. 
2006; FRAM study). In the FRAM study, peripheral lipoatrophy was more frequent 
in HIV women (28%) than controls (4%). There was no doubt for the consistency of 
these findings with those of Visnegarwala et al. (2007) who reported that total body 
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fat in the HIV-infected ART naïve group (Durnin & Womersley, 1974) was +5.95kg 
higher, p < .001 than the ART-naïve men. This implies that HIV-infected persons 
lose muscle just like was justified by early evidence that suggested that HIV infection 
has a direct effect on nutritional status (Kotler, 2000), as despite the maintenance of 
an ‘ideal’ body weight, body composition status may be affected. Several other 
researchers including Gallagher (2007) have confirmed the findings of Kotler (2000) 
more recently. 
 
For differing means of percent body fat between that derived by BIA and BMI, 
indeed BMI has been showed not to be the best indicator for assessing nutritional 
status, more so in diseased populations. In such an instance, Shah and Bilal (2009), 
have called for a more direct measure of FFM and FM. This is yet to be explained 
better after analysing results of the ‘gold standard’ technique, dilute deuterium oxide 
solution. Ones’ age and the percent fat derived from BMI had no positive correlation 
despite previous evidence (Jackson et al., 2002). On the other hand, the outputs 
additionally implied that only 24.3% of the percent mean body fat estimated by the 
BIA technique was explained by the age of the participants in this pilot study. This 
finding may have been as a result of limited age variance since the mean age was 
38±8. Consequently, this means that the age did not differ widely enough to cause 
impact. Although it has scientifically been proven that age correlates with fat, this 
was not the case in this pilot study. 
 
Generally, morphological alterations existed in either direction (loss or gain), even 
when majority of the participants infected with HIV reported no changes. Lipid 
abnormalities are often manifested as the appearance of a buffalo hump; increased fat 
deposition in the abdomen, breasts and visceral adipose tissue; and decreased fat 
deposition in the face, arms, legs and buttocks (Grinspoon, 2005), a condition 
referred to as lipodystrophy. An earlier study of lipoatrophy (fat loss) in HIV-1 male 
patients on HAART using a questionnaire and clinical examination reported the 
problem in 14% of the 168 patients who had been on HAART for a median length of 
17 months (Worm et al., 2002). This finding was consistent with an earlier study 
where lipoatrophy was seen in 14% of the patients who had been on HAART for a 
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median of 18 months (Martinez et al., 2001). However, there was very strong 
evidence not to reject the null hypothesis and concluded that all morphological 
changes after initiation of AIDs medication were independent of whether a 
participant was on HAART or not, the time one was on the medication and that for 
which they had known themselves to live with the virus. This pilot report may 
attribute these findings to the very small sample size that was conveniently used to 
address objectives of the pilot study. Otherwise, other scholars (Galli et al. 2003) 
have reported a significant difference as such and attributed ATAs to long term use 
of ARVs. We are yet to compare pilot results with the actual study, which has 
embarked on using a bigger and randomly selected but much more representative of 
the population we are dealing with. 
 
This pilot study assessed body fat distributions by skinfold thickness (calf, abdomen 
as well as iliac crest) and girth measurements (upper maximum arm). The study 
found that there was no dependency of the body fat distribution on HIV status of the 
participants. However, just like the case of small sample size was for the 
morphological changes, which may have been a similar situation due to the very 
small sample size that was conveniently used to address objectives of the pilot study. 
Anthropometric measurements are indicative of muscle mass and subcutaneous fat. 
Muscle is the major protein store in the body; a measure of muscle protein can be 
indicative of body protein reserves. Mid-upper-arm muscular circumference and arm 
muscle area (AMA) were measured and results revealed bigger AMA in the HIV-
infected study group than their counterparts. Although these measurements have been 
useful in the elderly populations because of the fat redistribution in humans as one 
grows older (Enoki et al., 2007), this did not hold in this pilot study. Perhaps further 
analysis of the data will better explain a finding that preliminary results cannot 
explain for now. 
 
vii. Conclusion and recommendations 
This pilot studied 20 participants from the Mildmay Uganda general population of 
whom 50% were known to live with HIV/AIDs. Recruitment was based on full 
information of what the pilot study activities aimed at everyone who participated did 
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so voluntarily, and hence no random selection of those who were involved and it was 
upon receipt of signed consent forms. Results revealed a similar mean body mass 
(kg) of the two groups was not significantly any different but these findings differed 
from those of Visnegarwala et al. (2007) who previously reported that non-infected 
participants were heavier (+17.8kg, p < .001) than the ART naïve counter parts. In 
addition, more than half (55%) were found to be in the overweight category, followed 
by those considered to have a normal weight for their square height (35%) and 10% 
found to be obese respectively. We thought that overweight could be because 
participants are generally from urban settings which is evident as people’s lifestyles 
change. Recently in the national survey report, more than 22% of women in the 
reproductive age have been reported to be overweight (UDHS, 2007).  
 
Percent body fat between the HIV-infected and the pilot group with an unknown 
infection status equally differed. For differing means of percent body fat between that 
derived by BIA and BMI, the latter has been showed elsewhere not to be the best 
indicator for assessing nutritional status, more so in diseased populations. Better 
information on this is yet to be explained after analysing results of the ‘gold standard’ 
technique, dilute deuterium oxide solution. Age and percent fat derived from BMI 
had no positive correlation despite previous evidence (Jackson et al., 2002) and 
results implied that only 24.3% of the percent mean body fat measured by BIA was 
explained by older age. This finding may have been as a result of limited age 
variance since the mean age was 38±8. Consequently, this means that the age did not 
differ widely enough to cause impact.  This means that the actual study ahead must 
randomly assign participants comprising the age categories for find if what others 
have claimed holds in this population.  
 
Generally, morphological alterations existed in either direction (loss or gain), even 
when majority of the participants infected with HIV reported no changes. This was 
again expected as that is what other scholars have previously reported and prompted 
this very research. Although results showed that there was very strong evidence not 
to reject the null hypothesis and concluded that all morphological changes after 
initiation of AIDs medication were independent of whether a participant was on 
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HAART or not, the time one was on the medication and that for which they had 
known themselves to live with the virus. And the pilot report attributed these findings 
to the very small sample size that was conveniently used to address objectives of the 
pilot study. We therefore recommend that these results be compared with the actual 
study, which has since been embarked on using a bigger and randomly selected but 
much more representative of the population we are dealing with. 
 
This pilot study assessed body fat distributions by skinfold thickness (calf, abdomen 
as well as iliac crest) and girth measurements (upper maximum arm). The study 
found that there was no dependency of the body fat distribution on HIV status of the 
participants. Nevertheless, just like the case of small sample size was for the 
morphological changes, which may have been a similar situation due to the very 
small sample size that was conveniently used to address objectives of the pilot study. 
Mid-upper-arm muscular circumference and AMA were measured and results 
revealed bigger AMA in the HIV-infected study group than their counterparts. 
Although these measurements have been useful in the elderly populations because of 
the fat redistribution in humans as one grows older (Enoki et al., 2007), this did not 
hold in this pilot study. Perhaps further analysis of the data is yet to better explain 
some findings that preliminary results could not explain. 
 
viii. Strengths, limitations and procedural adjustments based on pilot 
findings 
The study had proposed to randomly recruit for participation but there was an 
overwhelmingly high cost of making initial phone calls to discuss the study and no 
body turned up based on such a phone call, consequently, study consent into the main 
study was based on voluntary basis. During pilot testing, there were several reasons 
given for not undergoing long hours of fasting, including drug recommendations of 
having to take medications just before or during mealtime and not on an empty 
stomach. This limited the usual and previously proposed procedure of dosing 
participants with ‘heavy water’ during daytime as there was no alternate on 
controlling food intake. Consequently, ‘heavy water’ dosing and collecting of urine 
samples were readjusted to be carried out at night, when no medication was taken. 
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Although participants were requested to avoid strenuous physical activity during the 
measurement period to avoid fractionation due to water vapour loss as a result of 
increased breathing and transdermal evaporation, nearly everybody asked to be away 
for different reasons before the time for sample collection was finished. Clearly, 
some returned with visible sweat and fatigue on their faces. Consequently, it was 
decided that dosing and urine sample collection for the major project takes place at 
night when all participants were rested and this was assumed to avoid fractionation 
due to water vapour. After all, body composition assumptions are invalid in altered 
hydration (Pialoux et al., 2004). 
 
Two TB-medicated subjects had been received during the pilot study but could not 
collect urine samples at the required and calculated hours; they were consequently 
excluded from taking part in the main study based on this; 
 
Before undertaking the pilot study, the proposal was to collect data on biochemical 
metabolites from patient medical files, unfortunately, for all the subjects that 
participated in the study, there was no such information in their files. It was for one 
simple reason that at the study site then, lipid profile was not a routine laboratory 
procedure due to the cost involved. However, where lipid profile was documented 
was after suspicion or after a patient presented with clear symptoms for risk of 
metabolic syndrome. It was then decided that plasma was to be collected for 
biochemical metabolites analysis. 
 
 
 
  
231 
 
9.3: Ethics approvals (i.e. approvals, participant’s information) 
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PARTICIPANT INFORMATION for QUT RESEARCH PROJECT 
“Nutritional status of Ugandan women living with HIV/AIDs: anthropometry and body 
composition assessment” 
Evaluation Team Contacts 
Hanifa Namusoke PhD candidate 
Professor Andrew Hills, Principal 
Supervisor 
+61 435200491 (Australia), 0782722303 (Uganda) +61 7 31386087 (Australia) 
hanifa.namusoke@student.qut.edu.au a.hills@qut.edu.au 
Description 
This project is being undertaken as part of a PhD program of QUT but Mildmay-
Uganda is the study site. We plan to evaluate about 200 Mildmay-Uganda female 
patients between 15 and 49 years of age; half of you will have been on treatment 
(ART) for HIV for at least 12 months, and the other half will not yet be on treatment. 
 
The aims of this evaluation are to assess your nutritional wellbeing, to measure how 
much body fat you have, and where on your body you have fat. This is important 
because women who have HIV and who are on treatment (ART, HAART) may have 
problems with their nutritional status and body composition. Changes in fat may 
happen when taking HIV treatment for a long period. We want to compare the fat and 
nutritional status of women who are on ART, with women who are not yet on 
treatment. We also want to know the best way of evaluating fat and nutritional status, 
by comparing the results of different methods of measurement.  
Procedures 
If you agree to be in this evaluation, we will measure your weight, height, and size of 
different parts of your body (arms, back, waist and hip). This will take about 30 
minutes. We will draw about 3 mL of your blood to evaluate your lipid/cholesterol 
and glucose content. This will be done from our laboratories. By looking at the 
results of your routine tests in your medical file at Mildmay, we shall be able to 
obtain your medical history. We will assess how much body fat you have using a 
simple portable device called a bioelectrical impendence analysis machine. You will 
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be lying down on a comfortable flat bed in the Therapies department at Mildmay in a 
private room. We will attach 4 small wires, two to the right arm and two to the right 
leg. This machine will pass a small amount of electricity through your body-the 
amount is so small that you will not feel it and it is not harmful. This procedure will 
last about 15 minutes. We will evaluate how much body fat you have, by measuring 
the “heavy” water in your urine, after you drink a small sample. It will taste like 
regular clean water, and you will not be able to tell the difference. “Heavy water 
(deuterium oxide) occurs in nature therefore taking this small amount is not harmful. 
We will collect your urine before you drink the “heavy water” and at the 4th and 6th 
hour after you drink it. We will compare the amount of heavy water you have in these 
samples of urine. We will also ask about anybody changes you may have noticed in 
the recent past. Upon your consent, we will also take several photos of your waist, 
hips, neck, back, arms, etc as this is one of the best ways to look at fat distribution. 
This will take about 30 minutes. The entire assessment might take up to six hours, 
including waiting time. All evaluations will be conducted from Lweza, Mildmay 
Uganda Physiotherapy unit in the Therapies department. The urine samples will be 
sent to QUT for analysis. 
Participation 
The evaluation team is requesting you to participate because you are a woman enrolled in 
Mildmay, and are between 15 and 49 years of age. You have been chosen at random from 
a list of all women eligible for the study. We can only take measurements two weeks after 
your menstruation as this will make measurements more accurate. We ask that you do not 
take any form of alcohol 12 hours before the beginning of the study measurements. Avoid 
exercise and taking any foods/drinks at least six hours before you report for the study. 
Your participation in this project is completely voluntary. If you provide consent but later 
change your mind about participating in the study, you can withdraw at any time without 
comment or penalty. Your decision to participate will in no way impact upon the current 
or future services available to you from Mildmay Uganda. 
Eligibility  
You cannot be part of this study if you are less than 15 years old, or more than 49 years 
old, are pregnant or breastfeeding, or feel too ill to finish the evaluation. Also, you cannot 
be in this study if you have any metal in your body, such as a coil to prevent pregnancy, or 
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any metal in place for broken bones. Fillings in teeth are not a problem. If you are 
between 15 and 18 years old, then we need your parent, guardian, or caregiver to provide 
consent. They will need to read this form, or have it read and explained to them. 
Expected benefits 
There is no direct benefit for being in the study.  However, the findings of your nutritional 
status and fat distribution may be helpful to the doctor who is treating your HIV disease. 
Your results will be given to you on several pieces of paper, and you can show them to 
your doctor if you decide to do so. The results of the study will provide important 
information about which measurements are the best to evaluate the nutrition status of 
HIV-infected women, particularly in resource-limited settings such as Uganda. We 
hope these findings will also help health professionals better understand HIV disease 
and its treatment. 
Risks 
There are only minimal risks associated with your participation in this study. Along with 
the typical tests, you will participate in a range of measurements not currently being used 
by Mildmay Uganda. The heavy water and the electrical impendence tests do not pose 
any risks, and you will not feel any side effects. However, you may experience some 
minor bruising or discomfort from the blood draw. 
Compensation  
There is no compensation for being in this study. We will provide you with a transport 
refund at the end of the evaluation. A bottle of soda may be provided depending on the 
amount of time you will be required to spend at the site. In case you are called upon by 
the research team at a later date for another appointment, a transport refund will still be 
refunded. 
Confidentiality  
All comments and responses will be treated confidentially. We will record your name so 
that your results can be included in your medical file for you and your doctor to review. 
All your information will be kept in your personal form and entered into our medical file, 
then entered on a secure database. All forms will be kept in a secure and locked file 
cabinet only accessible by the evaluation team. Your name will not be used in any reports, 
abstracts, or presentations. 
Consent to Participate 
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We would like you to sign a written consent form (enclosed) to confirm your agreement 
to participate in the study.  
Questions / further information about the project 
Please contact the evaluation team members named above if you have any questions or 
require further information about the project. You can also speak to a counsellor of your 
choice at Mildmay free of charge. If you have questions during the evaluation itself, 
please ask the staff directly to help you. 
Concerns / complaints regarding the conduct of the project 
The Mildmay centre and Queensland University of Technology are committed to 
researcher integrity and the ethical conduct of research projects.  If you have any concerns 
or complaints about the ethical conduct of the project you may contact Mr. Tom Lutalo of 
Uganda Virus research Institute (UVRI) on +256414321962, Mildmay Uganda’s research 
officer Esther Kawuma on 0312 210200; Dr. William Musoke, the centre’s senior 
manager to the clinics, or the Queensland University of Technology Research Ethics 
Officer on +61 7 3138 2340 or ethicscontact@qut.edu.au. Each of these people is 
independent of the research project and can help address your concerns without bias. 
 
 
 
CONSENT FORM for QUT RESEARCH PROJECT 
“Nutritional status of Ugandan women living with HIV/AIDS: anthropometry and body 
composition assessment” 
 
Statement of consent 
By signing below, you are indicating that you have read and understood the information 
document regarding this project; have had any questions answered to your 
satisfaction; understand that if you have any additional questions you can contact the 
research team; understand that you are free to withdraw at any time, without 
comment or penalty; understand that you can contact Mr. Tom Lutalo of Uganda Virus 
research Institute (UVRI) on +256414321962, Mildmay Uganda research officers Esther 
Kawuma and Dr. Kenneth Mutesasira; Dr. William Musoke, the centre’s senior manager 
to the clinics, or the Research Ethics Officer at QUT on +61 7 3138 2340 or 
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ethicscontact@qut.edu.au if you have concerns about the ethical conduct of the 
project; agree to participate in the project. For participants between 15-18 years, have 
discussed the project with your parent or caregiver, the research team shall access your 
medical file for data relevant to the aims of the study. A photo may be requested and that 
you agree to this; sign……………………………………… 
Disagree with this; sign…………………………………… 
Participant’s name 
Signature 
Date 
 
As witnessed by: 
Name 
Witness’s signature 
Date 
 
Statement of Child consent 
Your parent or guardian has given their permission (as signed below) for you to be 
involved in this research project.   
Parent/guardian’s name 
Signature 
Date 
 
This form is to seek your personal agreement to be involved. And to be sure that you 
have read and understood the information document regarding this project. In 
addition, that any questions you have has been answered to your satisfaction and you 
understand that if you have any additional questions you can contact the research 
team. Lastly, you understand that you are free to withdraw at any time, without 
comment or penalty and understand that you can contact Mr. Tom Lutalo of Uganda 
Virus research Institute (UVRI) on +256414321962. The other office to be contacted is 
the Mildmay Uganda research officers Esther Kawuma and Dr. Kenneth Mutesasira; Dr. 
William Musoke, the centre’s senior manager to the clinics, or the Research Ethics 
Officer at QUT on +61 7 3138 2340 or ethicscontact@qut.edu.au if you have 
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concerns about the ethical conduct of the project; agree to participate in the project 
the research team shall access your medical file for data relevant to the aims of the study. 
A photo may be requested and that you agree to this; sign……………………………… 
Disagree with this; sign…………………… 
 
By signing below, you are indicating that the project has been discussed with you and you 
agree to participate in the project. 
Name 
Signature 
Date 
As witnessed by: 
Name 
Witness’s signature 
Date 
 
Mildmay Uganda confidentiality agreement 
Mildmay Uganda provides out-patient and in-patient Specialist Palliative Care 
services for people living with HIV/AIDS. 
 
As professionals working in a Healthcare Centre, we are bound by the rules of 
confidentiality, respecting every patient/client’s right to privacy. We ask you to sign 
below to indicate your agreement that you will never speak outside Mildmay about 
patients or Clients whom you may meet at the Centre in any way that can identify the 
person, without his/her specific permission in writing. 
 
Name (In 
Caps):…………………………………………………………………………… 
 
Signature:………………………………………………………………………… 
 
Date:  
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Translated copies - Obubaka eri abetabyemu 
 
OBUBAKA ERI ABETABYE MU KUNOONYEREZA KWA QUT 
“Embeera y’eby’endiisa mu bakyala ba Uganda abalina akawuka/obulwadde bwa mukenenya: 
okwekenneenya enkula n’enzimba y’omubiri” 
Endagiriro z’abanoonyereza 
Hanifa Namusoke PhD candidate 
Professor Andrew Hills, Omuluamya 
omukulu 
+61 435200491 (Australia); 0782722303 (Uganda) +61 7 31386087 (Australia) 
hanifa.namusoke@student.qut.edu.au a.hills@qut.edu.au 
Okunnyonnyola 
Okunoonyereza kuno kukolebwa ng’ekitundu ky’omulimu gw’okusomerera ddiguli 
ya PhD. Okunoonyereza kugenderera, Okwekenneenya embeera yo mu by’endiisa 
nga tupima obuzito, obuwanvu, n’obugazi bw’ebitundu by’omubiri ebitali bimu; 
 Okwekenneenya amasavu mu mubiri gwo nga tukozesa akuuma akatono 
akatambuzibwa akayitibwa bioelectrical impedance machine n’okunywa ‘amazzi 
ag’enjawulo’ ge tukebera mu musulo gwo; Okwekenneenya emmere emaze 
okumulungulwa mu mubiri gwo (bino bijja kuggyibwa mu biwandiiko byo 
eby’eddwaliro ebikuumirwa ku kitebe kya Mildmay).  
Abanoonyereza bakusaba obayambe kubanga ggwe osobola okutuwa ekifaananyi 
ekituufu mu mazima n’obwesimbu. 
Okwetabamu  
Okwetaba kwo mu kunoonyereza kuno kwa kyeyagalire, okuggyako eccupa ya sooda 
emu yokka ejja okigabibwa olw’ekiseera ekiwanvu ky’onooba omazze ku ddwaliro. 
Bw’onooba omaze okukkiriza okwetaba mu kunoonyereza kuno kyokka ate 
oluvannyuma n’okyusa ekirowoozo kyo, osobola okuvaamu ekiseera kyonna awatali 
kunenyezebwa oba kutanzibwa. Okusalawo kwo okwetabamu tekulina ngeri yonna gye 
kujja kukosa nkolagana eriwo kati oba eribaawo gye bujja wakati wo ne Mildmay. 
 
Okwetabamu kwo kujja kubaamu okwekebejjebwa mu ddwaliro mwe tujja 
okupimira obuzito bwo, obuwanvu, n’obugazi bw’ebitundu by’omubiri gwo ebitali 
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bimu omuli ekiwato n’amakudde. Enzimba y’omubiri gwo (ebikola omubiri gwo) 
naoy ejja kupimwa nga tukozesa akuuma akangungu akatalina bulabe bwonna 
akayitibwa bioelectrical impedance machine ng’ogalamidde wansi ku kitanda 
ekirungi ekitereevu obulungi mu kitongole ekijjanjabirwamu abalwadde. Ojja 
okujjibwako omusaayi era ojja kulagirwa okunywa ku ‘mazzi ag’enjawulo’ 
n’oluvannyuma tukusabe otuwe sampolo z’omusulo gwo eziwerako tuzikebere. Era 
tujja na kukubuuza otubuulire oba walio enkyukakyuka ey’engeri yonna gy’oyinza 
okuba ng’ofunye gye buvuddeko. Engeri esingayo obulungi ey’okwetegereza 
enkyukakyuka mu mubiri  kwe kwekubya ekifaananyi – kino kijja kukolebwa singa 
onooba okkirizza. Okwekenneenyezebwa kwonna awamu kujja  kutwala essaawa 
ezitasukka mukaaga nga muno mulimu n’ekiseera ky’onoomala ng’olinda. Buli 
kyonna ekinaakolebwa kijja kukolerwa mu kisenge ekijjanjabirwamu abalwadde mu 
kitongole ky’eby’endiisa ku kitebe kya Mildmay. 
Emigaso egisuubirwamu 
Tusuubira nti okunoonyereza kuno kujja kukugasa kubanga ojja kusobola okutegeeza 
omusawo wo by’onooba ozudde ggwe wennyini. Ebinaavamu era bijja kuyamba abasawo 
okutegeera omugaso gw’okweyambisa ebipimo bino okusobola okugeraageranya 
embeera y’eby’endiisa mu bantu abalala abalina akawuka ka mukenenya n’okuyamba mu 
kussaawo obujjanjabi obw’omutindo ogusingako obulungi. N’ekisingira ddala obukulu, 
ebinazuulibwa bijja kutuyamba okwongera okutegeera  n’okumanya emitendera 
obulwadde mwe buyita n’omugaso gw’abakugu b’eby’obulamu abatali bamu abalina 
okunoonyereza kwe baliko.  
 
Emitawaana egiyinza okubaawo 
Emitawaana egiyinza okubaawo mitono ddala, nga tegisukka ku mbeera za bulijjo 
ezekuusa ku kwetaba kwo mu kunoonyereza kuno. Ng’oggyeeko okwekebeza okwa 
bulijjo okumanyiddwa, ojja kupimibwa ebintu ebiwerako ebitakolebwa kati ku kitebe kya 
Mildmay. Bw’oba olina ekibuuzo oba okutya okw’engeri yonna, oba singa ofuna ekintu 
kyonna ekikweraliikiriza, totya kutegeeza mubuzibuzi yenna gw’obeera osiimye nga 
weyambisa enteekateeka ya Mildmay ey’okubuulirira abantu ku bwereere.  
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Kitegeere nti tosobola kwetaba mu kunoonyereza kuno singa obeera oli lubuto, oba 
ng’olina ekyuma eky’engeri yonna mu mubiri gwo (nga kannamuziga akatangira omuntu 
okufuna olubuto) era tetusobola kukupima okuggyako nga wayiseewo ssabbiiti bbiri 
okuva lw’obeera ovudde mu nsonga z’abakyala. Okubirizibwa obutanywa kitamiiza 
kyonna ng’ebula essaawa 12 ekiseera ky’okupimibwa mu kunoonyereza kuno kituuke. 
Wewale okuzannyisazannyisa omubiri n’okulya oba okunywa ekintu kyonna ng’ebula 
essaawa waakiri mukaaga olyoke ojje mu kunoonyereza.   
Okukuuma ebyama 
Ensonga zonna zijja kukwatibwa mu ngeri ya kyama. (amannya g’abantu ssekinnoomu 
getaagibwa okukakasa nti ebinaafuluma ebikukwatako bigenda mu biwandiiko byo 
eby’eddwaliro). 
Okukkiriza okwetabamu 
Twagala okukusaba osse omukono ku kiwandiiko ky’okukkiriza (kiri muno) okukakasa 
nti okkirizza okwetaba mu kunoonyereza kuno. 
Ebibuuzo/ebisingawo ebikwata ku kunoonyereza kuno 
Tukusaba otuukirire abanoonyereza abamenyeddwa waggulu bw’oba olina ekibuuzo 
kyonna oba nga wetaaga okumanya ebisingawo ebikwata ku kunoonyereza kuno. 
Okutya/okwemulugunya okukwata ku ngeri okunoonyereza kuno gye kukolebwamu 
Ekitebe kya Mildmay ne Yunivasite eyitibwa Queensland University of Technology 
bamalirivu ku nsonga y’omunoonyereza okubeera ow’emmizi n’eky’okuba nti 
okunoonyereza kukolebwa mu ngeri egoberera empisa ennungi. Singa obeera olina 
okweraliikirira oba okwemulugunya okw’engeri yonna okukwata ku ngeri 
okunoonyereza kuno gye kukolebwamu, osobola okutuukirira Mw. Tom Lutalo owa 
Uganda Virus research Institute (UVRI) ku ssimu +256414321962, abakungu 
abakola ku by’okunoonyereza mu kitebe kya Mildmay Esther Kawuma ku ssimu 0312 
210200; Dr. William Musoke, omukungu omukulu akulira obulwaliro mu kitebe 
kino, oba omukungu akola ku by’empisa mu kunoonyereza mu Queensland 
University of Technology ku ssimu +61 7 3138 2340 oba ethicscontact@qut.edu.au. 
Buli omu ku bantu bano yetongodde okuva ku kunoonyereza kuno era asobola 
okuyamba okugonjoola ensonga yonna gy’oyinza okuba nayo awatali kyekubiira 
asobola okuyamba okugonjoola ensonga yonna gy’oyinza okuba nayo awatali kyekubiira. 
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Ekirayiro ky’okukkiriza 
Bw’ossaako omukono gwo wano wammanga, obeera olaga nti: 
Osomye era n’otegeera bulungi ekiwandiiko ekiriko obubaka obukwata ku kunoonyereza 
kuno; Ebibuuzo by’obadde nabyo byonna biddiddwamu bulungi mu ngeri ekumatiza 
Okimanyi bulungi nti singa obeera n’ekibuuzo ekirala kyonna osobola okutuukirira 
abanoonyereza; Okimanyi bulungi nti oli wa ddembe okuvaamu ekiseera kyonna, 
awatali kunenyezebwa oba kutanzibwa; Okimanyi bulungi nti osobola okutuukirira 
Mw. Tom Lutalo owa Uganda Virus research Institute (UVRI) ku ssimu 0414321962, 
abakungu abakola ku by’okunoonyereza mu kitebe kya Mildmay nga Esther Kawuma ku 
ssimu 0312 210200 ; Dr.William Musoke, omukungu omukulu akulira obulwaliro mu 
kitebe kino, oba omukungu akola ku by’empisa mu kunoonyereza mu QUT ku ssimu 
+61 7 3138 2340 oba ethicscontact@qut.edu.au singa obeera olina okweraliikirira 
okw’engeri yonna okukwata ku ngeri okunoonyereza kuno gye kukolebwamu 
Okkirizza okwetaba mu kunoonyereza kuno. Eri abetabamu abali wakati w’emyaka 15 
ne 18 egy’obukulu, okunoonyereza kuno okukubaganyizzaako ebirowoozo ne mukadde 
wo oba omuntu akulabirira. Abanoonyereza bajja kukebera mu biwandiiko byo 
eby’eddwaliro bafunemu amawulire agakwata ku bigendererwa by’okunoonyereza kuno 
Oyinza okusabibwa ekifaananyi nti era kino okikkirizza; 
omukono……………………………… 
Tokikkirizza; omukono…………………………………… 
Erinnya ly’eyetabyemu 
Omukono 
Ennaku z’omwezi 
Abaddewo ng’omujulizi: 
Erinnya ly’omujulizi  
Omukono 
 
EKIWANDIIKO KY’OKUKKIRIZA OKWETABA MU KUNOONYEREZA KWA 
QUT 
“Embeera y’eby’endiisa mu bakyala ba Uganda abalina akawuka/obulwadde bwa mukenenya: 
okwekenneenya enkula n’enzimba y’omubiri” 
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Ennaku z’omwezi 
Ekirayiro ky’okukkiriza kw’omwana omuto 
Mukadde wo oba omuntu akulabirira akkirizza (nga bw’ataddeko omukono 
wammanga) wetabe mu kunoonyereza kuno.   
Erinnya ly’omuzadde/omukuza 
Omukono 
Ennaku z’omwezi 
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Ekiwandiiko kino kikusaba ggwe wennyini okuwaayo okukkiriza kwo okwetabamu. 
Era olw’okwagala okukakasa nti osomye n’otegeera bulungi ekiwandiiko ekiriko 
obubaka obukwata ku kunoonyereza kuno; Ebibuuzo by’obadde nabyo byonna 
biddiddwamu bulungi mu ngeri ekumatiza; Okimanyi bulungi nti singa obeera 
n’ekibuuzo ekirala kyonna osobola okutuukirira abanoonyereza; Okimanyi bulungi 
nti oli wa ddembe okuvaamu ekiseera kyonna, awatali kunenyezebwa oba 
kutanzibwa; Okimanyi bulungi nti osobola okutuukirira Mw. Tom Lutalo owa Uganda 
Virus research Institute (UVRI) ku ssimu +256414321962, abakungu abakola ku 
by’okunoonyereza mu kitebe kya Mildmay Esther Kawuma ku ssimu 0312 210200; 
Dr.William Musoke, omukungu omukulu akulira obulwaliro mu kitebe kino, oba 
omukungu akola ku by’empisa mu kunoonyereza mu QUT ku ssimu +61 7 3138 2340 
oba ethicscontact@qut.edu.au singa obeera olina okweraliikirira okw’engeri yonna 
okukwata ku ngeri okunoonyereza kuno gye kukolebwamu. Okkirizza okwetaba mu 
kunoonyereza kuno; Abanoonyereza bajja kukebera mu biwandiiko byo eby’eddwaliro 
bafunemu amawulire agakwata ku bigendererwa by’okunoonyereza kuno. 
Oyinza okusabibwa ekifaananyi nti era kino okikkirizza; 
omukono……………………………… 
Tokikkirizza; omukono…………………………………… 
Bw’ossaako omukono gwo wano wammanga, obeera olaga nti okunoonyereza kuno 
kukubaganyiziddwako ebirowoozo naawe nti era okkirizza okukwetabamu. 
Erinnya 
Omukono; Ennaku z’omwezi 
Abaddewo ng’omujulizi 
Erinnya ly’omujulizi; Omukono; Ennaku z’omwezi 
 
 
 
EKIWANDIIKO KY’OKUKKIRIZA OKWETABA MU KUNOONYEREZA KWA 
QUT 
“Embeera y’eby’endiisa mu bakyala ba Uganda abalina akawuka/obulwadde bwa mukenenya: 
okwekenneenya enkula n’enzimba y’omubiri” 
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9.4: ARV – food restrictions 
ARV combinations prescribed at Mildmay Uganda during 2007/2008 
ARV combination Class of treatment number of patients 
ZDV/LMV/NVP 1
st 
 1,560 
ZDV/LMV/EFV 1
st
 1,263 
STV/LMV/NVP 1
st
 515 
FCT/TDF/NVP 1
st
 105 
TDF/LMV/KLT 2
nd
  46 
ABC/DDI/KLT 2
nd
 29 
FTC/TDF/KLT 2
nd
 2 
STV/DDI/KLT 2
nd
 12 
ZDV/KLT/DDI 2
nd
 12 
STV/LMV/KLT 2
nd
 12 
ABC/LMV/STV 1
st
 9 
ABC/ZDV/EFV 1
st
 5 
ABC/ZDV/LMV 1
st
 9 
ZDV/LMV/IDV 1
st
 5 
ABC/TDF/KLT 2
nd
 3 
ABC/LMV/NVP 1
st
 3 
TDF/LMV/NVP 1
st
 4 
ZDV/FTC/TDF/KLT 2
nd
 1 
IDV/RTV/LMV/NVP 2
nd
 2 
ATZ/FTC/TDF/KLT 2
nd
 1 
ZDV/LMV/RTV 1
st
 2 
ZDV/DDI/EFT 1
st
 2 
ABC/KLT/STV 2
nd
 1 
ABC/LMV/KLT 2
nd
 2 
ATZ/LMV/SQV/r 2
nd
 1 
STV/LMV/NFV 1
st
 1 
DDI/LMV/KLT 2
nd
 1 
FTC/TDF/IDV/r 2
nd
 1 
STV/DDI/NVP 1
st
 2 
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STV/DDI/EFT 1
st
 1 
TDT/LMV/EFT 1
st
 1 
ZDVLMV/DDI/KLT 2
nd
 1 
Total  4,151 
(Source: The Mildmay Centre Uganda 2007/2008 annual report; unpublished) 
 
Prescription details for the above ARVs are detailed by Alliance international (next 
page) which states that a health worker, based on approved treatment guidelines and 
protocols, must only prescribe ARV treatment. The alliance mentions that the fact 
sheet is only for the use of those who provide treatment support to members of the 
public and that it does not contain sufficient information for prescribing treatment for 
any individual. 
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What are antiretroviral drugs (ARVs)? 
 Antiretrovirals (ARVs) are medicines used to treat HIV infection. They reduce 
the amount of HIV in the body (the viral load), which protects the immune 
system and allows it to recover. 
 ARV treatment must be taken for life. A person must take at least three different 
ARVs for it to be effective. This is called triple therapy or HAART 
 Please see Fact Sheets 1 and 2 for more general information on HIV and ARVs.  
 
ARVs do not cure HIV – but they can reduce its effects and help a person to live 
a longer, healthier life. 
 
Why is it important to know about ARVs? 
 People who understand basic information about their medicines are usually able 
to adhere better to their treatment regime. 
 People need to understand the importance of their ARVs. If they are taking 
several different medicines, it is essential that they understand which are ARVs 
and which are for other purposes. 
 
What ARVs are currently available? 
 Currently, the types of ARVs that can be used are: 
- NRTIs (nucleoside or nucleotide reverse transcriptase inhibitors) 
- NNRTIs (non-nucleoside reverse transcriptase inhibitors) 
- PIs (protease inhibitors) 
- Entry inhibitors 
Antiretroviral (ARV) treatment Fact Sheet 07 
Commonly used ARVs – basic information 
  
251 
 
 They are all called inhibitors because they prevent the activity of HIV in the CD4 
cell. Each different type works in a different part of the CD4 cell to prevent HIV 
from breaking in and using the contents of the CD4 cell to make new copies of 
HIV which can then infect other CD4 cells. 
 If three or more ARVs of different types are used together, this improves the 
chances of stopping HIV from reproducing itself. That is why triple therapy is 
used – to ensure that treatment will be successful.  
 Sometimes two or three drugs are combined in the same tablet (double or triple 
combinations). This makes them easier to take. 
 Brief information on each drug is given here. They are grouped according to type 
and generic name. 
 
  
266 
 
Triple combinations containing more than one type of ARV 
Generic name 
Abbreviation 
Trade name 
 
 
Type of ARV 
Stavudine + Lamivudine + Nevirapine  
3TC + NVP + d4T 
TRIOMUNE; NEBULAM-SN; 
TRIVIRO; TRIVIRO-LS;  
TRIVIRO-LNS; VIROLANS  
Triple combination with 3 different ARVs from 2 categories (two NRTIs + one NNRTI) 
Presentation 
 
Tablets, each containing: 
- stavudine 40mg + lamivudine 150mg + nevirapine 200mg OR 
- stavudine 30mg + lamivudine 150mg + nevirapine 200mg 
Dose 
 
Adults: 
1 tablet per dose, 2 doses per day 
Food No special requirements 
Main side effects See separate information on stavudine, lamivudine, nevirapine 
Drug interactions - See separate information on stavudine, lamivudine, nevirapine  
 Do not take with zidovudine/ZDV/AZT 
Storage Room temperature 
 
Generic name Lamivudine+Zidovudine+Nevirapine 
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Abbreviation 
Trade name 
Type of ARV 
d4T + ZDV/AZT + NVP 
DUOVIR-N 
Triple combination with 3 different ARVs from 2 categories (two NRTIs + one NNRTI) 
Presentation 
 
Tablets, each containing: 
lamivudine 150mg + zidovudine 300mg + nevirapine 200mg 
Dose 
 
Adults: 
1 tablet per dose, 2 doses per day 
Food No special requirements 
Main side effects See separate information on zidovudine, lamivudine, nevirapine 
Drug interactions See separate information on zidovudine, lamivudine, nevirapine  
Do not take with stavudine/d4T 
Storage Room temperature 
 
NRTIs – Nucleoside or nucleotide reverse transcriptase inhibitors:  
Generic name Abbreviation 
Trade names 
 
Type of ARV 
Lamivudine  
3TC  
EPIVIR; LAMIVIR; ANOLAM; HEPTAVIR; AVOLAM; VIROLAM  
NRTI 
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Presentation 
 
- Tablets, 150mg or 300mg 
- Oral solution 10mg/ml 
Dose 
 
Adults: - 1 tablet 150mg per dose, 2 doses per day OR  
1 tablet 300mg, 1 dose per day 
Children:- Oral solution 4mg/kg per dose, 2 doses per day  
Food No special requirements 
Main side effects Sometimes, serious fatigue, muscle spasm and frequent cramps, abdominal pain, nausea, vomiting, 
difficulty in breathing – these indicate possible lactic acidosis; see doctor immediately 
Drug interactions  Not usually used with zalcitabine/ddC 
Storage - Tablets: below 30°C 
- Oral solution: below 25°C. Keep open bottle of oral solution up to 1 month only 
 
Generic name 
 Abbreviation 
Trade name 
 
Type of ARV 
Stavudine 
d4T 
ZERIT; ZERIT XR; STAG; STAVIR;  
VIROSTAV®; AVOSTAV  
NRTI 
Presentation 
 
- Capsules, 40, 30, 20, 15mg 
- Capsules (slow-release), 100, 75, 50, 37.5mg 
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- Powder for oral solution, 1mg/ml 
Dose 
 
Adults over 60 kg: 
- 1 capsule 40mg per dose, 2 doses per day OR 
- 1 slow-release capsule 100mg per dose, 1 dose per day 
Adults less than 60 kg: 
- 1 capsule 30mg per dose, 2 doses per day OR 
- 1 slow-release capsule 75mg per dose, 1 dose per day 
Children less than 30 kg: 
- Oral solution 1mg/kg per dose, 2 doses per day 
Children more than 30 kg: 
- Same as adults less than 60kg 
Food No special requirements 
Main side effects - Tingling or loss of feeling in the feet or hands (peripheral neuropathy). Consult the doctor 
- Rarely, pancreatitis, with symptoms such as abdominal pain, nausea, vomiting, confirmed by blood tests 
- Loss of fat from the face, buttocks or thighs, arms, legs 
- Sometimes, serious fatigue, muscle spasm and frequent cramps, abdominal pain, nausea, vomiting, 
difficulty in breathing – these indicate possible lactic acidosis; consult a doctor immediately 
Drug interactions - Do not take d4T with drugs that are toxic to the nervous system; for example some anti-TB drugs 
- d4T should not be used with ribavirin (hepatitis C treatment)  
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- d4T should not be used with ddI due to increase risk of side effects 
- d4T must not be used with ZDV 
Storage Room temperature 
 
Generic name  
Abbreviation 
Trade names 
 
Type of ARV 
Zidovudine 
ZDV or AZT 
RETROVIR; ZIDO-H; ZIDOVIR;  
VIRO-Z; ZIDOVUDINA  
NRTI 
Presentation 
 
- Tablets, 300mg,  
- Capsules, 100mg, 250mg 
- Oral solution, 10mg/ml 
- Injection for intravenous infusion, 200mg/ml 
Dose 
 
Adults:  
-1 capsule 250mg per dose, or 1 tablet 300mg per dose, 2 doses a day 
Children: 
- 4mg/kg, 2 doses a day 
Food No special requirements 
Main side effects At the start of treatment: 
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- Nausea, sometimes severe, which usually reduces over time. Can be treated with anti-nausea drugs 
During treatment: 
- Decreased levels of red or white blood cells. If severe, the doctor might decide to change treatment  
- Muscle pains; can be related to muscle damage. Consult a doctor immediately 
- Headache, mild fatigue, dark coloration of nails and  skin 
- Sometimes serious fatigue, muscle spasm and frequent cramps, abdominal pain, nausea, vomiting, 
difficulty in breathing – these indicate possible lactic acidosis; see doctor immediately 
Drug interactions Do not use zidovudine/ZDV with stavudine/d4T  
Storage Room temperature 
 
Generic name 
Abbreviation 
Trade names 
 
Type of ARV 
Lamivudine + Stavudine 
3TC + d4T 
COVIRO-LS; VIROLIS;  
LAMIVIR-S 
NRTI – combination of 2 drugs 
Presentation 
 
Tablets, each containing:  
- stavudine/d4T 40mg + lamivudine/3TC 150mg OR 
- stavudine/d4T 30mg + lamivudine/3TC 150mg 
Dose 1 tablet per dose, 2 doses per day  
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Food No special requirements 
Side effects & interactions See separate information on each drug 
Storage Room temperature 
 
Generic name 
 Abbreviation 
Trade names 
 
Type of ARV 
Lamivudine + Zidovudine 
(3TC + ZDV/AZT) 
COMBIVIR®; DUOVIR®;  
AVOCOMB®; ZIDOLAM®  
NRTI – combination of 2 drugs 
Presentation Tablets, each containing 150mg lamivudine/(3TC) + 300mg zidovudine/ZDV/AZT 
Dose 1 tablet per dose, 2 doses per day 
Food No special requirements 
Main side effects At the beginning of treatment: 
- Nausea, sometimes severe, which usually reduces over time. Can be treated with anti-nausea drugs/ 
During treatment: 
- Decreased levels of red or white blood cells. If severe, the doctor might decide to change treatment  
- Muscle pains; can be related to muscle damage. Consult a doctor immediately 
- Headache, mild fatigue, dark coloration of nails and skin 
- Sometimes, serious fatigue, muscle spasm and frequent cramps, abdominal pain, nausea, vomiting, 
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difficulty in breathing – these indicate possible lactic acidosis; see doctor immediately 
Drug interactions Do not use at same time as stavudine 
Storage Room temperature 
Generic name 
Abbreviation 
Trade name 
Type of ARV 
Abacavir 
ABC 
ZIAGEN 
NRTI 
Presentation - Tablets, 300mg  
- Syrup, 20mg/ml 
Dose 
 
Adult: 
- 1 tablet twice a day (total of 2 tablets a day) 
Child: 
- 8mg/kg twice a day 
Food Take with or without food 
Main side effects At the start of treatment: 
- Tiredness 
- Digestive problems 
- Stiffness, pain in muscles 
Abacavir can cause some people serious allergic reactions (hyper-sensitivity) in, especially between 1 and 
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6 months after starting treatment but it can also happen later. Symptoms are: 
- skin becomes hot and red/dark, indicating fever – consult doctor immediately if this happens 
- nausea and/or vomiting and/or diarrhoea and/or mouth ulcers 
- tiredness and/or muscular stiffness and/or generally feeling ill 
- sore throat and/or cough and/or breathing difficulty  
Never restart Abacavir if treatment was stopped due to allergic reaction  
During treatment: 
- Tiredness 
- Joint pains 
- Lactic acidosis 
Drug interactions  No interactions known 
Storage Room temperature below 30°C 
 
Generic name 
 Abbreviation 
Trade name 
Type of ARV 
Didanosine 
ddI 
Videx 
NRTI  
Presentation 
 
- Capsules (delayed release), 400, 250, 200, 125mg 
- Tablets, chewable or dispersible (mixed with water to drink),  
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200, 100, 25mg 
- Powder to make oral solution, in sachets of 2g or 4g 
Dose 
 
Adult over 60kg:  
- 1 capsule 400mg daily in 1 dose, or 2 tablets 200mg daily in 1 dose 
Adult less than 60kg:  
- 1 capsule 250mg once daily 
Children over 6 years:  
- Capsules 240mg/sq.m. daily, or oral liquid 5mg/kg per dose, 2 doses a day 
Food Take ddI capsules on an empty stomach, at least 2 hours before or 2 hours after a meal; a good time to take 
it is with a large glass of water on getting up from bed, about 30–45 minutes before breakfast 
Main side effects At the start of treatment: 
- sometimes, nausea, vomiting, diarrhoea 
During treatment 
- Tingling or loss of feeling in feet/hands (peripheral neuropathy). See doctor 
- Bloating of the abdomen (gas) 
- Mouth ulcers 
- Rarely, pancreatitis, with symptoms such as abdominal pain, nausea, vomiting, confirmed by blood tests 
- Sometimes: serious fatigue, muscle spasm and frequent cramps, abdominal pain, nausea, vomiting, 
difficulty in breathing – these indicate possible lactic acidosis; consult a doctor immediately 
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Drug interactions  -Do not use ddI at the same time as ribavirin (hepatitis C treatment) 
- ddI increases blood concentration of ganciclovir (cytomegalovirus treatment)  
- Do not take ddI tablets with indinavir  
- Do not use ddI and d4T together 
- take ddI 2 hours before atazanavir if using these two ARVs together 
Storage Room temperature 
 
Generic name 
 Abbreviation 
Trade name 
Type of ARV 
Emtricitabine 
FTC  
EMTRIVA 
NRTI 
Presentation 
 
- Capsules, 200mg  
- Oral solution, 10mg/ml 
Dose 
 
Adults: 1 capsule 200mg once daily 
Children:: 4mg/kg once daily (if capsules are used, not more than 200mg per day; if oral solution is used, 
not more than 240mg per day) 
Food No special requirements 
Main side effects - Vertigo 
- Insomnia 
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- Diarrhoea, nausea, vomiting, abdominal pain 
- Pruritus (severe skin itching), urticaria (red, itchy areas of skin) 
- Anaemia (low red blood cell count) 
Drug interactions Do not use together with lamivudine/3TC or zalcitabine/ddC 
Storage Room temperature 
 
Generic name  
Abbreviation 
Trade name  
Type of ARV 
Tenofovir 
TDF 
VIREAD 
NRTI 
Presentation Tablets, 300mg 
Dose 1 tablet in 1 dose per day 
Food Can be taken with or without food 
Main side effects - Fatigue, vertigo 
- Nausea, vomiting, diarrhoea, flatulence (gas) 
- Kidney problems (rare) 
Drug interactions - Do not use TDF with other drugs that are toxic to the kidneys 
- TDF increases the blood concentration of ddI when ddI is taken as capsules 
Storage Room temperature 
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Generic name 
Abbreviation 
Trade name 
Type of ARV 
Zalcitabine 
ddC 
HIVID®  
NRTI  
ATTENTION: Zalcitabine/ddC causes a high rate of side effects and is no longer recommended 
Presentation 
 
- Tablets, 0.750 and 0.375mg 
- Syrup for children, 0.1mg/ml 
Dose 
 
Adults: 
- 1 tablet 0.750mg per dose, 3 doses a day. Sometimes 1.125mg per dose, 2 doses a day 
Children: 
- 0.01mg/kg per dose, 3 doses a day 
Food No special requirements 
Main side effects At the start of treatment: 
- Sometimes digestive problems: nausea, vomiting, diarrhoea. These usually disappear within a few weeks  
During treatment: 
- Tingling or loss of sensation in feet or hands (peripheral neuropathy). Consult the doctor 
- Mouth ulcers 
- Rarely, pancreatitis, with symptoms such as abdominal pain, nausea, vomiting, confirmed by blood tests 
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- Decrease in levels of red or white blood cells and platelets 
- Sometimes serious fatigue, muscle spasm and frequent cramps, abdominal pain, nausea, vomiting, 
difficulty in breathing – these indicate possible lactic acidosis; consult doctor immediately 
Drug interactions Do not use with lamivudine/3TC 
Storage Room temperature 
 
Generic name 
Abbreviation 
Trade name 
Type of ARV  
Abacavir + Lamivudine + Zidovudine  
ABC + 3TC + ZDV 
TRIZIVIR®  
NRTI - combination of 3 drugs  
Presentation 
 
Tablets 300mg zidovudine/ZDV + 150mg lamivudine/3TC + 300mg abacavir/ABC  
Dose 1 tablet per dose, 2 doses per day 
Food No special requirements 
Main side effects At the start of treatment: 
Abacavir in this combination causes allergies in some patients, especially in the first 6 weeks of treatment. 
Symptoms are: 
- skin becomes hot and red/dark, indicating fever – consult doctor immediately if this happens 
- nausea and/or vomiting and/or diarrhoea and/or mouth ulcers 
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- tiredness and/or muscular stiffness and/or generally feeling ill 
- sore throat and/or cough and/or breathing difficulty  
See information on Abacavir 
During treatment: 
- Nausea 
- Decreased levels of red cells or white blood cells 
- Muscle pains 
- Headache, tiredness, brown colouring of the nails and skin 
- Joint pains 
- Lactic acidosis 
Drug interactions Do not use these drugs with stavudine/d4T or zalcitabine/ddC 
Storage Room temperature, below 30°C 
 
NNRTIs – Non-nucleoside reverse transcriptase inhibitors 
 
Generic name 
Abbreviation 
Trade name 
Type of ARV 
Efavirenz 
EFV 
SUSTIVA; STOCRIN; EFAVIR  
NNRTI 
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Presentation 
 
- Tablets, 600mg 
- Capsules, 50, 100, 200mg 
- Syrup, 30mg/ml 
Dose 
 
Adults:  
- 1 tablet 600mg or 3 capsules 200mg per dose, 1 dose per day (preferably in the evening, after a meal 
and before going to bed). 
- If the person is also on TB treatment, increased doses of efavirenz are needed: up to 800mg per dose, 
1 dose per day  
Children:  
- According to weight, based on a fixed-dose schedule provided by the producer 
Food Avoid oily or fatty food before taking efavirenz/EFV – these foods can increase side effects  
Main side effects At the beginning of treatment: 
- Frequently: vertigo, insomnia, problems with concentration, sleepiness, nightmares 
- Rarely: hallucinations 
- Risk of allergy, appearing as red/dark or purplish areas on the skin (more frequent in children). 
Consult a doctor 
- Children: Agitation 
During treatment: 
- Problems such as vertigo, insomnia, continuing nightmares  
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- After several weeks, possible depression, aggression, suicidal ideas and psychiatric problems 
- Increase in the amount of fat in the blood (cholesterol) 
- Hepatitis (inflammation of the liver), confirmed by blood tests 
Drug interactions - Many interactions 
- Efavirenz/EFV reduces blood concentrations of some protease inhibitors such as amprenavir, 
atazanavir, indinavir and saquinavir. It increases the blood concentration of other protease inhibitors – 
nelfinavir and ritonavir 
Storage Room temperature 
 
Generic name 
Abbreviation 
Trade names 
 
Type of ARV 
Nevirapine 
NVP  
VIRAMUNE; NEVIPAN; NEVIVIR; NEVIMUNE 
NNRTI 
Presentation 
 
- Tablets, 200mg  
- Oral solution, 50mg/5ml 
Dose 
 
Best to start treatment with a half dose for first 14 days of treatment, to reduce risk of side effects 
Adults During first 14 days of treatment,  1 tablet 200mg, 1 dose a day, always at the same time each 
day 
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After the first 14 days, increase to  
- 1 tablet per dose, 2 doses a day 
Children During first 14 days of treatment - 4mg/kg, 1 dose a day, always at the same time each day 
After the first 14 days:  
- 7mg/kg, 2 doses a day for children less than 8 years old 
- 4mg/kg, 2 doses a day for children more than 8 years old (no more than total of 400mg per day) 
New-born infants (PMTCT): 
- 2mg/kg in 1 dose  
Food No special requirements 
Main side effects At the start of treatment: 
Risk of allergy, appearing as red/dark areas on skin, rashes or other skin problems and/or fever. This 
can affect women more than men. Consult a doctor. Also, possible nausea 
During treatment: 
Liver function can be affected, shown by symptoms such as jaundice, nausea, vomiting, fever, serious 
fatigue 
Drug interactions - Many interactions 
- Nevirapine/NVP reduces blood concentrations of some ARVs: amprenavir, fosamprenavir, indinavir, 
lopinavir, nelfinavir and saquinavir 
Storage Room temperature 
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Generic name 
Abbreviation 
Trade name 
Type of ARV 
Delavirdine 
DLV  
RESCRIPTOR  
NNRTI 
Presentation Tablets, 100mg 
Dose 
 
Adults:  
- 4 tablets per dose, 3 doses a day 
Children:  
- Not normally used for children 
Food No special requirements, but it is best to avoid very oily or fatty food 
Main side effects At the start of treatment: 
- Risk of allergies: if red/dark patches appear on the skin, consult a doctor 
- Digestive problems: nausea, diarrhoea which gradually gets less and stops 
Drug interactions - Many interactions 
- Delavirdine increases the concentration in the blood of indinavir, nelfinavir and saquinavir, and of 
anti-TB drugs 
Storage Room temperature 
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PIs – Protease inhibitors: 
 
Generic name 
Abbreviation 
Trade name 
 
Type of ARV 
Lopinavir + ritonavir 
LPV+RTV  
ALUVIA (tablets) or  
KALETRA (capsules) 
PI 
Presentation 
 
- Tablets 200mg lopinavir + 50mg ritonavir (new, July 2006) 
- Capsules, 133.3mg lopinavir + 33.3mg ritonavir 
- Oral solution, 80mg/ml lopinavir + 20mg/ml ritonavir 
Dose 
 
Adults: 
- 2 tablets per dose, 2 doses per day 
do not chew, break or crush the tablets 
- 3 capsules per dose, 2 doses per day  
- 4 capsules per dose, 2 doses per day, if taken with efavirenz 
If a person has not received any ARV treatment before: 
- 4 tablets per dose, 1 dose per day 
do not chew, break or crush the tablets 
Children: using oral solution only; do not break or crush adult tablets to provide doses for children 
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According to body weight: 
- 7 to 15kg: 12mg lopinavir + 3mg ritonavir per kg, twice per day 
- 15 to 40kg: 10mg lopinavir + 2.5mg ritonavir per kg, twice a day 
According to surface area: 
 Under 40kg: 230mg lopinavir + 57.5mg ritonavir per sq.m. 
Food Take with food 
Main side effects At the start of treatment: 
In the early stages of treatment, some side effects are common: tiredness, nausea, vomiting, diarrhoea 
During treatment: 
- Digestive problems (nausea, vomiting, diarrhoea) 
- Increased levels of fat and sugar in the blood (triglycerides, cholesterol and glucose) 
- Tingling sensations around the mouth, loss of ability to taste 
- Tingling (‘pins and needles’) in the feet and hands (peripheral neuropathy) 
Drug interactions - Many interactions.  
- Do not use with anti-TB drugs  
- Ritonavir increases blood concentrations of other protease inhibitors 
- Efavirenz decreases blood concentration of lopinavir  
Storage Tablets – not sensitive to heat, keep container closed against moisture 
Oral liquid or capsules – keep in a refrigerator; if stored at room temperature, use within two months 
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Generic name 
Abbreviation 
Trade name 
Type of ARV 
Amprenavir 
APV  
AGENERASE  
PI 
Presentation 
 
- Capsules 150mg, 50mg 
- Syrup 15mg/ml 
Dose 
 
Adults:  
-8 capsules per dose, 2 doses per day (total 16 capsules per day) 
- with low-dose ritonavir: amprenavir 4 capsules per dose + ritonavir 1 capsule 100mg per dose, 2 
doses each drug a day (total 10 capsules a day) 
Children: 
- 20mg/kg per dose, 2 doses per day if taken as capsules 
- 17mg/kg per dose, 3 doses per day if taken as syrup 
Do not give to children under 4 years old 
Food No special requirements. Never take Amprenavir/APV with very fatty or oily foods 
Main side effects At the start of treatment: 
Possible of skin problems, see doctor 
During treatment: 
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- Digestive problems, especially nausea 
- Tiredness, headache 
- Increase in fat and sugar in the blood 
Drug interactions - Many interactions 
- Do not take anything containing vitamin E at same time as Amprenavir 
- Ritonavir increases the blood concentration of amprenavir 
- Efavirenz reduces the blood concentration of amprenavir 
Storage Room temperature 
 
Generic name 
Abbreviation 
Trade name 
Type of ARV 
Fosamprenavir  
 
TELZIR, LEXIVA 
PI 
Presentation 
 
- Tablets, 700mg  
- Oral solution, 50mg/ml 
Dose 
 
Adults: 
- 1 tablet 700mg fosamprenavir and 1 capsule 100mg ritonavir per dose, 2 doses per day 
OR 
- 2 tablets 700mg fosamprenavir and 2 capsules 100mg ritonavir per dose, 1 dose per day 
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Food No special requirements 
Main side effects At the start of treatment: 
Possibility of skin problems. Consult a doctor. 
During treatment: 
- Digestive problems, especially nausea 
- Increased amounts of fat and sugar in the blood 
Drug interactions - Many interactions 
- Do not take Vitamin E or products containing vitamin E at the same time as fosamprenavir 
- Ritonavir increases the blood concentration of fosamprenavir 
- Efavirenz reduces the blood concentration of fosamprenavir 
Storage Room temperature 
 
Generic name 
Abbreviation 
Trade name 
Type of ARV 
Atazanavir 
ATV  
REYATAZ  
PI 
Presentation Capsules 150mg, 200mg 
Dose 
 
Adults: 
1 dose per day of one of the following possible combinations: 
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- ATV+RTV: 2 capsules 150mg atazanavir + 1 capsule 100mg ritonavir 
- ATV+RTV+EFV: 2 capsules 150mg atazanavir + 1 capsule 100mg ritonavir + 3 capsules 200mg or 1 
capsule 600mg efavirenz 
- ATV+FTV: 2 capsules 200mg atazanavir + 6 capsules 200mg FTV (saquinavir soft-gel) 
- ATV+RTV+TDF: 2 capsules 150mg atazanavir + 1 capsule 100mg ritonavir + 1 tablet 300mg 
tenofovir 
Food Take during a meal. Do not take grapefruit juice at the same time 
Main side effects At the start of treatment: 
Possibility of skin problems at the start of treatment 
Atazanavir can cause jaundice (yellow colouring of the skin or eye, cause by an increase in levels of 
bilirubin in the blood); this is not harmful 
During treatment: 
- Diarrhoea, nausea, abdominal pain 
- Headache, fatigue 
Drug interactions - Many interactions  
- Atazanavir increases the blood concentration of saquinavir 
- Ritonavir increases the blood concentration of atazanavir (these drugs are often used together) 
- Efavirenz, nevirapine and tenofovir reduce the blood concentration of atazanavir 
Storage Room temperature 
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Generic name 
Abbreviation 
Trade name 
 
Type of ARV 
Indinavir 
IDV  
AVIRODIN; CRIXIVAN; INDIVIR;  
INDIVAN  
PI 
Presentation Capsules 400mg, 333mg, 200mg 
Dose 
 
Adults:  
- 2 capsules 400mg per dose, 1 dose every 8 hours (3 doses per day), take when the stomach is empty 
(at least one hour before or two hours after eating) 
Several other possible doses can be prescribed, sometimes with ritonavir 
Children: 
- 500mg/sq.m. per dose, 1 dose every 8 hours 
- With ritonavir: 600mg/sq.m indinavir + 100mg/m2 ritonavir 
Food - Take on an empty stomach 
- Take with plenty of water (3 - 4 glasses of water within half hour after dose) to prevent kidney stones 
or ‘gravel’ in urine 
  
292 
 
Main side effects At the start of treatment: 
- Tiredness 
- Nausea, serious vomiting, diarrhoea (common at the start of treatment, but usually reduce as 
treatment continues) 
During treatment: 
- Dry skin, sore lips 
- ‘Gravel’ in urine, kidney stones; causing pain in middle of back or bladder (lower abdomen), 
sometimes in testicles, and sometimes blood in the urine; consult the doctor 
- Ingrowing toe nails 
- Loss of hair in beard, body or head 
- Increased fat and sugar in the blood (triglycerides, cholesterol, glucose) 
- Fat increase: abdomen, breasts, neck 
- Loss of fat: limbs, cheeks, hips,  thighs 
Drug interactions - Many interactions 
- Nelfinavir increases blood concentration of indinavir 
- Nevirapine reduces blood concentration of indinavir 
Storage Protect from moisture 
 
Generic name Nelfinavir 
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Abbreviation 
Trade name 
Type of ARV 
NFV  
VIRACEPT  
PI 
Presentation 
 
- Tablets, 625mg, 250mg 
- Powder to mix with oral liquid (such as juice), 50mg/1g 
Dose 
 
Adults: 
- 2 tablets 625mg per dose, 2 doses per day OR 
- 3 tablets 250mg per dose, 3 doses per day OR 
- 5 tablets 250mg per dose, 2 doses per day  
Children: 
- 50 to 55mg/kg per dose, 2 doses per day OR 
- 25 to 30mg/kg per dose, 3 doses per day 
Food Nelfinavir must be taken in the middle of a meal, to improve absorption of the drug into the body. For 
the morning dose it is therefore important to have an adequate breakfast 
Main side effects At the start of treatment: 
- Tiredness 
- Nausea, vomiting, diarrhoea 
- Skin rashes 
Common at the start of treatment, but usually reduce as treatment continues 
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During treatment: 
- Diarrhoea (frequent, sometimes serious) 
- Bloating of the abdomen, nausea, flatulence 
- Increased fat and sugar in blood (triglycerides, cholesterol and glucose) 
- Build-up of fat on abdomen, breasts, neck 
- Loss of fat on limbs, cheeks, hips or thighs 
Drug interactions - Many interactions 
- Indinavir, efavirenz and some other ARVs increase the concentration of nelfinavir in the blood 
Storage Room temperature 
 
Generic name 
Abbreviation 
Trade name 
Type of ARV 
Ritonavir 
RTV  
NORVIR 
PI 
Presentation 
 
- Capsules, 100mg 
- Oral solution, 80mg/ml 
Dose 
 
Adults: 
- 6 capsules 100mg per dose, 2 doses per day (rarely used - full doses difficult to tolerate) 
- more often used to improve effects of other protease inhibitors, using 1 to 4 capsules ritonavir per 
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dose, 2 doses a day 
Children: 
- 350 to 400mg/sq.m., 2 doses a day (maximum 600mg twice a day) 
Food Take ritonavir during a meal 
Main side effects At the start of treatment: 
Better tolerated if a low starting dose is given, gradually increasing to full dose over 14 days 
During the first 4 to 6 weeks, side effects are common: tiredness, nausea, vomiting, diarrhoea 
During treatment: 
- Digestive problems (nausea, vomiting, diarrhoea) 
- Increased fat and sugar in the blood (triglycerides, cholesterol and glucose) 
- Tingling sensations around the mouth, loss of ability to taste 
- Tingling (‘pins and needles’) in the feet and hands (peripheral neuropathy) 
Drug interactions - Many interactions. 
- Do not use with anti-TB drugs  
- Ritonavir increases blood concentrations of other protease inhibitors and efavirenz 
Storage - Store capsules in refrigerator if room temperature exceeds 25°C. 
- Never store oral solution in refrigerator 
 
Generic name Saquinavir soft gel 
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Abbreviation 
Trade name 
Type of ARV 
SQV-SG or FTV  
FORTOVASE 
PI 
Presentation 
 
Capsules (soft-gel), 200mg 
Note: Fortovase and Invirase both contain saquinavir but they act differently in the body because they 
are made in a different way – do not substitute one for the other except when planned with the doctor 
Dose 
 
Adults: 
- 6 capsules 200mg per dose, 3 doses per day, OR 
- 8 capsules 200mg per dose, 2 doses per day 
- Alternative doses are used, depending which other ARVs are included in the regimen 
- If 3 doses per day are taken, the time between the evening and morning doses should be 8 hours; this 
means having a late evening meal and an early breakfast 
Children: 
Usually used with another protease inhibitor; for example: 50mg/kg saquinavir + 55mg/kg nelfinavir 
Food Take saquinavir during or just after a meal 
Main side effects At the start of treatment: 
- Tiredness, digestive problems 
During treatment: 
- Digestive problems 
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- Increased fat and sugar in the blood (triglycerides, cholesterol and glucose) 
Drug interactions - Many interactions 
- Ritonavir, Kaletra and nelfinavir increase the blood concentration of saquinavir  
- Nevirapine and efavirenz decrease the blood concentration of saquinavir in the blood 
Storage Store capsules in a refrigerator if room temperature exceeds 25°C 
 
Generic name 
Abbreviation 
Trade name 
Type of ARV 
Saquinavir hard gel 
SQV-HG or INV 
INVIRASE 
PI 
Presentation 
 
- Tablets, 500mg  
- Capsules (hard gel), 200mg 
Note: Invirase and Fortovase both contain saquinavir but they act differently in the body because they 
are made in a different way – do not substitute one for the other except when planned with the doctor 
Dose 
 
Adults: 
Invirase is usually used along with low-dose ritonavir 
- 2 tablets 500mg + 1 capsule 100mg Ritonavir per dose, 2 doses per day (total per day: 6 tabs/caps) 
- 5 capsules 200mg + 1 capsule 100mg ritonavir per dose, 2 doses per day (total per day: 12 capsules) 
- 2 capsules 200mg + 4 capsules 100mg Ritonavir per dose, 2 doses per day (total per day: 12 capsules) 
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- 8 capsules 200mg + 1 capsule 100mg Ritonavir, 1 dose per day (total per day: 9 capsules) 
Food Take saquinavir during a meal or just after 
Main side effects At the start of treatment: 
Tiredness, digestive problems 
During treatment: 
- Digestive problems 
- Increased fat and sugar in the blood (triglycerides, cholesterol and glucose) 
Interactions with other drugs 
 
- Many interactions 
- Ritonavir, Kaletra and nelfinavir increase the blood concentration of saquinavir  
- Nevirapine and efavirenz decrease the blood concentration of saquinavir in the blood 
Storage Room temperature 
 
Generic name 
Abbreviation 
Trade name 
Type of ARV 
Tipranavir 
TPV  
Aptivus 
PI 
Presentation Capsules, 250mg 
Dose 
 
Adults: With ritonavir:  
2 capsules 250mg tipranavir +  
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2 capsules 100mg Ritonavir per dose, 2 doses per day 
Food Take tipranavir during or just after meal 
Main side effects At the start of treatment: 
- Tiredness 
- Nausea, vomiting, diarrhoea; common at the start of treatment, but usually reduces as treatment 
continues 
During treatment: 
- Increased fat and sugar in the blood (triglycerides, cholesterol and glucose) 
- Digestive problems 
- Possible liver problems 
Drug interactions Tipranavir is used with ritonavir, which interacts with many ARVs and other drugs that are removed 
from the body by the liver 
Storage Room temperature 
 
Entry Inhibitor: 
 
Generic name 
Abbreviation 
Trade name 
Enfuvirtide 
T20 
FUZEON  
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Type of ARV Entry inhibitor 
Presentation 
 
Powder for injection, single-use vial 108mg + 1.1ml vial, water for injection 
Dose 
 
Adults: 
- 90mg (1ml) injection, subcutaneous (under the skin), into the upper arm, abdomen or upper thigh, 2 
doses per day 
Children: 
- 2mg/kg injection, subcutaneous (under the skin), do not exceed  90mg per injection in 2 injections 
per day 
Food No special requirements 
Main side effects -Fuzeon can cause skin reactions at the site of injection: reddening, pain, small swellings, hardening of 
skin.  
- Avoid injecting in areas where there is risk of irritation. Avoid areas 2 to 3cm around the navel 
General side effects: 
- Headache 
- Pain and numbness in the feet and legs 
- Insomnia 
- Loss of appetite 
- Muscle pains 
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- Constipation 
Drug interactions No interactions known 
Storage - Store at room temperature in the original packaging.  
- While the injection solution is being prepared, must be stored in refrigerator for up to a maximum of 
24 hours (some time is needed for the powder to dissolve properly in the water) 
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9.5: Determining lipid profile (manufacturer specifications) 
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9.6: Protocol for data collection 
Patient (4-digit code) ID e.g. 1001, 1002 etc  
Date of assessment  
Data to be collected from the files 
Date at HIV diagnosis (dd/mm/yyyy)   
Time with HIV to date (years)  
 
Disease progression by CD4; record as far as can be traced 
Date          
CD4          
 
Data to be collected from the patient 
Date at HIV diagnosis (DD/MM/YYYY)   
Time with HIV to date (years)  
Possible initial infection time (month and year) with HIV 
Morphological changes since HIV diagnosis before and after initiation of ART 
Morphological alterations since HIV diagnosis 
Site Before start of ART (both 
groups) 
After start of ART 
(ART group only) 
Face   
Neck   
Breasts   
Abdomen   
Arms   
Legs   
Buttocks   
Overall weight change   
Other   
(Record increase, decrease, no change) 
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If currently on medication, record treatment profile 
Participant medication profile 
ART class Example (circle/write out) *HAART (Yes/no) Medication start date 
(DD/MM/YYYY) 
Time on medication 
(years) 
Reverse 
Transcriptase 
Inhibitor 
NNRTIs 
efavirenz- EFV, nevirapine – NVP, etravirine, 
delavirdine  
Atripla 
Kaletra 
Combivir 
Trizivir 
Epzicom 
Truvada 
  
NRTIs 
abacavir -  ABC, didanosine – ddI,  
lamivudine – 3TC, stavudine – d4T, tenofovir – 
TDF, zidovudine – AZT, emtricitabine - FTC 
 
Protease 
Inhibitor 
indinavir – IDV, lopinavir – LPV, nelfinavir – 
NFV, ritonavir – RTV, saquinavir – SQV, 
darunavir, atazanavir – ATV, fosamprenavir, 
tipranavir – TPV, kaletra 200/50- 
(lopinavir+novir) 
 
*Atripla – tenofovir + emtricitabine + efavirenz; *Kaletra – lopinavir + norvir; *Combivir – lamivudine + zidovudine; *Trizivir – abacavir 
+ lamivudine + zidovudine; *Epzicom – lamivudine + abacavir; *Truvada – tenofovir + emtricitabine 
If ever been on different medication rather than the above, record the treatment profile then 
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Participant medication profile 
ART class Example (circle/write out) *HAART (Yes/no) Medication start date 
(DD/MM/YYYY) 
Time on medication 
(years) 
Reverse 
Transcriptase 
Inhibitor 
NNRTIs 
efavirenz- EFV, nevirapine – NVP, etravirine, 
delavirdine  
Atripla 
Kaletra 
Combivir 
Trizivir 
Epzicom 
Truvada 
  
NRTIs 
abacavir -  ABC, didanosine – ddI,  
lamivudine – 3TC, stavudine – d4T, tenofovir – 
TDF, zidovudine – AZT, emtricitabine - FTC 
 
Protease 
Inhibitor 
indinavir – IDV, lopinavir – LPV, nelfinavir – 
NFV, ritonavir – RTV, saquinavir – SQV, 
darunavir, atazanavir – ATV, fosamprenavir, 
tipranavir – TPV, kaletra 200/50- 
(lopinavir+novir) 
 
*Atripla – tenofovir + emtricitabine + efavirenz; *Kaletra – lopinavir + norvir; *Combivir – lamivudine + zidovudine; *Trizivir – abacavir 
+ lamivudine + zidovudine; *Epzicom – lamivudine + abacavir; *Truvada – tenofovir + emtricitabine 
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Reasons for changing art regimen 
____________________________________________________________________ 
 
Anthropometry record Date…………………….  Time………………………… 
(Take trial 1 for all sites till the end, then trial 2 and lastly trial 3 if applicable) 
Measure Trial 1 Trial 2 Mean Trial 3 if 
applicable 
Median 
Weight (kg)      
Height (cm)      
SF sites (mm) 
Triceps      
Biceps      
Sub scapular      
Iliac crest      
Medial calf      
Abdominal      
Girths (cm) 
Arm circumference      
Calf      
Waist      
Abdomen      
Hip      
 
Total body water (TBW); BioImpedence Analysis 
Record from above anthropometry section; the mean or median (where applicable)  
Age 
(years) 
 
Weight 
(kg) 
 
Height 
(cm) 
 
Waist 
(cm) 
Hip 
(cm)  
Activity level (tick one) 
Inactive 
Moderately active 
Very active 
 
Recording results from the BIA out put 
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characteristic Participant 
record 
Recommended cut 
offs  
remark 
Fat %   Body fat (%)  
Fat (kg)   BF (kg) 
Lean weight %   FFM (%) 
Lean weight (kg)   FFM (kg) 
Dry lean weight (kg)    
Water (%)   TBW (%) 
Water (liters)   TBW (L) 
BMI (kg/ m
2
)  20-25  
WHR   ≤ 0.80 normal 
*R (Ω)    at 50KHZ 
 
*R (the current resistance); FFM = TBW/ 0.7; TBW = 0.830 + 0.714(Ht
2
/ R); FM = 
weight – FFM; body fat (%) = FM/ weight X 100 
 
TBW; Deuterium dilution 
Administration of the 10% solution of 99.9% deuterium oxide 
Subject 
ID  
Weight 
(kg) 
Required dose 
(0.5 x 86.6 kg) 
bottle + 
cover (g) 
bottle + 
cover + 
Dose (g) 
bottle + 
cover 
(post 
drink) (g) 
Actual dose 
(g) 
e.g. 101 86.6  43.3 g 4.15 g 47.66 4.23 g 43.43  
 
 
      
 
Urine sample collection 
Urine sample collection timeline 
Timing Urine sample Received 
duplicate (tick) 
0.00 (4 hours after last evening meal) Pre-dose (bottle 1)  
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4 hour (4 hours after drinking ‘heavy water’) 4-hour (bottle 2)  
6 hour (6 hours after drinking ‘heavy water’) 6-hour (bottle 3)  
 
TBW (kg) = [(W x A/a) x (Ea – Et)/ (Es – Ep)/ (1000 x 1.041)] (adapted from 
Abrahams & Wong, 2003) 
W = volume of tap water (mL) that (a) diluted in (200 mL) – shall use 200 mL 
A = dose given in grams (cup + dose minus cup) 
a = amount of dose diluted in 200 mL 
Ea = delta value of (a) the dose given in tap water 
Et = delta value of tap water 
Es = 6 hour delta value 
Ep = delta value of pre dose sample (baseline sample) 
 
FFM = TBW/0.73 
FM = weight – FFM 
% BF= FM/ body weight X 100 
 
Participant biochemical metabolites 
IDF
1 
Technique to be used Must have central obesity +  
any 2 others
 
Participant 
record 
Obesity 
 
Anthropometry Must: central obesity or BMI > 
30 kg/ m
2 
 
Raised 
triglycerides 
GPO-PAP method* ≥ 150 mg/ dL  
Reduced HDL 
cholesterol 
Direct homogeneous 
test* 
< 50 mg/ dL  
Raised blood 
pressure 
Digital BP technique 
(OSZ5 Welch Allyn) 
Systolic BP ≥130 mm Hg / 
Diastolic ≥ 85 mm Hg 
 
Raised fasting 
plasma glucose 
GOD-PAP method* ≥ 100 mg/ dL or diabetic  
Diet/ nutrition history 
Please circle the typical meals/snacks that you consume on an average day 
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Breakfast  
Break  
Lunch  
Evening snack  
Supper   
Any other (specify) 
FFQ: Indicate average number of days in a week you often eat the following 
foods 
Food  5-7/ wk half the 
wk 
rarely never remark 
Fruits 
 
     
Vegetables 
 
     
High fat (e.g. fat cuts of meats, 
poultry, whole dairy products, 
palm oil, kimbo, cowboy etc.) 
     
Low fat (e.g. low fat dairy 
products, fish, lean meats, refined 
cereals, legumes, roots/ tubers 
     
Whole cereals/ grains etc.)      
 
Lifestyle Questions 
Do you drink coffee?  
Yes No 
 
If yes, how many liters of coffee do you drink on average per day? 
…………………… 
 
If you did drink coffee in the past, in which year & month did you give up? Yyyy/mm 
………………………… 
Do you drink alcohol?  
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Yes No 
 
If yes, what are your average liters of alcohol intake over?  
Week days Week ends 
If you did drink alcohol in the past, when did you give up?  
Yyyy/mm ………………………… 
 
Do you smoke? 
Yes No 
 
If yes, how many sticks of cigarette per day? ………………………… 
 
If you did smoke in the past, when did you give up?  
Yyyy/mm ………………………… 
 
Are you currently taking any vitamin/nutritional supplements or herbal remedies?  
Yes No 
 
If yes, please list: 
Brand name Daily dosage 
 
Activity level 
How would you describe your general daily activity level? (E.g. sedentary _ very 
active, tick one) 
 
A. Sedentary (sit at work a lot, sit at home most times, lie down most times) 
  
B. Lightly active (standing & normal walking, less sitting)  
C. Active (physical labourer, gardening, much housework)  
 
Do you take regular physical activity/exercise? 
  
316 
 
Yes No 
 
If yes, please give details of:  
Type of activity 
 
 
Usual/average duration How often/frequency done per 
week? 
 
Attitude towards physical activity 
 
“Doing physical activity/exercise does ……...” Not likely - Most likely 
i Allows me to cope with stress better 1 2 3 4 5 
ii Helps me avoid falling ill 1 2 3 4 5 
iii Gives me a powerful sense of personal achievement 1 2 3 4 5 
iv Improves my physical strength 1 2 3 4 5 
v Makes me strong & less dependent on others 1 2 3 4 5 
vi Improves my ability to concentrateon what I do 1 2 3 4 5 
vii Gets me occupied or kill boredom 1 2 3 4 5 
viii Causes pain/soreness/discomfort/injury 1 2 3 4 5 
ix Makes me very tired 1 2 3 4 5 
 
Medical history 
Are there any biological family members known to have or have had: 
Diabetes 
Yes No 
Hypertension 
Yes No 
 
Stroke 
Yes No 
Any known heart diseases 
Yes No 
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Thank you for completing this questionnaire 
Researcher’s initials  _______Signature    
___________Date_____________________  
